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Chronic Lymphocytic Leukaemia (CLL) is a proliferative B cell malignancy characterised by an 
accumulation of mature B cells in the peripheral blood, lymph nodes and bone marrow. The disease 
is heterogenous in both clinical presentation and response to treatment. Despite the well-established 
immunochemotherapy and recently introduced molecularly targeted therapies such as ibrutinib and 
venetoclax, CLL is still incurable. One possible cause of relapse in patients is the involvement of the 
tissue microenvironment which supports CLL-cell survival and confers drug resistance. Nurse like cells 
(NLCs) are a major component of the CLL microenvironment. However, the exact molecular 
mechanisms mediating interactions between CLL cells and NLCs are still not fully understood. The aim 
of this study was to investigate how NLCs and CLL cells influence each other at the level of gene 
expression and to uncover molecules and pathways that are responsible for prolonging survival and 
conferring drug resistance of CLL cells. I therefore independently characterised the development of 
NLCs using fresh peripheral blood samples from CLL patients and applied a co-culture system where 
primary CLL cells were cultured with NLCs. I showed that the development of NLCs varies considerably 
between the individual CLL samples. Consequently, I developed an NLC scoring system to reflect the 
variable nature of the NLC development. I also confirmed the pro-survival effect of NLCs on CLL cells. 
To address the issue of variation in developing NLCs, I developed a cell-line model using human THP-
1 monocytic leukemic cells to mimic NLCs. The cell line model closely resembled the morphology and 
phenotype of NLCs. Like NLCs, it also provided pro-survival signals to CLL cells when in co-culture, as 
THP-1 cell-derived macrophages protected CLL cells from spontaneous and fludarabine-induced 
apoptosis. Finally, I prepared mRNA samples from the co-cultured CLL cells and primary NLCs, together 
with their respective cells cultured alone as controls, and generated the comprehensive, global gene 
expression datasets using next generation sequencing technology (RNA-seq). Through the application 
of contemporary bioinformatics analysis techniques, I identified 326 out of 19,595 expressed genes 
that are significantly differentially expressed in co-cultured CLL cells. Gene set enrichment analysis 
revealed that gene expression profile of CLL cells co-cultured with NLCs resembled that of the tissue 
resident CLL cells from the lymph nodes, thus validating the use of the co-culture system in mimicking 
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the CLL microenvironment. Further analysis of differentially expressed genes led to identification of 
several signalling pathways that are critically involved in mediating the interaction between CLL cells 
and NLCs. These include some known pathways such as toll-like receptor and tumour necrosis factor, 
activation of which all lead to eventual activation of NF-ĸB, the master transcription factor of B cells. 
Furthermore, my analysis revealed other less well-known signalling pathways such as hypoxia-
inducible factor that are also involved in cross-talk between CLL cells and NLCs. The novel observations 
from my study has thus provided a rational basis for future studies to investigate the molecular 
mechanisms responsible for the functions of these signalling pathways and associated molecules, 
which may lead to identification of potential targets for therapeutic intervention to overcome 














Narrated Abu Huraira: 
The Prophet (may blessings and peace be upon him) said, "There is no disease that God has created, 
except that He also has created its treatment."  




"For indeed, with hardship [will be] ease. Indeed, with hardship [will be] ease" 
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1 General Introduction 
1.1 Chronic Lymphocytic Leukaemia 
Chronic Lymphocytic Leukaemia (CLL) is characterised by the clonal expansion and accumulation of 
mature, CD5+ B-cells in the blood, bone marrow and spleen (Fabbri & Dalla-Favera 2016). As of 2017, 
it is the most common type of adult leukemia in UK, which predrominantly affects males (Chronic 
lymphocytic leukaemia (CLL) statistics). 
The treatment of CLL patients with fludarabine, cyclophosphamide, rituximab (FCR) and targeted 
therapy such as ibrutinib, idelalisib and venetoclax alone or in combination have improved the 
outcomes of CLL (Furstenau et al. 2019; Kipps et al. 2017). However,  patients with 11q deletion and/or 
ATM mutations respond poorly to purine analogues (e.g. fludarabine) (Bosch & Dalla-Favera 2019). 
The deletion of 17p or TP53 mutation renders the chemotherapeutic drugs ineffective and thus 
patients with 17p deletion or TP53 mutations are treated with ibrutinib, a novel inhibitor of Bruton’s 
tyrosine kinase (BTK), a kinase that is critically involved in B cell receptor (BCR) signalling (Hallek 2017; 
Kipps et al. 2017; Mir et al. 2019; Provan et al. 2015). Alternatively, venetoclax (ABT-199) can be 
offered to CLL patients who are not suitable for FCR (Hallek 2015, 2017).  
Despite the development of the novel therapies, relapse of the disease still occurs (Kipps et al. 2017). 
One cause of relapsed disease is the existence of minimal residual disease (MRD) in CLL (Furstenau et 
al. 2019). Accumulating evidence suggests that CLL cells residing in the lymphoid tissues such as bone 
barrow, lymph nodes and spleen are the major source of MRD (Furstenau et al. 2019). MRD is defined 
as presence of CLL cells detected in the peripheral blood (PB) or bone marrow (BM) by flow cytometry 
following treatment (Furstenau et al. 2019). Undetectable MRD (defined as <1 CLL cells in 10,000 
leukocytes) is a strong indicator for longer progression-free survival (Furstenau et al. 2019). Early 
studies in CLL have also shown that CLL cells survived prolonged period in vivo, but underwent 
apoptosis rapidly when cultured in vitro (Collins et al. 1989), which indicated that the survival of CLL 
cells depends on factors present in the tissue microenvironment including the bone marrow and 
lymph nodes. Therefore, better understantanding of how CLL cells interact with the microenvironment 
is vitally important. Below, I will provide an overview on the CLL biology and microenvironment based 




1.2 Pathogenesis of CLL 
1.2.1 Cell origins of CLL 
In most patients of CLL, clonal expansion of B cells is arrested in the B-cell differentiation pathway, 
between pre-B cells and mature B Cells (Figure 1.1). Morphologically, they resemble mature 
lymphocytes (Hallek 2017; Mir et al. 2019; Zhang & Kipps 2014). It has been stated that mutations can 
occur anytime and contribute to the development of CLL cells. Mutations can even occur in 
hematopoietic stem cells (HSCs). During normal B cell development, the immature B cells leave the 
bone marrow and complete maturation where they differentiate, depending on micro environmental 
stimuli, into various B cell subtypes (Rickert 2013). CLL cells originating from B cells that have 
undergone Ig mutations lead to M-CLL (with mutated immunoglobulin heavy chain variable region 
gene (IGHV)), and those that have not are UM-CLL (with unmutated IGHV). Furthermore, it was shown 
that all CLL patients share a specific gene expression signature in their leukemic cells where it 
supported a model of CLL having a common cell of origin (Rosenwald  et al. 2001). It was suggested 
that CLL cells are related to memory B cells more than to naïve B cells, based on their gene expression 
profile analysis. The involvement of genetic lesions, BCR stimulation and microenvironment 






Figure 1.1 Cellular origin of CLL. Subsets of CLL based on IGHV mutation. 
 
 
1.2.2 B-Cell Receptor Signalling 
The B-cell receptor (BCR) complex is comprised of the membrane bound heavy and light chains of 
immunoglobulins (mIg) and CD79A and CD79B proteins (Geisberger, Lamers & Achatz 2006).  
This complex is expressed on the surface of B lymphocytes from very early developmental stage till it 
becomes a plasma cell (Geisberger, Lamers & Achatz 2006). Before a B cell leaves the bone marrow, 
the mIg exists as the IgM isotype and subsequently starts to express a second isotype IgD when it 
enters into the peripheral lymphoid organs (Geisberger, Lamers & Achatz 2006). Contrast to normal 
naïve B cells, CLL-B cells express low levels of sIgM where in U-CLL the expression is down-modulated 
to a lesser extent than M-CLL (Packham & Stevenson 2010; Stevenson et al. 2011). 
It has been suggested that in the hematopoietic stem cells (HSCs), that genetic events (lightning symbols) occur which lead 
to CLL. This could lead to the expansion of polyclonal B cells. Further stimulation may lead to clones and expansion of 
mature B cells. CLL cells with mutations in immunoglobulin heavy chain variable (IGHV-M) come from post-germinal centre 
(GC) B cells with CD5+CD27+. CLL cells with unmutated IGHV (IGHV-UM) are from pre-GC B cells with CD5+CD27-. The 
formation of germinal centre cells is T cell dependant and the formation of Pre-GC B cells is T cell independent. Monoclonal 
B lymphocytosis (MBL) and overt CLL is mandated by additional genetic and epigenetic lesions (indicated by lightning 




Upon binding to the antigen, the BCR is internalized (Geisberger, Lamers & Achatz 2006; Packham & 
Stevenson 2010). Activation results in the oligomerization of the BCR and the phosphorylation of 
immunoreceptor tyrosine-based activation motifs (ITAMs) CD79A and CD79B by LYN which also 
phosphorylates spleen tyrosine kinase (SYK) (Packham & Stevenson 2010; Stevenson et al. 2011). 
Through a ‘trigger’ event, the newly formed complex of kinases and scaffold proteins mentioned is 
called a ‘signalosome’ (Stevenson et al. 2011). Other motifs are involved and recruitment of PI3K is 
initiated after the formation of the signalosome (Stevenson et al. 2011). Subsequently, PI3K recruits 
AKT and Bruton’s tyrosine kinase (BTK) to the membrane and eventually a further complex forms 
consisting of LYN, SYK, PI3K, BTK and PLC-γ2. This complex leads to downstream pathways such as NF-
kB and RAS-ERK (Packham & Stevenson 2010; Zhang & Kipps 2014). The final phase of events involves 
downstream regulators, where modulation will mediate cell proliferation, survival and migration 
(Packham & Stevenson 2010; Stevenson et al. 2011). 
Compared to normal naïve B cells, CLL cells express low level of CD79b and IgM proteins (Guo et al. 
2016). There is a variable response to BCR stimulation in CLL cells (Packham & Stevenson 2010; 
Stevenson et al. 2011). There is an increased expression of LYN, SYK and ZAP70 in CLL where the levels 
of ZAP70 is used as a prognostic indicator for poor prognosis (Nabhan, Raca & Wang 2015; Packham 
& Stevenson 2010; Rassenti et al. 2008; Stevenson et al. 2011). 
In summary, BCR signalling in CLL facilitates the prolonged survival and expansion of CLL cells. Thus, a 
wide range of proposed targets in BCR signalling of CLL cells were aimed to combat the CLL presence 
in the body. 
 
1.2.3 Surface IgM and IgD 
IgM and IgD receptor isotypes are co-expressed on mature B cells, and their function in B cell 
development and maturation is widely interchangeable (Ten Hacken et al. 2016). They bear the same 
antigenic specificity and differ only in terms of their H chains, with IgMs carrying mu (µ) chain and IgDs 
carrying delta (δ) chains, respectively (Ten Hacken et al. 2016). Most CLL cells express both IgMs and 
IgDs, and numerous studies have characterized the importance of IgM BCRs for CLL-cell survival, cell 
cycle entry and proliferation (Burger & Chiorazzi 2013; Ten Hacken et al. 2016). The function of IgD in 
CLL has been studied, although there have been some controversial results mostly related to effect of 
its stimulation on inducing cell survival (Zupo et al. 2000) or apoptosis (Tavolaro et al. 2013). In one 
study, it was shown that cross linking with IgD prolonged cell survival instead of apoptosis (Zupo et al. 
2000). Yet, another study showed significant apoptosis was observed when cross-linked with IgD 
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(Tavolaro et al. 2013). This suggests that it is still not clear the exact role of IgD in CLL cell survival. The 
function of sIgD remains mysterious even in normal B cells (Packham & Stevenson 2010). 
 
1.2.4 Evasion of apoptosis in vivo 
CLL cells when cultured in vitro die rapidly from apoptosis (Collins et al. 1989), whereas they are long-
lived in vivo. This strongly indicates that CLL cells rely on microenvironmental factors, from sites such 
as bone marrow and lymph nodes, to prolong their survival in vivo. The BCL-2 family of proteins are 
important in the regulation of apoptosis (Cang et al. 2015).  
Within the family the anti-apoptotic proteins include BCL-2, BCL-XL, MCL1, BFL1/A1 and BCL-W. The 
pro-apoptotic proteins of BCL-2 family were further sub-divided into two groups: multi-BH domain 
proteins such as BCL-2-associated X protein (BAX) and BCL-2 antagonist/killer 1 (BAK) and BH3-only 
proteins. BH3 proteins such as BID, BCL-2-like 11 (BIM) and BCL-2 binding component 3 (PUMA) are 
also known as activators and BCL-2-associated agonist of cell death (BAD), BMF and NOXA are 
regarded as sensitizers (Buggins & Pepper 2010). 
BCL-2 family of proteins regulates apoptosis, particularly the intrinsic pathway, by controlling the 
permeability of the outer mitochondrial membrane (Buggins & Pepper 2010; Cang et al. 2015). Since 
some of the proteins are anti-apoptotic and pro-apoptotic, when the balance of scales is more in 
favour of apoptosis (i.e. there are more pro-apoptotic proteins), this results in increased permeability 
of the outer mitochondrial membrane (Buggins & Pepper 2010; Cang et al. 2015). This causes the 
release of pro-apoptotic factors such as cytochrome-C from the inner mitochondrial membrane 
through the outer mitochondrial membrane into the cytoplasm (Buggins & Pepper 2010; Cang et al. 
2015). The cytoplasmic cytochrome-c then forms a complex with apoptotic protease activating factors 
(APAF1), the complex is known as ‘apoptosome’, and this initiates caspase cascade by activating 
caspase-9 (Buggins & Pepper 2010; Cang et al. 2015). The resulting biological changes are apoptosis 
and cell death (Buggins & Pepper 2010; Cang et al. 2015). 
In CLL, the anti-apoptotic protein, BCL-2 is over expressed (Buggins & Pepper 2010; Pekarsky, Balatti 
& Croce 2018). This high expression of BCL-2 is also observed in follicular lymphomas where there is 
chromosomal translocation t(14;18) (Kelly & Strasser 2011). High levels of BCL-2 were also detected 
in DLBCL and mantle cell lymphoma (Kelly & Strasser 2011). 
The overexpression of BCL-2 is the result of loss or downregulation of miR-15/16 in 13q of CLL cells 
(Kelly & Strasser 2011; Pekarsky, Balatti & Croce 2018). The expression of both miR-15 and miR-16 is 
linked with the level of BCL-2 expression in almost all CLL cases (Pekarsky, Balatti & Croce 2018). When 
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there is a high expression of miR-15/16 it was seen that there is low expression of BCL2 (Pekarsky, 
Balatti & Croce 2018). In CLL, there is deletion of 13q resulting in loss of miR-15/16 and/or a mutation 
resulting in loss of function (Pekarsky, Balatti & Croce 2018). This in turn results in an overexpression 
of BCL2 and the final outcome is a high level of BCL-2 anti-apoptotic protein which causes the CLL cells 
to evade apoptosis (Kelly & Strasser 2011; Pekarsky, Balatti & Croce 2018). 
 
1.2.5 Tumour Microenvironment 
The concept of the microenvironment and link with cancer was first described in the late 1960s by 
Stephen Paget who proposed the ‘seed (tumor cells) and soil (microenvironment)’ hypothesis (Bakker 
et al. 2016; Witz 2009). Cancer cells are surrounded by a complex milieu. This cancer cell niche is called 
the tumor microenvironment, and it contributes to the development and metastasis of tumors. 
In CLL, the tumour microenvironment (summarised in Figure 1.2) comprises of the CLL cells, a mixture 
of cancer associated stromal cells (CAS)/ bone marrow stromal cells (BMSC), T cells via CD40 ligands, 
endothelial cells, follicular dendritic cells (FDC) and nurse-like cells (NLCs). It is presently recognised 
that CLL is a microenvironment-dependent disease (Burger 2011a; Caligaris-Cappio, Bertilaccio & 
Scielzo 2014; Ten Hacken & Burger 2016). The field of study in tumour microenvironment is currently 






Figure 1.2 Schematic diagram of the CLL Microenvironment. 
Schematic showing cross-talk between CLL cells and the microenvironment in secondary lymph nodes. CLL cells have B-cell 
receptor (BCRs) which respond to soluble antigen or cell surface antigens. This in turn activates BCR signalling which activates 
kinases such as spleen tyrosine kinase (SYK), Bruton tyrosine kinase (BTK) and PI3K. This signalling activates chemokine 
receptors such as CXC-chemokine receptor 4 (CXCR4) and CXCR5 and adhesion molecules (integrins). Activated T cells 
promote growth of CLL cells by CD40 ligand (CD40L)- CD40 receptor linkage. Nurse-like cells (NLCs) express B cell-activating 
factor (BAFF) and a proliferating-inducing ligand (APRIL) which activate receptors on the CLL cell. BAFFR, B cell-activating 
factor receptor; BCMA, B cell maturation antigen; CCR, CC-chemokine receptor; TACI, transmembrane activator. Schematic 
diagram adapted from a review by Burger and Wiestner (2018). 
  
1.2.5.1 Hypoxia 
In solid tumours, the vasculature becomes insufficient when its diameter grows more than 2mm, 
resulting in a local hypoxic (oxygen concentration <3%) and anoxic condition (oxygen concentration 
<0.1%) (Yang et al. 2015). Evidence has shown that 50-60% of tumours grow under hypoxic conditions 
(Yang et al. 2015). Metabolism is very high in areas of tumour growth and so the demand of oxygen 
would outweigh the supply of oxygen, thus causing hypoxia (Henze & Mazzone 2016; Petrova et al. 
2018; Yang et al. 2015).  
Hypoxia induces a wide range of biological changes, such as decreased cell proliferation, increased 
expression of drug-resistance genes, selection of apoptosis-resistant clones, facilitation of tumor 
invasion and metastasis, reduced expression of DNA repair genes and increased genomic instability 
(Kim et al. 2009). Preclinical evidence shows that hypoxia correlates with poor prognosis in solid 
tumors (Henze & Mazzone 2016; Kim et al. 2009).  
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The hypoxic response is to restore the oxygen availability and on the cellular level this is seen as 
induction of angiogenesis, metabolic reprogramming, proliferation, self-renewal and autophagy. 
However, all these processes are exploited to aid in tumor progression and metastatic dissemination. 
Oxygen deprivation contributes to a hostile microenvironment that selects for a more aggressive 
cancer phenotype (Henze & Mazzone 2016; Petrova et al. 2018). The hypoxic response is mediated 
by, among others, hypoxia-inducible transcription factors HIF1α and HIF2α (Henze & Mazzone 2016; 
Kim et al. 2009; Petrova et al. 2018; Serra et al. 2016). HIF activity switches the cell metabolism into 
glycolytic mode, increasing glucose consumption and pyruvate, lactate and H+ production (Petrova et 
al. 2018), thus creating a more acidic pH environment. 
The excessive release of angiogenic factors within the tumor microenvironment under hypoxic 
conditions results in a tortious vascular network that does not effectively restore the blood supply. In 
fact, an irregular vascular structure is formed and this further contributes to spatiotemporal changes 
in oxygen delivery. This leads to altering the phenotype of the tumors that may contribute to worse 
prognosis (Henze & Mazzone 2016). 
Hypoxic conditions cause only the most aggressive cells to survive these hostile growth conditions and 
driving tumor growth. Oxygen shortage results in electron leakage and formation of reactive oxygen 
species (ROS), which can oxidize proteins and cause DNA damage. The net outcome of this is the 
hypoxic cells experience genomic instability, which might further influence parameters to then 
accelerate malignant progression (Henze & Mazzone 2016). 
In CLL, high concentrations of ATP are present in the intracellular compartment, whereas low 
concentrations are typically available extracellularly (Serra et al. 2016). However, under conditions of 
increased cellular turnover and/or inflammation, such as those present in the tumor 
microenvironment, extracellular nucleotide levels can surge. ATP may then bind to specific receptors, 
which activate a signaling cascade, or it may be enzymatically converted to adenosine which is a 
potent immunosuppressant (Serra et al. 2016). 
In vivo evidence confirms that hypoxia acts partly though the activation of A2A adenosine receptor 
(ADORA2A) signaling (Serra et al. 2016). Although circulating CLL cells express active HIF-1α, its role in 
regulating CLL survival and its mechanism of action remain incompletely understood (Serra et al. 
2016). 
HIF-1α was found to be intensely positive in CLL lymph nodes (LNs) in areas corresponding to 
proliferation centers (Serra et al. 2016). HIF-1α expression was highest in CLL cells recovered from LNs 
compared to Peripheral Blood (PB) and Bone Marrow (BM) (Serra et al. 2016). 
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At 1% O2, purified cultured CLL cells didn’t change their HIF-1α expression at the mRNA level, but an 
upregulation of the protein was apparent (Serra et al. 2016).  
Expression of A2A adenosine receptor (ADORA2A) was markedly increased in hypoxic CLL cells. CLL 
cells adapt to hypoxia (Koczula et al. 2016; Serra et al. 2016) by upregulating HIF-1α signaling, in turn 
increasing nucleotide scavenging and activating adenosine signaling through the A2A receptor (Serra 
et al. 2016). 
When deprived of oxygen, tumor cells quickly promote energy production through glycolysis. This 
metabolic adaptation is transcriptionally mediated by HIF-1α. Under normoxia, CLL cells 
predominantly obtain energy through oxidative phosphorylation. However, at 1% O2, CLL cells 
markedly increased expression of genes involved in glycolysis (Koczula et al. 2016; Serra et al. 2016; 
Vander Heiden, Cantley & Thompson 2009). 
In summary, hypoxic conditions brought on by tumor cells in the microenvironments creates an acidic, 
vasculature deprived environment where the metabolic demand of oxygen outweighs the supply. This 
initiates the expression of HIF proteins which aides in adapting the CLL cells to sustain energy 
productions through means of aerobic glycolysis “Warburg effect”. 
 
1.2.5.1.1 Warburg Effect 
Briefly, aerobic glycolysis, also termed as Warburg effect, refers to the cells predominantly produce 
their energy through a high rate of glycolysis followed by lactic acid fermentation even in the presence 
of abundant oxygen (Vander Heiden, Cantley & Thompson 2009). 
In 1924, Otto Warburg’s observed cancer cells metabolize glucose in a manner that is distinct from 
that of cells in normal tissues (Vander Heiden, Cantley & Thompson 2009). He found that unlike most 
normal tissues, cancer cells tend to “ferment” glucose into lactate even in the presence of sufficient 
oxygen to support mitochondrial oxidative phosphorylation (Vander Heiden, Cantley & Thompson 
2009). It was originally hypothesized by Warburg that cancer cells develop a defect in mitochondria 
that leads to impaired aerobic respiration and a subsequent reliance on glycolytic metabolism. 
However, subsequent work showed there was no impairment of mitochondrial function in most 
cancer cells (Vander Heiden, Cantley & Thompson 2009). 
Cells that are deficient in ATP often undergo apoptosis. Normal proliferating cells can also undergo 
cell cycle arrest and reactivate catabolic metabolism when their ability to produce ATP from glucose 
is compromised, and signaling pathways exist to sense energy status (Vander Heiden, Cantley & 
Thompson 2009). During growth, glucose is used to generate biomass as well as produce ATP. One 
10 
 
glucose molecule can generate up to 36 ATPs, or 30 ATPs and 2 NADPHs (if diverted into the pentose 
phosphate shunt). The conversion of both glucose and glutamine to lactate involves the enzyme 
lactate dehydrogenase (LDH), where inhibiting this enzyme activity impairs cell proliferation. The 
excess generation of lactate that accompanies the Warburg effect would appear to be an inefficient 
use of cellular resources (Vander Heiden, Cantley & Thompson 2009). 
Although tumor hypoxia is clearly important for other aspects of cancer biology, the available evidence 
suggests that it is a late-occurring event that may not be a major contributor in the switch to aerobic 
glycolysis by cancer cells (Vander Heiden, Cantley & Thompson 2009). 
Although, when oxygen was available, the tricarboxylic acid (TCA) cycle appeared to be supported by 
glutaminolysis as evidenced by consumption of glutamine and O2, associated with the production of 
glutamate, pyruvate, lactate and alanine. Hypoxia induced HIF-1α activity acts to sustain glycolysis, as 
CLL cells transit from oxygenated to hypoxic environments and that lactate production is largely 
mediated by the consumption of glucose (Koczula et al. 2016). 
HIF-1α independently differentiates utilization of pyruvate in oxygenated and hypoxic conditions. 
When oxygenated, CLL cells exported pyruvate but as oxygen concentration dropped below 1%, CLL 
cells imported pyruvate. This pyruvate import is in response to hypoxia-associated oxidative stress 
rather than hypoxia per se, as CLL cells imported pyruvate when treated with H2O2 (which induced 
oxidative stress) under normoxic conditions (Koczula et al. 2016). 
In summary, Warburg effect is observed in CLL cells by HIF-1α activity that permits glycolysis through 
multiple sources of energy when in hypoxic or anoxic conditions within the tumor microenvironment. 
This is also seen in other cancer conditions particularly solid tumors. 
 
 
1.2.5.2 T cells 
The interactions between CD40 from B cells and CD40 ligand (CD40L) on activated T cells, are 
important in the antigen presentation and initiating normal B-cell responses (Ten Hacken & Burger 
2015; van Kooten & Banchereau 2000). In CLL, the T cells display impaired immunological synapses 
(Ramsay et al. 2012; Ramsay et al. 2008). This is viewed as an impaired T cell cytoskeletal 
rearrangement compared to that expected from non-CLL T cells and antigen presenting cells (APC) in 
order to proliferate and produce interleukin 2 (IL-2) (Ramsay et al. 2008). It is understood as chronic 
activation and ‘exhaustion’ of the T-cells is due to the CLL cells (Choi, Kashyap & Kumar 2016). It has 
been shown that activation of malignant B cells by CD40 ligation promotes survival of CLL cells (Kitada 
et al. 1999). CLL cells express high level of programmed cell death protein 1 ligand (PD-L1) 
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(McClanahan et al. 2015). Thus, interrupting the programmed cell death protein 1 (PD-1) and the PD-
L1 axis can restore immune functions and inhibits CLL development in a mouse model of CLL 
(McClanahan et al. 2015). Taken altogether, these reports suggest that T cells have reduced activity, 
which may explain the evasion of CLL cells from immune-mediated cell death (Ten Hacken & Burger 
2015).  
Similar to T-cells, Natural killer cells (NK cells) have an immune dysfunction with defective actin 
polymerization and impaired immune synapse formation (Choi, Kashyap & Kumar 2016; Maki et al. 
2008).  
 
1.2.5.3 Stromal Cells 
There are multiple cell types involved in forming the tumour stroma within the tumour 
microenvironment (Yang et al. 2015). Mesenchymal stromal cells (MSCs) such as bone marrow stromal 
cells (BMCs) are ‘feeder’ layers for hematopoietic progenitor cells and take part in normal bone 
marrow architecture (Yang et al. 2015). The BMCs have been shown to protect CLL cells from 
spontaneous and drug-induced apoptosis via direct contact (Kurtova et al. 2009; Lagneaux et al. 1998; 
Ten Hacken & Burger 2015). BMCs also secrete chemokines which regulate CLL cell trafficking and 
tissue homing and also provide additional signs that support their survival and encourage drug 
resistance (Burger et al. 2009a). BMCs were found to reduce the expression of CD20 on CLL cells which 
may implicate resistance to anti-CD20 antibody treatment (rituximab) (Marquez et al. 2015). Other 
studies have suggested promotion of cell survival and drug resistances by BMCs through the 
involvement of NOTCH signaling, protein kinase C beta II (PKCβII) expression and NF-ĸB pathway 
activation (Jitschin et al. 2015; Lutzny et al. 2013).  
Ding et al. (2010) showed that CLL induces proliferation and induction of PI3K signaling by activating 
BMSC through platelet-derived growth factor (PDGF) receptor activation (Choi, Kashyap & Kumar 
2016; Mangolini & Ringshausen 2020). 
A cross-talk between CLL and stromal cells have also been suggested by the secretion of microvesicles 
by CLL that activate AKT pathway in BMCs (Choi, Kashyap & Kumar 2016; Ghosh et al. 2010). 
It was seen that in CLL, the BMSCs take up the amino acid cystine which is then converted to cysteine 
and released into the microenvironment, which becomes available for the CLL cells (Zhang et al. 2012). 
This metabolic remodeling promotes CLL cells viability and drug resistance (Mangolini & Ringshausen 




1.2.5.4 Endothelial cells and follicular dendritic cells 
Endothelial and follicular dendritic cells (FDCs) are essential for tissue homing and retention of CLL 
cells to tissues (Ten Hacken & Burger 2015). The adhesion to the endothelial cells promotes survival, 
activation and drug resistance of CLL cells (Badoux et al. 2011; Hamilton et al. 2012). CLL cells can bind 
to integrins and BAFF and APRIL that are expressed on the surface of endothelial cells (Cols et al. 2012). 
The endothelial cells help promote CLL-cell survival and resistance to drug-induced apoptosis (Ten 
Hacken & Burger 2015). It was also shown that in vitro FDCs delays spontaneous apoptosis of CLL cells 
by direct contact via CD44 ligation and upregulation of the myeloid cell leukemia 1 (MCL-1) protein 
which is a member of anti-apoptotic proteins of the BCL2 family (Pedersen et al. 2002). 
It was seen that CD27 influences CLL binding to stroma, where its expression is correlated with ZAP-
70 expression, elevated on BCR cross-linking and correlates with functional ability to adhere to stromal 
cells. Antibody blockade of CD27 was shown to impair binding of CLL cells to the stroma (Choi, Kashyap 
& Kumar 2016; Lafarge et al. 2015). 
 
1.3 Nurse Like Cells: A history 
As nurse like cells (NLCs) are essentially the macrophages derived from the circulating monocytes, I 
would like to introduce general biological aspects of macrophages first. 
 
1.3.1 Macrophages: A spectrum 
Macrophages can be of circulating monocyte origin, or originating from tissue resident monocytes. 
The blood monocyte is a motile cell that can migrate alone vessel walls and has the ability to adhere 
to surfaces. The monocytes respond to inflammation and chemotactic stimuli by diapedesis 
(movement through intact walls of capillaries) into inflammatory sites, where they mature into 
macrophages, with greater phagocytic ability and increased composition of hydrolytic enzymes 
(Lichtman et al. 2011a). Classic studies in the 1930s and 1940s showed that monocytes transform into 
macrophages in vitro. Macrophages can be produced from monocyte culture with cytokines such as 
granulocyte-macrophage colony-stimulating factor (GM-CSF) or macrophage-CSF (M-CSF) (Lichtman 
et al. 2011a). Macrophages are characterized by increased cell size and increase in the number of 
cytoplasmic granules, in heterogeneity of cell morphology and in the number of cytoplasmic clear 
vacuoles (Lichtman et al. 2011a). 
Macrophages exist in either M0 (immediately differentiated from monocytes), M1 (tumoricidal) or M2 
(tumorogenic) phenotype along the M1/M2 spectrum (Figure 1.3) (Italiani & Boraschi 2014; Murray 
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et al. 2014). Their position on the spectrum depends on the type of stimuli monocytes received and 
how they respond to the stimuli (Figure 1.3). On one end of the spectrum are the M1 macrophages 
and on the opposite end are the M2 macrophages.  Therefore, a newly differentiated monocyte first 
appears to be in the middle of the macrophage spectrum (M0), displaying neither M1, nor M2 
phenotypes. Upon further stimulation, the same macrophage moves towards either end on the 
spectrum. Process of the differentiation of a macrophage to the extreme ends is also known as 
polarisation. 
 
Figure 1.3 M1 and M2 macrophages 
 
 
1.3.1.1 M1: The Classically Activated Macrophage 
The major function of naive macrophages is clearance of apoptotic debris produced as part of the 
normal cellular process of homeostasis. In response to various endogenous signals, macrophages 
produce pro-inflammatory mediators and alter surface markers (Figure 1.3) (Tan et al. 2016).  Classical 
M1 and M2 macrophages: the extremes of a continuum. Macrophage activation is associated with changes in gene 
expression profiles where exposure to different stimuli induces distinct polarization profiles, associated with expression 
of selected molecules. Classical macrophage activation (M1 macrophage) is induced by exposure to IFN-γ and LPS (red). 
Alternative activation (M2 macrophage) can be induced by different stimuli such as IL-4 and IL-13 (induce M2a yellow), 
immune complexes (IC) + LPS (induce M2b magenta), and IL-10 (induce M2c green). IL-4 + IL-13 or IL-10 induce both M2a 
and M2c (blue). Abbreviations: IFN-γ, interferon gamma; IL-1 ra, IL-1 receptor antagonist; LPS, lipopolysaccharide; MR, 
mannose receptor; RNI, reactive nitrogen intermediates; ROI, reactive oxygen intermediates; TLR, Toll-like receptor. 
Image is modified from a review by Mantovani et al. (2004). 
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M1 activation is induced by intracellular pathogens, bacterial cell wall components such as 
lipopolysaccharide (LPS), Th1 (type 1 helper T cells) cytokines such as interferon gamma (IFN-γ) and 
tumour necrosis factor alpha (TNF-α) (Jablonski et al. 2015; Roszer 2015; Zhang et al. 2013). These 
polarized M1 macrophages harbour immune-stimulatory properties and cytotoxic function against 
tumour cells (Zhang et al. 2013). 
M1 macrophages are characterized with inflammatory cytokine secretion and production of nitric 
oxide (NO), resulting in an effective pathogen elimination mechanism (Jablonski et al. 2015; Roszer 
2015). Besides, M1 macrophage is associated with higher aerobic glycolysis and extracellular 
acidification rate; increase of HIF-1𝛼 further enhances IL-1𝛽 promoter activity, thus maintaining IL-1𝛽 
production in M1 macrophages (Tan et al. 2016).M0-type macrophages are induced to polarize into 
M1 macrophages by LPS and IFN-γ, causing the cells to flatten to a round, pancake-like shape within 
24h of stimulation (McWhorter et al. 2013).  
As macrophage display a spectrum of phenotypes in vivo, it is not easy to distinguish macrophage 
phenotypes (Jablonski et al. 2015). Using expression profiling data, a study has found that as a result 
of different activation stimuli, M1 and M2 macrophages co-expressed many genes, referred to as 
shared signatures (Jablonski et al. 2015). Moreover, the same study also identified several distinct 
genes exclusively expressed in M1 macrophages, namely CD38, Gpr18 (G-protein coupled receptor 
18) and Fpr2 (formyl peptide receptor 2) and established them as novel M1 markers (Jablonski et al. 
2015). 
 
1.3.1.2 M2: The Alternatively Activated Macrophage 
Alternative M2 activation is induced by fungal cells, parasites, immune complexes, complement, 
apoptotic cells, macrophage colony stimulating factor (M-CSF), interleukin-4 (IL-4), IL-13, IL-10, 
tumour growth factor beta (TGF-β) and various other signals (Figure 1.3) (Jablonski et al. 2015; Roszer 
2015). 
Innate immune cells such as basophils and mast cells and other adaptive cells produce IL-4 and IL-13, 
priming M2 alternative phenotype (Tan et al. 2016). IL-4-induced M2 macrophages expressed high 
concentration of IL-10, decoy receptor IL-1R, IL-1R antagonist, chemokines CCL22 and CCL17, and 
intracellular enzyme arginase-1 (Figure 1.3) (Tan et al. 2016). All of these result in the recruitment and 
activation of Th2 immune response and immune-suppressive function of M2 macrophages. In addition 
to Th2 immune response, IL-4-induced macrophages stimulate arginase activity by converting arginine 
to polyamines and collagen precursors for tissue modelling and wound healing (Tan et al. 2016) . M2 
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macrophages also produce VEGFα, EGF, and IL-8 that are responsible for angiogenesis and lymph-
angiogenesis (Tan et al. 2016) . 
Apart from IL-4-induced phenotype, different schemes of M2 macrophages classification have been 
proposed due to the overlapping properties of alternatively activated macrophages. The activation of 
M2 macrophages stimulated by addition of either IL-4 and IL-13, TGF𝛽, immune complexes, 
glucocorticoids, or IL-10 may yield distinct activation profiles (Tan et al. 2016) . This gives a series of 
subtypes of M2 macrophages depending on how they were activated (Figure 1.3). The changes in 
shape of M0-type macrophages when induced to polarize into M2 macrophages with IL-4 and IL-13 
was seen to be elongation of the cell (McWhorter et al. 2013). 
M2 macrophages have high phagocytosis capacity, producing extracellular matrix (ECM) components, 
angiogenic and chemotactic factors and IL-10 (Jablonski et al. 2015; Roszer 2015). In addition to 
pathogen defence, they also clear apoptotic cells, mitigate inflammatory response, and promote 
wound healing (Jablonski et al. 2015; Roszer 2015). These anti-inflammatory features aid in growth of 
tumour tissues.  
Cellular metabolism especially lipid metabolism also plays an important role in providing energy fuel 
for activation of alternative M2 macrophages. As opposed to M1 classical activation, M2-regulated 
gene transcription occurs in conditions favouring mitochondrial metabolism and oxidative glucose 
metabolism, in which the M2 phenotype tends to be switched towards anti-inflammatory state under 
low oxygen condition (Tan et al. 2016). This suggests that hypoxic conditions are favourable for M2 
macrophages to thrive. 
In a study analysing the expression profiling data, described earlier, authors also found several distinct 
genes highly expressed in M2 macrophages, including Egr2 (early growth response 2) and c-Myc and 
suggested that they can be used as novel M2 markers (Jablonski et al. 2015). 
 
1.3.2 Tumour Associated Macrophages (TAM) 
Macrophages represent up to 50% of the tumour mass (Solinas et al. 2009) and they have an important 
role to play. Tumour associated macrophages (TAMs) are macrophages expressing M2 phenotype and 
display mainly anti-inflammatory, pro-tumoral properties that promote tumour cell survival, 
proliferation and spread (Mantovani et al. 2002; Solinas et al. 2009).  
The presence of TAMs is not always correlated with bad prognosis, but studies have shown a link 
between their abundance and the process of metastasis (Mantovani et al. 2017; Solinas et al. 2009). 
TAMs have been considered to originate from the cells in circulation, recruited by tumour and non-
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tumour cells in the tumour microenvironment by the release of chemotactic signals (Mantovani et al. 
2017). Monocyte differentiation is influenced by their position relative to the tumour mass by an IL-
10 gradient, where this prevents formation into dendritic cells and is encouraged to differentiate into 
macrophages (Allavena et al. 1998). One hallmark of TAM is their tendency to accumulate into necrotic 
regions of tumours, characterized by low oxygen tension (Solinas et al. 2009). This preferential 
localization is regulated by tumor hypoxia, which induces the expression of hypoxia inducible factor 1 
(HIF-1)-dependent molecules (vascular endothelial growth factor VEGF, C-X-C motif chemokine 12 
CXCL12, and its receptor C-X-C chemokine receptor type 4 CXCR4) that modulate TAM migration in 
avascular regions (Solinas et al. 2009). TAMs also display immune suppressive activity by producing IL-
10 and secretion of chemokines that attract naïve T cells in the microenvironment (Solinas et al. 2009). 
TAMs have been shown to be present in solid tumour types, such as in breast, prostate, Ovary, cervix, 
stomach, lung, bladder, and glioma (Bingle, Brown & Lewis 2002a). In solid tumours they also provide 
pro-survival conditions to the tumour cells and allow their proliferation (Mantovani et al. 2017).  
TAMs have also been isolated from the peripheral blood, spleen, and lymph nodes in CLL patients 
where they have shown to be essential for CLL cell survival in the tumor microenvironment (Edwards 
et al. 2018). Nurse-like cells (NLCs) or lymphoid-associated macrophages (LAMs) in CLL, share a similar 
gene expression profile to TAMs derived from other tumor types (Mantovani et al. 2017; Ysebaert & 
Fournie 2011). From this point onwards, TAMs and NLCs will be used interchangeably with NLC 
referring specifically to CLL. 
 
1.3.3 Nurse-Like Cells: Origin 
Nurse-like cells were first recognized in situ in the thymus, where they form characteristic complexes 
with immature T lymphocytes and play an important role in thymocyte maturation and differentiation, 
and the interaction is thus characterized by invasion into thymic nurse cells by thymocytes 
(emperipolesis) (Burger et al. 2000). 
In CLL, leukemic B-cells were observed to crawl under these supporting cells but not become 
internalized. Therefore, this process is pseudo-emperipolesis, and the supporting cells are termed 
nurse-like cells (NLCs) with the initial characteristics of interacting physically with CLL cells and 




1.3.4 Initial characterisations of NLCs 
In the initial study, immunophenotyping of the NLCs was also performed, which showed that these 
cells express cell markers vimentin, STRO-1 (a mesenchymal stem cell marker) and CD68 (Burger et al. 
2000). They do not express B-cell nor T-cell differentiating markers or CD83 (a marker for mature 
dendritic cells) (Burger et al. 2000). Strikingly, the morphology and immunophenotype of adherent 
cells derived from the peripheral blood of healthy donors were different to the adherent NLC from 
CLL blood samples (Burger et al. 2000). 
Vimentin, encoded by VIM gene for intermediate filaments and mediating changes in cell shape, is 
involved in motility and adhesions, as well as cytoskeletal interactions (Mendez, Kojima & Goldman 
2010; Stelzer G et al. 2016).  
CD68 (a member of lysosome-associated membrane proteins) is highly expressed on monocytes and 
macrophages (Stelzer G et al. 2016), suggesting that the adherent NLC cells are from myelomonocytic 
lineage.  
Also, the study investigated if trisomy 12 can be detected in the NLCs as some blood samples used in 
the study were obtained from patients whose CLL cells contained Trisomy 12. The study showed no 
observation of trisomy 12 in ‘an overwhelming majority of NLCs from the same patient’ (Burger et al. 
2000). This suggests that NLC and CLL populations do not share the same chromosome defect, thus 
proving that NLC are not part of the CLL clone (Burger et al. 2000). 
NLCs were found to express mRNA for stromal derived factor-1 (SDF-1), also known as C-X-C motif 
chemokine 12 (CXCL 12), which is a potent chemo-attractant for CLL B cells and mediator in their 
interaction with bone marrow stromal cells (Burger et al. 2000). Synthetic SDF-1 alone was also shown 
to be capable of rescuing CLL B cells from apoptosis (Burger et al. 2000). 
A more in-depth study investigating distinctive features of these nurse-like cells in CLL was carried out 
later on. It was shown that one to two weeks after culturing blood mononuclear cells on plastic culture 
plates, NLCs formed a ‘sparse monolayer of large, round, and sometimes bi-nucleate cells’, where 
clusters of CLL B cells were attached around these NLCs (Nobuhiro Tsukada 2002). 
It was also shown on flow cytometry analysis that NLCs typically had a larger forward and side scatter 
properties than CLL cells (indicating larger cell size of NLCs) (Tsukada et al. 2002). They expressed 
CD14, CD45 and HLA-DR but not CD3. This suggests that NLCs express surface markers of 
hematopoietic cells and surface antigens consistent with blood monocytes (Nobuhiro Tsukada 2002). 
NLCs also expressed CD33 which has been known to be expressed on cells of myelomonocytic lineage 
that may facilitate cell-cell adhesion (Nobuhiro Tsukada 2002). 
18 
 
Collectively, the above findings show that NLCs are derived from blood monocytes, however, the 
expression levels of CD14 and CD33 in these cells are significantly lower than typical monotypes 
(Tsukada et al. 2002). Meanwhile, NLCs express higher levels of CD68 than blood monocytes, 
macrophages, or monocyte-derived dendritic cells (Nobuhiro Tsukada 2002). 
To confirm that NLCs were derived from blood monocytes, the authors further showed that CLL PBMCs 
depleted of CD14+ cells (monocytes/macrophages) did not develop NLCs when cultured under the 
identical conditions (Tsukada et al. 2002). Also, PBMCs cultures depleted of CD2 (T cells/NK cells) 
developed NLCs of similar appearance to the unsorted PBMC culture (Nobuhiro Tsukada 2002). 
However, the exact duration and date of culture when comparisons were made was not provided. 
A thorough antigen profile revealed that NLCs expressed significantly higher CD68 and lower CD33 
than any other cells (Nobuhiro Tsukada 2002). Monocyte-derived dendritic cells expressed 
significantly higher levels of CD1a, CD40, CD80 and CD86 than NLCs (Nobuhiro Tsukada 2002). 
Interestingly, it was shown in the study that CD14+ cells from PBMCs of healthy donors can also 
differentiate to NLCs (based on morphology, phenotype and function) when co-cultured with CLL cells 
(Nobuhiro Tsukada 2002). However, NLCs derived from PBMC of CLL patients expresses a greater level 
of CD68 than those from healthy donors. 
Using a trans-well membrane separating CD14+ cells from CLLs, it was shown that NLCs were not 
developed (levels of expression of CD14 and CD33 were similar to CD14+ mononuclear cells cultured 
alone), suggesting that direct contact of CD14+ cells with CLL cells is needed to develop NLCs 
(Nobuhiro Tsukada 2002). 
Finally, to test if NLCs exists in vivo, CD14+ splenocytes from CLL patients were examined and shown 
to display NLC morphological features and express higher levels of CD68 than CD14+ splenocytes 
obtained from patients without CLL (Nobuhiro Tsukada 2002). 
Some studies reported a link between elevated peripheral blood monocyte count at the time of 
diagnosis in patients with CLL and poor clinical outcomes (Edwards et al. 2018; Friedman et al. 2016). 
It is thus speculated that high number of monocytes could lead to high number of NLCs, resulting in a 
more protective tumor microenvironment. However, the exact relationship between the number of 




1.3.5 Biological functions of NLCs 
1.3.5.1 Protection of CLL cells against spontaneous and drug-induced apoptosis when in co-culture 
In the early 2000s, in-vitro coculture with marrow stromal cells was found to have prolonged the 
viability of CLL cells when compared to CLL cells cultured alone (Burger et al. 2000). Adherent cells 
(nurse-like cells) were found to be present in such cultures after 3 days of culture and their numbers 
increased with time in culture (Burger et al. 2000). After separating the CLL cells from NLCs after 14 
days, the CLL cells displayed decline in viability (Burger et al. 2000). The proof of apoptosis was the 
reduction in mitochondrial membrane potential (Burger et al. 2000). To further prove the effect of the 
NLCs, the CLL cells were re-plated onto them and their viability was stabilised over time compared to 
their counterparts cultured alone which continued a decline in viability (Burger et al. 2000). This 
phenomenon was confirmed in other studies (Burger et al. 2005; Nishio et al. 2005; Tsukada et al. 
2002).  
When cultured with NLCs, CLL cells were found to be less sensitive to dexamethasone and 
chlorambucil compared to CLL cells cultured alone (Filip, Cisel & Wasik-Szczepanek 2015). It was also 
shown that the NLCs protected CLL cells from spontaneous and drug-induced apoptosis by 
fludarabine, cladribine, methylprednisolone, bortezomib, valproic acid and flavopiridol (Burger et al. 
2005; Fiorcari et al. 2016; Stamatopoulos et al. 2012). Therefore, there were clear evidence that NLCs 
can have cytoprotective effect on CLL cells when they were cultured together. However, how NLCs 
exert such effect on CLL cells is not well understood. 
 
1.3.5.2 Effect of NLC on expression of IgM and IgD on CLL cells 
Recently it was shown that NLCs cause a significant downregulation of surface expression of IgM and 
IgD on CLL cells when cultured together (Ten Hacken et al. 2016) . The expression of surface IgM and 
IgD recovered during 72hrs in culture in the absence of NLC, which resembles the recovery pattern of 
BCR in CLL cells when cultured in vitro in the absence of antigenic stimulation (Ten Hacken et al. 2016). 
It was postulated that NLC can present yet to be identified antigens that can trigger BCRs in CLL cells, 
resulting in down-modulation of both IgM and IgD. Although it was challenging to investigate BCR 
signaling responses with this coculture system, these data suggested that IgM and IgD may both be 
engaged and involved in activating BCR signaling in CLL cells when in coculture with NLC (Ten Hacken 
et al. 2016). 
 
1.3.5.3 Effect of CLL on NLC 
CD14+ monocytes co-cultured with CLL cells developed large, adherent  cells with cell morphology 
typical of NLCs (Nobuhiro Tsukada 2002). These cells also expressed higher level of cytoplasmic CD68, 
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when compared with CD14+ monocytes cocultured with the CD19+ cells of healthy donors (Tsukada et 
al. 2002). This indicates that CLL cells can also influence the differentiation of CD14+ monocytes into 
NLCs in vitro. 
The above finding has been confirmed by a separate study where CD14+ monocytes co-cultured with 
CLL cells displayed more characteristic features of NLCs than their counterparts co-cultured with non-
malignant B cells (Bhattacharya et al. 2011). Furthermore, CLL cells induced significant changes in 
expression of proteins involved in antigen presenting and immunity pathways in CD14+ cells. It was 
shown that NLCs had reduced levels of lysosome activity and decreased expression of CD74 and HLA-
DR in-vitro while expression of FCGR2B was increased (Bhattacharya et al. 2011). FCGR2B is an 
important inhibitory Fc-gamma receptor present on macrophages and immature dendritic cells that 
down-regulates the process of internalization (phagocytosis) (Bhattacharya et al. 2011). This in-vitro 
study suggests that CLL cells may specifically down-regulate genes in NLCs that are involved in 
immunocompetence (Bhattacharya et al. 2011). 
 
1.3.5.4 Commonalities and differences of TAMs in CLL and in other cancers 
Cancers that are not solid are generally grouped together as blood cancers and thus have differences 
in their disease presentation, pathology and progression. However, the tumor microenvironment 
within solid tumors provide the general protective function in a similar way to that in hematologic 
malignancies such as CLL disease (Petty & Yang 2019). 
It is known that macrophages infiltrate solid tumors and studies have shown that in human 
malignancies such as hepatocellular, colon, breast and lung carcinoma, poor prognosis is associated 
with high level of macrophage infiltration (Mantovani et al. 2017; Minami et al. 2018). Tumor 
associated macrophage (TAM) markers such as CD68 and CD163 have been measured to predict 
patient outcomes after chemotherapy for cancers such as follicular lymphoma, Hodgkin lymphoma, 
colorectal cancer and pancreatic cancer (Mantovani et al. 2017). Some studies have investigated role 
of TAM in these cancers using cell lines such as HepG2 (hepatoma cells) or A549 (lung adenoma cells) 
(Genin et al. 2015). 
In acute lymphocytic leukemia (ALL), it was seen that higher numbers of CD163 positive cells were 
correlated with poor prognosis (Petty & Yang 2019). Coculture with M2 macrophages in vitro induced 
cell proliferation of T-ALL cells (Petty & Yang 2019). 
In acute myeloid leukemia (AML), it was seen that the number of M2-like TAMs that expressed CD163 
CD206 was significantly increased in bone marrow (BM) compared to healthy donors (Petty & Yang 
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2019). The number of M2-like TAMs in spleen, but not in bone marrows, was correlated with poor 
prognosis in AML patients (Petty & Yang 2019). 
In Hodgkin’s lymphoma and non-Hodgkin’s lymphoma, the presence of CD68+ or CD163+ TAM is also 
a strong predictor of poor clinical outcome (Petty & Yang 2019). 
Therefore, there are many commonalities in the properties of TAM within tumor microenvironment 
between CLL and other cancers. As described in previous section 1.3.1, the research of NLCs in CLL is 
relatively new in comparison with research of TAMs in solid tumours. Even within the field of CLL 
research, other components of the CLL microenvironment (e.g. T cells and stromal cells) have been 
well characterized (Petty & Yang 2019). Therfeore, there are a need to inverstigate further the biology 
of NLCs in CLL, which will be the focus of this project. 
 
1.4 Molecules mediating interaction between NLCs and CLL cells 
1.4.1 CXCR4, CXCR5, CCL3, CCL4, CCL22 
While the cytoprotective effect of NLCs on CLL cells have been reported, the mechanisms mediating 
interaction between NLCs and CLL cells were also being investigated. It was thus shown that circulating 
CLL cells expressed high levels of the chemokine receptor CXCR4 (CD184), which mediates chemotaxis, 
migration across vascular endothelium, actin polymerization and migration under bone marrow 
stromal cells (BMSCs) in response to CXCL12 (SDF-1) (Burger 2011b). CLL cells in the tissue express 
lower levels of CXCR4 (Burger 2011b). The signalling of CXCR4 can be inhibited by PI3K-δ, SYK and BTK 
inhibitors (Burger 2011b). 
CXCR5 (CD185), the receptor for CXCL13, is also expressed on CLL cells, which regulates homing and 
positioning within lymphoid follicles. CXCL13 induces recruitment of naïve B cells into follicles and also 
induces activation via PI3K family of kinases. CXCL13 mRNA and protein are also expressed by NLC 
(Burger 2011b).  
CLL cells have been shown to secrete CCL3, CCL4 and CCL22, which are chemo-attractants for T 
lymphocytes as well as monocytes (Hartmann et al. 2016; Sivina et al. 2011; Zucchetto et al. 2009). 
The CLL cells also secrete CCL3 and CCL4 in response to BCR stimulation and in co-culture with NLCs 




1.4.2 BAFF and APRIL 
CLL cells express B-lymphocyte stimulator (BLyS), otherwise known as B cell-Activating Factor of the 
tumor necrosis factor (TNF) Family (BAFF) (Kern et al. 2004; Nishio et al. 2005). BAFF is a type 2 
transmembrane protein that exists as a membrane-bound or soluble form to promote B cell survival 
(Nishio et al. 2005). It was found in a mouse study that disruptive mutations of either BAFF or its 
receptor (BAFF-R) caused extensive loss of mature B-cells, suggesting that BAFF-BAFF-R interactions 
are important in the differentiation and/or survival of mature B cells. Other receptors were found to 
interact with BAFF, including B-cell maturation antigen (BCMA) and transmembrane activator and 
calcium modulator and cyclophilin ligand interactor (TACI) (Nishio et al. 2005). 
BCMA and TACI also can bind to A Proliferating Inducing Ligand (APRIL), a factor which can also 
contribute for the survival of B-cell survival (Nishio et al. 2005). BAFF-R is specific to BAFF and cannot 
bind to APRIL. APRIL was initially observed in tumor cells which was secreted as soluble molecule 
through the action of furin proteases present in the Golgi (Nishio et al. 2005). It was shown that CLL 
cells also express surface APRIL (Cols et al. 2012; Kern et al. 2004; Nishio et al. 2005). It has been 
reported that NLCs expressed high levels of BAFF and APRIL (Nishio et al. 2005). Viability of CLL cells 
was enhanced when BAFF and APRIL were added to the culture medium (Nishio et al. 2005). However, 
the viability was still not as high as that seen when CLL cells were cultured with NLCs (Nishio et al. 




In a recent study, it was shown that damage-associated molecular patterns (DAMP) molecule HMGB1 
(high-mobility group protein B1) was released from CLL cells and promoted the differentiation of NLCs 
(Li Jia 2014). HMGB1 is a DNA-binding protein and the HMGB1-DNA complex can trigger the immune 
response through the interaction with Receptor for Advanced Glycation End products (RAGE) and Toll-
like receptor 9 (TLR9) (Al-Malti, Gribben & Jia 2012; Li Jia 2014). 
In this study, HMGB1 was found in the nucleus as well as in the cytoplasm of CLL cells prior to its 
release. NLC differentiation in vitro was associated with HMGB1 release from CLL cells, whereas 
blockade of the HMGB1-RAGE/TLR9 signaling pathway prevented NLC differentiation (Li Jia 2014). 
Active release of HMGB1 was also observed in CLL lymph nodes where there was no necrotic cells 
detected (Li Jia 2014). Therefore, the authors concluded that the leukemic B cells were actively 




1.4.4 Nurse Like Cells and Hypoxia 
In a study to investigate the role of hypoxia in shaping the CLL lymph node microenvironment, a 
comparative analysis of the expression of ATP-metabolizing enzymes in NLCs uncovered a significant 
increase in expression of CD73 under hypoxia (Serra et al. 2016). CD73 is an ecto-5'-nucleotidase (5'-
NT), an enzyme which converts AMP to adenosine and is essential in generation of adenosine (Resta, 
Yamashita & Thompson 1998). Further analysis showed an increased adenosine accumulation in NLC 
cultures when exposed to extracellular AMP under hypoxia, which was not seen in their normoxic 
counterparts (Serra et al. 2016). Both mRNA and protein levels of adenosine A2A receptor were 
markedly increased in NLCs as well as in CLL cells under hypoxia condition. Increased adenosine 
production and signalling via the A2A receptor facilitated protection of CLL cells from drug-induced 
apoptosis and differentiation of monocytes from CLL PBMCs to M2 macrophages (Serra et al. 2016). 
In addition, a marked upregulation in CCL3 mRNA in NLCs was reported by the study, suggesting that 
differentiated macrophages upon hypoxia actively recruits myeloid cells. Also, optimal chemotaxis of 
normal monocytes toward conditioned media of NLCs cultured under hypoxia was observed. This 
chemotaxis was increased by A2A agonist and reduced by the antagonist (Serra et al. 2016). Finally, 
NLCs differentiated under hypoxia showed greater protection of CLL cells against cell death than those 
differentiated under normoxia (Serra et al. 2016). Therefore, the study showed that hypoxia can 
modulate the CLL microenvironment by activating adenosine signalling through the A2A receptor in 
both NLCs and CLL cells.  
 
1.4.5 Changes in molecular interactions by Lenalidomide 
Lenalidomide (Revlimid) is an immunomodulatory drug that has no direct cytotoxic effect on CLL cells 
(Chanan-Khan et al. 2011; Schulz et al. 2013). It was shown that levels of inflammatory cytokines were 
changed in patients treated with lenalidomide (Lee et al. 2011; Schulz et al. 2013). This drug was 
described to induce apoptosis in CLL cells indirectly via targeting components of the 
microenvironment (Schulz et al. 2013). A study was carried out to examine effect of lenalidomide on 
viability of CLL cells co-cultured with NLCs and reported that the mean survival rate of CLL was 
significantly reduced from 72% to 59.1% when lenalidomide was present (Schulz et al. 2013). However, 
the magnitude of response to this drug varied from patient to patient where some CLL samples even 
showed no reduction in viability of CLL cells when treated with lenalidomide (Schulz et al. 2013). 
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CCL2 (a chemokine that is involved in chemotactic activity for monocytes as well as differentiating to 
M2 type macrophages) is highly upregulated in monocytes after contact with CLL cells, was shown to 
be reduced after cultures were treated with lenalidomide (Schulz et al. 2013).  
IL-10 (an immunosuppressive cytokine) levels were shown to be increased in cultures treated with 
lenalidomide. It was shown to induce apoptosis in CLL cells via activation of STAT1 pathway (Schulz et 
al. 2013). The study also found that lenalidomide had no or minimal effect on the viability of CLL cells 
cultured alone, or that of monocytes and NLCs in culture (Schulz et al. 2013). Lenalidomide was also 
been shown to reduce migration capability of CLL cells in this study (Schulz et al. 2013). 
This suggests that some effects of lenalidomide extends to the monocytes via changes in  levels of 
CCL2 and to CLL cells via changes in levels of IL-10 and migration ability  (Schulz et al. 2013). 
 
1.5 Prognostic factors in relation to the Microenvironment 
A gold standard of prognostic marker is the mutational status of IGHV, which were first reported by 
by two independent groups (Hamblin et al. 1999; Damle et al. 1999). CLL cells with sequences in IGHV 
gene that are 2% or more non-homologous to that of the nearest germline are considered to have 
undergone somatic hypermutation (Ghia et al. 2006) (also known as M-CLL). Conversely, CLL cells 
having sequences of IGHV gene that are more than 98% homologous to that of the germline are 
considered to express un-mutated IGHV (also known as UM-CLL). Study conducted by Hamblin and 
colleagues showed that, regardless of clinical stage of the disease, the survival rate of patients with 
UM-CLL was significantly worse than those with M-CLL (Hamblin et al. 1999). In addition, work from 
Damle and colleagues showed that patients with UM-CLL had a higher percentage of CD38+ B-CLL cells 
(>30%) than patients with M-CLL and that those patients with UM-CLL and also having >30% CD38+ B-
cells did not respond well to chemotherapy drugs and their survival was shorter (Damle et al. 1999). 
Through in vitro experiments, it was shown that CLL cells from patients with UM-CLL are more likely 
to undergo rapid spontaneous apoptosis than CLL cells from patients with M-CLL (Coscia et al. 2011). 
This suggests that CLL cells with unmutated IGHV are more dependant on survival stimuli from the 
microenvironment than cells with mutated IGHV. 
ZAP70 expression has also been associated with poor prognosis of CLL (Crespo et al. 2003). It has been 
shown that ZAP70+ CLL B cells have stronger migratory ability and are characterized by a special gene 
signature associated with migration, homing or CXCR5/CXCL12 pathways (Dubois et al. 2020). 
Another prognostic marker for poor clinical outcome in CLL is the increased level of expression of CD38 
(Damle et al. 1999). It was shown that CLL cells with high expression of CD38, together with ZAP30, 
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had a greater migratory potential, which was associated with aggressive disease (Deaglio et al. 2007). 
It was suggested that the changes in expression of CD38 during the course of disease reflect the 
dynamic status of the stromal cell-CLL cell interactions in vivo (Dubois et al. 2020). 
Study by Herishanu et al. (2011) showed that levels of CCL3 and CCL4 were increased in CLL cells from 
bone marrow and lymph nodes (Herishanu et al. 2011). This increase is indicative of an in vivo 
interaction between CLL cells and NLCs as well as stromal cells (Dubois et al. 2020). 
Collectively, the prognostic markers mentioned above are associated with the in vivo interactions 
between CLL and the microenvironment, which highlight the importance of further research in 
understaning the the molecular mechanisms mediating the interactions between CLL cells and 
components of the microenvironment. 
 
1.6 Drug resistance: an area of unmet need  
Despite the advancement of our understanding of the biology of the disease and progress in 
development of new drugs, patients with CLL still develop relapsed disease even though they initially 
respond to treatment (Bakker et al. 2016). Drug resistance is thus still a serious clinical challenge in 
management of the patients with CLL.   
Advances in understanding the role of tumour microenvironment (TME) in leukaemia including CLL 
uncovered new therapeutic opportunities to target disease development and progression (Bakker et 
al. 2016; Woyach & Johnson 2015).  
The BTK inhibiter ibrutinib has been successfully developed to treat the patients with CLL as a result 
of better understanding of the interaction of CLL cells with the microenvironment. As described 
earlier, BCR signalling plays an important role in CLL cell survival and proliferaltion in response to 
antigen stimulation within the CLL microenvironment and BTK is a critical component of the BCR 
signalling complex  (Figure 1.2). Ibrutinib has been shown to reduce secretion of BCR-dependent 
chemokines (CCL3, CCL4) by the CLL cells, thus inhibiting chemoattraction of macrophages and T cells 
(Ponader et al. 2012). In the meantime, ibrutinib inhibited migration of CLL cells in response to tissue 
homing chemokines (CXCL12, CXCL13) secreted by T cells and macrophages (Niemann et al. 2016; 
Ponader et al. 2012). In patients on ibrutinib treatment, it has been shown that ibrutinib decreased 
overall T-cell numbers and disrupted the interaction between macrophages and CLL cells in the bone 
marrow (Niemann et al. 2016). Ibrutinib has also been shown to induce egress of CLL cells from the 
lymph nodes into the blood (Boissard et al. 2015b). Previous work from our Department has also 
shown that ibrutinib prevented CLL cells from entering into and retension within the lymph nodes by 
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inhibiting chemokine-induced integrin activation (Till, Pettitt & Slupsky 2015). Despite its impressive 
clinical activity, patients who fail to respond or relapse even after long periods of remission have been 
reported (Molica et al. 2020; Woyach & Johnson 2015). 
Meanwhile, due to the fact that CLL cells over-express anti-apoptotic protein BCL-2 for reasons  
described previously in section 1.2.4 and that overexpression of BCL-2 is associated with 
chemotherapy resistance and shortened overall survival in CLL patients (Kang & Reynolds 2009), 
intensive efforts have been put into developing a therapeutic agent to target BCL-2 in CLL.  Successful 
development of venetoclax, a small molecule inhibitor of BCL-2 (Souers et al. 2013), and its 
introduction into the CLL clinics have significantly improved the treatment of patients with CLL, 
particularly in those with refractory/relapsed disease or with defective p53 (Roberts et al. 2016). 
However, resistance to venetoclax has recently been reported (Blombery et al. 2019; Herling et al. 
2018). 
There are two main causes of drug resistance: intrinsic (i.e. mutations and defective activation of 
signalling pathways within cancer cells) and extrinsic (i.e. enhanced pro-survival signalling activated 
by certain components from the microenvironment) (Bakker et al. 2016). An example of intrinsic 
causes of resistance is seen in chronic myeloid leukaemia (CML) where mutations within the catalytic 
domain of ABL kinase render tyrosine kinase inhibitor imatinib ineffective as these mutations prevent 
binding of the imatinib to target effectively, resulting in drug resistance (Quintas-Cardama, Kantarjian 
& Cortes 2009).  
Drug resistance caused by extrinsic factors, also known as ‘environment-mediated drug resistance’, 
occur as a result of protective effect provided by the microenvironment (Bakker et al. 2016). An 
example of this was seen in CLL cells localised in lymph node microenvironment where CLL cells were 
exposed to varieties of pro-survival stimuli such as CD40 and/or BCR stimulation and expressed high 
levels of anti-apoptotic proteins such as MCL-1 and BCL-XL, resulting in resistance to venetoclax 
(Bojarczuk et al. 2016; Elías et al. 2018; Thijssen et al. 2015; Vogler et al. 2009; Woyach & Johnson 
2015) 
Drug resistance can also be acquired from continuous presence of the chemotherapeutic drug, which 
leads to genetic and epigenetic changes in the cells that cause resistance (Bakker et al. 2016). An 
example of this is where in CLL patients receiving ibrutinib treatment acquired mutations occurs on 
BTK at C481 which is the binding site of ibrutinib.  This leads to reduced binding affinity of ibrutinib for 
BTK, rendering ibrutinib ineffective (Woyach & Johnson 2015).  
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Regardless of what causes drug resistance, the outcome is the relapse of the disease following 
treatment (Woyach & Johnson 2015). Therefore, CLL is still an incurable disease. To improve the 
treatment of CLL, further research is required to better understand how drug resistance develop in 
the first place with the objective of developing a rational strategy for a therapeutic intervention to 




1.7 Hypothesis and Aim 
CLL is still an incurable disease and the microenvironment play an important role in disease 
progression and development of drug resistance. As described in the previous section 1.2.5, the CLL 
microenvironment comprises of CLL cells and a mixture of accessory cells including BMSCs, T cells, 
endothelial cells  and NLCs. Within the microenvironment, CLL cells interact with the various accessory 
cells. These interactions are believed to be bidirectional and CLL cells are actively involved in turning 
the surrounding into a supportive milieu, in favour of their survival and proliferation. NLCs is a major 
component of CLL microenvironment. However, molecular mechanisms mediating the interaction 
between NLCs and CLL cells are not yet fully characterised. I thus hypothesise that interactions 
between NLCs and CLL cells will activate certain pro-survival genes and pathways that are responsible 
for drug resistance. 
To test the hypothesis, I set out to address the following research questions: 
1. What are the optimum conditions to develop NLCs in vitro? 
2. What are the main biological effects of NLCs on CLL cells in co-culture? 
3. Whether the observed effects of NLCs on CLL cells can be reproduced using a cell line model? 
4. By applying the next-generation-sequencing technology (e.g. RNA-Seq), can I identify any 
previously unknown, differentially expressed genes in CLL cells following co-culture with NLCs 
that are associated with CLL-cell survival and drug resistance? 
The overall aim is to understand the molecular mechanisms mediating the interactions between NLCs 
and CLL cells at the transcriptional level with a particular emphasis on detecting changes in gene 








2.1.1 Collection of primary CLL cells 
2.1.1.1 CLL sample selection 
Blood samples from patients diagnosed with CLL were obtained with informed consent and with the 
approval of the Liverpool Research Ethics Committee (REC reference no. 06/Q1505/82). The diagnosis 
of CLL was based on the revised Rai and Binet staging systems, standard morphological and 
immunophenotypic criteria (Cheson et al. 1988; Kotiah 2019; Mir et al. 2019; Rai et al. 1975). All the 
CLL samples were collected and stored by the Liverpool Blood Disease Biobank (LBDB). As there was a 
lack of readily available bone marrow or lymph node material, only peripheral blood mononuclear 
cells (PBMCs) from patients with CLL were used in the study.  
 
2.1.1.2 Isolation of fresh CLL PBMCs 
PBMCs were isolated by centrifugation of blood from CLL patients over Lymphoprep® solution (Axis-
Shield PoC AS, Oslo, Norway), as indicated in Figure 2.1, as per LBDB protocol (see Appendix 7.14.1).  
 
 
Figure 2.1 Peripheral blood mononuclear cells (PBMCs) preparation 
Lymphoprep is added to the falcon tube in a volume ratio of 2:1 (blood to lymphoprep). Blood is gently poured on top (left). 
The tube is centrifuged at 800G for 30mins. The multiple layers are formed (right) at the end of centrifugation. The PBMC 
layer (highlighted in red) is collected using a sterile Pasteur pipette. This layer is then washed, resuspended in fresh complete 
medium and cell numbers counted on Cellometer. Some of the fresh CLL PBMCs are used for NLCs development experiments. 
Centrifuge at 800 G 












(Lymphocytes and Monocytes) 
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The rest of CLL samples was resuspended in ice-cold fetal bovine serum containing 10% DMSO and stored in the -150oC 
freezer in LBDB Biobank. 
 
After separation by Lymphoprep, CLL PBMCs were washed in fresh medium and resuspended in 100% 
Fetal bovine serum (FBS) with cell numbers countered using Cellometer. A portion of this fresh CLL 
PBMCs was used for the purpose of development of NLCs. These CLL samples were spun and 
resuspended in standard RPMI conditions, as described below. The remaining CLL PBMCs were 
resuspended in ice-cold FBS containing 10 % DMSO and stored in -150oC freezer in the LBDB Biobank. 
 
2.1.1.3 Thawing cryopreserved CLL PBMCs samples 
 Selected vials of cryopreserved CLL samples were thawed as per protocol from the LBDB Biobank (see 
Appendix 7.14.1) by adding complete RPMI 1640 medium supplemented with 100 U/mL penicillin, and 
100 μg/mL streptomycin, 2 mmol/L L-Glutamine and 10 % heat inactivated FBS (Life 
Technologies/Thermo Fisher Scientific, Paisley, UK). After recovery for 1 h in the incubator containing 
5% CO2 at 37oC, cell numbers and viability (Trypan blue exclusion) were then measured on Cellometer 
and the cell concentration was then adjusted according to the desired experiment. Clinical and 
laboratory characteristics of the CLL samples that I used in my study are summarized in Appendix Table 
7.1. 
 
2.1.2 Cell culture of primary CLL cells 
2.1.2.1 CLL cells cultured under standard conditions 
Primary CLL cells were maintained in RPMI-1640 medium supplemented with 10 % heat-inactivated 
fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin (Life 
Technologies/Thermo Fisher Scientific, Paisley, UK), in a 37°C, 5% CO2 humidified incubator. 
For development of NLCs, initial viability and cell count were measured by trypan blue exclusion using 
the automated cell counter (Nexcelom USA CellometerTM Auto T4 cell counter). Cells were cultured at 
a high density of 10 x 106/ml in RPMI medium in a 37oC incubator containing 5% CO2 for up to 14 days, 
with partial replacement of fresh medium on alternate days. In co-culture experiments (with NLCs or 





2.1.2.2 Development of nurse-like cells (NLCs) from primary CLL PBMCs 
To mimic the in-vivo interaction of NLCs with CLL cells in the lymph node microenvironment, NLCs 
were first developed from fresh CLL PBMCs for up to 14 days, as described earlier.  The CLL cells from 
the original fresh PBMC cultures were washed away by gently pipetting (to avoid disrupting the 
monolayer of NLCs). The monolayer was observed under microscope to ensure minimum number of 
CLL cells remaining on the surface of the plate. NLCs in such conditions were ready for co-culture 
experiments Autologous CLL cells were thawed and resuspended in fresh RPMI medium at a 
concentration of 3 x 106/ml which were then plated on the monolayer of NLCs and maintained at 37oC 
for an appropriate period of time. 
 
2.1.2.3 CLL cells co-cultured with NLCs 
Autologous CLL cells were thawed and resuspended in fresh RPMI medium at a concentration of 3 x 
106/ml which were then plated on top of the monolayer of NLCs and maintained at 37oC for an 
appropriate period of time. Care was taken in handling the plates during observations and partial 
replacement of medium to avoid dislodging monolayer of NLCs.  
At the end of co-culture, CLL cells were harvested by gentle pipetting. The plate was checked under 
the phase contrast microscope to ensure most of the CLL cells have been collected. The collected CLL 
cells were then counted and used for analysis such as apoptosis assay by flow cytometry. 
 
2.1.3 Cell culture of THP-1 cell line 
2.1.3.1 THP-1 cells cultured under standard conditions 
Human THP-1 cell line was obtained from European Collection of Authenticated Cell Cultures (ECACC 
88081201). THP-1 cells were maintained in complete RPMI as mentioned above and incubated in a 
37oC, 5% CO2 humidified Incubator. Similar to NLCs development as mentioned above, PMA-
differentiated THP-1 cell line was prepared in advance by allocating 5 x 105 cells/ml of THP-1 cells in 
complete RPMI medium, followed by polarizing to M1 or M2 macrophages as required (see details 
below). Once the monolayers were prepared and confirmed by microscopy, the supernatant was 
removed and the monolayer of THP-1-derived macrophages was washed gently with PBS before 




2.1.3.2 Induction of differentiation of THP-1 cells into macrophages 
2.1.3.2.1 THP-1 M0 
Adjusted to a cell concentration of 5×105 cells/ml in complete RPMI 1640 medium (as described 
earlier), THP-1 cells were treated with 5ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, 
Gillingham, UK) for approximately 2 days to induce differentiation into macrophages, as described 
(Daigneault et al. 2010; Park et al. 2007). 
The cells were checked under the light microscope and observed for formation of adherent 
macrophages, which was usually achieved after 24-48 h of incubation. These cells were generally 
considered as M0 macrophages (Daigneault et al. 2010; Park et al. 2007). 
 
2.1.3.2.2 THP-1 derived M1 macrophages 
Following differentiation of THP-1 cells to M0 macrophages, the supernatant was removed and 
replaced with complete RPMI medium with the addition of interferon-γ (IFNγ) (20ng/ml) (PeproTech 
EC Ltd, London, UK) and lipopolysaccharides (LPS) (Sigma-Aldrich) (10pg/ml) and incubated for 24 h, 
as described (Chanput, Mes & Wichers 2014; Jablonski et al. 2015; McWhorter et al. 2013; Park et al. 
2007). The polarisation into M1 macrophages was confirmed upon visualising a ‘large oval’ 
appearance under phase contrast microscope, which  was also confirmed later by 
immunophenotyping, as described (Chanput et al. 2013; Chanput, Mes & Wichers 2014; Genin et al. 
2015; Jablonski et al. 2015; McWhorter et al. 2013). 
 
2.1.3.2.3 THP-1 derived M2 macrophages 
Following differentiation of THP-1 cells to M0 macrophages, the supernatant was removed and 
replaced with complete RPMI medium with the addition of interleukin-4 (IL-4) (30 ng/ml) (R&D 
Systems, Oxford, UK) for 72 h with additional 30ng/ml IL-4 added at 48 h (without replacement of 
supernatant). This method was considered optimal after more elongated cells were observed with this 
method as compared to other variations (Chanput et al. 2013; Chanput, Mes & Wichers 2014; Genin 
et al. 2015; Jablonski et al. 2015; McWhorter et al. 2013). The total duration of incubation with IL-4 is 
72 h. 
 
2.1.3.3 CLL cells co-cultured differentiated THP-1 cells 
After THP-1 cells were differentiated into adherent macrophages with PMA, usually taking 24-48 h 
cryopreserved CLL cells from the Biobank were thawed and resuspended in complete RPMI medium 
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as per LBDB protocol (see Appendix 7.14.1 for detail). Cell count and viability were measured following 
staining cells with 0.1% Trypan blue dye on automated Cellometer (Nexcelom USA CellometerTM Auto 
T4 cell counter). CLL cells were then adjusted to 3 x 106/ml with complete RPMI medium and cultured 
alone or co-cultured with differentiated THP-1 cells. Before adding CLL cells to the monolayer of 
differentiated THP-1 cells, the culture medium of the THP-1 cells was fully removed and washed with 
fresh RPMI medium to remove any remaining PMA. CLL cells in suspension were then gently added 
onto the monolayer. 
Preparation of M1 (24hr incubation with IFNγ and LPS) or M2 macrophages (72 h incubation with IL-
4) from differentiated THP-1 cells also involved complete removal of culture medium of the THP-1 
cells in order to remove residual PMA before addition of the respective stimuli. Again, before adding 
CLL cells to the monolayer of M1 or M2 macrophages, the culture medium of these cells was fully 
removed and washed with fresh RPMI medium to remove any remaining respective stimuli. Table 2.1 
below provided a time plan when M0, M1 and M2 macrophages were prepared so that the co-culture 
experiments can start at the same time. 
Afterwards, the CLL cells on co-cultures or cultured alone were harvested for viability assays using 
Annexin/PI on FACS. 
Table 2.1 Timetable to prepare M0, M1 and M2 macrophage cultures 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Population Desired 
THP-1+ PMA  IL-4  IL-4 
Experiment 
M2 
  THP-1+ PMA  IFNγ + LPS M1 
   THP-1+PMA  M0 
 
2.1.3.4 Harvesting CLL cells from co-cultures with THP-1 cells derived macrophages 
Similar to harvesting CLL cells from NLCs co-cultures, CLL cells co-cultured with THP-1 cells derived 
macrophages were collected by gentle pipetting. To ensure that most of the CLL cells were harvested, 
the culture plates were checked under the light microscope. After which, the harvested cells were 
counted and cell viability was examined on FACS with Annexin V/PI staining. Since the THP-1 cells 
derived macrophages were larger than the CLL cells, a gating strategy was followed to ensure that only 
the CLL cell population was analysed.  
As seen in Table 2.1, M2 macrophages were prepared first since they took the longest time to differentiate (5 days). M1 
macrophages were then prepared afterwards (3 days) and M0 took the least time to be prepared (1-2 days). 
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2.1.4 Light Microscopy 
2.1.4.1 Basic principle 
A typical microscope that uses transmitted light to observe targets at high magnification. Generally, a 
slide is placed on a flat stage, held by stage clips where a light source is directed and intensity is 
adjusted using diaphragm and brightness knobs. The image is magnified and visualised using the 
objective lens as well as eye piece. A camera may be attached as well. The image is focussed using 
coarse or fine adjustment. 
The light microscope is often used to observe morphology of cells attached to slides which are stained 
with various dyes. 
 
2.1.4.2 Staining the peripheral blood mononuclear cells with Romanowsky stain 
May Grünwald Giemsa stain, a high quality Romanowsky stain (Hoffbrand, Moss & Pettit 2006; 
Lichtman et al. 2011b), was used with a phosphate buffer of pH6.8 for staining the cells cultured on 
slides after fixing them with absolute methanol.  
Romanowsky stains contain both acidic and basic dyes in an optimal proportion dissolved in acetone 
free absolute methanol. The acidic and basic dyes stain the different cellular components with 
different intensity, thus producing shades of colours to give a good differentiation. The slides can then 
be inspected under the light microscope for the study of morphology of the NLCs and CLL cells.  
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2.1.5 Fluorescence microscopy 
2.1.5.1 Basic principle 
Fluorescence microscopy is a tool mainly used to visually examine the cell physiology, in particular the 
dynamic details of cellular events (Sanderson et al. 2014). Like all techniques to visualise cells, 
fluorescence microscopy is subject to practical physical limitations, the most important of which is 
resolution (Sanderson et al. 2014).  Understanding the methods of microscope alignment, properties 
of light, wavelength selection, image recording techniques and image analysis all aid in achieving the 
best resolution of an image. 
The principle of fluorescence microscope is essentially the same as described in flow cytometry, in 
that it involves the absorption of light energy (photon) by an indicator followed by the emission of 
some of this light energy a few nanoseconds later. Some energy is lost in this process, the emitted 
photon has less energy than the absorbed photon (Sanderson et al. 2014). Generally, the excitation 
and emission wavelengths should be distinct. However, due to the broad spectrum of emission and 
excitation wavelengths, sometimes it can be difficult to monitor the different fluorophores because 
of spill-over of wavelengths from one fluorophore to the other (Sanderson et al. 2014). The preferred 
approach is to take separate sequential images with filters designed for each fluorophore, but some 
spill-over is still possible (Sanderson et al. 2014). 
A parallel beam of light simultaneously illuminates the whole specimen to excite the fluorophore(s) 
on the specimen (Sanderson et al. 2014). Care should be taken to minimize observation times and 
photo bleaching, where the area is illuminated but not captured, thus degrading the fluorophore due 
to prolonged exposure. This is why fluorescence microscopy is done in the dark. Auto-fluorescence 
occurs within cells as well as in whole tissues. It can interfere with imaging because it can mislead the 
observer into believing the fluorescent structure is related to the fluorophore conjugated anti-bodies 








Fluorescence microscopes are used to visualise cells following staining with specific fluorochrome-
conjugated antibodies. This technique can be used on tissue sections, cultured cell lines or individual 
cells. On viewing the slides, the distribution of cells, proteins, surface and intracellular markers can be 
analysed. The localization of the antigens of the cells can also be appreciated. Mixtures of cells can be 
distinguished and their physical characteristics can be appreciated in relation to each other. Multiple 
markers can be identified and overlapped to form an image that shows a complex representation of 
 
 
Cover slips are placed on the bottom of the culture plate wells (A), the cells are cultured as normally done (B). At the end of culture, 
the cover slips are removed carefully (C). The cover slips are placed on parafilm (D), fixed with absolute ethanol, blocked, incubated 
with antibodies by flipping the cover slip onto the droplet of the solutions (green arrow). Finally, the coverslip is placed on a droplet 
of mounting medium on a glass slide (E), to be stored in the dark at 4oC.  
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all the stained regions. Additionally, when compared with an isotype control, the intensity of the 
fluorescence can be measured (Waters 2009) using ImageJ software and this can give a semi-
quantitative assessment in the level of expression of the markers ('Quantification of Fluorescence 
Intensity of Labeled Human Mesenchymal Stem Cells and Cell Counting of Unlabeled Cells in Phase-
Contrast Imaging: An Open-Source-Based Algorithm'  2010). A protocol was developed for measuring 
fluorescence using ImageJ software and was used (Burgess et al. 2010; McCloy et al. 2014). 
 
2.1.5.3 Procedure 
The steps in immunofluorescence microscopy includes preparing the cell culture on circular cover slips 
(13mm diameter, Appleton Woods, Cat. No. MS002) that fit into 24-well culture plates represented in 
Figure 2.2, so that the cells remain adherent on it. The supernatant is gently pipetted and the cover 
slip is collected. The cells are then immediately fixed and permeabilised onto the surface. 0.1% sodium 
borohydride (NaBH4) is added to remove auto-fluorescence, the cells are blocked with donkey serum 
and Fc blocker to prevent non-specific binding. The cells are then incubated with the selected 
antibodies and counterstained with nuclear staining. The cover slip is gently mounted using a 
mounting medium on a pre-cleaned glass slide and left to dry in cold temperature (4oC), stored in the 
dark, as it is prepared for microscopy. 
When ready for microscopy, in the dark room the machine is switched on and warmed up. The lens is 
adjusted and with the viewing eye-piece, the cells are located and focused using the DAPI filter at low 
exposure. When satisfied with the field of view, the selection of filters is made and sequential photos 
are taken by the machine and overlapped using the machine software. The files are saved in a TIF 
format to be further analyzed using ImageJ software. 
Using ImageJ software, the control images are used to determine the appropriate viewing parameters 
to use on the test images. The intensity of the images is thus normalized with their control images. 





2.1.6 Flow cytometry 
2.1.6.1 Basic principle 
Flow cytometry is a technique that has long been considered as the useful tool in clinical diagnosis as 
well as  in research in the area of Haematology (Rane et al. 2017). Flow cytometry measures numerous 
characteristics of cells in liquid suspensions simultaneously in a quick and detailed form as they pass 
through a beam of light. Such examples of usage include immunophenotyping cells based on their 
surface markers to identify particular subsets of blood cells. 
Cells or particles between 0.2-150µm are suitable for analysis by most flow cytometers. One of the 
limitations of flow cytometry is the need for cells of interest to be in suspension and therefore any 
solid tissue cells would require disaggregating into suspension form in order to be analysed (Depince-
Berger et al. 2016). This would obviously affect the cell shape and there will also be loss of cells during 
the procedure, thus potentially introducing bias to the final results (Depince-Berger et al. 2016).  
Flow cytometers measures and analyses multiple physical characteristics of a single cell/particles They 
measure the relative size, relative granularity/internal complexity and relative fluorescence intensity 
of the cells or particles of interest (Depince-Berger et al. 2016; Rane et al. 2017).  
There are 3 main components of a flow cytometry: fluidics, optics and electronics. 
Fluidics are the transportation of the cells in a stream to the laser beam for interrogation. Optics 
consists of lasers to illuminate cells in the sample stream and optical filters to direct the resulting light 
signals to detectors. Electronics converts the detected light signals into electronic signals that can be 
processed by a computer. Additionally, if the machine can sort, it is capable of initiating sorting 
decisions based on the parameters given (Depince-Berger et al. 2016). 
In fluidics, there is hydrodynamic focusing which causes the individual cells to flow in a single file 
through a narrow tunnel, as seen in Figure 2.3. A higher sample pressure is used for more qualitative 
measurements, where there is increased flow rate and so more cells can pass through in a given time 
(Depince-Berger et al. 2016). 




Figure 2.3 Fluidics schematic of flow cytometry. 
Cell samples that are present in suspension are introduced in the collection column and hydrodynamically focused to a single 
file. The cells are then exposed to the laser light source on passing the channel and the resulting scatter of the light and 
fluorescence are detected by light detectors and converted in to electronic signals. Figure modified from abcam.com, using 
BioRender online tools. 
 
Fluorescent compounds absorb light energy and the electrons are raised to a higher energy level 
(excitation level) where when the electron returns to original state, photons of light are emitted 
(emission level) (Figure 2.4). An ideal experiment should ensure that the excitation and emission 
wavelengths of the chosen fluorochromes do not overlap one another (Figure 2.4). Alternatively,  a 
compensation tool is used  to remove the overlapped section, however, care should be given on the 




Figure 2.4 Excitation and Emission waves of the fluorochromes used in Flow Cytometry. 
The excitation of the fluorochromes are shown in dotted lines and the emission waves are the sold color lines. Each 
fluorochrome wavelength has a peak range which can be detected through certain filters, seen as rectangular bands. Figure 




Optics involve laser and lens to shape and focus the laser beam, these are known as excitation optics. 
Collection optics are those that collect the light emitted and optical mirrors and filters to route specific 
wavelengths of collected light to the designated optical detectors as seen in Figure 2.5 (Depince-





Figure 2.5 Optics and Electronics schematic diagram of flow cytometry. 
As the cells pass through the column, they are hit by a single beam of laser light with a particular wavelength s. The light 
emitted from the cells is passed through multiple mirrors and filters to the respective detector. The amount of the 
fluorescence acquired by the detector is then converted into digital numbers which can be displayed in a graph. Figure 
adapted from bitesizebio.com, using BioRender online tools. 
 
2.1.6.2 Applications 
2.1.6.2.1 Analysis of Purity of CLL cells 
In most cases, CLL cells were analysed for purity using flow cytometry. Fresh and thawed CLL cells 
(1x106) were incubated with fluorochrome-conjugated antibodies against CD19 and CD5 (PE and FITC, 
respectively) or with their respective isotype controls in order to identify the CLL B Cells. The gating 
strategies were applied to exclude debris and select the homogenous populations for subsequent 
analysis. The population that co-expressed both CD19 and CD5 was considered to be B-CLL cells as 
seen in Figure 2.6. The CLL samples containing greater than 90% B-CLL cells were used in subsequent 
experiments.  
In practice, equal number of cells are collected and spun and washed with PBS and resuspended with 
staining buffer. The cells are then mixed with fluorochrome-conjugated anti-CD19 and anti-CD5 
antibodies or respective isotype controls and incubated in the dark for 30-60mins. The cells were then 
spun to remove the excess antibodies and resuspended in appropriate volume of staining buffer and 




Figure 2.6 Gating strategies for measuring purity of CLL cells. 
  
At the selected voltages, the CLL population (seen as the dense population) is gated excluding debris. This gated 
population is then analysed using BL1 and BL2 channels for their respective antibodies. A control is used (where isotype 
controls were used for the respective antibodies) as comparison. The B-CLL purity was assessed by CD19, CD5 positivity, 
using CD19-PE and CD5-FITC antibodies and control- PE, FITC antibodies on the Attune. Quadrant plots showing CD5+ 




2.1.6.2.2 Detection of cell death 
Annexins are a family of calcium-dependent phospholipid-binding proteins that preferentially bind 
phosphatidylserine (PS) (Demchenko 2013). Under normal physiologic conditions, PS is predominantly 
located in the inner leaflet of the plasma membrane. Upon initiation of apoptosis, PS loses its 
asymmetric distribution across the phospholipid bilayer and is translocated to the outer leaflet of the 
membrane, marking cells as targets of phagocytosis. Once on the outer surface of the membrane, PS 
can be detected by fluorescently labelled Annexin V in a calcium-dependent manner.  
In early-stage apoptosis, the plasma membrane of cells retains its integrity and excludes viability dyes 
such as propidium iodide (PI). These cells will stain positive for Annexin V but not a viability dye, thus 
distinguishing cells in early apoptosis. However, in late-stage apoptosis, the cell membrane loses 
integrity thereby allowing access of PS to the interior of the cell (Demchenko 2013; Rieger et al. 2011). 
The viability dye (PI) can be used to distinguish these late-stage apoptotic and necrotic cells (both 
Annexin V and viability dye-positive) from the early-stage apoptotic cells (Annexin V positive, viability 
dye negative) (Demchenko 2013; Rieger et al. 2011). 
In practice, equal number of cells are collected, spun and resuspended in Annexin binding buffer. They 
are then incubated with Annexin V for approximately 10 minutes in the dark. PI is the added to the 
cells before flow cytometry analysis. 
Analysis was carried out using the Attune Flow Cytometer (Life Technologies). Live cells appear as 
Annexin V-PI -/-, dying as Annexin V-PI +/- and dead cells as Annexin V-PI +/+, respectively seen in 
Figure 2.7. 
 
Figure 2.7 Viability assay of CLL cell population using Annexin V and PI 
 
As an example, CLL sample (3631) at Day 0, where 10,000 events were analysed within the gated area in blue (87.75% of all 
events) and from there the included events were analysed for level of fluorescence with Annexin V (BL1 channel) and PI 
(BL3 channel) in a quadrant plot. Those that were double negative for Annexin and PI (-/-) were considered as the viable 
population (74.1%). Those that were single positive for Annexin (+/-) were the dying population and those that were double 
positive for Annexin and PI (+/+) were considered as the dead population (combined to be 24.28%). 
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2.1.7 Enzyme-linked immunosorbent assay 
2.1.7.1 Basic principle 
Enzyme-linked immunosorbent assay (ELISA) is a method of detecting and quantifying specific 
antigens in a solution with the use of enzyme-bound antibodies that emit a detectable light. 
The method used was a sandwich ELISA Figure 2.8, whereupon a capture antibody is fixed on a solid 
surface. The antigen that we want to measure are added and incubated to allow binding at the 
designated sites. A detection antibody is then added which is bound to Biotin. Following this, a 
complex is formed with an enzyme-conjugated reagent. The enzyme in this complex can breakdown 
a specific substrate which produces a detectable colour. A stopping media is added to stop the 
function of the enzyme reaction and the colour is then detected by a spectrophotometer. The intensity 
of the colour detected is proportional to the amount of the antigen present and bound to the antibody 
coated on the surface of the plate. The antigen is therefore quantified using ELISA method. 
 
Figure 2.8 Diagram of Sandwich ELISA. 
Schematic of Sandwich ELISA method. 1. A multiwall ELISA assay plate is coated with a known quantity of capture antibody. 
2. Non-specific binding sites are blocked using blocking buffer and the antigen containing sample is added to the plate. 3. 
After washing to remove unbound antigen, a specific detection antibody (Biotin bound) is added which binds to the antigen. 
4. Enzyme-conjugated detection reagent complex (Avidin-HRP bound to Biotin) is added and binds to the detection antibody. 
5. A substrate is added which is converted by enzymes (Avidin-HRP) to produce a color and the reaction is stopped by an 
acidic solution. The resulting color is measured by spectrophotometer at 450nm which then determines the quantity of the 





2.1.7.2 Applications: Measurement of CCL3 and CCL4 
The ELISA 96-well plates (Nunc-Immuno™ MicroWell™, Sigma-Aldrich) are coated with antibodies that 
bind specifically to human target antigens. We used ELISA to detect CCL3 and CCL4 (Thermo Fisher) 
proteins in the supernatant of cell cultures.  
Human CCL3 (MIP-1 alpha) and Human CCL 4 (MIP-1 beta) detection kits were obtained from 
Affymetrix eBioscience which is now part of Thermo Fisher Scientific (Catalog Number 88703588 and 
88703488 respectively). 
Primary PBMC samples from CLL patients were placed in long-term cultures to generate NLCs as 
detailed earlier as well as co-cultured with differentiated THP-1 cells, described previously. 
Supernatants were obtained at 4, 5, 6, 8, 10 and 13 days of primary culturing and day 1, 2 and 3 after 
co-culture with the THP-1 cells. The supernatant samples were then assayed for CCL3 and CCL4 protein 
concentrations by ELISA (see Appendix 7.14.8 for detailed operation and sample selection for testing 
by ELISA). 
 
2.1.8 Polymerase chain reaction (PCR) 
2.1.8.1 Basic principle 
PCR is an in-vitro procedure to amplify selected DNA fragments to reach a very high concentration. 
This allows researchers to exponentially copy and amplify regions of DNA of their choosing so that 
they can investigate them further by cloning, sequencing, quantification and size measurement, etc. 
The double strand DNA template is separated in denaturation and nucleotide primers are annealed 
complementarily to each of the template strands. With the aid of a polymerase enzyme, the four free 
deoxynucleotide triphosphate nucleotides (A, C, G and T) bind to their complementary counterparts 
on the template, allowing an extension to produce a complimentary copy strand of the template. This 
cycle is repeated numerous times and the total strands increases in an exponential pattern each cycle. 
After a set number of cycles, the amplified product can then be measured. 
In conventional PCR, the amplified product is detected by end-point analysis, by running the DNA on 
an agarose gel after the reaction is completed. In contrast, real-time PCR permits detection of 
amplified products as the reaction progresses. This is made possible by including a fluorescent 





2.1.8.2.1 Major steps 
2.1.8.2.1.1 mRNA extraction and cDNA generation 
The RNA that was extracted (See 5.3.2) is converted to complementary DNA (cDNA) through reverse 
transcription. cDNA is much more stable and doesn’t degrade very quickly even in room temperature 
compared to RNA. Usually, oligo (dT) primers were used to complementally binds to poly (dA) tail at 
the 3’ end of the single strand RNA. The SuperScript III reverse transcriptase, which has a high thermal 
stability, is used to synthesize cDNA replacing U with T nucleotides. The transcriptase functions 
optimally at temperature range of 42-55oC, giving a high specificity and great yield of full-length 
cDNAs. The cDNA then remains in its double stranded helix state. To perform reverse transcription, 
the condition requires RNAse free water, oligo (dT) primers, free nucleotides (dNTPs) and RNAse 
inhibitor and the Reverse Transcriptase (Superscript III). Given a known concentration of RNA 
measured at the start, an expected concentration of cDNA can thus be predicted to be later diluted 
for PCR experiments. 
 
2.1.8.2.1.2 PCR procedure 
As seen in Figure 2.9, the double stranded cDNA is denatured to be made single stranded again by 
raising the temperature to 95oC, where the hydrogen bonds that link the double helix are broken. At 





Figure 2.9 Diagram of PCR components and the steps of PCR. 
PCR components (top) consisting of Thermal cycler, cDNA sample, primers, nucleotides, Taq Polymerase, mix buffer and PCR 
tubes. A single cycle of PCR (bottom) consists of Denaturation, Annealing and Extension. This process is repeated depending 
on the number of cycles programmed. Image adapted from bosterbio.com using BioRender online tools. 
 
A pair of oligonucleotide primers (forward and reverse) initiates the process of annealing and 
extension. These primers are aligned alongside their respective starting points of the DNA fragments 
which will be amplified. Synthetic deoxynucleotides (dNTPs) are used as building blocks to extend the 
PCR products along the cDNA template from the primer using the DNA polymerase till they reach their 
respective ends (Figure 2.9). Taq-polymerase from Thermophilus aquaticus is used as this species of 
bacteria is extremophilic microorganism accustomed to living in such extremely high temperature 
conditions. This allows the enzyme to retain its function when denaturing temperatures are applied. 
The temperature is then cooled to allow the double strand to form and one cycle is ended. 
After a period of time, the PCR solution is heated again at denaturing temperatures to initiate another 
cycle for several cycles to amplify the product exponentially (Figure 2.10). Usually 20-30 standard PCR 




Figure 2.10 Diagram of Amplification of original template strand of cDNA to produce multiple copies per cycle 
 
 
2.1.8.2.1.3 Reverse transcription quantitative PCR (RT-qPCR) 
Since I am using reverse transcription PCR products from RNA and quantifying them in real time, it 
would be Reverse Transcription Quantitative PCR (RT-qPCR) following the MIQE guidelines on 
nomenclature (Bustin et al. 2009). 
Following the MIQE guidelines (Bustin et al. 2009), Quantitative PCR methods allow estimation of an 
amount of sequence of a sample. This is an established tool to measure accumulation of DNA products 
after every round of amplification during PCR, which can then determine the level of gene expression 
(Bustin et al. 2009; Haimes & Kelley ; Livak & Schmittgen 2001). 
For every pair of strands to copied, another pair is made per cycle. There is an exponential increase in number of copies as the 
number of cycles increase. Eg. By the end of the 3rd Cycle there will be 8 copies, the 4th cycle would have 16 and so on. 
Eventually at the end of 30 cycles there will be 230 copies. Diagram made using BioRender online tools  
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The amplified sequences are measured in real-time using the fluorescence signal that is released from 
the SYBR green dye, as it binds to the minor groove of the newly synthesized DNA double strands 
during the elongation phase of the PCR reaction. Relative quantification is performed using a reference 
Housekeeping gene, in this case GAPDH, hereby described as Reference Gene (Bustin et al. 2009). The 
LightCycler 480 PCR machine is used to perform the RT-qPCR.  
The samples prepared for PCR were optimized by using a control sample for comparison, a PCR grade 
water with only the primer as a negative control (to observe for contamination and primer dimers). 
See Appendix 7.14.17.3 for the arrangements. 
When performing the experiment on optimized melting temperatures, the samples were all used, 
along with a control sample and negative control for each primer plate. See Appendix 7.14.17.4 for 
arrangements. 
A specific threshold is set for when a fluorescence detection level is reached. The threshold is based 
on the overall parallel pattern of lines is seen from all the samples. This ensures that there is minimal 
bias on each sample/condition. The cycle in which the sample achieves the fluorescence, is quantified 
and used to compare with other samples. Whereby, an earlier cycle suggests a greater quantity of the 
targeted DNA fragment in this sample compared to a later cycle in another sample. 
 
2.1.8.3 Designing Primers 
Designing Primers was made possible using available resources in literature (Dieffenbach, Lowe & 
Dveksler 1993) and online guides by Premier Biosoft 
(http://www.premierbiosoft.com/tech_notes/PCR_Primer_Design.html) and online designing tools 
by NCBI (https://www.ncbi.nlm.nih.gov/tools/primer-blast/).  
The primers were designed to satisfy certain conditions that was found to be most beneficial, such as 
the primer length was long enough to be specific to a targeted site on the DNA, but not too long to 
use up the nucleotides in the mixture during PCR steps (Dieffenbach, Lowe & Dveksler 1993).  
The primer melting temperature (Tm) is the temperature where half of the DNA duplex will denature 
to become a single strand, indicating the stability of the duplex. Melting temperatures in the range of 
53-58oC is suggested to produce best results, where temperatures above 65oC are prone to develop 
secondary annealing. The GC content of the sequence provides a decent estimate of the primer Tm, 
where it is the number of G’s and C’s in the primer as a percentage of total bases (Dieffenbach, Lowe 
& Dveksler 1993). The melting temperatures are calculated automatically through websites and 
programs when designing the primers. 
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The primer annealing temperature (Ta) is the melting temperature where it is an estimate of the DNA-
DNA stability. Too high a Ta, would produce insufficient primer-template interaction, resulting in poor 
PCR product yield (Dieffenbach, Lowe & Dveksler 1993). Too low Ta, would results in multiple non-
specific products decreasing the overall PCR specificity (Dieffenbach, Lowe & Dveksler 1993). 
It is important to avoid chances of hairpins and self-dimer formations, where the primer folds on itself 
(hairpin) or anneals with another primer in the mix (self-dimer) at temperatures close to those in PCR 
steps. The presence of these artefacts results in less PCR yield from the DNA template and an 
inaccurate representation of the true expression from the DNA. 
Using the NCBI BLAST tool, the primers design is check to ensure that the primer is specific to only the 
gene of interest. If it is not specific, then other genes may be amplified in the mixture and give a false 
positive reading of the desired gene expression level of interest. 
When the primers are designed, they are ordered and received as lyophilized powder which is then 
resuspended with Molecular grade H2O into a Master stock and frozen down for storage. The Master 
stock (100x) of each primer is then diluted to produce a working stock (10x) for experiments. 
 
2.1.8.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is a technique used in molecular biology for separation, quantification and 
purification of DNA fragments based on their length as measured by base pairs. The procedure uses 
an electrical field to separate DNA fragments within agarose gels where high percentage gels are used 
for small DNA fragments, and low percentage gels for large DNA fragments. The DNA fragment size is 
determined by comparison to a DNA ladder which is composed of DNA fragments of known base pair 
length. 
Agarose gels were prepared by weighing the desired amount of granular agarose (ULTRAPURE) and 
adding 50ml of Tris-borate-ethylenediaminetetraacetic acid (EDTA)(TBE) buffer (diluted from a 10X 
stock consisting of 0.445M Tris borate, 0.01M EDTA pH=8.2-8.4). The agarose is then melted by 
heating in a microwave for about 1.5minutes. The agarose is mixed and left to cool down but not 
solidify. At this point 1ul of Midori Green Advance DNA Stain was added to the agarose solution before 
slowly pouring it into a gel tray in order to avoid air bubble formation. The dye is added so that DNA 
can be visualized under ultraviolet (UV) light. In the event there are bubble formations, the bubbles 
are quickly fished to the side using pipette tips. With the well comb in place, the agarose solution is 
then allowed to solidify for at least 20-30minutes. 
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The solid agarose gel is placed in an electrophoresis tank with the comb gently removed. This tank is 
then filled with TBE until the gel is covered. The DNA samples prepared by mixing DNA preparations 
with DNA buffer, and then carefully pipetted into the wells. Appropriate DNA ladders (Quick-Load 
Purple 100bp and 1kb) were also used. 
An electrical field was then applied (110V constant voltage) for 1h. At this point separated DNA 
fragments were able to be seen under UV light using a manual adjust system for exposure time when 
obtaining images. 
 
2.1.9 Statistical analysis 
Where appropriate, a paired two-tailed Student’s t test was performed to determine the statistical 
significance of the difference between the two groups of data. An alpha error of 0.05 was accepted as 
a cut-off of statistical significance. SPSS version 21 and Microsoft Office Excel 2017 was used. 
 
2.2 Materials 
2.2.1 Antibodies used for flow cytometry 
The details of primary and secondary antibodies used for Phenotyping are provided in Table 2.2 and 
Table 2.3 for FACS analysis and Immunofluorescence Microscopy. Details of reagents used for Viability 





Table 2.2 Antibodies used for flow cytometry and immunofluorescence microscopy 
 Company Description Cat # 
CD19 Merck Millipore Mouse anti-Human MAB1794 
IgG2a kappa BD Pharmingen Mouse anti-Human 550339 
PE-CD19 (4G7) BD Pharmingen Mouse anti-Human 345777 
PE-IgG2a kappa BD Pharmingen Mouse anti-Human 555574 
FITC-CD5 (L17F12) BD Pharmingen Mouse anti-Human 345781 
FITC IgG2a kappa BD Pharmingen Mouse anti-Human 555573 
CD20cy Dako Mouse anti-Human IR604 
CD14 BD Pharmingen Mouse anti-Human 550376 
FITC-CD14 BD Pharmingen Mouse anti-Human 555397 
PE-Cy7-CD14 BD Pharmingen Mouse anti-Human 560919 
PE-Cy7 IgG2a kappa BD Pharmingen Mouse anti-Human 557907 
CD68 Dako Mouse anti-Human M087629-2 
PE-CD68 BD Pharmingen Mouse anti-Human 556078 
PE-IgG2b kappa BD Pharmingen Mouse anti-Human 556078 
CD163 Abcam Rabbit anti-Human ab100909 
IgG Abcam Rabbit anti-Human ab172730 
PerCP-Cy5.5-CD163 BD Pharmingen Mouse anti-Human 563887 
PerCP-Cy5.5 IgG1 kappa BD Pharmingen Mouse anti-Human 550795 
CD38 Abcam Rabbit anti-Human ab183326 
PE-Cy5 CD38 BD Pharmingen Mouse anti-Human 555461 
PE-Cy5 IgG1 kappa BD Pharmingen Mouse anti-Human 555750 
CD206 BD Pharmingen Mouse anti-Human 555953 
IgG1 kappa BD Pharmingen Mouse anti-Human 555746 
FITC-CD206 BD Pharmingen Mouse anti-Human 551135 
FITC IgG1 kappa BD Pharmingen Mouse anti-Human 555748 
EGR2 LifeSpan Biosciences Inc. Mouse anti-Human LS-C174298 
APC-IgM BD Pharmingen Mouse anti-Human 551062 
APC-IgG1 kappa BD Pharmingen Mouse anti-Human 555751 
RPE-IgM Dako Rabbit anti-Human R5111 
RPE-F(ab')2 Dako Rabbit anti-Human X0930 




Table 2.3 Secondary antibodies 
 Company Description Cat # 
Alexa Fluor 488 Life Technologies Donkey A21202 
Alexa Fluor 647 Life Technologies Donkey A31573 
 
Table 2.4 Reagents for Viability Assay by Flow Cytometry 
 Company Cat # 
FITC-Annexin V BD Pharmingen 556420 
Propidium Iodide (PI) SIGMA-ALDRICH 25535164 
 
2.2.2 Reagents used for MGG staining 
Using standard glass slides and 8 well glass slides (Chamber slide, Lab-Tek™ glass, 8-well, Thermo 
Scientific Nunc, Cat. No. 10051021), May Grünwald Giemsa (MGG) staining was performed and viewed 
under standard light microscope. Table 2.5 provides details of reagents used for MGG staining. 
Table 2.5 Reagents for MGG staining 
 Company Cat # 
May Grünwald SIGMA-ALDRICH 32856 





2.2.3 Reagents used for immunofluorescent staining 
Using coverslips (13mm diameter, Appleton Woods, Cat. No. MS002) and mounted on standard glass 
slides, the cells were viewed under Immunofluorescence Microscope in a dark room. Table 2.6 
provides details of reagents and Table 6 provides details of antibodies used for Immunofluorescence 
staining. 
Table 2.6 Reagents for Immunofluorescence staining 
 Company Description Cat # 
Aqua-Poly/Mount Polysciences Europe GmbH Mounting Media 18606-20 
Donkey Serum Merck Millipore Donkey serum for blocking S30-100ML 
TruStain FcX BioLegend Fc Blocker 422302 




Thermo Fisher Scientific Nuclear Stain D1306 
 
2.2.4 Reagents used to induce differentiation of THP-1 cells into macrophages 
Human THP-1 cell line was obtained from European Collection of Authenticated Cell Cultures (ECACC 
Cat. No. 88081201). The cell line was authenticated with 100% Match with ATCC® Number of TIB-202, 
Designated as THP-1 Acute Monocytic Leukemia Human and using 9 loci (D5S818, D13S317, D7S820, 
D16S539, VWA, TH01, AM, TPOX and CSF1PO). This was performed using Cell Line Authentication 
Services by Ms. Patricia Gerard and Dr Lakis Liloglou at the Department of Molecular and Clinical 
Cancer Medicine of University of Liverpool. Table 2.7 provides details of the reagents used to 
differentiate the THP-1 cell line. 
Table 2.7 Reagents for Cell line differentiation 
  Company Cat # 
M0 Phorbol 12-ymristate 13-acetate 
(PMA) 
Sigma-Aldrich 16561-29-8 
M1 Interferon Gamma (IFNγ) Perprotech 300-02 
M1 Lipopolysaccharide (LPS) Sigma-Aldrich 8630 





2.2.5 Cytotoxic agents used to induce apoptosis 
2.2.5.1 Fludarabine 
Fludarabine (Cat. No. 21679141, Sigma-Aldrich) seen in Figure 2.11 was made up to 20 mM stock in 
DMSO and aliquoted in 10 l/tube, stored in -20oC freezer. 
 
Figure 2.11 Fludarabine 
2.2.5.2 ABT-199 
ABT-199 (Cat. No. GDC-0199, Selleckchem.com) seen in Figure 2.12 was made up to 10 mM stock in 
DMSO and aliquoted in 5 µl/tube, stored in -20oC freezer. 
 
Figure 2.12 Venetoclax (ABT-199) 
2.2.6 ELISA Kits 
ELISA kits were ordered and ELISA was performed on 96-well plates (Nunc-Immuno™MicroWell™, 
Sigma-Aldrich, Cat. No. M9410-1CS), using manufacturer’s instructions. The plates were measured 
using Densitometer µQuant (BioTek). Table 2.8 provides details of the kits used. 
Table 2.8 ELISA Kits 
 Company Cat # 
CCL3 (MIP-1 alpha) Affymetrix eBioscience 887035 









3 Characterising nurse-like cells derived from peripheral blood 
mononuclear cells of patients with CLL 
3.1 Introduction 
The study of nurse-like cells (NLCs) in CLL took off in the early 2000’s with the initial reports of these 
cells appearing as ‘large adherent cells’ displaying morphologic and phenotypic features of 
macrophages and demonstrating pro-survival effect on CLL cells when co-cultured together (Burger 
et al. 2000; Tsukada et al. 2002). 
The studies of NLCs continued and later established the critical role of NLCs within the CLL 
microenvironment. This led to the identification of, in addition to SDF1 (CXCL12), BAFF and APRIL that 
were expressed by NLCs to activate the pro-survival signalling pathways in CLL cells (Nishio et al. 2005). 
Meanwhile, chemokines such as CCL3 and CCL4 released from activated CLL cells in the lymph nodes 
have been shown to attract T cells and other immune cells to the tissue microenvironment (Burger et 
al. 2009b), supporting the notion that CLL cells are also actively involved in developing the favourable 
microenvironment (Burger 2011a; Caligaris-Cappio, Bertilaccio & Scielzo 2014). It is now known that 
NLCs most likely originate from blood monocytes and accumulate in the lymphoid tissues such as 
lymph nodes, bone marrow and spleen (Boissard et al. 2016a; Burger et al. 2000; Jia et al. 2014; 
Tsukada et al. 2002).  
However, when my research was started back in 2015, the molecular mechanisms mediating the pro-
survival and drug resistance following interaction of CLL cells with nurse-like cells were not well 
understood. In particular, cross-communication between nurse-like cells and CLL cells at the level of 
gene expression is not fully characterised.  A good understanding of these molecular mechanisms is 
important as it may help identify key molecules that mediate survival and drug resistance in vivo. In 
turn, this may lead to discovery of novel therapeutic agents that could target these molecules and 
restore drug sensitivity. 
Therefore, whilst the overall aim of my PhD study is to understand the molecular mechanisms 
mediating effects of NLCs on CLL and vice versa, the focus of this chapter is to independently validate 
the development of NLCs using primary peripheral blood mononuclear cells obtained from patients 
with CLL and confirm the biological effects of co-culture with NLCs on CLL cells that have been reported 
in the literature. The specific objectives of this part of my PhD study are therefore: 
1. Validating the optimum culture conditions for developing NLCs in vitro; 
2. Further characterisation of the morphology and immunophenotype of NLCs; 
3. Expanding investigation of the cytoprotective effects of NLCs on CLL cells on co-culture; 




3.2.1 Development of NLCs 
To generate the nurse like cells, fresh mononuclear cells prepared from the peripheral blood of CLL 
patients were re-suspended in complete RPMI 1640 medium supplemented with 10 % heat-
inactivated fetal bovine serum, 2 mM L-glutamine, 100 U/mL penicillin, and 100 μg/mL streptomycin 
(Life Technologies/Thermo Fisher Scientific, Paisley, UK). The cells were incubated in a 37°C, 5% CO2 
humidified incubator and followed up by observing for morphological changes under phase contrast 
microscope. They were initially cultured at different densities in 24 well plates. 
Every day, the plates were viewed under microscopy for a minimum of 3 random fields. The visual 
changes relating to the cell shape, size, and general arrangement were noted and followed for each 
sample and compared with other densities and the previous day findings. 
 
3.2.2 Replacement of media 
In order to provide nutrition for the cells during the experiment involving long-term culture, I used 
partial replacement of media as a maintenance strategy as the cytokines/chemokines released from 
the cultured cells into the supernatant could be important for the longevity of the CLL cells as well as 
NLC differentiation. Partial replacement of either ½ or 1/3 of culture media with fresh complete RPMI 
medium was performed depending on the observations seen under microscope, as needed usually 
every 3-4 days. By gently tipping the plate to one side, without shaking the plate, the supernatant was 
collected from the top so as not to disturb the already settled cells. Fresh RPMI was added by gently 
pipetting along the walls of the wells. In the cases where there was too much localisation of cells to 
the centre, gentle drops were added to disperse the CLL cells, but not to dislodge the NLCs. 
 
3.2.3 Co-culture of CLL cells with NLCs 
To prepare a co-culture experiment, NLCs are first developed as described previously (Burger et al. 
2000)  up to 14 days where their condition is checked under microscope. The CLL cells that were 
present during the 14 days in fresh PBMC are gently washed away by combination of gentle agitation, 
tipping of the plate at an angle and collecting the supernatant by pipetting. Gentle washing using warm 
complete media is used on surfaces of the plate and the area is checked under microscope. The plates 
that are not to be co-cultured with autologous CLL cells are provided with equal volume of complete 
media and kept aside in the incubator. Plates to be used for co-culture experiments are temporarily 
resuspended with warmed complete media and kept in incubator while autologous CLL cells are 
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thawed and resuspended in fixed cell density of 3x106/ml in warm complete media (as described in 
Methodology). The plates to be used are taken out and the supernatant is drained. The media mixture 
containing thawed CLL cells is then added onto the plates containing NLCs and is labelled as co-culture 
wells. A portion of thawed CLL cells is generally sent for viability testing by Trypan blue and or flow 
cytometry using Annexin/PI for record keeping as Day 0. 
 
3.2.4 Statistical Analysis 
Where appropriate, a paired two-tailed Students t test was performed to determine the statistical 
significance of the difference between the two groups of data. Chi squared test was performed to 
determine the statistical significance of the difference between two nominal and or ordinal groups of 
data and Fisher-Freeman-Halton exact test was used where Chi squared was not appropriate. SPSS 




3.3.1 Optimising cell density of CLL PBMCs in culture for developing NLCs 
When I started my project, I noticed that the cell density of CLL PBMCs used to develop NLCs that was 
reported in the literature was different from study to study, ranging from 3 x 106 cells/ml (Filip et al. 
2013b) to 10 x 106 cells/ml (Nishio et al. 2005) to 15 x 106 cells/ml (Burger et al. 2000). Therefore, I 
first set out to establish the optimal cell density to develop NLCs in standard culture conditions. When 
I first cultured fresh CLL PBMCs at low density (7.5 x 106/ml) (Figure 3.1 left), the development of NLCs 
were poor. This is most likely due to the lower number of cells used where cell-cell interaction was 
insufficient, resulting in earlier apoptosis of CLL cells. 
At higher cell density (15 x 106/ml), the field of view looked very crowded with multilayers of cells 
heaped on top of each other (Figure 3.1, middle). This was therefore deemed an inefficient condition 
to develop NLCs from PBMC.  
In contrast, at the cell density of 10 x 106/ml, I could observe clear morphology of cells under the 
microscope and appearance of NLCs with an enlarged oval or elongated shape (Figure 3.1, right). 
These NLCs continue to differentiate into macrophage-like cells over time.  
 
   
Figure 3.1 PBMCs cultured at different cell densities affects the development of NLCs. 
Phase contrast image of fresh PBMC (3465 Day 8) cultured at cell density of 7.5 x 106/ml (left) giving a sparse arrangement 
of poor viability CLL cells (appearing as dark and shrivelled cells, blue arrows) and few NLCs (orange arrows). Phase contrast 
image of fresh PBMC (3460 Day 4) cultured at density of 15 x 106/ml (middle) giving multiple layers, obscuring the view in 
majority of viewing fields. Phase contrast image of fresh PBMC (3484 Day 6) cultured at cell density of 10 x 106/ml (right) 




3.3.2 Morphological features of NLCs 
3.3.2.1 Phases of monocyte/ macrophage differentiation observed via phase contrast microscopy 
and MGG staining. 
Upon initial culturing the fresh CLL PBMCs in RPMI at Day 0, the appearance of monocytes was almost 
indistinguishable from lymphocytes seen in Figure 3.2, even though monocytes are generally larger 
than lymphocytes (Bain et al. 2012; Lichtman et al. 2011b).  
 
Figure 3.2 Monocytes indistinguishable from lymphocytes in fresh PBMCs cultured under standard conditions at Day 0. 
Phase contrast microscopy of the fresh PBMCs (3470) plated on Day 0 in RPMI. Based on initial appearance upon plating, it 
was almost impossible to differentiate the monocytes from lymphocytes. 
 
I next performed May Grünwald Giemsa (MGG) staining on the same cells that I observed under the 
phase contrast microscope. 
With minimal agitation, the monocytes can be distinguished by having a slightly larger circular 
appearance and displayed mild adherent properties. This can be seen as early as 24 hours to 48 hours 
later. With MGG staining as seen in Figure 3.3 (left), the monocytes have a lower nuclear (N): 
cytoplasm (C) ratio, characteristic vacuoles in the cytoplasm which is not very granular and dense. The 




   
Figure 3.3 Monocytes and macrophages are distinguishable from lymphocytes by their morphology. 
(Sample 3464 Day 12) MGG-stained cells showing a single lymphocyte and a monocyte (left). The leukocyte is showing a high 
N:C ratio with diameter just under 10um. The monocyte is having a lower N:C ratio, showing characteristic vacuoles in the 
cytoplasm which is not very granular and dense. (Sample 3470 Day 4) MGG stained slide showing a group of lymphocytes in 
close proximity to a single big macrophage (right). The macrophage is having a very large oval appearance with cytoplasmic 
vacuoles and the cytoplasm appears to have ill-defined borders being heterogeneously stained as well. 
 
Overtime, the monocytes were differentiated into large oval adherent cells, which is consistent with 
NLCs as previously described (McWhorter et al. 2013). As seen in Figure 3.3 (right), multiple 
lymphocytes are seen in close proximity to a single macrophage. The macrophage is having a large 
oval appearance with more cytoplasmic vacuoles, with the cytoplasm having an ill-defined border 
being heterogeneously stained as well. 
Also, adherent cells with varying shapes were observed where the cytoplasm was stretched and the 
membrane appeared elongated. Illustrated in Figure 3.4 (A) is an example of an adherent cell with a 












Figure 3.4 Tail-like projection, spindled-shaped and elongated appearance from an adherent cell. 
(3464 Day 12) MGG stained slide showing a group of adherent cells with characteristic cytoplasmic vacuoles and lightly 
stained cytoplasm (A). One of the adherent cells has an extended cell membrane giving a tail-like appearance. (3464 Day 12) 
MGG stained slide showing a single macrophage in close proximity to lymphocytes (B). The lymphocyte is showing a high N:C 
ratio with diameter just under 10um as mentioned in literature. The Macrophage is having extension of the cell membrane 
of both poles from nucleus giving an elongated spindle shaped appearance. (3464 Day 12) MGG stained slide showing a 
single macrophage with characteristic cytoplasmic vacuoles, lightly stained cytoplasm and fine granules (C). The macrophage 
demonstrates an elongated appearance where the nucleus as well as the cell membrane are elongated. All macrophages are 
having a lower N:C ratio, showing characteristic vacuoles in the cytoplasm which is not very granular and dense. 
 
Sometime, these tail-like projections increase in number to give a spindle shaped appearance, where 
the nucleus appears to be in the middle and the tails extending towards the two opposite directions 
as seen in Figure 3.4 (B).  
Eventually some macrophages display an overall elongated appearance and seen in Figure 3.4 (C), the 
overall shape is as stated, with cytoplasmic vacuoles as well as fine granules within the cytoplasm. In 
fact, the nucleus is also appeared to be elongated in contrast to having a general oval appearance. 
Usually these adherent cells were seen in close proximity with lymphocytes forming small clusters. An 





Figure 3.5 Pleomorphism and cluster formation of adherent cells developed after culturing CLL PBMCs under standard 
conditions.  
CLL PBMCs (3460 Day 6) cultured in RPMI medium developed adherent cells with distinct appearance from lymphocytes (i.e. 
circular/oval cells with a diameter of just under 10um, blue arrow). These adherent cells appeared to have differentiated 
into macrophage-like cells displaying a larger more pleomorphic morphology with large oval or elongated shapes under 
phase contrast microscopy (left orange arrow). (3464 Day 12) MGG stained slide showing multiple lymphocytes and 
macrophage-like adherent cells forming a cluster (right). The lymphocyte (blue arrow) is showing a high N:C ratio with 
diameter of just under 10µm. The adherent cells (orange arrow) are having a lower N:C ratio, showing characteristic vacuoles 
in the cytoplasm which is not very granular and dense. 
 
Figure 3.6  and Figure 3.7  shows more examples of adherent cells that have formed from the CLL 
PBMCs cultures. The lymphocytes are again seen as those with densely stained nuclei, having a large 
N:C ratio and appearing in close proximity to the adherent cells. The macrophage-like adherent cells 
are pleomorphic with the appearances described above, but all having characteristic cytoplasmic 




Figure 3.6 A diverse cluster of macrophage-like adherent cells with CLL cells emerges from CLL PBMCs culture. 
(3469 Day 14) MGG stained slide showing a cluster of adherent cells with lymphocytes in close proximity. The adherent cells are distinguishable from their characteristic vacuoles in their 
cytoplasm of which is mildly granular with a lower N:C ratio than the leukocytes. The adherent cells are showing more pleomorphism where one is very large with heterogeneously densely 




Figure 3.7 Clusters of adherent cells with CLL cells is apparent. 
(3469 Day 14) MGG stained slide seen under oil immersion showing multiple clusters of pleomorphic adherent cells closely 
surrounded by leukocytes. The leukocytes have a high N:C ratio with a deeply stained nucleus. The NLCs have a broad range 
of morphology from large oval appearance to elongated and spindle shaped and having characteristic vacuoles with granular 
cytoplasm. 
 
These groups of cells may then form clusters near a greater mix of spherical/oval and elongated, tailed 
monocytes. A cluster is considered as a collection of the cells in such close proximity and overlapping 
so that their margins are not distinguishable.  
These clusters may then grow further consisting of more pleomorphic monocytes and lymphocytes to 
the point that it is seen with the naked eye in the culture plate thereby defined as colonies. As seen in 
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Figure 3.8, the visual field shows clusters formed consisting of multiple layers of cells that have 
aggregated there. Focusing on cells became difficult as a result. 
 
Figure 3.8 Abundance of cells consisting of NLCs and CLL cells populated as dense islands. 
Phase contrast a PBMC sample (3460 Day 13) where a close up is visualised of a colony formed by a very large collection of 
lymphocytes and macrophages. 
 
There was a period of plateau where there were no obvious changes in size, shape, density appearance 
of monocytes or clusters. 
After this point, the conditions of the clusters deteriorate. Eventually, dead/dying cells appear as 
floated or shrivelled cells with a darker granulated background which I considered as an apoptotic 
phase. As seen in Figure 3.9, the visual field shows multiple shrivelled cells where some have 
aggregated (left) and the macrophage-like adherent cells also start to lose their glow (right). 
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Figure 3.9 Apoptotic features start to occur in prolonged cultures. 
Phase contrast images of CLL PBMCs (3460) cultured to Day 21 showing widespread apoptosis. The CLL cells appear as 
shrivelled cells either individually or clumped together with other shrunken cells (left). The adherent cells appear apoptotic 
as well based on their dense cytoplasm and blebbing (right). 
 
Eventually there were few cells remaining adhered to the surface and the majority were dead cells. 
Collectively, the above was the overall representation describing the development of macrophage-
like adherent cells from the CLL PBMCs cultures from their initial appearance to their inevitable 
demise. The total duration of this was variable from sample to sample, however the phases described 
appeared to be consistent in all the samples examined. For the purposes of recording morphological 
features of these macrophage-like adherent cells in chronological pattern, a summary of detailed 
description of these features during different phases of their development was provided in the 
Appendix 7.4. 
Therefore, using phase contrast microscopy and light microscopy following MGG staining I have 
characterised the morphological features of the macrophage-like adherent cells that developed from 
the CLL PBMCs cultures. All these features are consistent with that of NLCs described previously 
(Burger et al. 2000; Tsukada et al. 2002). I next examined the immunophenotype of these adherent 
cells because NLCs have been shown to display a phenotype similar to that of M2 macrophages (Filip 




3.3.3 Immunophenotyping of macrophage-like adherent cells 
Following the morphological characterization of the macrophage-like adherent cells, I proceeded to 
investigate the expression of protein markers typical of the NLCs, including the M2 macrophage 
markers CD68 and CD163, as previously reported (Tsukada et al, 2002; Jia et al, 2014; Hume & 
Freeman, 2014; Mills, 2015; Boissard et al, 2015). First, I attempted a method of immunofluorescent 
staining for flow cytometry analysis. However, I faced many challenges. 
These macrophage-like cells were firmly attached to the culture plates. Previous attempts at 
harvesting the cells (described in Methodology) included the use of enzyme Trypsin, or cold disodium 
ethylenediaminetetraacetic acid (EDTA) buffer or a combination of both (Tsukada et al. 2002) or a 
plate cell scraper (Filip, Cisel & Wasik-Szczepanek 2015).  
I tried all the above methods to harvest the adherent cells and incubated these cells with antibodies 
against CD68 and CD163. As shown in Figure 3.10, the forward scatter and side scatter plots showed 
there wasn’t a homogenous population of intact cells within the gated region for subsequent analysis. 
Most of the cells appeared to be broken, which formed a dense cluster of debris at the bottom of the 
plots. Another difficulty I faced was that immunophenotyping by flow cytometry method required a 
large number of adherent cells to begin with. This in turn required the use of even larger number of 
CLL PBMCs, which was not always possible to obtain.  This is in contrast to other studies (Coscia et al. 
2011; Giannoni et al. 2014; Jia et al. 2014; Polk et al. 2016; Tsukada et al. 2002). I therefore used 
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Figure 3.10 Immunophenotyping of adherent cells using flow cytometry. 
Adherent cells were harvested using a plate cell scraper (left) or by Trypsin/EDTA (right) and stained with CD68 and CD163 
antibodies as described in the Methods. 10,000 events were acquired on a flow cytometer and analysed using the channels 
BL2 and BL3 for CD68 and CD163, respectively. Histogram of fluorescence of gated events are shown. Isotype control 
antibodies were used in parallel. 
 
Immunofluorescence (IF) microscopy was thus performed using 8-well chamber slides which can be 
viewed under fluorescence microscope (described in Methodology).  
In order to optimize the conditions for IF staining, I used human monocytic THP1 cell line (see 
Appendix 7.14.6 for detail). I then applied the optimised IF conditions to immunophenotyping 
adherent cells. As shown in Figures 11-14, the lymphocytes were distinguishable from the adherent 
cells initially by their DAPI staining. The CLL lymphocytes were identified by dense DAPI staining (blue) 
and the size of the nucleus is generally smaller than that of NLCs. 
Specific staining with respective antibodies also confirmed the differential expression of protein 
markers unique for each cell type. As seen in Figure 3.11, CD19 was detected only on the CLL cells, 
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following incubation with anti-CD19 antibody. This is in contrast to the adherent cells which were 
stained positive only for CD163 which covered the whole cells, consistent with the cytoplasmic 
localisation of this plasma membrane marker (Pontén, Jirström & Uhlen 2008). 
A further example was seen in Figure 3.12 where the cells sample was immuno-stained on Day 9. 
Again, CD14 (a marker of monocyte) was detected in macrophage-like adherent cells but not in CLL 
cells. CD14 was localised in part of the cytoplasm and near the nucleus of the adherent cells. The 
staining by CD163 revealed an elongated structure of an adherent cell with the CLL cells closely 
positioned next to it.  
Also shown in Figure 3.13 were images from dual staining of the cells cultured for 4 days with 
antibodies against CD68 and CD163, classical markers for NLCs (Boissard et al. 2015a; Hume & 
Freeman 2014; Jia et al. 2014; Mills 2015; Tsukada et al. 2002). Reassuringly, CD68 was detected only 
in macrophage-like adherent cells that were also positive for CD163, whereas CLL cells were clearly 
stained negative for either marker. CD68 expression was localised within the adherent cells near the 
nucleus as part of the cytoplasm.  
The same CLL sample was dual-stained again at Day 11 of being in culture in order to detect changes 
in expression of these markers and morphology of the adherent cells. Again, the adherent cells were 
stained positive for both CD14 and CD163, whereas CLL cells were negative for either marker (Figure 














Figure 3.11 Immunofluorescence microscopy of adherent cells developed from CLL PBMCs culture. 
Immunofluorescence staining of CLL PBMCs (sample 3529) culture at Day 9 using DAPI (blue), CD19 antibody (green) and CD163 antibody (red) and their respective isotype controls. Fresh 
PBMCs were cultured as described till Day 9, fixed, stained with primary antibodies against CD19 and CD163, followed by incubating with respective secondary antibodies, counterstained 











   
 
Figure 3.12 Immunofluorescence microscopy of adherent cells developed from CLL PBMCs culture at day 9. 
Immunofluorescence staining of CLL PBMCs (sample 3529) culture at Day 9 using DAPI (blue), CD14 antibody (green) and CD163 antibody (red) and their respective isotype controls. Fresh 
PBMCs were cultured as described till Day 9, fixed, stained with primary antibodies against CD14 and CD163, followed by incubating with respective secondary antibodies, counterstained with 
nuclear staining dye DAPI and viewed under fluorescence microscope in the dark. Images were prepared using ImageJ software. 
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Figure 3.13 Immunofluorescence microscopy of adherent cells developed from CLL PBMCs culture at day 4. 
Immunofluorescence staining of CLL PBMCs (sample 3530) culture at Day 4, using DAPI (blue), CD68 antibody (green) and CD163 antibody (red) and their respective isotype controls. Fresh 
PBMCs were cultured as described till Day 4, fixed, stained with primary antibodies against CD68 and CD163, followed by incubating with respective secondary antibodies, counterstained with 
nuclear staining dye DAPI and viewed under fluorescence microscope in the dark. Images were prepared using ImageJ software. 
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Figure 3.14 Immunofluorescence microscopy of adherent cells developed from CLL PBMCs culture at day 11. 
Immunofluorescence staining of CLL PBMCs (sample 3530) culture on Day 11, using DAPI (blue), CD14 antibody (green) and CD163 antibody (red) and their respective isotype controls. Fresh 
PBMCs were cultured as described till Day 4, fixed, stained with primary antibodies against CD14 and CD163, followed by incubating with respective secondary antibodies, counterstained with 
nuclear staining dye DAPI and viewed under fluorescence microscope in the dark. Images were prepared using ImageJ software.  
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Taken together, the results from immunofluorescence microscopy showed that CD14, CD68 and 
CD163 were detected in adherent cells only, whereas CD19 was detected by CLL cells, as expected.   
Therefore, combined observations from morphological study and immunofluorescence microscopy 
confirmed the macrophage-like adherent cells developed from the CLL PBMCs cultures under the 
conditions used in my study are indeed the nurse-like cells (NLCs). I will thus use the term NLCs in the 
thesis thereafter. 
Whilst I successfully developed NLCs from the CLL PBMCs cultures, I also noticed considerable 
variation in the extent to which NLCs could be generated from fresh CLL blood samples under the 
experimental conditions I used. More specifically, the pace and number of the NLCs developed varied 
significantly from sample to sample. 
 
3.3.4 Variation in the development of NLCs from the CLL PBMCs samples 
Based on the morphological changes that were associated with the different phases during the 
development of NLCs that I have described (see Appendix 7.4), I noted down for each sample used 
and color-coded them in a time-course chart with the initial appearance of large oval adherent cells 
(coded purple) and appearance of maximum number of fully differentiated NLCs (coded orange) 
(Table 3.1).  It was thus obvious that the majority of samples had initial adherent appearance of NLCs 





Table 3.1 Phases of development of NLCs among CLL samples collected, from the appearance of large oval adherent cells 












































3460                                           
3461                                           
3463                                           
3464                                           
3465                                           
3469                                           
3470                                           
3471                                           
3472                                           
3481                                           
3482                                           
3483                                           
3484                                           
3485                                           
3490                                           
3491                                           
3492                                           
3493                                           
3494                                           
3500                                           
3502                                           
3504                                           
3505                                           
3506                                           
3507                                           
3508                                           
3510                                           
3511                                           
3512                                           
3492                                            
3513                                           
3516                                           
3519                                           
3520                                           
3522                                           
3523                                           
3526                                           
3527                                           
3528                                           
3529                                           
3530                                           
3536                                           
3537                                           
3539                                           
3542                                           
3561                                           
3564                                           
3566                                           
3568                                           
3574                                           
3576                                           
3577                                           
3579                                           
3582                                           
3585                                           
3587                                           
3589                                           
3599                                           
3602                                           
3603                                           
3605                                           
3606                                           
3607                                           
3609                                           
3610                                           
3611                                           
3612                                           
3613                                           
3620                                           
3621                                           
3627                                           
3631                                           
3637                                           
3639                                           
3640                                           
3642                                           
3644                                           
3645                                           
3647                                           
3650                                           
3674                                           
3679                                           
3682                                           
3684                                           
3686                                           
3691                                           
3694                                           
3696                                           
3697                                           
3707                                           
 
It was worth noting that some samples did not have any NLC development at all even the early phase 
presentation (e.g. #3536, #3537, #3539, #3542, #3564, #3568). Additionally, it was noted that not all 
samples gone through all the phases observed by the time they reached their plateau (e.g. #3519, 
#3528, #3602, #3603, #3609). The plateau period varied from sample to sample, where some samples 
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reached plateau on Day 8 (eg. #3465, #3471, #3472, #3485, #3511, #3519,) and others can last up to 
Day 14 (e.g. #3511, #3520, #3522).  
 
3.3.4.1 Scoring of NLCs developed from individual CLL samples 
Because of the considerable variation in development of NLCs among the CLL PBMCs samples used, I 
decided to assign a score of NLCs development to each individual CLL samples based on the following 
considerations:    
• Day of first sight of large oval cells (usually Day 4-6) 
• Number of NLCs of any morphology average per field at 200x magnification (≥30, 10-30, <10) 
• Progression through different phases (all or some, up to plateau) 
• Presence or absence of clusters of NLCs 
• Day of plateau phase where maximum number of fully differentiated NLCs developed (usually 
day 8-12). Plateau phase also refers to a period of little or no significant changes. This period 
is generally followed by features of apoptosis. 
Table 3.2 below provides a rough guide on how I assigned a score to individual samples. Figure 3.15, 
Figure 3.16, Figure 3.17 and Figure 3.18 were the microscopic images representative of morphology/ 





Table 3.2 NLC Scoring system 
Description of Score NLC Score 
• Large oval cells seen at Day 4 (+/- 2 days) 
• Number per field >=30 cells 
• Progressed through all phases up to plateau 
• Cluster +ve 
And/ or 
 
• Plateau Reached (Day 8-12) 
3 (+++) 
• Large oval cells seen at Day 4 (+/- 2 days) 
• Number per field >=30 cells or 10-30 
• Progressed through most phases up to plateau 
• Cluster +ve or -ve 
And/ or 
 
• Plateau Reached (Day 8-12) 
2 (++) 
• Large oval cells seen at Day 4 (+/- 2 days) or after 
• Number per field 10-30 cells or <10 
• Progressed through phases (1-3) up to plateau 
• Cluster +ve or -ve 
And/ or 
 
• Plateau Reached (Day 8-12) 
1 (+) 
• Large oval cells seen well after Day 4 (+/- 2 days) 
or 
• Number per field <10 cells 
• Progressed through only one phase 
• Cluster -ve 
And/ or 
 





3.3.4.1.1 NLC Score 0 
Starting at the lowest score, as seen in Figure 3.15, a broad view (large circle) shows a generally 
homogenous appearance. Here there are no obvious presence of large oval cells. The number of NLCs 
are minimal to absent, therefore there was no development of NLCs. The samples that have had this 
score generally underwent widespread apoptosis in the early days of the culture. 
 
Figure 3.15 Example of NLCs with score 0. 
Phase contrast image of CLL PBMCs (#3500) cultured over approximately 8 days to allow development of NLCs. Here the 





3.3.4.1.2 NLC Score 1+ 
As seen in Figure 3.16, few NLCs are present by broad visual inspection under the phase contrast 
microscope (large circle). At a closer look, the NLCs can be seen in contrast to the lymphocytes as large 
oval cells. Although the NLCs were present, their number is actually quite low. Upon follow-up checks, 
it was found that they had a very slow progression and reached their plateau after passing through 
only a few phases. Also, there were hardly any group/ cluster of NLCs to be seen. Apoptotic signs of 
the cells appear quickly in general.  
Therefore, samples with NLC score 1+ generally presented with low number of NLCs at a later date, 
with hardly any clusters to be seen. This is followed by the sign of apoptosis. 
 
Figure 3.16 Example of NLCs with score 1. 
Phase contrast image of CLL PBMCs (#3502) cultured over approximately 11 days, displaying a range of morphologies, from 




3.3.4.1.3 NLC Score 2+ 
As shown in Figure 3.17, a greater number of NLCs is seen throughout the fields. On closer inspection 
a diverse collection of phases where the presence or absence of clusters were observed. These 
samples were considered as having moderate development of NLCs. Generally, samples with NLCs 2+ 
are suitable for most subsequent co-culture experiments. 
 
Figure 3.17 Example of NLCs with score 2. 
Phase contrast image of CLL PBMCs (#3529) cultured over approximately 5 days, displaying a range of morphologies, from 
large oval shape (blue arrow) to elongated or spindle-shaped appearance (orange arrow). Here numerous NLCs are seen in 




3.3.4.1.4 NLC Score 3+ 
This type of sample is considered as sample with fully developed NLCs. As shown in Figure 3.18, a very 
large number of NLCs can be seen broadly (large circle). On close inspection there were numerous 
cluster formations seen as multiple layers of cells, which make it difficult to distinguish the cells. The 
clusters consist of a very diverse group of monocytes/macrophages as well as lymphocytes. The 
clusters can be so big that it can be seen by the naked eye as small specs or spots on the plate 
(colonies). The samples with score 3+ are used for subsequent co-culture experiments. 
 
Figure 3.18 Example of NLCs with score 3. 
Phase contrast image of CLL PBMCs (#3484) cultured over approximately 15 days, displaying a range of morphologies, from 
large oval shape to elongated or spindle-shaped appearance. 
 
Using the NLC scoring system I carried out scoring all the CLL samples summarized in Table 3.3. It 




Table 3.3 Variation in generation of NLCs from all CLL samples studied 
Category No. of CLL samples examined Proportion (out of 88 samples) 
Well developed (3+) 24 27.3% 
Moderately developed (2+) 18 20.5% 
Poorly developed (1+) 43 48.9% 
No NLC development (0) 3 3.4% 
Total 88 100% 
 
Samples with NLC score of 2 or 3 were therefore considered for the subsequent co-culture 
experiments, whereas those with 1 were left with morphology observations and phenotyping. Those 
with NLC score of 0 were unsuitable for any further experiments. To explain why this phenomenon 
was seen, I went back to the clinical data and performed some descriptive analysis.   
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3.3.4.2 Correlation of NLCs development with clinical features of the CLL samples 
For this part of the study, a total of 88 CLL samples were used for NLC development, consisting of 
patients who gave re-bleeds (ie. Same patient gave more than one sample over time). The total 
number of samples that were not re-bleeds from the same patient was 65 and the summary of clinical 
information of these samples is displayed in Table 3.4. A more detailed view of the clinical data can be 
seen in Appendix Table 7.1.  





Age at diagnosis Mean: 65.63 (95% CI: 62.33-68.93) 



























*Prior therapy included steroid, chlorambucil, or fludarabine plus cyclophosphamide and rituximab. 
#WBC (white blood cell count) was performed at the time of sampling. 
¶FISH (fluorescence in situ hybridisation) was performed at or prior to sampling. 
∆IGHV status refers to somatic mutation in IGHV gene of CLL cells as compared with the gene sequence of the nearest 
germ-line using 2% as a cut-off.  
 
Initial descriptive analysis of clinical information showed that there was a predominance of samples 
from males (>70%) over females (<30%) in this study, as well as more cases of mutated IGHV (M-IGHV) 
and un-mutated TP53 (Figure 3.19). The majority of cases (almost 50%) were of Stage C, followed by 
Stage A (31%) and Stage B (21%). 
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When categorising those treated and untreated, I grouped them into ’Untreated’, ‘Previously treated 
but not currently’ and ‘On current treatment’. As seen in Figure 3.19, almost 56% of cases in the study 
were untreated, almost 17% were previously on treatment but not on a current treatment and 27% 
were on treatment at the time of sample collection. 
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Figure 3.19 Summary of Clinical Data Analysis. 
 
 
Percentage Distribution of cases based on Gender (top left), IGVH mutational status (top middle), Staging (top right), TP53 mutational status (bottom left), Treatment category 
(bottom middle) and Risk stratification based on chromosomal abnormalities (bottom right). Statistical Analysis and figures generated by SPSS 2.4 
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As seen in Figure 3.20, only 3 cases did not develop any NLCs (NLC Score 0) and combined with poor 
NLC Score (+), this gave just under 50% of all samples. Those that gave a Moderate NLC Score (++) 
accounted for about 20% of all cases and those that gave a High NLC Score (+++) accounted for about 
30% of all cases (Figure 3.20 top left).  
I then performed statistical analysis to see if there is a significant correlation between NLCs score and 
any of clinical features using Chi squared and Fisher-Freeman-Halton exact test. There was no 
significant trend seen when comparing the proportions of NLC Score distribution within IGHV 
mutational status (p=0.729), nor TP53 (p=0.259) and Chromosomal abnormalities (p= 0.175).  
There was no trend seen with regard to NLC score distribution and treatment category with p=0.931 
(Figure 3.20 top right).  
When subdividing CLL samples according to the clinical stage, it appeared that samples with poor NLC 
Score (1+) covered just under half of Stage A and C but only 23% in Stage B (Figure 3.20, middle). 
Moderate NLC score (2+) samples accounted the most in Stage B cases (38%) followed by Stage C 
(28%) and finally Stage A (9%). High NLC score (3+) accounted the most in Stage A (45%), followed by 
Stage B (38%) and finally Stage C (16%). Interestingly, samples with the lowest NLC Score (0) were all 
in the category of Stage C (Figure 3.20, middle). This trend, however, was not significant using Fisher-
Freeman-Halton exact test (p=0.54). 
I wanted to find out if this pattern can be explained due to treatment, so I separated the samples into 
treated and untreated subgroups (See Appendix Table 7.2). The trend that was seen earlier was indeed 
replicated within untreated samples (Figure 3.20, bottom left) but not really seen with treated 
samples (Figure 3.20, bottom right). The NLCs score was inversely correlated with the clinical stage, 
which was statistically significant when analysed using Chi Squared test (p value <0.05). 
Next, I wanted to see if there was a correlation between the amount of monocytes in circulation (i.e. 
in the PBMC) and the development of NLCs (i.e. NLC score). In order to answer this, I calculated and 
used the percentage of monocytes from the sum of absolute monocytes and lymphocytes for each 
PBMC samples used. As seen in Figure 3.21, there was no significant trend seen when comparing the 
percentage of monocytes in PBMC with NLC Score, nor with the mean percentage of monocytes in 
PBMC with NLC score. 
Additionally, I analysed repeated samples (re-bleeds from same patients) to observe for any trends on 
NLC score with subsequent samples (See Appendix Figure 7.1). It is worth noting that generally with 
re-bleeds, it is usually taken before the start of treatment if not newly started. There were no 






Figure 3.20 Summary of Clinical Data in the context of NLC Scores. 
 
Distribution of cases based on NLC score (top left), NLC Score distribution based on treatment category (top right), 
Distribution of NLC scoring based on Staging (middle), NLC score distribution amongst samples that were Untreated (bottom 
left) vs Treated (bottom right) and their staging at the time of sample collection. The trend seen in staging with NLC Score 3 
amongst untreated group was analysed using Chi Square test after subdividing the data into Low (0, 1, 2) and High (3) and 









Comparison of NLC scores with percentage monocytes in PBMC (left) and mean percentage monocytes in PBMC (right). With the percentage monocytes in PBMC (left) the y-axis is in log 
scale and the dark lines are Median average values. Using One Way ANOVA, there was no significant difference between the mean values (right) from the different groups. Statistical Analysis 
and figures generated by SPSS 2.4 
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3.3.5 Effects of co-culture on CLL cells 
3.3.5.1 Preparing co-culture experiments 
To confirm that NLCs exert cytoprotective effect on CLL cells when in co-culture, as previously reported 
(Burger et al. 2000), co-culture experiments were to be performed by culturing thawed autologous 
CLL cells with the NLCs developed from the same CLL samples. Viability of CLL cells with and without 
co-culture on the established NLC layer was quantified by FACS analysis (described in Methodology). 
To prepare the NLC monolayer, the NLCs were developed as previously mentioned until they reached 
their plateau phase. Figure 3.22 provides an example what NLCs look like before co-culturing with 
autologous CLL cells (A) and during co-culture with CLL cells (B). The CLL cells were removed by gentle 
pipetting so as to leave behind the NLC monolayer (A). On close view it can be seen that minimal or 
no CLL cells remained. Given that the monolayer was prepared, autologous CLL cells were thawed and 











Figure 3.22 Phase contrast images of co-culture of CLL cells with NLCs. 
Phase contrast images (#3484) of a typical visual field of a culture plate where NLCs were developed for about 15 days at low 
magnification. CLL cells were washed off, leaving behind the adherent NLCs at low magnification (A), autologous CLL cells 





3.3.5.2 Analysis of spontaneous cell death 
When preparing the co-culture experiments to evaluate effects of co-culture of CLL cells with NLCs, I 
also prepared both types of cells cultured alone so that I can not only directly compare the viability of 
the co-cultured CLL cells to that of CLL cells cultured alone, but also monitor how the NLCs behave in 
the absence of CLL cells. Therefore, I prepared wells on multi-well plates with CLL+NLC, NLC alone and 
CLL alone and observed for morphology and viability measured over 4 days. By morphological 
observation under the phase contrast microscope it was apparent that the CLL cells maintained their 
healthy, glowing appearance upon co-culture when compared with CLL cells cultured alone (Figure 
3.23).  
 
Figure 3.23 Co-culture conditions maintained healthy, glowing appearance of both NLCs and CLL cells when compared to 
their respective cells cultured alone. 
Phase contrast images of co-cultured NLCs and CLL cells (3484) on Day 6 (left panel), NLCs cultured alone (middle panel) and 
autologous thawed CLL cells cultured alone (right panel). Fresh PBMCs was cultured as described till the fully developed NLCs 
appeared at approximately Day 14. Cryopreserved autologous CLL cells were then thawed and cultured with the NLCs. 
 
Interestingly, the NLCs also displayed a healthy, glowing appearance when in co-culture with CLL cells 
as compared with NLCs cultured alone (Figure 3.23, compare right panel to middle panel). The NLCs 
cultured alone appeared to be dislodged from the groups/clusters and some NLCs seemed to lose 
glowing appearance. Eventually the NLCs also started to disintegrate. It was not possible to quantify 
the viability of the NLCs by flow cytometry due to the difficult and inefficient method of harvesting 
them form the culture plate. I therefore focused on analysis of cell death of CLL cells harvested from 
both culture conditions by flow cytometry. 
As shown in Figure 3.24, in contrast to CLL cells cultured alone, the CLL cells in co-culture retained 
better viability throughout the 4-day period of observation. This coincided with what was seen under 
phase contrast microscope. In total, 8 CLL samples were used and the difference in viability between 
CLL cells in co-culture and cultured alone was statistically significant from Day 2 with a p value of less 
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than 0.05. Therefore, co-culturing CLL cells with NLCs protected them from spontaneous death, a 





Figure 3.24 Co-culture with NLCs protected CLL cells against spontaneous cell death. 
Cryopreserved CLL cells were thawed and co-cultured with NLCs as described in Methods. CLL cells cultured alone were used a control. Viability of CLL cells was monitored over 4 days by flow 
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*p < 0.05 
Day 0 Day 1 Day 2 Day 3 Day 4 
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3.3.5.3 Levels of CCL3 and CCL4 in the culture medium 
It has previously been reported that NLCs induce CLL cells to secrete the T-cell chemokines CCL3 and 
CCL4 into the culture medium where they can be measured by ELISA (Burger et al, 2009). I therefore 
also measured levels of CCL3 and CCL4 in the supernatant collected from co-cultures of CLL cells with 
NLCs.  
As seen in Figure 3.25, the levels of CCL3 (blue) and CCL4 (red) were increased from day 5 and reached 
a plateau by day 10, which continued to day 13. This result was similar to what has been reported 
(Burger et al. 2009b). 
 
3.3.5.4 Expression of sIgM and sIgD 
It has also been shown that CLL cells co-cultured with NLCs displayed significant reduction in surface 
expression of IgM and IgD, which may indicate that NLCs can engage B cell receptors (BCR) of CLL cells 
(Ten Hacken et al, 2016). I therefore monitored expression of surface IgM (sIgM) and IgD (sIgD) in CLL 
cells co-cultured with NLCs on days 0, 8/9 and 13/14 by flow cytometry.  
As seen in Figure 3.26 (top), the average sIgM expression appeared to have been quite low at the start, 
then rose by two-fold on Day 8/9 of co-culture and then fell back to base-line on Day 13/14. Overall 
the changes in sIgM was not significant and there was no consistent trend of either direction (i.e. 
increase or decrease). The average sIgD expression was quite high at initial stage on Day 0, in contrast 
to sIgM (Figure 3.26 bottom). At the subsequent time points the levels of sIgD seemed to have 






Figure 3.25 CCL3 and CCL4 protein expression in CLL-NLC cultures. 
CLL PBMCs were cultured for up to 13 days with concurrent development of NLCs and supernatant samples at the indicated time points were collected for analysis of CCL3 (blue line) and 
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Figure 3.26 Surface expression of IgM and IgD of CLL cells cultured with NLCs over 14 days. 
Surface expression of IgM (top) and IgD (bottom) of CLL cells cultured with NLCs over 14 days. Fresh PBMCs was cultured as 
described for up to 14 days. Surface IgM and IgD of CLL cells was monitored three times during the 14 days by flow cytometry 
as described. Data represent mean ± SD of independent experiments using 3 different CLL samples. Mean fluorescence 
intensity ratio (MFIR) of CLL cells stained with respective isotype control antibodies (Control) was also shown as mean ± SD. 
 
Taken altogether, a pro-survival effect by NLCs on CLL cells was seen compared to CLL cultured alone. 
There was a trend of rising CCL3 and CCL4 in the supernatant of PBMC cultures till Day 5 where they 
remained high till the end of the experiment. sIgM of CLL cells did not give a clear trend with the 





In this chapter, I confirmed and expanded the previous finding that NLCs can be developed using fresh 
PBMCs from CLL patients under standard culture conditions. The optimal cell density for development 
of NLCs I found was 10 x 106 cells/ml. This is consistent with conditions described previously by some 
researchers (Nishio et al. 2005). However, others have reported to develop NLCs using much lower 
cell densities of CLL PMBCs (Filip et al. 2009; Jia et al. 2014; Nishio et al. 2005; Polk et al. 2016). Use of 
higher cell densities to develop NLCs was also being reported (Burger et al. 2000). It thus indicates 
that, although the cell density of 10 x 106/ml was an optimal concentration of cells used to develop 
NLCs under the culture conditions in my study, it is not a critical factor in determining whether NLCs 
can be developed in vitro.  
My description of NLCs detailing their pleomorphism (ranging from large oval, tail-like projections, 
spindle appearance, elongated, group/cluster formation, etc.) independently confirmed the dynamic 
process of NLCs development. The early description of NLCs in literature, e.g. being ‘oval/adherent’ 
by (Burger et al. 2000) or ‘large/round/adherent’ (Tsukada et al. 2002) provided a basic description of 
morphological features of NLCs. In my study, I used the MGG staining technique and produced images 
with more detailed cellular structure and shape of NLCs, revealing the vibrant process of 
differentiation from monocytes to macrophages. For example, the descriptions of large oval adherent 
and tail-like projections suggests that NLCs exhibited features of cell motility, similar to motile cells 
such as fibroblasts (Herant & Dembo 2010).  
The time course observation that I recorded revealed that most CLL PBMCs samples present with 
distinguishable NLCs as early as 2 days after culturing and NLCs reach their plateau by Day 8-12. I 
performed my co-culture experiments as soon as NLCs reached plateau. This is in contrast with other 
researchers who performed their experiments at Day 14 (Burger et al. 2000; Gautam et al. 2016; Jia 
et al. 2014), which may explain the different results observed between the studies. Reassuringly, one 
of the earlier studies also mentioned the appearance of the NLCs after 3 days in culture, which 
increased in number in the following  days and finally formed a layer of large, round adherent or 
fibroblast-like cells after 14 days in culture (Burger et al. 2000). This description was entirely consistent 
with what I have observed in my study. 
The most striking observation I made was the wide variation in developing NLCs from primary CLL 
PBMC samples and this variation applied to both the kinetics and magnitude of NLCs generated. 
Although it has been previously reported that not all CLL PMBC samples developed NLCs (Jia et al, 
2014), the extent of the variation prompted me to devise an NLC score system to assign an NLC score 
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for each and every samples used. To investigate if the NLC scores correlate with any clinical features 
of CLL samples, I collected available clinical information for all the samples used. Over the course of 
over 4 years, 88 samples were used for this chapter, 65 of which were samples not re-bled from the 
same patient. The clinical data analysis showed that the samples were primarily from male patients, 
almost half of samples from treatment naive patients, and majority of the patients with a Stage C 
progressive disease. Most of the samples had 13q- or no chromosomal abnormalities, accounting to 
over 50% of the cohort. The clinical information is thus very similar to the general population of CLL 
patients (Baliakas et al. 2019). The samples used in my study is thus a representative cohort of CLL 
patients.  
When subgrouping CLL samples based on the NLC scores, I did not find any correlation between NLC 
score and IGHV mutation, TP53 mutation, treatment history nor chromosomal abnormalities. 
However, when analysing clinical staging I observed that samples with increasing NLC Scores inversely 
correlated with clinical staging of the disease. This inverse correlation was statistically significant in 
CLL samples from untreated patients. The exact cause is yet unknown and would thus require further 
work to explain.  
Previous studies have reported the correlation between number of NLCs and clinical outcome of 
disease. In a study where authors examined the development of NLCs from CLL PBMC samples from 
65 treatment naïve patients, they found that various number of NLCs was developed in 58 samples 
(Filip et al., 2009 and 2013). Among the samples that have developed NLCs, 49 CLL samples developed 
more than 20 NLCs/mm2 and 9 samples developed fewer than 20 NLCs/mm2. They found that the 
number of NLCs was positively correlated with serum level of β2-microglobulin and absolute 
monocyte count (AMC). However, no correlation was found between number of NLCs and clinical 
stage of the disease, whole blood count, lymphocyte count, or CD38 and ZAP70 expression. 
Interestingly, during a 6-year follow-up a shorter overall survival was observed in patients whose CLL 
samples produced a higher NLC count (i.e. >20 NLCs/mm2), albeit not statistically significant (Filip et 
al., 2009 and 2013). Higher number of NLCs was also reported to correlate with shorter treatment-
free survival and shorter overall survival (Boissard et al. 2016).  
Meanwhile, higher AMC has been reported in CLL patients compared to normal healthy controls 
(Maffei et al. 2013). Higher AMC has been linked to progressive disease and early treatment in CLL 
(Herishanu et al. 2013, Friedman et al. 2016).  
In my study, however, there was no significant correlation between the blood monocyte count and 
the NLC scores, which is in disagreement with the findings from the previous studies (Filip et al., 2009 
and 2013). This may be due to the fact that the studies by Filip et al. (2013a) recorded the amount of 
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NLCs as absolute upon counting rather than categorising into NLC scores. Perhaps if I were to use 
meticulous methods to record absolute counts of NLCs, I may be able to perform accurate statistical 
analysis to correlate with absolute monocyte count. The NLC scoring could possibly be refined to 
include absolute NLC count. 
Regarding the phenotypic marks of NLCs, I was able to confirm the expression of CD14, CD68 and 
CD163 in NLCs and CD19 CLL cells, respectively, by immunofluorescence microscopy. CD14 and CD68 
were exclusively present in NLCs, localised within the cytoplasm near the nucleus. They also had 
variable levels of expression during the different phases of NLC development. CD163 was also present 
exclusively in NLCs and localised throughout the cytoplasm depicting the actual shape of the cells. It 
was also present throughout all phases of development of NLC. This suggests that CD163 may be a 
potential marker for NLCs in vivo. This notion is in agreement with the finding from a study 
investigating the relationship of NLCs with disease progression of CLL (Boissard et al. 2016a), where 
CD163 was considered to be the most reliable marker for NLCs as compared to CD68. The above result 
was also consistent with reports from others that NLCs express CD68, CD163 and CD14 (Boissard et 
al. 2015a; Fiorcari et al. 2015; Marchesi et al. 2015). Other studies had also shown that the expression 
of CD163 and CD68 was detected in monocytes/macrophages in the spleen (Nagelkerke et al. 2018; 
Ysebaert et al. 2010) and lymph nodes (Giannoni et al. 2014; Ysebaert et al. 2010). This suggests that 
what is seen in vitro of NLCs derived from CLL PBMCs culture is also relevant in vivo within the tumour 
microenvironment such as lymph nodes and spleen. I have observed the variation in levels of CD68 
and CD14 during the different phases of development of NLCs. The levels of CD68 and CD14 expression 
may influence differentiation of the NLCs, particularly for the subsequent polarisation towards M2-
type macrophages, as suggested by Gu et al. (2019). Therefore, the biological significance of the 
variation in expression of CD68 and CD14 by NLCs is still unclear and merits further investigation. 
The co-culture experiments I have performed clearly demonstrated the protective effects of NLCs on 
CLL cells, which is entirely in agreement with the findings reported by numerous studies (Burger et al. 
2000; Filip et al. 2013b; Nishio et al. 2005; Tsukada et al. 2002). My co-culture experiments 
predominantly used CLL samples with an NLC Score of 2 or 3. Co-cultured NLCs and CLL cells, as well 
as their respective counterparts cultured alone, were closely monitored under light microscope for 
morphologic changes. Indeed, compared with their counterparts cultured alone, CLL cells co-cultured 
with NLCs looked more viable, as indicated by their healthy-looking appearance. One study, however, 
reported that samples with lower viability developed NLCs faster and those with higher viability failed 




Unexpectedly, compared to NLCs cultured alone, NLCs co-cultured with CLLs also displayed healthy-
looking appearance. This suggests that CLL cells could also actively influence the wellbeing of NLCs. As 
of yet, there have been no report in the literature describing the effect that CLL cells have had on NLCs 
in vitro. This effect clearly merits further study as it could potentially unravel how CLL cells participate 
in shaping the microenvironment into a safe haven for the leukemic cells.    
I also examined the levels of CCL3 and CCL4 in the medium of the co-cultures as it was shown that 
NLCs can induce CLL cells to express CCL3 and CCL4 and that increased levels of CCL3 and CCL4 were 
detected in the supernatant collected from medium of CLL PBMCs cultures over time (Burger et al., 
2009; Zucchetto et al. 2009).  The increased levels of CCL3 and CCL4 was also linked to unfavourable 
clinical outcome of CLL patients (Hartmann et al. 2016; Sivina et al. 2011). Solid cancers such as colon 
cancer, as well as local reaction to pathogenic challenge and wounding have been shown to secrete 
CCL3 and CCL4 which lead to recruitment of macrophages (Pollard 2004). 
I also investigated the effect of NLCs on CLL cells regarding changes in surface expression of IgM and 
IgD of co-cultured CLL cells. Decrease in levels of sIgM and sIgD could be a result of activation of BCR 
signalling pathway, which plays a critical role in CLL biology (Ten Hacken et al. 2016). My results 
showed a continuous decrease in the level of sIgD in co-cultured CLL cells over the 14 days of co-
culture, although the decrease is not statistically significant. In contrast to sIgD, changes in sIgM did 
not occur in a clear trend. Instead, overall expression of sIgM of CLL cells remained low throughout 14 
days of co-culture. My results thus were in contradiction to a previous report where a significant 
decrease in both IgM and IgD of CLL cells was seen during a 14-day co-culture with NLCs using 4 CLL 
samples from patients with un-mutated IGHV (Ten Hacken et al. 2016). This discrepancy could be 
because of a low number of samples examined in my study. It is thus important that a greater number 
of randomly selected CLL samples should be used to get a clearer picture as to whether NLCs affect 
the expression of sIgM and sIgD in CLL cells. 
In summary, after I optimised conditions to develop NLCs from fresh CLL PBMCs, I have confirmed 
many features of NLCs in terms of their morphology, expression of phenotypic markers and biological 
effects of on CLL cells. In addition, I made an important observation on the wide variation in both 
temporal and spatial terms in development of NLCs between individual CLL samples. This variation 
may well reflect the heterogeneous nature of the disease. This observation is thus relevant to the in 
vivo interaction between NLCs and CLL cells in the tumour microenvironment such as lymph nodes, 
bone marrow and spleen. To better understand the molecular mechanisms mediating the in vivo 
interactions of NLCs with CLL cells, further study is required to understand how NLCs and CLL cells 
cross-communicate each other at the level of the gene expression.  
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One further point to make is that study of NLCs requires continuous supply of fresh CLL PBMCs 
samples. Given the difficulty experienced in obtaining fresh CLL samples on a regular basis and the 
laborious, time-consuming techniques used to prepare the NLCs for subsequent experiments, 
together with the considerable variation in generating NLCs from CLL PBMC samples, there is clearly 
a need to explore the use of a cell line model of NLCs. In the next chapter, I will therefore describe the 








4 Development of a cell line model using THP-1 cells to mimic the 
pro-survival effects of NLCs on CLL cells 
 
4.1 Introduction 
I have shown in the previous chapter that the interaction between NLCs and CLL cells is a complex 
process which clearly impacted on the survival of CLL cells. Better understanding of this process is 
important as it may shed light to how CLL cells evade apoptosis within the tissue microenvironment 
via the interaction with NLCs and eventually develop resistance to therapies. However, I have also 
shown that there was a huge variation in the amount of NLCs generated from individual CLL samples. 
Among the 88 CLL samples I used in the previous part of the study, only about half of the samples 
developed adequate amount of NLCs that can be used for the subsequent co-culture experiments. 
Although this variation was not overly surprising given the heterogeneous nature of the disease, it 
caused a significant problem to me in obtaining consistent and reproducible results. This problem, 
together with some practical constraints such as entirely relying on supply of fresh CLL blood samples 
and continuous maintenance of primary cell cultures (for up to 2 weeks for each sample), prompted 
me to look for a cell line model of NLCs so that I can use it to perform experiments consistently and 
efficiently. 
Cell lines have been used by cancer research scientists as model systems of cancer cells ever since the 
first human cancer cell line (i.e. Hela cells) was established in the 1950s (Masters 2002). Discoveries 
made from cell line-based research have complemented that from studies using tumor cells/tissues 
and animal models for different types of cancers. Together, they advanced our understanding of the 
biology of cancer and contributed to development of new treatment of cancer. Therefore, cell lines 
are valuable tool for discovery. However, cell lines have major limitations, namely the genetic 
instability acquired during long term culture, selective growth of subclones of cancer cells caused by 
culture condition and lack of interaction of components within the tumour microenvironment 
(Gazdar, Gao & Minna 2010; Kaur & Dufour 2012). Additional differences in other characteristics are 
summarized in Table 4.1. Therefore, with the advantages and limitations of cell lines in mind I set out 




Table 4.1 Brief summary of characteristics of primary cells vs cell Lines 
Characteristics: Primary Cells Immortalized Cell Lines 
Lifespan Limited  Infinite  







Since NLCs are monocyte derived macrophages, I focused my search on cell lines of monocytic origin. 
 
4.1.1 Choice of human monocytic cell lines 
Monocytes are circulatory cells from myeloid origin that when migrating from circulation to tissues, 
can develop into macrophages or dendritic cells (Chanput, Peters & Wichers 2015). They serve three 
main functions in the immune system, namely phagocytosis, antigen presentation and cytokine 
production. The cell lines THP-1 and U937 are of monocytic origin that can be differentiated into 
various types of macrophages (Chanput, Peters & Wichers 2015). 
 
4.1.1.1 THP-1 cell line 
The THP-1 cell line is derived from leukemic cells from a patient with acute monocytic leukemia, with 
the cell line established in 1980 (Chanput, Peters & Wichers 2015; Tsuchiya et al. 1980). THP-1 cells 
retain morphological and differentiation properties of primary monocytes and macrophages. They 
appear in a large, round single-cell morphology and express distinct monocytic markers (Chanput, 
Peters & Wichers 2015; Tsuchiya et al. 1980). They can be differentiated into macrophages with the 
addition of phorbol 12-myristate 13-acetate (PMA). They grow in suspension and do not adhere to 
surface of the plastic culture plates/flasks (Chanput, Peters & Wichers 2015; Takashiba et al. 1999; 
Tsuchiya et al. 1980). 
THP-1 cells have relatively homogenous genetic background, resulting in fewer changes in cell 
phenotype (Chanput, Mes & Wichers 2014; Chanput, Peters & Wichers 2015). Their average doubling 
time is around 35-50 h (Chanput, Mes & Wichers 2014). The growing rate in complete RPMI medium 
is much higher as compared to that of primary PBMC-derived monocytes (Chanput, Mes & Wichers 
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2014). There is no report for presence of infectious viruses in the THP-1 cells, making them relatively 
easy and safe to use (Chanput, Mes & Wichers 2014). It was reported that this cell line can be cultured 
in vitro for up to 25 passages (approximately 3 months) with no detectable changes in cell phenotype 
and function (Chanput, Mes & Wichers 2014). The availability of primary PBMC-derived monocytes is 
often limited and these monocytes are not suited for long-term storage in liquid nitrogen (Tedesco et 
al. 2018). THP-1 cells, however, can be stored for a number of years following appropriate storage 
protocol, without any obvious effects on monocyte-macrophage features and cell viability (Chanput, 
Mes & Wichers 2014). Co-cultivation of THP-1 cells with other cell types has been reported for use as 
cell line models to mimic in-vivo situation (Chanput, Mes & Wichers 2014). 
 
4.1.1.2 U937 cell line 
The U937 cell line is derived from human myeloid leukaemia cells that was isolated from the histiocytic 
lymphoma of a 37-year-old male patient (Chanput, Peters & Wichers 2015). Similar to THP-1 cells, 
U937 cells also exhibit many features of monocytes, differentiate into macrophages with typical 
morphology and characteristics (Chanput, Peters & Wichers 2015; Mendoza-Coronel & Castanon-
Arreola 2016). It is used to study the behaviour and differentiation of monocytes, as U937 cells can be 
induced to differentiate in response to a number of stimuli (Chanput, Peters & Wichers 2015; Rots et 
al. 1999; Strefford et al. 2001).  
Similar to THP-1 cells, U937 cells can also be cultured in vitro for up to passage 25 or higher (Chanput, 
Peters & Wichers 2015). Unlike THP-1 cells originated from blood monocytes with less differentiation 
characteristics, U937 cells are of tissue origin, thus maintain more differentiation features (Chanput, 
Peters & Wichers 2015). For example, U937 cells can be induced to differentiate into macrophages 
with the use of 1,25-dihydroxyvitamin D3 (VD3 at 100nM) or 12-O-tetradecanoylphorbol-13-acetate 
(TPA at 20ng/ml) (Chanput, Peters & Wichers 2015). 
Other cell lines with similar properties to THP-1 and U937 cells include ML-2, HL-60 and Mono Mac 6 
cells, but there are far fewer reported studies using them (Chanput, Peters & Wichers 2015).  
Given the information described above, together with the fact that far more studies were published 
using THP-1 cells than U937 cells and that THP-1 cells closely resemble primary monocytes, I decided 




4.1.2 PMA vs VD3 for chemically differentiating the cell line monocytes to macrophages 
PMA inhibits the growth and allow differentiation of THP-1 and U937 cell line in dose dependent 
pattern. PMA does this by activation of Protein Kinase C (PKC) because it mimics the physiological 
Diacylglycerol (DAG) which is a PKC activator (Chang et al. 2012; Schwende et al. 1996). PKC comprises 
of a series of kinases that are involved in the regulation of cell proliferation, differentiation, and other 
cellular functions (Schwende et al. 1996). 
High concentrations of phorbol ester results in downregulation of certain isoforms of PKC and 
decreased activity of PKC so this will lead to downregulation of certain transcriptional factors 
(Schwende et al. 1996). 
According to one study, THP-1 responded better with PMA with an almost complete arrest in 
proliferation but VD3 was less effective with unchanged division up to 48h (Schwende et al. 1996). 
THP-1 cells incubated with PMA became adherent and developed a macrophage-like appearance but 
not with exposure to VD3 (Schwende et al. 1996). THP-1 was able to phagocyte target foreign bodies 
and the phagocytic activity was enhanced with PMA and VD3-differentiated cells. PMA-differentiated 
cells showed almost 2-fold higher phagocytic activity than those with VD3 (Schwende et al. 1996). 
Based on literature, 0.5x106/ml of THP-1 monocytes fully differentiated into macrophages after 48h 
incubation at minimal concentration of 100ng/ml of PMA, resulting in macrophages with a phagocytic 
capacity for latex beads and expressing cytokine profiles that resembled PBMC monocyte-derived 
macrophages (Chanput, Mes & Wichers 2014; Chanput, Peters & Wichers 2015). 
Given the information, I decided to use PMA as the agent of choice to chemically differentiate the 
THP-1 cell lines to macrophages for the study. 
 
4.1.3 Polarization of THP-1 macrophages 
THP-1 cell lines have been shown to differentiate into macrophages using phorbol 12-myristate 13-
acetate (PMA) (Aldo et al. 2013; Chang et al. 2012; Chanput et al. 2013; Daigneault et al. 2010; Genin 
et al. 2015; Kohro et al. 2004; Park et al. 2007; Ramprasad et al. 1996; Schwende et al. 1996). Once 
differentiated with PMA (M0), they do not proliferate further and adhere to the surfaces of culture 
plates (Aldo et al. 2013; Chanput et al. 2013; Chanput, Mes & Wichers 2014; Chanput, Peters & 
Wichers 2015; Daigneault et al. 2010; Forrester et al. 2018; Genin et al. 2015; Kohro et al. 2004; Park 
et al. 2007; Qin 2012; Ramprasad et al. 1996; Schwende et al. 1996; Takashiba et al. 1999; Tsuchiya et 
al. 1980).  
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When exposed to interferon gamma (IFN-γ) and lipopolysaccharide (LPS), the M0 cells differentiate to 
M1 phenotype (Chanput et al. 2013; Genin et al. 2015; Park et al. 2007; Takashiba et al. 1999), and 
with exposure to interleukin-4 (IL-4) the M0 cells differentiate into M2 phenotype (Chanput et al. 
2013; Genin et al. 2015; GmbH 2015; Gordon 2003; Gordon & Martinez 2010; Italiani & Boraschi 2014; 
Jablonski et al. 2015; Mantovani et al. 2002; McWhorter et al. 2013; Mills 2015; Roszer 2015; Sica et 
al. 2008).  
It is important that the monocyte be PMA-differentiated first (M0) and then polarized to either M1 or 
M2, as the THP-1 cell (unexposed to PMA) would not change their morphology into macrophage-like, 
and only mild expression of some M1/M2 marker genes were observed (Chanput, Mes & Wichers 
2014). 
This THP-1 cell line was also used in co-culture experiment studies, with platelets, T-lymphocytes, 
vascular smooth muscle cells (Aslam et al. 2007; Azenabor et al. 2011; Chanput, Mes & Wichers 2014; 
Qin 2012; Zhang et al. 2008), and interestingly with adipocytes where it was shown that co-cultured 
primary human adipocytes with THP-1 macrophages resulted in a induced shift of THP-1 macrophages 
to M2 phenotype (Chanput, Mes & Wichers 2014; Spencer et al. 2010). 
 
4.2 Objectives 
• To determine if THP-1 cells can be developed as an in-vitro model of NLCs, 
• To compare the similarities and differences of the cell line model to NLCs in aspects of 







4.3.1 Summary of CLL samples used for this part of the study 
For this chapter, a total of 14 CLL samples were used and the summary of clinical information of these 
samples is displayed in Table 4.2. A more detailed view of the clinical data can be seen in Appendix 
Table 7.1. The samples were selected based, in part, on their sensitivity to fludarabine.  















IGHV# Un-mutated 2 






*Prior therapy included steroid, chlorambucil, or fludarabine plus cyclophosphamide and rituximab. 
¶FISH (fluorescence in situ hybridisation) was performed at or prior to sampling. 
#IGHV status refers to somatic mutation in IGHV gene of CLL cells as compared with the gene sequence of the nearest 
germ-line using 2% as a cut-off.  
 





4.3.2 Culturing and differentiation of THP-1 cells.  
The THP-1 cell line (derived from human monocytic leukaemia cells) was obtained from the European 
Collection of Authenticated Cell Cultures (Salisbury, UK), and maintained in culture flasks containing 
the complete RPMI-1640 medium as described above. To induce differentiation into macrophages, 
THP-1 cells (5 x 105 cells/mL) were treated with 5 ng/mL phorbol 12-myristate 13-acetate (PMA) 
(Sigma-Aldrich, Gillingham, UK) for 2 days, as previously described (Daigneault et al. 2010; Park et al. 
2007). For polarization to M1 macrophages, the medium of PMA-differentiated THP-1 cells was 
removed and replaced with fresh complete medium containing 20 ng/mL interferon- γ (IFN-γ) 
(PeproTech EC Ltd, London, UK) and 10 pg/mL lipopolysaccharides (LPS) (Sigma-Aldrich) for 24 h, as 
previously described (Chanput, Mes & Wichers 2014; Genin et al. 2015; Jablonski et al. 2015). To 
induce M2 macrophages, the medium of PMA-differentiated THP-1 cells was removed and replaced 
with the fresh complete medium containing 30 ng/mL interleukin-4 (IL-4) (R&D Systems, Oxford, UK) 
and incubated for 72 h, with additional IL-4 (30 ng/mL) being added at 48 h (Chanput, Mes & Wichers 
2014; Jablonski et al. 2015; McWhorter et al. 2013; Park et al. 2007). As described in Methodology, to 
perform a combined set of experiments using M0, M1 and M2 a timetable (Table 2.1) is followed to 
allow all conditions to be ready by the time the experiments are started. 
 
4.3.3 Co-culture experiments 
As described in Methodology, cryopreserved CLL samples were thawed and co-cultured at 3 x 106 
cells/mL with differently differentiated THP-1 cells for the indicated times. 
 
4.3.4 Analysis of cell death by flow cytometry 
As described in Methodology, CLL cells co-cultured with differentiated THP-1 cells in the presence or 
absence of cytotoxic agents were harvested at the end of indicated time points and analysed for cell 
death by flow cytometry following staining with FITC-labelled Annexin V (BD Biosciences, Oxford, UK) 
and propidium iodide (Sigma-Aldrich). 
 
4.3.5 Immunofluorescence microscopy 
As described in Methodology, cells were fixed with 4% paraformaldehyde and permeabilized in PBS + 
0.2% Triton X-100 in accordance with the manufacturer’s protocol (BD Biosciences) before staining 
with primary antibodies and their corresponding isotypic controls. Fluorescence-labelled secondary 
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antibodies were then applied to amplify the signal and the nuclei counterstained with diamidino-2-
phenylindole (DAPI).  
 
4.3.6 Measuring CCL3 and CCL4.  
As described in Methodology, levels of human CCL3 and CCL 4 in the culture medium were measured 
using commercial ELISA kits, in accordance with the manufacturer’s instructions (Thermo Fisher 
Scientific). The colour-metric changes were read using a spectrophotometer at 450nm. 
 
4.3.7 Surface IgM and IgD 
The THP-1-derived M0 and M2 macrophages are prepared as previously described. A level of surface 
IgM and IgD on CLL after thawing is measured as described  (Ten Hacken et al. 2016) and used as a 
basal level of expression (Day 0). The levels of expression in IgM and IgD on CLL cells co-cultured with 
M0 or M2 macrophages were measured for 3 consecutive days using 3 different CLL samples and then 
compared to Day 0. Following 3 days in co-culture, CLL cells were collected from the co-cultures and 
incubated at 3x106/ml under standard culture conditions and the levels of IgM and IgD on CLL cells 
were monitored for another 3 days. The expression levels are measured at 24, 48 and 72hrs, as 
described in Methodology. 
 
4.3.8 Measuring drug-induced cell death 
To determine drug-specific effect on cell death, cells that were not treated with the drug was used as 
a control. The amount of cell death in the control is considered as spontaneous cell death. Using 
Equation 4.1 below, the percentage of drug induced cell death can be calculated, as previously 
described (Zhuang et al, 2014). 
 
Equation 4.1 Drug Induced Cell Death 
% drug-induced cell death = 100 x (% cell death of drug-treated cells – % cell death of untreated cells) 




4.3.9 Statistical analysis 
Where appropriate, the paired, two-tailed Student’s t test was performed to determine the statistical 
significance of the difference between the two groups of data using SPSS (version 21) and Microsoft 







4.4.1 Morphological features of PMA-treated THP-1 cells resembled that of macrophages 
As shown previously, NLCs were developed from circulating monocytes and exhibited a macrophage 
phenotype. To differentiate THP-1 cells into macrophages, I added phorbol 12-myristate 13-acetate 
(PMA) as described in Methods. This caused the cells to become adherent and their proliferation 
ceased as expected from other studies (Chanput, Peters & Wichers 2015; Spano, Barni & Sciola 2013).  
As seen in Figure 4.1 (left), the PMA-treated THP-1 cells became adherent with a flattened oval and 
elongated shape, which resembled NLC cells.  Next, I wanted to see if there were any further changes 
of the PMA-treated THP-1 cells in the presence CLL cells. 
It is known from other studies that PMA induces differentiation of CLL B cells (Ghamlouch et al. 2014), 
so it was imperative to remove PMA from the differentiated THP-1 culture medium. Therefore, I 
removed the supernatant and washed the culture plate with pre-warmed PBS to remove residual PMA 
and any undifferentiated THP-1 suspension cells. I then plated thawed CLL cells on top of adherent 
THP-1 cells (Figure 4.1, middle). CLL cells were plated alone as a control (Figure 4.1, right).  
 
Figure 4.1. PMA-treated THP-1 cells co-cultured with CLL cells when compared to their counterparts cultured alone. 
Phase contrast images of THP-1 cells treated with PMA for 48 h when cultured alone (left), co-cultured with CLL cells (middle, 
red arrow head) and CLL cells cultured alone (right). THP-1 cells were plated at 5 x 105/ml and treated with PMA as described. 
Supernatant was removed and the monolayer was gently washed with PBS before adding CLL cells. CLL cells were thawed as 
described and plated with PMA-treated THP1 cells as well as cultured alone as described. 
 
A previous study has examined morphology of PMA-treated THP-1 cells using MGG staining and shown 
that they looked similar to NLCs displaying a flattened adherent morphology (Tsai et al. 2016). Thus, 
PMA-treated THP-1 cells displayed morphology similar to NLCs. Next, I looked at the 
immunophenotype of these cells using immunofluorescence microscopy.  
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4.4.2 Immunophenotype of PMA-treated THP-1 cells resembled that of NLCs 
There had been numerous studies characterising the phenotype of differentiated THP-1 cells where 
expressions of CD14 and CD68 were reported (Aldo et al. 2013; Forrester et al. 2018; Genin et al. 2015) 
as well as CD163 (Chimal-Ramirez et al. 2016; Genin et al. 2015; Riddy et al. 2018). In my study, 
immunofluorescence microscopy showed that the PMA-differentiated THP-1 cells expressed both 
CD14 and CD163 (Figure 4.2). As seen in Figure 4.2, the DAPI staining revealed the location of the cell 
nuclei. CD163 was scantly detected in the cytoplasm of the cells, whereas CD14 expression was more 
confined within the cytoplasm.  
 
Figure 4.2. PMA-treated THP-1 cells expressed CD14 and CD163. 
Immunofluorescence microscopy of PMA-differentiated THP-1 cells stained with DAPI (blue), antibodies against CD14 (green) 
and CD163 (red), and their respective isotype controls. Images were prepared using ImageJ software. 
 
The above result was in agreement with phenotype of NLCs described in the previous chapter where 
the expression of both CD14 and CD163 was detected. Expression of CD68 in PMA-treated THP-1 cells 
was also confirmed in previous studies (Genin et al. 2015; Maeß et al. 2014). 
Taken together, the morphology and phenotype of PMA-differentiated THP-1 cells resembled that of 
NLCs. I then proceeded to assess the functional features of PMA-treated THP-1 cells. 
 
  

















4.4.3 Effects of co-culture of PMA-treated THP-1 cells on CLL cells 
To investigate if PMA-differentiated THP-1 cells exert any cytoprotective effect on CLL cells when in 
co-culture like NLCs, I performed the co-culture experiments the same way as previously described 
with NLCs. Cryopreserved CLL cells were first thawed and recovered and then cultured at a density of 
3 x 106/ml over the washed monolayer. CLL cells cultured alone were used as controls. Viability of CLL 
cells with and without co-culture with the PMA-differentiated THP-1 monolayer was measured using 
FACS analysis (described in Methodology). 
 
4.4.3.1 Analysis of spontaneous cell death 
As seen in Figure 4.3, the co-cultured conditions preserved the viability of CLL cells significantly better 
than CLL cells cultured alone from as early as day 1 after co-culture. The average viability of CLL cells 
alone (blue) decreased following initial culturing, however, the average viability of CLL cells in co-
culture (red) did not decrease as drastically. From Day 1 the co-cultured CLL cells had a significantly 
higher viability can those cultured alone. 
 
Figure 4.3 Co-culture with PMA-treated THP-1 cells preserved the viability of CLL cells over 3 days when compared to CLL 
cells cultured alone. 
CLL cells were cultured alone and with PMA-differentiated THP-1 cells and the viability was monitored over 3 days. Viability 
of CLL cells was measured using Annexin V/ PI staining by flow cytometry. Data points represent mean ± SEM of 5 































Cultured alone   +           -           +            -           +          -           +           -           
In co-culture       -            +          -             +          -           +          -            +         
Day 0 Day 1 Day 2 Day 3 
* * * * p= <0.05 
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Thus, like NLCs, PMA-treated THP-1 cells protected CLL cells from spontaneous cell death when in co-
culture. Next, I wanted to examine if PMA-treated THP-1 cells also protect CLL cells against drug-
induced cell death. 
 
4.4.3.2 Analysis of drug-induced cell death 
Fludarabine, a major component of first line therapy in treatment of CLL was used as a cytotoxic agent 
to assess if the co-culture conditions could protect CLL cells from fludarabine-induced cell death. It 
was previously shown that 10µM fludarabine is capable in killing CLL cells following 48h incubation 
under standard culture conditions (Zhuang et al. 2014). Also, since CLL cells with 17p deletion do not 
respond to fludarabine-induced apoptosis (Turgut et al. 2007), I selected CLL samples that do not 
contain 17p deletion for the experiment. I incubated CLL cells with 10µM fludarabine for 48h and cell 
death was measured by flow cytometry.  
Percentage of fludarabine-induced cell death was calculated as described (Zhuang et al, 2014). Figure 
4.4 showed that there was a significant difference in cell death between co-cultured CLL cells and CLL 
cells cultured alone. On average, fludarabine killed ~50% of CLL cells when they were cultured alone, 
whereas only ~20% of CLL cells co-cultured with PMA-differentiated THP-1 cells were killed. This 






Figure 4.4 Fludarabine drug-induced cell death was significantly reduced in CLL cells co-cultured with PMA-treated THP-1 
cells when compared to CLL cells culture alone.  
Cryopreserved primary CLL cells were thawed and plated in co-culture with PMA-treated THP-1 cells or cultured alone in 
standard conditions. CLL cells cultured in respective conditions were incubated with 10µM fludarabine for 48 hrs. The viability 
of CLL cells was measured by flow cytometry following annexin V/ PI staining. The percentage of drug-induced killing was 
calculated as described in Methods. Data points represent mean ± SEM of 2 independent experiments, each experiment 
performed using 4 different CLL samples. * refers to p value of <0.05 which is considered statistically significant. 
 
Taken altogether, the above results have shown that similar to NLCs, PMA-treated THP-1 cells 
conferred protection to CLL cells against spontaneous and drug-induced apoptosis. Importantly, co-
culture with PMA-treated THP-1 cells significantly protected CLL cells from fludarabine-induced cell 
death, resulting in drug resistance in CLL cells.  
As NLCs have been shown to more closely resemble M2 than M1 macrophages (Ysebaert et al, 2011; 
Filip et al, 2013), I further polarized PMA-differentiated THP-1 cells (here designated as M0 
macrophages) into M1 macrophages by IFN-γ and LPS, and into M2 macrophages by IL-4, as previously 
described (McWhorter et al, 2013; Chanput et al, 2014; Genin et al, 2015; Jablonski et al, 2015). In 
doing so, I hope to establish the relative contribution of M1 and M2 macrophages to the 




































) * * p= <0.05 
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4.4.3.3 M1 and M2 macrophages can be distinguished using CD38 and EGR2 
Using the protocols reported from other studies to differentiate THP1 cells to M1 and M2 
macrophages (Chanput, Mes & Wichers 2014; Genin et al. 2015; Jablonski et al. 2015), I optimised 
conditions of polarisation of M1 and M2 macrophages from PMA-differentiated THP-1 cells for my 
study (See Appendix 7.14.7). To confirm phenotype of M1 and M2 macrophages, I examined the 
expression of the respective markers CD38 and EGR2 (Jablonski et al. 2015) by immunofluorescence 
microscopy. As seen in Figure 4.5, M0 macrophage did not express EGR2 nor CD38 (top row), M1 





 DAPI EGR2 CD38 Merged 
M0 
    
M1 
    
M2 
    
Figure 4.5. M0, M1 and M2 macrophages were distinguishable by the unique expression of EGR2 or CD38. 
Immunofluorescence microscopy of PMA-differentiated THP-1 cells (M0 macrophages) and M1 and M2 macrophages, stained with anti-EGR2 (green), anti-CD38 (red) antibodies and 
counterstained with DAPI (blue). THP-1 cells were PMA differentiated for 24-48 hr (top row), M1 macrophages were prepared using IFN-γ and LPS (middle row) and M2 macrophages were 
prepared using IL-4 (bottom row) as described in the Methods. Images were prepared using ImageJ software. 
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4.4.3.4 M1 and M2 macrophages have distinguishable morphological features 
I also examined morphological features of M1 and M2 macrophages using corresponding polarising 
protocols. As seen in Figure 4.6 it was noted that M1 macrophages appear as large, oval-shaped cells 
(top left panel) whereas M2 macrophages are large and elongated (top right panel). These 
observations were consistent with the respective morphology of M1 and M2 macrophages 
(McWhorter et al. 2013).Co-culture with CLL cells did not alter the distinct morphology of M1 or M2 
macrophages (Figure 6, bottom panels). 
 
Figure 4.6. M1 and M2 macrophages have distinct morphological features with or without CLL cells. 
Phase contrast microscopy of PMA-differentiated THP-1 cells which were further polarized to M1 (Top left), and to M2 
macrophages (Top right). M1 and M2 macrophages were prepared using IFN-γ + LPS and IL-4, respectively as described in 





























4.4.4 Effects of co-culture with Polarised macrophages on CLL cells 
4.4.4.1 Analysis of spontaneous cell death 
I next repeated the same co-culture experiments I performed with M0 macrophages described 
previously, but this time using M1 and M2 macrophages for up to 3 days (Figure 4.7). CLL cells cultured 
alone were used for comparison. As shown in Figure 4.7, CLL cells co-cultured with M1 macrophages 
retained a higher viability than CLL cells cultured alone, however, the difference was not significant. 
In contrast, CLL cells co-cultured with M2 macrophages retained greatest viability than that of CLL cells 
cultured alone, which was statistically significant as early as 24h after co-culture. Furthermore, the 
viability of CLL cells co-cultured with M2 macrophages was significantly higher than those with M1 
macrophages from day 2 onwards. 
Therefore, both M1 and M2 macrophages provided protection against spontaneous apoptosis of CLL 
cells. However, M2 macrophages provided significantly greater protection than M1 macrophages. 






Figure 4.7 Co-culture with M2 macrophages provided greater protection than M1 macrophages against spontaneous apoptosis of CLL cells over 3 days. 
Primary CLL cells were cultured alone or co-cultured with M1 or M2 macrophages derived from differentiated THP1 cells and their viability was monitored over 3 days by flow cytometry 
following annexin V/ PI staining. M1 and M2 macrophages were prepared using IFN-γ + LPS and IL-4 respectively as described in Methods. Data points represent mean ± SEM of independent 
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* p= <0.05 
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4.4.4.2 Analysis of drug-induced cell death 
I repeated the same co-culture experiments I performed with M0 macrophages described earlier but 
this time with M1 and M2 macrophages in the presence of 10µM fludarabine CLL cells cultured alone 
were used for comparison. As shown in Figure 4.8, co-culture with M0 macrophages significantly 
protected CLL cells from fludarabine-induced cell death, compared to CLL cells cultured alone. CLL cells 
co-cultured with M2, and to a lesser extent M1, macrophages were also protected from fludarabine-
induced cell death, although not statistically significant. Interestingly, protection against fludarabine-
induced cell death provided by M2 macrophages was not as great as M0 macrophages. 
 
Figure 4.8. Co-culture with M0 macrophages provided the greater protection than M1 or M2 macrophages against 
fludarabine-induced cell death of CLL cells. 
M0, M1 and M2 macrophages derived from PMA-differentiated THP-1 cells were prepared as described in Methods. Primary 
CLL cells were incubated alone or in co-culture with M0, M1 or M2 macrophages, as described in Methods, in the presence 
of 10µM fludarabine for 48 h and their viability were monitored by flow cytometry following annexin V/ PI staining. The 
percentage of drug-induced killing was calculated as described in Methods. Data points represent mean ± SEM of 2 
independent experiments, each experiment performed using 3 different CLL samples. * refers to p value of <0.05 which is 
considered statistically significant. 
 
Next, I was interested to see what effect the co-culture condition would have with ABT-199, a BCL-2 
specific inhibiter, which showed impressive clinical activity in CLL (Roberts et al. 2016). As expected, 
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However, ABT-199-induced cell death of CLL cells were not affected by co-culture with M0 (yellow 
line), M1 (blue line) or M2 macrophages (green line). The above result showed that the cytoprotective 
effect against fludarabine shown earlier was lost in the presence of ABT-199, suggesting that this 
protective effect is BCL-2-dependent. It also showed that ABT-199 is effective killing n CLL cells that 
are in co-culture with macrophages. 
 
Figure 4.9 Co-culture with M0, M1 or M2 macrophages failed to protect CLL cells against ABT-199-induced cell death. 
M0, M1 and M2 macrophages derived from PMA-differentiated THP-1 cells were prepared as described in Methods. Primary 
CLL cells were incubated alone or in co-culture with M0, M1 or M2 macrophages, as described in Methods, in the presence 
of ABT-199 at the indicated concentrations for 24 h and their viability were monitored by flow cytometry following annexin 
V/ PI staining. The percentage of drug-induced killing was calculated as described in Methods. Data points represent mean 
± SEM of 2 independent experiments, each experiment performed using 3 different CLL samples. 
 
Taken together, the cytotoxic effect of fludarabine on CLL cells was impeded by co-cultures with M0, 
M1 and M2 macrophages derived from PMA-differentiated THP-1 cells, but the greatest protection 
was provided by co-cultures with M0 macrophages. Co-cultures with M2 macrophages provided the 
greater protection than M1 macrophages against fludarabine-induced cell death of CLL cells, even 
though not as great as M0 macrophages. 
In contrast, the cytotoxic effects of ABT-199 on CLL cells was not impeded by co-cultures with M0, M1 
or M2 macrophages, suggesting that the drug is still effective in killing co-cultured CLL cells and that 
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4.4.4.3 Levels of CCL3 and CCL4 in the culture medium 
It has previously been reported that NLCs induce CLL cells to secrete the T-cell chemokines CCL3 and 
CCL4 into the culture medium where they can be measured by ELISA (Burger et al. 2009b). I therefore 
sought to establish if the differentiated THP-1 cells have the same effect. As described in the previous 
chapter, the levels of CCL3 and CCL4 proteins in the culture medium were increased from day 5 and 
reached a plateau by day 10 from fresh CLL PBMC cultures. I thus measured levels of CCL3 and CCL4 
in the supernatant of differentiated THP-1 cells. As shown in Figure 4.10, PMA-differentiated THP-1 
cells (M0 macrophages) alone secreted high levels of CCL3 and CCL4. In keeping with previous reports 
(Mantovani et al. 2004; Mantovani et al. 2002), THP-1 cell-derived M1 macrophages cultured alone 
secreted even more CCL3 and CCL4 (Figure 4.10). In contrast, levels of CCL3 and CCL4 in the medium 
of M2 macrophages cultured alone were similar to those produced by CLL cells alone (Figure 4.10). 
Culturing CLL cells with various differentiated THP-1 cells (M0, M1 or M2) did not increase the total 
amount of CCL3 and CCL4 that were secreted into the supernatant for up to 3 days (Figure 4.10). My 
results thus indicated that, THP-1 cell-derived M0 and M1 macrophages secreted CCL3 and CCL4, but 




Figure 4.10 Co-culture conditions did not affect the levels of CCL3 and CCL4 in the medium of CLL cells co-cultured with M0, M1 or M2 macrophages. 
CLL cells were cultured alone or with various differentiated THP-1 cells for 3 days and supernatant samples at the indicated time points were collected for analysis of CCL3 (top panel) and CCL4 
(low panel) by ELISA. The medium of M0, M1 and M2 macrophages cultured alone was also collected for analysis of CCL3 and CCL4 in a similar manner. Levels of CCL3 and CCL4 were measured 





























































4.4.4.4 Expression of sIgM and sIgD 
It has also been reported that CLL cells co-cultured with NLCs displayed significant reduction in sIgM 
and sIgD expression and that these CLL cells re-expressed both IgM and IgD following in-vitro culture 
in the absence of NLC, indicating that NLCs can engage B cell receptors (BCR) of CLL cells (Ten Hacken 
et al. 2016). I thus tried to determine if the cell line model replicated this activity. First, I screened CLL 
samples to select those that recover the expression of IgM when cultured alone under standard 
conditions This is because it has been shown that not all CLL samples are able to recover the expression 
of IgM under such culture conditions and that ability to re-express IgM is strongly correlated to BCR 
signalling capacity (Mockridge et al. 2007). As shown in Figure 4.11, on average the expression of IgM 
in all 9 CLL samples increased over three days of incubation under standard culture condition. 
However, CLL samples 3557, 3609 and 3691 clearly recovered expression of IgM well, whereas sample 
3684 hardly recovered expression of IgM (Figure 4.11). 
 
Figure 4.11 Surface expression of sIgM on CLL cells when cultured for three days under standard conditions. 
Surface expression of IgM on CLL cells cultured under standard conditions over 3 days were measured by FACS as described 
in Methods. Data points represent mean ± SD of independent experiments using 9 different CLL samples. 
 
I next measured expression of IgD of these samples in a similar manner. To my surprise, these CLL cells 
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Figure 4.12 Surface expression of sIgD was not increased on CLL cells when cultured for three days under standard conditions.  
Surface expression of IgD on CLL cells cultured under standard conditions over 3 days were measured by FACS as described 
in Methods. Data points represent mean ± SD of independent experiments using 9 different CLL samples. 
 
Next, I decided to use M2 macrophages for co-culture experiments as NLCs were described as 
displaying predominantly ‘M2 subset’ by literature (Ysebaert & Fournie 2011). I used M0 for 
comparison as the unpolarised macrophage subset. I also used CLL cultured alone as a control. 
As shown in Figure 4.11, all nine CLL samples initially exhibited reduced expression of IgM 24 h after 
incubation in vitro. However, some but not all samples recovered their expression of IgM at 48 h. We 
next used these samples for co-culture with M0 or M2 macrophages for up to 72 h and compared the 
surface expression of IgM and IgD on co-cultured CLL cells to that on CLL cells cultured alone (Figure 
4.13). As shown in Figure 4.13, the expression of IgM on CLL cells cultured alone was reduced at 24 h, 
but recovered at 48 h and further increased at 72 h. Similar to CLL cells cultured alone, CLL cells co-
cultured with M0 or M2 macrophages expressed reduced IgM at 24 h, but restored expression of IgM 
at 48 h and increased the expression further at 72 h (Figure 4.13). At all these time points the levels 
of expression of IgM on CLL cells co-cultured with either M0 or M2 macrophages were not lower than 
that on CLL cells cultured alone.  
I monitored the expression of IgD on CLL cells cultured in the three culture conditions described above 
and observed a similar trend of the increase in expression of IgD as with IgM on CLL cells over 72 h 
(Figure 4.14). Overall, the surface expression of IgM and IgD was not reduced in CLL cells co-cultured 
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Figure 4.13 Surface expression of IgM was not decreased in CLL cells co-cultured with M0 or M2 macrophages for 3 days. 
THP-1 cells were differentiated into M0 or M2 macrophages as described in the Methods. Primary CLL cells were cultured alone or co-cultured with M0 or M2 macrophages over 3 days and 
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Figure 4.14 Surface expression of IgD was not decreased in CLL cells co-cultured with M0 or M2 macrophages for 3 days. 
THP-1 cells were differentiated into M0 or M2 macrophages as described in Methods. Primary CLL cells were cultured alone or co-cultured with M0 or M2 macrophages over 3 days and surface 
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Taken altogether, a pro-survival effect was seen by co-cultures with differentiated THP1 on CLL cells 
when compared to alone. Co-culture with M2 macrophages provided the best survival environment 
for CLL cells against spontaneous apoptosis. 
M0 and M2 co-cultures offered the best protection against fludarabine-induced cell death upon CLL 
cells, where M0 was the best condition. There was no protection seen at all against ABT-199 induced 
cell death. 
There was no clear trend seen on the levels of CCL3 and CCL4 in the supernatants of co-culture 
conditions. Rather, it appears that there is a very high level of CCL3 and CCL4 secreted by the cell lines, 
which may conceal any minor changes expected. 
Finally, although I demonstrated that the CLL samples selected regained their sIgM expression when 
cultured alone, the expression levels were not decreased when in co-culture with M0 and M2 





4.5 Summary of Results 
I showed that THP-1 cell line can be used to differentiate into macrophages by incubating with PMA. 
In order to mimic the distribution of NLCs seen in the previous chapter, a density of 5x105/ml was 
preferred. Upon PMA differentiation, the THP-1 cells demonstrated the morphological features of 
adherent macrophages with oval and elongated shapes. The differentiated THP-1 cells (M0 
macrophages) were distinguishable from CLL cells by their shape and size when in co-cultures.  
Through IF staining, the M0 macrophages demonstrated some expression of CD14 and CD163. 
Although the expressions were weak, this was consistent with the observations from other studies 
who performed more in-depth investigations on PMA differentiated THP-1 cells (Chimal-Ramirez et 
al. 2016; Neu et al. 2013; Tedesco et al. 2018).  
Co-culture with M0 macrophages showed significantly improved viability of CLL cells over 3 days of 
co-culture compared to CLL cells cultured alone. This co-culture condition also showed significant 
protection against fludarabine-induced cell death of CLL cells. 
The phenotype of M1 and M2 macrophages were confirmed by IF techniques for CD38 and EGR2. 
When comparing morphology of M1 and M2 macrophages that were developed by using the 
respective polarising techniques, they exhibited distinct morphological features. Co-culture of CLL 
cells with M1 or M2 macrophages showed an improved viability of CLL cells for 3 consecutive days 
comparing to CLL cells cultured alone. The protection against fludarabine-induced cell death of CLL 
cells was found to be most pronounced with co-culture conditions with M0 macrophages, followed by 
with M2 macrophages with M1 macrophages offering the least protection.  
However, no such protective effect against ABT-199-induced apoptosis was seen in CLL cells co-
cultured with M0, M1 or M2 macrophages. 
M0 and M1 macrophages produced high levels of CCL3 and CCL4 in the culture medium, whereas M2 
produced low levels of the two chemokines when cultured alone. There was no increase in the amount 
of CCL3 and CCL4 in the culture medium for up to 3 days when CLL cells were co-cultured with M0 or 
M1 macrophages. These findings suggested that M0 and M1 macrophages derived from THP-1 cell 
line secreted CCL3 and CCL4 but did not induce CLL cells to secrete them. 
CLL cells were found to recover the expression of sIgM upon thawing for up to 3 days, however in co-
culture conditions it was not found to be decreased. CLL expression of sIgD was generally found to 







In this chapter I showed that THP-1 cell line can be used to investigate the function of NLCs by 
differentiating them into macrophages using PMA. Generally, human primary monocytes from 
circulation are isolated and commonly used as precursors for study of macrophages in vitro (Tedesco 
et al. 2018). However, these primary monocyte-derived macrophages (MDMs) cannot be stored in 
liquid nitrogen, plus the evident heterogeneity between the monocyte samples (Tedesco et al. 2018). 
Cell lines are thus used to compensate these issues as they can be easily expanded and stocked in 
frozen temperatures in non-differentiated state (Tedesco et al. 2018). THP-1 cell lines have been used 
in numerous studies demonstrating that they can be differentiated to macrophages which can be 
further polarised to M1 and M2 macrophages (Aldo et al. 2013; Daigneault et al. 2010; Forrester et al. 
2018; Park et al. 2007; Tedesco et al. 2018). Alternatives to THP-1 cell line are U937, ML-2, HL-60 and 
Mono Mac 6 cells (Chanput, Peters & Wichers 2015), however there are limited information available 
in the literature because of significantly fewer published studies reporting using these cell lines. 
Between THP-1 and U937 cells, the choice was based the fact that THP-1 cell line was derived from 
blood monocytic cells whereas U937 cells from tissue resident monocytic cells (Chanput, Peters & 
Wichers 2015).  In addition, in studies comparing the difference and similarities of two cell lines, it has 
been found that, although they both can be differentiated into macrophages with the similar stimuli, 
U937 cells can also be differentiated into macrophages using retinoic acids, Vitamin D3 and TPA 
(Chanput, Peters & Wichers 2015; Chun et al. 2001). Differentiated THP-1 cells yielded a ‘macrophage-
only’ phenotype where there was no expression of dendritic cell markers CD80 or CD86 (Riddy et al. 
2018). U937 cells did not migrate in response to any chemoattractant whereas THP-1 cells and PBMCs 
migrated well in response to chemoattractant using trans-well migration assay (Riddy et al. 2018). 
PMA was the preferred choice for differentiating into macrophages as it was the most widely used 
chemical for differentiation of monocyte cell lines (Riddy et al. 2018). 
I selected a density of 0.5x106/ml of THP-1 cells to be differentiated into macrophages for subsequent 
experiments because this closely represent the distribution of well-developed NLCs as described in 
the previous chapter. This cell density used in my study was similar to that reported by some studies 
(Forrester et al. 2018; Park et al. 2007; Takashiba et al. 1999), but different to that from other studies 
(Aldo et al. 2013; Daigneault et al. 2010; Schwende et al. 1996; Genin et al. 2015). Since the studies 
using the density of 0.5x106/ml had also prepared THP-1 cells for co-culture experiments, I therefore 
used this density for my co-culture experiments. Next, I was able to demonstrate the similarities in 
morphology and phenotype of PMA-differentiated THP1 (M0 macrophages) with those of NLCs 
described in the previous chapter.  
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The morphology and phenotype of CD14 in M0 macrophages observed were consistent with the 
results found with studies from Genin et al. (2015) and Chimal-Ramirez et al. (2016). They showed the 
macrophages displayed a flattened appearance with mild expression of CD14. Regarding the 
expression of CD163, some studies did not observe the expression of CD163 in PMA-differentiated 
THP-1 cells (Forrester et al. 2018; Tedesco et al. 2018) whereas others did observe its expression 
(Chimal-Ramirez et al. 2016; Genin et al. 2015; Riddy et al. 2018). Thus, my study agreed with the latter 
group where expression was observed in PMA-differentiated THP-1 cells by immunofluorescence 
microscopy. 
I further polarised M0 macrophages into M1 or M2 subtype. This was carried out by using an 
established procedure of polarising the M0 into M1 and M2 using LPS+ IFNγ and IL-4, respectively. To 
distinguish the subsets, I observed the morphology under phase-contrast microscope and IF following 
staining the cells using CD38 and EGR2. The M1 macrophages expressed CD38, whereas M2 expressed 
EGR2 and M0 expressed neither. This is in agreement with a study using these markers to define the 
M1 and M2 populations (Jablonski et al. 2015).  
Furthermore, by observation of morphology, I found that M1 macrophages as appeared to be round 
and flattened after the addition of LPS and IFNγ and M2 macrophages displayed the elongated 
appearance upon addition of IL-4. It has been reported that the degree of elongation correlates with 
the phenotypic polarization of M2 macrophages (McWhorter et al., 2013). The study showed that 
preventing cell elongation inhibits the complete polarization of M2 macrophages following incubation 
with IL-4. Therefore, elongation and polarisation possibly represent a unified process leading to fully 
differentiated M2 macrophages. Reassuringly, elongated and polarised NLCs similar to M2 
macrophages were also seen in CLL PBMC cultures as described in the previous chapter, thus providing 
further evidence that NLCs resemble M2 macrophages (Hanna et al, 2015; Marchesi et al, 2015, 
Ysebaert and Fournie, 2011; Ysebaert et al, 2010).  
Likewise, I was also able to demonstrate the pro-survival effects of THP-1-derived macrophages on 
CLL cells as compared to CLL cells cultured alone. Unexpectedly, co-culture with M0 macrophages 
displayed the greatest protection against spontaneous and fludarabine-induced apoptosis of CLL cells, 
with M2 macrophages offering modest protection and M1 macrophages with the least protection. My 
result was thus in disagreement with that reported by a study where HepG2 (human hepatoma) and 
A549 (lung adenoma) cancer cells were co-cultured with THP-1 cells-derived M1 or M2 macrophages 
and etoposide-induced apoptosis was significantly reduced in cancer cells that were incubated with 
M2 macrophages (Genin et al. 2015). 
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The reason why M0 macrophage condition was better than M2 macrophage condition, to protect 
against fludarabine induced cell death, is still unclear. A study by Caras et al. (2011) using tumour-
secreted soluble factors on THP-1 cell line, found that THP-1 macrophages were able to switch their 
phenotype or induce functional polarization towards a mixture of M1/M2 phenotype. This occurred 
when the macrophages were incubated with supernatant of primary tumour cells which contained 
tumour-secreted soluble factors (Caras et al. 2011; Chanput, Mes & Wichers 2014). In my study, I did 
not inspect the phenotype of M2 macrophages after co-culture with CLL cells. Therefore, further 
studies are required to check if the phenomenon of phenotype switching occurs and thus be able to 
offer some explanation. The differentiated THP-1 cells offered no protection against Venetoclax (ABT-
199)-induced cell death, the result is consistent with a report that NLCs failed to protect CLL cells from 
ABT-199 induced apoptosis (Boissard et al. 2015b). 
In an attempt to reproduce the effect of NLCs in inducing CLL cells to express CCL3 and CCL4 
chemokines when in co-culture, I co-cultured CLL cells with the THP-1 cells-derived macrophages and 
monitored the level of CCL3 and CCL4 in the culture medium.  Although there was an increase in levels 
of CCL3 and CCL4 in the medium from CLL cells co-cultured with M0 or M1 macrophages compared to 
CLL cells cultured alone, similar increases were also observed in the medium from the corresponding 
macrophages cultured on their own. Thus, the increase in levels of CCL3 and CCL4 was likely due to 
the presence of differentiated THP-1 cells in the co-culture system. It has been shown that M1 
macrophages intrinsically expressed higher levels of certain chemokines such as CCL3 and CCL4 than 
M2 macrophages (Mantovani et al. 2002). My results were thus consistent with the findings reported 
in this study. In this regard, the cell-line model therefore does not appear to fully recapitulate the 
chemokine-inducing properties of primary NLCs (Burger et al. 2009b).  
Another functional difference between primary NLCs and cell-line model was highlighted by the 
finding that CLL cells co-cultured with M0 or M2 macrophages over 72 h did not express reduced levels 
of IgM or IgD, whereas CLL cells co-cultured with primary NLCs displayed significant reduction in 
surface expression of IgM and IgD (Ten Hacken et al. 2016). One possible explanation can be that IL-4 
enhances the expression of sIgM in CLL cells (Aguilar-Hernandez et al. 2016) and that IL-4 has been 
shown to be secreted in small amounts by macrophages themselves (La Flamme et al. 2012), although 
it is unclear if NLCs specifically secrete IL-4. To confirm this, an experiment observing the levels of IL-
4 in CLL cells co-cultured with M0/M1/M2 as well as cultured alone needs to be performed, in parallel 
to the experiment using primary NLCs as a comparison. 
137 
 
Taken together, I have shown that the THP-1 cells derived macrophages do share many functional 
similarities to NLCs. However, I have also found some differences between THP-1 cells derived 
macrophages and NLCs. Here, I gave my explanations to potential causes to these differences. 
One possible explanation for the dissimilarities with NLC experiments is the use of PMA to 
differentiate THP-1 cells to M0 macrophages. PMA is a known potent mitogen which activate many 
immune cells including monocytes and induces TNF-α production in these cells (Mendoza-Coronel & 
Castanon-Arreola 2016). TNF-α signals through the receptors TNFR1 and TNFR2 and regulates cell 
functions such as proliferation, survival, differentiation and apoptosis. Macrophages secrete TNF-α  
and are also highly responsive to TNF-α, thus rendering TNFα as a “master-regulator” of inflammatory 
cytokine production where it mediates the cytokine cascade in inflammatory diseases (Parameswaran 
& Patial 2010). 
Therefore, cell line model is subject to manipulation by PMA which could result in non-naturally 
occurring functions. This may explain why the cell line model could not recapitulate the effects of BCR 
stimulating and chemokine induction of CLL cells by NLCs. Another explanation is that, as M1 and M2 
macrophages represent the two opposing ends of a continuum (Mantovani et al, 2002) whereas NLCs 
are heterogeneous in their development as described in previous chapter, it is possible that NLCs could 
be a mixture of M1 and M2 macrophages, despite that they have been shown to resemble 
predominantly the M2 macrophages. Therefore, the results from the cell line model that M0 
macrophages conferred greater protection than the M1 or M2 macrophages against spontaneous and 
fludarabine-induced cell death may reflect what NLCs did to CLL cells.  
Last but not the least, it is important to recognise the weakness of in-vitro cell cultures, both primary 
cells and cell lines, where they are being studied in the absence of their local environment in-vivo. It 
is also well established that cell lines cannot replace primary cells despite their ease to use and 
providing consistent results (Kaur & Dufour 2012; Riddy et al. 2018). Therefore, great caution was 
needed when interpreting the results from studies using cell lines. In addition, validation experiments 
should ideally be replicated in primary cells. For these reasons, in the next part of my study to 
investigate how CLL cells and NLCs influence each other at the level of gene expression, I chose to use 
primary NLC cells as the overall objective of my study is to understand the mechanisms mediating the 







5 Identification of differentially expressed genes and significantly 




From the previous chapters I have shown that NLCs can be developed from CLL PBMC samples from 
patients with CLL and that they displayed many morphological features of macrophage and expressed 
CD68 and CD163, the phenotypic markers of M2 subset of macrophages.  The NLCs were able to 
reduce spontaneous apoptosis of CLL cells when in co-culture, as compared to CLL cells cultured alone. 
I have also shown that human THP-1 cell line can be used to mimic many behaviours of NLCs, 
particularly on the pro-survival effect on CLL cells against spontaneous apoptosis. However, the THP-
1 cell line model did not replicate all of biological effects of NLCs, especially in regulating the release 
of chemokines and expression of surface IgM and IgD on CLL cells. This disparity was further 
highlighted by the observation that cell lines such as THP-1 cells can only partially reproduce the 
genotypic and phenotypic properties of monocytes isolated from fresh PBMC samples (Riddy et al. 
2018). Therefore, to investigate the mechanisms mediating the interaction between NLCs and CLL cells 
at the level of gene expression, I chose to use fresh CLL PBMCs samples to develop NLCs and use 
cryopreserved autologous CLL cells for co-culture experiments.  
So far, the studies that have looked into the difference in gene expression between CLL cells co-
cultured with or without NLCs have relied on microarray techniques using a limited number of 
established gene sets to acquire targeted gene expression profiles (Bhattacharya et al. 2011; Boissard 
et al. 2016b; Burger et al. 2009b; Burgess et al. 2016; Fiorcari et al. 2015; Maffei et al. 2013). These 
studies helped identify several molecules potentially important in mediating the pro-survival effect of 
NLCs on CLL cells. The molecules included ICAM-1 and CD31 (Boissard et al. (2016b) and CSF-1 (Polk 
et al. (2016). However, subsequent studies showed that inhibition of these molecules or blocking NLC 
development did not significantly increase the spontaneous apoptosis (Boissard et al. 2016b) or 
ibrutinib-induced cell death of CLL cells (Polk et al. 2016), indicating that other yet-to-be-identified 
mechanisms may operate concomitantly to compensate the inhibition of the known targets. Further 
studies are thus still required in order to gain better understanding on how NLCs and CLL cells 
influence each other, resulting in sustained survival and expansion of CLL cells in the tissue 
microenvironment.        
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RNA-sequencing (RNA-seq), also called whole-transcriptome shotgun sequencing, is a newly 
developed, high throughput sequencing technology for characterising RNA content and composition 
in a sample of cells (Hrdlickova, Toloue & Tian 2017; Wang, Gerstein & Snyder 2009; Wolf 2013).  
Until the arrival of RNA-seq, microarrays were the standard method of gene expression quantification. 
However, RNA-seq can not only quantify the gene expression, but also give the precise location of 
transcript boundaries to a single base resolution (Wang, Gerstein & Snyder 2009). Short reads of 30-
base pair (bp) can uncover how two exons are connected whereas longer reads or pair-end short reads 
can reveal the connectivity between multiple exons (Wang, Gerstein & Snyder 2009). This allows the 
sequencing-based technique to identify different transcripts of individual genes.   
Compared with microarrays, RNA-seq can capture a wider range of expression values. The “Count 
data” is a digital measure and can be scaled linearly with no upper limit, whereas microarrays can 
display saturation of analogue-type fluorescent signals (Wolf 2013). It is structured as a table where it 
reports the number of sequence fragments detected to each gene for each sample (Nguyen et al. 
2016). RNA-seq has a very low background signal because sequences can be mapped to unique regions 
of the gene (Hrdlickova, Toloue & Tian 2017; Wang, Gerstein & Snyder 2009; Wolf 2013). RNA-seq can 
give information on RNA splice events, which are not easily detected by microarray (Wolf 2013). Thus, 
short reads of 30-base pair (bp) can uncover how two exons are connected whereas longer reads or 
pair-end short reads can reveal the connectivity between multiple exons (Wang, Gerstein & Snyder 
2009). This allows the sequencing-based technique to identify different transcripts of individual genes.  
RNA-seq produces results with high levels of reproducibility. As it does not involve cloning or 
amplification step, RNA-seq requires less RNA sample (Wang, Gerstein & Snyder 2009).  
In this Chapter, I will therefore describe the findings obtained through comparison of globe gene 
expression profiled by RNA-seq in different populations of cells, namely between CLL cells co-cultured 
with NLCs versus CLL cells cultured alone and between NLCs co-cultured with CLL cells versus NLCs 
cultured alone.  
 
5.2 Objectives 
• Establish a comprehensive list of differentially expressed genes in primary CLL samples 
cultured with or without NLCs through RNA-seq analysis, 
• Validate the RNA-seq results using RT-qPCR on selected genes from the list, 
• Identify molecules and pathways critically involved in survival and resistance of CLL cells to 




5.3.1 CLL cell samples and coculture 
In order to carry out the experiments, the NLCs were developed as described in Methodology and for 
this chapter the cases chosen had NLC Score of 2 or 3. This was to ensure a good number of NLCs were 
developed so enough RNA can be extracted. 6 CLL cases were used for the RNA-seq analysis and 
validation (#3577, #3599, #3627, #3682, #3679 and #3684). A further 8 cases were used for validation 
of RNA-seq results (#3620, #3645, #3686, #3605, #3607, #3621, #3631 and #3637).  Clinical 
information of CLL samples used in this part of the study was provided in Table 5.1. To meet the 
objectives of the study, I designed the following 4 populations: 
• CLL alone (CLL cells cultured alone) 
• CLL + NLC (CLL cells co-cultured with NLCs) 
• NLC alone (NLCs cultured alone) 
• NLC + CLL (NLC co-cultured with CLL cells) 
The changes seen on CLL + NLC when compared to CLL alone is due to the effects that NLCs have on 
CLL cells. Conversely, the changes seen on NLC+CLL when compared to NLC alone is due to the effects 
CLL cells have on the NLCs. 24-hour period of culture/co-culture was chosen based on the results 
described in the previous chapters where protection of CLL cells against spontaneous apoptosis was 
detected at that time point (see previous chapters).  This means that at the cellular level the protective 
effect of NLCs on CLL cells can be seen in 24 hours and that the changes in gene expression caused by 
the co-culture condition should have taken place within 24 h of co-culture.  
As illustrated in Figure 5.1, fresh CLL PBMC sample was first cultured under standard conditions in a 
multi-well culture plate until the NLCs have developed and reached their plateau. The CLL cells in the 
PBMC co-cultures were then removed by gentle pipetting to leave NLCs behind. Wells containing NLCs 
were equally divided.  For NLCs cultured alone, standard RPMI medium was added to the wells.  For 
NLCs selected for co-culture, autologous CLL cells were thawed and resuspended in complete RPMI 
medium and added onto the wells. Aliquots of thawed CLL cells from the same sample were cultured 
alone in a separate well as CLL alone. The three groups of cells were incubated for 24 hours in 
humidified incubator at 37oC at 4% CO2. Following the 24-hour incubation, the cells from the 3 groups 













































3577 85.7 75.8 1.4 ibrutinib NA 17p-  55 Male A 28/07/2017 1.813 77.2 9.3 9.1 2.1 2.09 
3599 63.9 59.2 0.9 untreated NA 13q- 62 70 Female A 13/09/2017 1.498 60.1 7.7 9.2 2.08 2.1 
3627 136.7 129.4 2 ibrutinib unmutated 13q del 58 68 Male C 06/12/2017 1.522 131.4 8.7 9 2 2.08 
3682 33.2 25.8 0.5 untreated NA normal 71 74 female A 13/06/2018 1.901 26.3 8.8 9.2 1.97 2.01 
3679 171.4 164.7 1.6 untreated NA 13q- 53 54 male C 06/06/2018 0.962 166.3 8.8 8.2 1.92 1.97 
3684 230.1 220.8 NA untreated mutated 13q- 75 84 male A 18/06/2018   8.4 9 1.97 1.98 
3620 145.9 142.6 1.2 untreated mutated normal 69 76 Female C 15/11/2017 0.834 143.8   1.91 1.95 
3645 264.1 258.8 1.5 untreated unmutated normal 68 72 male C 14/03/2018 0.576 260.3   2.09 2.07 
3686 38.5 31.3 1 untreated mutated trisomy 12 70 71 female A 25/06/2018 3.0960 32.3   1.97 1.94 
3605 252.8 244 1.6 untreated mutated 13q- 60 63 Male B 27/09/2017 0.651 245.6   2.15 2.21 
3607 254.2 247.7 2.2 untreated mutated normal 66 69 Male B 02/10/2017 0.880 249.9   2.05 2.1 
3621 70.2 60.6 2 ibrutinib mutated 13q- 58 59 Female B 15/11/2017 3.195 62.6   1.93 1.91 
3631 256.1 >200 4.7 ibrutinib mutated 13q- 60 64 Male B 13/12/2017     1.9 1.89 
3637 144.6 134.9 2.2 untreated unmutated 11q-, 13q- 66 69 Male A 24/01/2018 1.605 137.1   2.15 2.02 
Details of each sample with clinical data information and RNA sample information. Samples with blue highlight are indicated on those that were not included in RT-qPCR analysis, red 
marked samples are those that were sent for RNA-seq and green Highlight are those that are from the same patient. RIN is from QC performed by the outsourced Novogene. Purity 




Figure 5.1 Schematic of preparing samples for RNA extraction 
 
 
5.3.2 RNA preparation 
As seen in Figure 5.1, CLL cells from CLL alone and CLL in co-culture with NLCs are harvested by gentle 
washing and collected into 1.5 ml Eppendorf tubes total RNA was extracted using a commercial kit 
(RNeasy Mini Kit, Qiagen).In brief, the cell pellet was resuspended in 400ul RNA lysis buffer and mixed 
thoroughly before it was transferred to the 2ml Shredder spin column (QIAshredder, Qiagen). 
To extract RNA from NLCs cultured alone and NLCs in co-culture with CLL cells, NLCs were lysed by 
adding the RNA lysis buffer directly on the surface of the culture plate. The cell lysate was then 
collected and transferred to the shredder spin column, as described above. 
As shown in Figure 5.2, RNA was extracted following the Manufacturer’s instruction. Isolated RNA was 
then kept in ice cold temperature to assess for purity and quantity. The remaining RNA was then 
stored and kept at -80oC. 
Allow 
development of 
NLCs from fresh 
PBMCs to 
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days) giving a 
















CLL + NLCs 
NLC alone 
CLL alone 
24 hours incubation 
Diagram of experiment design to produce 4 populations to compare the effects of CLL cells on NLCs and NLCs on CLL cells. The 
starting CLL PBMC culture (red) produces developed NLCs (8-14 days later) and the CLL cells are washed off. Autologous CLL cells 
(green) are added. After the incubation period of 24 hours, the new co-culture condition CLL cells (purple) are collected leaving 
behind the new conditioned NLCs (blue). By the end of the 24 h incubation, all 4 populations of cells are harvested and RNAs from 




Figure 5.2 Procedure for extracting RNA from cells by Qiagen RNeasy Mini kit. 
Using the Qiagen RNeasy Kit and the Qiagen Shredder, a lysis buffer is prepared as per instructions and added to the cell 
samples. The lysate is then transferred to the QIA Shredder Column for homogenization to reduce viscosity (1). Together 
with the shredder it is spun for 2 minutes at max speed in a microcentrifuge (2). After discarding Shredder column, ethanol 
is added to flow-through solution and mix (3). The mixture is transferred to RNeasy Spin Column (4) and spun for 15s at 
≥8000g and the flow through is discarded while the RNA is bound to membrane on the RNeasy Spin Column (5). The column 
is washed three times with washing buffers provided within the kit and the follow through is discarded (6). Finally, RNAse 
free water is added to the column and the RNA is eluted (7) from the column as follow through (8). The RNA sample is then 
measured for purity and quantity and stored in freezer. Image adapted from Qiagen RNEasy Mini kit manual using BioRender 
online tools. 
 
5.3.3 Measuring Purity and Quantity of RNA 
The quality of extracted RNA was assessed using a Nanodrop 2000 spectrophotometer (Thermo Fisher 
Scientific, UK) and quantity was measured Qubit® 2.0 Fluorometer (Thermo Fisher Scientific, UK). 
In brief, 1ul of each RNA sample was used to measure the purity of the RNA extracted using the 
Nanodrop machine where it measures the absorbance ratio at OD260/280 and OD260/230, with 
RNAse-free water as a control. 
 
5.3.3.1 Quantification using Qubit 
Qubit® 2.0 Fluorometer is an instrument used for quantification of protein, DNA and RNA in the same 
principle as Beer-Lambert Law (relates to the reduction of amount of light to the properties of the 
media through which the light is travelling through). The Qubit uses fluorescent dyes to measure the 
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concentration where each dye is specific for one molecule i.e. DNA, RNA or protein. The natural 
absorbance light at 260nm is used to measure DNA and RNA whereas 280nm is used to measure for 
proteins.  The dyes have a low fluorescence until they bind to their targets, where upon their binding, 
they intensely fluoresce, which is then measured by the Qubit.  
Qubit is preferred for the quantitative measurement over Nanodrop due its greater sensitivity and 
specificity. Quantification is done by Qubit giving a concentration of ng/ul. The kit used for quantifying 
was the Qubit® RNA HS Assay Kit with quantitation range of 5-100ng (Thermo Fisher Scientific Life 
Technologies). Using this kit, including a buffer, a fluorochrome and the standards Standard 1 (with 
no RNA) and Standard 2 (with high RNA quantity), a linear curve is made. Based on that the sample 
RNA quantity would be measured against the concentrations within the ranges of the standard curve.  
Those RNA samples that had good quality and quantity as defined in 5.3.4 were reserved for 
commercial RNA-seq service, as described in Methods. The remaining RNA samples that had good 
quality but enough quantity for RNA-seq were stored in -80oC freezer. These RNA samples were 
subsequently used to synthesise cDNA (as described in Methodology) to be used for optimising and 
validation by RT-qPCR. The summary information of the RNA samples is provided in Table 5.2. 
The quality and quantity of the RNA was verified by Novogene as well as assessing the integrity of the 
RNA with RNA integrity number (RIN) values of 7 and higher. For more information on Integrity of 




Table 5.2 Summary information of RNA samples regarding RNA quality and quantity 
Sample 
ID 















Volume (ul) Total (ng) 
3577 
95.04% 95.10% CLL alone 2.1 238 30 7140 
  NLC alone 2.07 33.02 25 825.5 
  CLL from NLC+CLL 2.09 458 30 13740 
  NLC from NLC+CLL 2.08 57.3 25 1432.5 
3599 
99.20% 96.10% CLL alone 2.08 258 29 7482 
  NLC alone 2.1 187 29 5423 
  CLL from NLC+CLL 2.1 323 29 9367 
  NLC from NLC+CLL 2.12 101 29 2929 
3621 
91.94% 92.80% CLL alone 1.93 550 30 16500 
  NLC alone 2.05 37.2 30 1116 
  CLL from NLC+CLL 1.91 578 30 17340 
  NLC from NLC+CLL 1.99 68.8 30 2064 
3627 
90% 78% CLL alone 2 212 30 6360 
  NLC alone 2.07 344 30 10320 
  CLL from NLC+CLL 2.08 220 30 6600 
  NLC from NLC+CLL 2.07 364 30 10920 
3605 
98.64 87 CLL alone 2.15 488 35 17080 
  NLC alone NA 7.48 35 261.8 
  CLL from NLC+CLL 2.21 391 35 13685 
  NLC from NLC+CLL NA 11.2 35 392 
3607 
93.64 84.77 CLL alone 2.05 358 30 10740 
  NLC alone 2.53 21 30 630 
  CLL from NLC+CLL 2.1 570 30 17100 
  NLC from NLC+CLL 2.1 27 30 810 
3631 
93.911 74.11 CLL alone 1.9 165 30 4950 
  NLC alone 1.98 14.88 30 446.4 
  CLL from NLC+CLL 1.89 230 30 6900 
  NLC from NLC+CLL 1.92 22.2 30 666 
3637 
84.15 80.11 CLL alone 2.15 51.8 30 1554 
  NLC alone 2.18 12.4 30 372 
  CLL from NLC+CLL 2.02 282 30 8460 
  NLC from NLC+CLL 2.21 28.8 30 864 
3645 
84 85.6 CLL alone 2.09 103.5 30 3105 
  NLC alone 2.26 11.4 30 342 
  CLL from NLC+CLL 2.07 124.5 30 3735 
  NLC from NLC+CLL 2.07 22.4 30 672 
3620 
NA 20.35 CLL alone 1.91 990 29 28710 
  NLC alone 1.95 28.8 27 777.6 
 36.55 CLL from NLC+CLL 1.9 420 29 12180 
  NLC from NLC+CLL 1.95 63.6 28 1780.8 
3679 
97.12% 90.90% CLL alone 1.92 520 30 15600 
  NLC alone 2.01 58 30 1740 
  CLL from NLC+CLL 1.97 830 30 24900 
  NLC from NLC+CLL 1.96 63 30 1890 
3682 
95.00% 89.00% CLL alone 1.97 251 30 7530 
  NLC alone 2.07 189.6 30 5688 
  CLL from NLC+CLL 2.01 112 30 3360 
  NLC from NLC+CLL 2.05 118.4 30 3552 
3684 
97.38% 86.40% CLL alone 1.97 730 30 21900 
  NLC alone 2.09 49.2 30 1476 
  CLL from NLC+CLL 1.98 5000 30 150000 
  NLC from NLC+CLL 2.01 65.2 30 1956 
3686 
83.60% 83.00% CLL alone 1.97 289 30 8670 
  NLC alone 2.1 98.8 30 2964 
  CLL from NLC+CLL 1.94 306 30 9180 






5.3.4 RNA sequencing 
The samples that met the quality control criteria for RNA-seq sequencing, i.e. having ≥1µg RNA 
measured by Qubit®, purity measured by Nanodrop of OD260/280 ≥2.0 and OD260/230 ≥2.0, with a 
volume ≥20µL and RIN values ≥7.0 were used for sequencing by RNA-seq technology at Novogene 
(Novogene (UK) Ltd, Cambridge, UK). The details of RNA sequencing were described in Methodology. 
The completed sequencing data was returned electronically and analysed by the Bioinformatics 
specialists at Computational Biology Facility (CBF) of the University of Liverpool. 
Due to the technological requirement for sequencing, the population of RNA is converted to a library 
of cDNA fragments with adaptors attached to one or both ends of up to several base pairs which will 
undergo short reads. The transcripts first need to be reconstructed with these reads, referred to as de 
novo assembly. In the case where transcript or genome information readily available, the reads are 
aligned onto the reference. The number of reads that fall to a given transcript provides a digital 
measurement of the level of expression of each gene, which is a starting point for a biological 
conclusion (Hrdlickova, Toloue & Tian 2017; Wang, Gerstein & Snyder 2009; Wolf 2013). 
 
5.3.5 Sequencing Data Analysis 
The analysis portion was performed under the supervision of Professor Francesco Falciani of 
Computational Biology Facility (CBF) of the University of Liverpool. 
 
5.3.5.1 Quality Control 
The data generated by RNA-seq is in the format of bam and FastQ files. FastQ files contain sequences 
and quality scores for each nucleotide. 10% of the data was fed into FASTQC tool to check the quality 
of FastQ files. FASTQC generates an html file for each sample. All of this is fed into MultiQC which then 
gives an overview of quality control of all samples in a single html file as a one report. The graphs that 
are generated determine whether the samples pass or fail (see Appendix Figure 7.10).  
The sequence counts give number of reads sequenced from either direction. The base quality in DNA 
sequencing is presented by Phred Score. The larger the value the better the quality of a sequenced 
base. The average GC content of reads was also analysed in the QC report. The Sequence Duplication 
levels counts the degree of duplication for every sequence in the library and the plot shows the relative 
number of sequences with different degrees of duplication. A low level indicates a high level of 
coverage without enrichment bias. The frequency of A/T/C/G on each base position is measured as a 
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percentage and should be approximately constant across the read. Due to the very sensitive 
measurement, this commonly results in a ‘failed’ parameter in the report. 
 
5.3.5.2 Obtaining Counts 
The sequence reads are aligned onto a reference genome using Bowtie 2 and SAM tools. The reference 
genome chosen was homo_sapiens _NCBI_GRCh38. The prerequisite for mapping is having index files 
for the genome, which were built using Bowtie 2. Bowtie 2 outputs the alignments in SAM format 
where it is then processed using SAMtools resulting in bam files. From bam files, counts were 
generated using htseq_count tool. The counts were then used for data processing. 
 
5.3.6 Data Processing 
From the starting number of genes and their corresponding counts, the CBF team filtered out genes 
which had a sum of counts over all samples <10. The filtered counts were fed into DESeq2 which then 
makes corrections for library size. DESeq2 generates log2fold change values (CN vs CL), p-values and 
p-adj values using Benjamini-Hochberg correction. 
 
5.3.6.1 Principle Component Analysis  
Principal Component Analysis (PCA) is a method of spreading the whole data observations of possibly 
correlated variables as far apart based on the overall spatial orientation. PCA calculates the most 
separation among the data points. Therefore, if the data includes outliers, the outlier and the data 
points will have the largest separation. Through transformations of data, multiple PC values were 
obtained, labelled as PC1-PC20. The first principal component accounts for as much of the variability 
in the data as possible, and each succeeding component accounts for as much of the remaining 
variability as possible. The amount of variance that can be described by a principle component is 
usually represented as a percentage, where it represents how much of the variance is explained in the 
direction of the vector.  
 
5.3.6.2 Differential Gene Expression Analysis 
Two packages for R software (Bioconductor website) were applied to the RNA sequencing data in 
performing gene expression analysis: DESeq2 (Love, Huber & Anders 2014) and SAM using SAMseq 




This file is input to DESeq2 / SAM function to give out statistical information. DESeq2 and SAM are 
both methods of statistical analysis. From this the genes of statistically significant difference are 
separated out using adjusted p value of 0.05 as a cut-off. Those that are positive log2fold values are 
upregulated, whereas negative values are considered downregulated.  
While performing DESeq2 analysis, False Discovery Rate (FDR) 5% was used with Benjamini-Hochberg 
correction and genes with adjusted p value <0.05 were considered significantly 
upregulated/downregulated. 
For SAM, which is a more stringent method, the FDR was lowered to 10%.  
 
5.3.6.3 Functional annotation against Database for Annotation, Visualization and Integrated 
Discovery (DAVID) 
DAVID was originally a web based functional annotation tool that identifies enriched biological Gene 
Ontology (GO) terms and clusters the redundant ones (Dennis et al. 2003). A newer version provides 
a greater integrated annotation knowledgebase, built on the newly developed ‘DAVID Gene Concept’. 
It provides a more complex set of tools to methodically summarize relevant biological patterns from 
user-classified gene list (Dennis et al. 2003). 
 
5.3.6.4 Gene Set Enrichment Analysis 
All of the filtered genes were ranked based on “stat” values provided by DESeq2. Stat is a measure of 
log2fold change divided by its standard error. Gene sets selected (KEGG and Gene Ontology) were 
mapped onto the ranked genes. A gene set is considered to be either positively or negatively enriched 
if its genes are clustered high or low on the ranked list, respectively, and with the family-wise error 




Figure 5.3 Example of Positive enrichment gene set 
 
 
In order to visually represent Gene Set Enrichment Analysis (GSEA) results a bioinformatics analysis 
tool, REVIGO, was used that takes a long list of Gene Ontology terms and summarizes them by 
removing redundant GO terms (Supek et al. 2011). From GSEA results, they extracted GO terms only, 
fed them into  the web server 'Reduce and Visualize Gene Ontology’ (REVIGO) and the results are 
shown in a “TreeMap” as well as scattered plot representation (Supek et al. 2011). Each rectangle is 
representative of a single cluster. The representatives are joined into ‘superclusters’ of loosely related 
terms which are then visualized with different colors (Supek et al. 2011). The size of the rectangles 
may be modified to either the p-value, or the frequency of the GO term in the underlying GOA 
database (Supek et al. 2011). 
In scatterplot representation, cluster representatives (i.e. terms remaining after the redundancy 
reduction) are shown in a two dimensional space based on semantic similarity (Supek et al. 2011). 
 
Enrichment plot of a gene set ‘GO_RESPONSE_TO_INTERFERON_GAMMA’. The Enrichment score (ES) seen in the Y-axis (top). 
The score at the peak of the plot (the score furthest from 0.0) is the ES for the gene set (green). Gene sets with a distinct peak 
at the beginning (such as the one shown here) or end of the ranked list are generally the most interesting. The bottom portion 
of the plot shows the value of the ranking metric as you move down the list of ranked genes. The ranking metric measures a 
gene’s correlation with a phenotype. A positive value indicates correlation with the phenotype profile and a negative value 




5.3.6.5 Ingenuity Pathway Analysis (IPA) 
5.3.6.5.1 Downstream Effector Analysis (DEA) 
The IPA database of diseases and biological functions contains information on whether a gene is 
known to promote or inhibit a certain function. From gene matching, depending on the logFC, an input 
gene is matched to an increase or decrease of activity of a certain function. This is visualised by a 
“TreeMap” or a hierarchical heatmap, where the major boxes represent a family or category of related 
functions or diseases. Each individually coloured rectangle is referring to a particular biological 
function and if the function is found to be increasing, it will be shown in orange, otherwise it is shown 
in blue as decreasing (Kramer et al. 2014). A table of top categories of Disease and Function from IPA 
database is also generated. 
 
5.3.6.5.2 Upstream Regulator Analysis 
Differentially expressed genes in CLLcc (up and downregulated) along with their logFC were selected 
and input in the IPA database of prior knowledge of expected effects between transcriptional 
regulators and their target genes. Analysis examines how many known target genes of each 
transcription regulator are present in the input and compares target genes direction of change with 
the expected change if the transcriptional regulator increases/decreases its activity. If the direction is 
mostly consistent with activation/inhibition of the transcriptional regulator, a prediction is made 
about the activation state (Dennis et al. 2003). Upstream regulators were fed as official gene symbols 
into DAVID to classify them by function. Through DAVID, enriched biological themes (GO terms) can 
be identified, clustering of annotation terms can be made, genes can be visualized on KEGG pathway 





5.3.7 Real time Quantitative PCR (RT-qPCR) 
A selected number of genes from a list of differentially expressed genes from RNA-seq dataset (see 
Appendix Table 7.7) was chosen for validation by RT-qPCR following literature search for their function 
and relevance to CLL. Due to the large number of differentially expressed genes identified, for practical 
reason those genes with the biggest log2 fold-changes and the known association with the CLL 
microenvironment and NLC function were given the priority to be included for validation. In total, 20 
genes were initially selected for validation purposes.       
 
5.3.7.1 Primer Designing 
Designing primers is a very meticulous, but important step in ensuring correct amplification of a 
gene of interest (Ye et al. 2012). In brief, sensitivity and specificity of the primers to the 
complementary sequence of the genes of interest were carefully taken into accounts. A forward and 
reverse primer would ensure an accurate amplification during the polymerase chain reaction. The 
primer are designed in such a way that the primer itself is stable with melting temperatures (Tm) of 
50-60oC. The primer pairs should have a Tm within 5oC of each other. The primer pairs are designed 
to avoid complementary regions or be possible hairpin structures. The primers are prepared using 
the online tools from Ensembl Genome Browser 
(https://www.ensembl.org/Homo_sapiens/Info/Index), NCBI Primer Designing 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/), Oligonucleotide Properties Calculator 
(http://biotools.nubic.northwestern.edu/OligoCalc.html) and NCBI Homo sapiens (human) 
Nucleotide BLAST 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=OGP__9606__9558)
. Detailed sequences of the primers used for this chapter were provided in Appendix Table 7.7. 
 
5.3.7.2 Selection of Reference Gene 
GAPDH, RPL27 and ACTB were used for housekeeping/reference genes based on consensus in the 
literature (Eisenberg & Levanon 2013; Nakayama et al. 2018). Using the counts for each sample, the 
three mentioned genes were compared with each other using linear correlation. Those that had good 
correlation of at least 2/3 combinations was considered to be used as the Reference Gene of choice. 




5.3.7.3 The use of a Calibration Sample 
A calibration sample had to be included in all batches of RT-qPCR with all the primers. Ideally, the 
calibration sample had to have a high expression of all the primers to ensure appropriate technical 
replicates. Addition to that there must be enough cDNA of the calibration sample to be used in 
optimising as well as in the actual RT-qPCR experiments. Within the raw data of the RNAseq, the 
sample with the highest counts, for each primer was considered a good candidate. The CN of 3679 
and 3627 were therefore considered to be the calibration positive control samples. 
 
5.3.7.4 Calculation of Relative Gene expression 
The Livak Method for relative gene expression analysis (Livak & Schmittgen 2001) was used  where 
the result was expressed as the fold change of the expression of target gene in the test sample over 
that in the calibrator sample with expression of target gene in both test and calibrator sample 
normalized to the expression of a reference gene. Normalizing the expression of the target gene to 
that of the reference gene compensates for any difference in the amount of sample tissue. 
The CT of the target gene is normalised to that of the reference gene for both test sample and the 
calibrator sample to give ∆CT(test) (Equation 5.1). This is then normalised to that of the calibrator. 
Finally, the expression ratio is calculated, where the gene expression is considered increased if >1.0 
and decreased if <1.0. 
Equation 5.1 Calculation of Relative Gene expression. 
 
1. Normalise the CT 
∆CT(test) = CT(target, test) – CT(ref, test) 
∆CT(calibrator) = CT(target, calibrator) – CT(ref, calibrator) 
 
2. Normalise the ∆CT of the test sample to the ∆CT of the calibrator: 
∆∆CT=∆CT(test) - ∆CT(calibrator) 
 




Calculation of relative gene expression is by normalising the CT (1) and then normalising that of the test sample to that of the 
calibrator (2). Finally, the normalised expression ratio is calculated (3). 
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The RT-qPCR data, must meet the following criteria for analysis.  
1. GAPDH must be expressed in all sample pairs.  
a. If it is not expressed in one, the pair is excluded from interpretation. 
2. CT of the sample pair should ideally be less than 45 cycles.  
a. If both the sample pair is more than 45 cycles then the pair should be excluded.  
b. If one sample in the pair has CT more than 45 cycles then the sample pair can follow 





5.4.1 Case Summary 
In this chapter a total of 14 CLL samples were used and the summary was displayed in Table 5.3. A 
more detailed description of the clinical information of the CLL samples used in the study was provided 
in Appendix Table 7.1. 6 CLL cases were used for RNA-sequencing and validation by RT-qPCR (3577, 
3599, 3627, 3682, 2679 and 3684) and 8 cases for validation of RNA-seq results (3620, 3645, 3686, 
3605, 3607, 3621, 3631 and 3637).  
Table 5.3 Summary of clinical features of the CLL samples used in this chapter 









     































Staging at the 














*Prior therapy included steroid, chlorambucil, or fludarabine plus cyclophosphamide and rituximab. 
¶FISH (fluorescence in situ hybridisation) was performed at or prior to sampling. 
#IGHV status refers to somatic mutation in IGHV gene of CLL cells as compared with the gene sequence of the nearest germ-




5.4.2 Bioinformatics analysis of sequencing data generated by RNA-seq 
5.4.2.1 Quality Control 
After receiving the RNA-seq data, the Bioinformatics specialists at the Computational Biology Facility 
(CBF) of the University did the initial data quality control check and concluded that the quality of the 
sequencing data for each sample had passed the minimum requirement for downstream 
bioinformatics analysis. The details of their report were provided in the Appendix Figure 7.10. 
 
5.4.2.2 Data Processing 
After performing the quality control test on the RNA sequencing data, the Bioinformatics team was 
able to include 33,121 genes for subsequent data analysis. They filtered out genes which had a sum 
of counts of <10 over all samples, resulting in a total of 19,595 genes. Next, a file was produced after 
feeding the read counts into DESeq2, where log2fold change values were generated. The fold change 
was comparing the CLL cells cocultured with NLC (CN) versus CLL cells cultured alone (CL). Addition to 
log2fold change, p values and adjusted p values (padj) values were generated using Benjamini-
Hochberg correction method which can reduce the false discovery rate (FDR). 
 
5.4.2.2.1 Principle Component Analysis (PCA) 
PCA was then performed using the 19,595 genes from all 4 groups of samples. As seen in Figure 5.4, 
overall there was a clear separation between CLL and NLC populations among the 24 samples. Also, 
there was a separation among the 12 samples of CLL cells in the two groups, i.e. cultured alone versus 
co-culture. Regarding NLCs, however, there was no clear separation among samples in the two groups, 





Figure 5.4 Principal Components of all groups from filtered genes separates the CLL samples from the NLC samples 
PCA was repeated using only the CLL samples (alone and co-cultured). As shown in Figure 5.5, a mild 
form of separation was again seen.  
 
 
Figure 5.5 Principle Component analysis of CL vs CN samples among the filtered genes 
 
The data observations on the left are those from CLL alone (red) and CLL co-cultured with NLCs (green) and on the right are 
those from NLCs alone (black) and NLCs co-cultured with CLL cells (orange). This PCA plot used 24 samples and all genes from 
the filtered set of 19,595. 
The data observations are those from CLL alone (red) and CLL co-cultured with NLCs (green) This PCA plot used 12 samples 
and all genes from the initial filtered set of 19,595. 
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PCA was also repeated using only the NLC samples (alone and co-cultured). As shown in Figure 5.6, 
there was again no obvious separation among the samples. 
 
Figure 5.6 Principle Component analysis of NL vs NC samples among the filtered genes 
 
 
Upon performing differential expression analysis using DESeq2 (as described in Methods) on the 
19,595 genes, 333 genes were identified as significantly differentially expressed among all samples, 
with 326 differentially expressed genes from CLL samples (alone versus co-culture) and 7 from NLCs 
(alone versus co-culture) (for details, see Appendix Tables 7.3, 7.4, 7.5 and 7.6). PCA was again 
performed using the 333 differentially expressed genes. As seen in Figure 5.7, the CLL group was 
clearly separated from the NLC group. 
The data observations are those from NLCs alone (black) and NLCs co-cultured with CLL cells (orange). This PCA plot used 




Figure 5.7 Principal Components of all groups from filtered 333 genes that were significantly dysregulated, showed 
separation between the CLL samples and NLC samples. 
 
 
PCA was repeated only for CLL groups using 326 significantly differentially expressed genes. As seen 
in Figure 5.8, a separation between the CLL cells cultured alone (within the blue) and the CLL cells co-
cultured with NLCs (within the pink). 
  
The data observations on the left are those from CLL alone (red) and CLL co-cultured with NLCs (green) and on the right are 
those from NLCs alone (black) and NLCs co-cultured with CLL cells (orange). This PCA plot used 24 samples and all genes from 





Figure 5.8 Principle Component analysis of CL vs CN samples among the filtered 326 significant genes. 
 
PCA was repeated on the NLC group using 7 significantly differentially expressed genes. As shown in 
Figure 5.9, even with only 7 genes, there was a mild separation between the NLCs cultured alone 
versus in co-culture. 
 
Figure 5.9 Principle Component analysis of NL vs NC samples among the filtered genes 
 
The data observations are those from CLL alone (red) and CLL co-cultured with NLCs (green) This PCA plot used 12 samples 
and all significant genes from the initial filtered set of 326 from DESeq2 results with padjusted<0.05, FDR 5% and use of Benjamini-
Hochberg correction. 
The data observations are those from NLCs alone (black) and NLCs co-cultured with CLL cells (orange). This PCA plot used 12 




Based on the plots from PCA, there was clear indications that the global gene expression from the 4 
cell populations were indeed distinct from each other. 
 
5.4.2.2.2 DESeq2 vs SAM 
Differential Gene Expression Analysis (DGEA) was performed comparing the list of differentially 
expressed genes using DESeq2 and SAM R software packages. As described in Methods, the number 
of differentially expressed genes from DESeq2 was compared to SAM with their respective FDR on the 
CLL and NLC groups. Those with positive and negative log2fold values were upregulated and 
downregulated respectively. When comparing CLL alone (CLL) with CLL in co-culture (CLLcc) as seen in 






Figure 5.10 Differential Expression with two method comparing DESeq2 with SAM for CLL cells 
 
 
When comparing NLC alone (NLC) with NLCs in co-culture (NLCcc) as seen in Figure 5.11, more 
significant genes were detected in DESeq2. 
Signif. CLLcc vs CLL, ↑ in CLLcc  
264 58 5 
DESeq2, FDR 5% SAM, FDR 10% 
Signif. CLLcc vs CLL, ↓ in CLLcc  
Venn diagrams (top) showing the number of genes that were upregulated (left) and downregulated (right) among the CLL 
comparison group using DESeq2 and SAM method of differential gene expression analysis. DESeq2 (orange) results with 
padjusted<0.05, FDR 5%, Benjamini-Hochberg correction was used and SAM (blue) results with FDR 10%, Benjamini-Hochberg 
correction. Volcano plot (bottom) displaying the number and expression of genes, based on DESeq2 analysis, according to the 
log2foldchange and adjusted p value. The red indicates the genes that are having log2foldchange more than 2 with a 
significant p adjusted value. 
DESeq2, FDR 5%  SAM, FDR 10%  
4 0 





Figure 5.11 Differential Expression with two method comparing DESeq2 with SAM for NLCs 
 
 
Based on the findings, DESeq2 was preferred to be the method of choice for subsequent analysis as it 
was not as stringent as SAM. The list of differentially expressed genes were those from DESeq2 
analysis. 
 
Signif. NLCcc vs NLC, ↑ in NLCcc  Signif. NLCcc vs NLC, ↓ in NLCcc  
Venn diagram (top) showing the number of genes that were upregulated (left) and downregulated (right) among the NLC 
comparison group using DESeq2 and SAM method of differential gene expression analysis. DESeq2 (orange) results with 
padjusted<0.05, FDR 5%, Benjamini-Hochberg correction was used and SAM (blue) results with FDR 10%, Benjamini-Hochberg 
correction. Volcano plot (bottom) displaying the number and expression of genes, based on DESeq2 analysis, according to 
the log2foldchange and adjusted p value. The red indicates the genes that are having log2foldchange more than 2 with a 
significant p adjusted value. 
4 
DESeq2, FDR 5% SAM, FDR 10% DESeq2, FDR 5%  SAM, FDR 10%  
3 1 0 
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5.4.2.3 Comparison of differential gene expressions with those of microarray data on tissues 
A study that investigated effects of tumour-host interactions in vivo (Herishanu et al. 2011), were 
compared with our data. In that study, peripheral blood (PB), bone marrow (BM) and lymph node (LN) 
biopsy samples were collected from treatment naïve CLL patients and matched samples were taken 
from different anatomic compartments on the same day, processed and were analysed at the same 
time (Herishanu et al. 2011). The CLL patient cohort were a mix of male and female, Rai stage 1-4, 
mutated and unmutated IGHV and all common chromosomal aberrations investigated in CLL 
(Herishanu et al. 2011). SAM differential expressions on microarray data from the study, where gene 
expression profiling was performed on peripheral blood (PB), bone marrow (BM) and Lymph Nodes 
(LN), were compared with that of our data using FDR 0.5%, Benjamini correction. 
Gene set enrichment analysis was performed three times, each time using different differential 
expression microarray tissue data as input ranked list, comparing Lymph/Marrow, Lymph/Blood and 
Marrow/Blood. 
Four custom gene sets were generated using our differentially expressed genes (CLL_up, CLL_down, 
NLC_up, NLC_down, DE genes overlapping with tissue data only), when CLLcc was compared with CLL 
alone and NLCcc was compared with NLC alone as described earlier. 
The Bioinformatics team generated 322 genes that were significantly upregulated when comparing 
CLLcc with CLL alone. 4 genes were significantly downregulated when comparing CLLcc with CLL alone. 
These were then made into custom gene sets, however only CLL upregulated passed the size 
threshold. Therefore, this could not be performed with NLC genes of total of only 7. 
Using the microarray data from the study as described in Methods, the custom gene sets were 
compared with LN/BM and LN/PB ranked- retrieved positive enrichment only, and showed statistically 
significant comparisons (FWER p-value <0.05). Among the statistically significant gene sets were 61 
genes which can be seen in Table 5.4. This significant finding was not detected when comparing with 






















 1 RRM2 5 11.533 0.0376  32 GBP1 1903 2.424 0.3175 
2 ICAM1 106 6.935 0.0543  33 BHLHE41 1943 2.395 0.323 
3 CTSB 111 6.899 0.0767  34 COL8A2 1951 2.384 0.3304 
4 EGR2 158 6.321 0.0947  35 STAT1 1974 2.36 0.3369 
5 MKI67 170 6.269 0.1147  36 PARP9 2080 2.258 0.3379 
6 HJURP 296 5.412 0.1249  37 TICRR 2109 2.231 0.3435 
7 PKMYT1 530 4.467 0.1254  38 PHLDA3 2111 2.23 0.3508 
8 OAS3 565 4.384 0.1377  39 FNDC3B 2168 2.177 0.3546 
9 RCN1 581 4.339 0.1511  40 CR1 2197 2.145 0.3599 
10 C1QA 582 4.338 0.1653  41 WDFY1 2292 2.067 0.361 
11 LILRB4 621 4.213 0.1769  42 GADD45G 2588 1.856 0.3492 
12 PTGDS 637 4.175 0.1897  43 MREG 2596 1.845 0.3548 
13 C1QC 652 4.142 0.2025  44 FBXO6 2670 1.797 0.3563 
14 PKM 769 3.903 0.2082  45 UBE2L6 2698 1.776 0.3605 
15 MMP9 777 3.857 0.2205  46 CSF1 2700 1.773 0.3663 
16 MRC1 1018 3.457 0.2173  47 PARP14 2716 1.762 0.3712 
17 CXCL9 1064 3.383 0.2257  48 C1S 2851 1.669 0.3685 
18 GALNT6 1075 3.366 0.2361  49 EGLN3 2958 1.598 0.3673 
19 PLIN3 1122 3.298 0.2442  50 BPGM 3028 1.56 0.3683 
20 C1QB 1125 3.29 0.2549  51 CCL22 3042 1.55 0.3726 
21 EBI3 1131 3.284 0.2654  52 MT1E 3124 1.489 0.3725 
22 APOE 1158 3.234 0.2744  53 NUPR1 3203 1.443 0.3726 
23 SIRPA 1361 2.961 0.2719  54 FSCN1 3229 1.436 0.3758 
24 TAP1 1398 2.917 0.2793  55 PRR11 3314 1.388 0.3752 
25 STEAP3 1579 2.733 0.2773  56 QPRT 3416 1.328 0.3735 
26 TNFRSF9 1596 2.717 0.2853  57 CXCL12 3526 1.278 0.371 
27 ITGB2 1624 2.687 0.2925  58 PLAU 3531 1.275 0.375 
28 C17orf96 1628 2.682 0.3011  59 MMP14 3581 1.247 0.3761 
29 PGD 1709 2.603 0.3048  60 GPRC5B 3634 1.219 0.377 
30 LAP3 1802 2.524 0.3075  61 PRRG4 3643 1.214 0.3805 
31 PLOD1 1882 2.443 0.3108       
List of genes generated when comparing custom gene sets vs Lymph/Marrow, ranked – retrieved positive enrichment only. 
This custom gene set were inlcuding genes upregulated in CLLcc vs CLL, and was ranked with those from the study microarray 
data (Herishanu et al. 2011). 
To confirm the RNA-seq results, some of the differential expressed genes identified by RNA-seq were 
to be selected for validation in RT-qPCR.  
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5.4.3 Validation by RT-qPCR 
5.4.3.1 Selection of Primers 
I decided to select genes from my Differential Gene Expression Analysis (DGEA) list that were also 
found to be in the study of microarray genes as described in Methods. Among the 61 genes listed, I 
selected 13 candidate genes. Primer designing difficulties and lack of available resources forced us to 
exclude the other genes of interest. On deciding the most appropriate reference gene out of GAPDH, 
RPL27 and ACTB, the comparison using R2 calculation in linear correlation and regression analyses 
revealed that GAPDH has a closer positive correlation with other two and is therefore used  as house-
keeping gene (see Appendix Figure 7.11). I proceeded to test all the cDNA samples for their expression 
of GAPDH using gel electrophoresis. As seen in Figure 5.12, it was clear that GAPDH are not amplified 
to an acceptable level in some samples, likely due to insufficient RNA, thus unsuitable for RT-qPCR. 
These samples (3599, 3577 and 3637) were therefore scrutinised with caution when interpreting the 
results. 
 
Figure 5.12 PCR gel of GAPDH Primer for all the samples used with a DNA ladder, to determine which samples are suitable 




Agarose gel electrophoresis was performed, as described in Methodology, on PCR products of the cDNA samples (as 
described). The Quick-Load Purple 100bp DNA ladder was used. Both CN and CL samples were used for each sample. 
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5.4.3.2 Optimising Conditions of the RT-qPCR  
All the primers were prepared as described and RT-qPCR was performed for each of them using either 
of the mentioned calibration samples with a negative water control. I first observed the melting curves 
for each primer. As seen in Figure 5.13, there are two peaks formed. The start of the bigger peak is 
the temperature which should be set for detection of maximum fluorescence.  
 
Figure 5.13 Example of Melting curve of all samples with GAPDH Primer run on RT-qPCR. 
 
 
It is seen that the smaller peak is the location of primer dimer formation which appeared to be present 
in most of the samples. Individually, this phenomenon can be seen per sample, as seen in Figure 5.14. 
The use of water control without cDNA shows at what temperature the primer forms primer dimers. 
Melting curve from RT-qPCR of all cDNA samples showing the presence of primer dimer formation at 77-83oC (left peak).  The 
detection temperatures should be adjusted to 84oC. cDNA is synthesised from RNA as described. cDNA for RT-qPCR is 




Figure 5.14 Melting curve of sample 3679, control positive sample and control negative water, all with GAPDH Primer 
showing the presence of primer dimer formation at 77-83oC 
 
 
Addition to melting curves made by the LightCycler 480 PCR machine, I also ran an agarose gel 
(described in Methodology) to observe how specific the Primers were. As seen in Figure 5.15, most of 





Melting curve from RT-qPCR of cDNA sample 3679,  control positive sample and control negative water, all with GAPDH Primer 
showing the presence of primer dimer formation at 77-83oC (left peak).  The detection temperatures should be adjusted to 
84oC to detect the peak formed (right). Control negative water is used with GAPDH primer to show the position of primer dimer 
formations. cDNA is synthesised from RNA as described. cDNA for RT-qPCR is prepared as described using standard protocol 




Figure 5.15 Agarose gel using a control sample with all the primers of interest. 
 
 
Based on the results (Figure 5.15), depicting the presence of primer dimers identified as detection at 
half the expected product length (eg. EGLN3) as well as non-specific binding as detection higher than 
the product length (eg. CCL13), these primer results were to be highly scrutinized with caution. 
Based on all the data from position of melting curves of RT-qPCR as well as bands formed from PCR 
gel electrophoresis, an optimised set of conditions was prepared to read the level of fluorescence for 
each primer (Table 5.5). 
  
Using a control sample with all the primers of interest (column #3-#16). The Quick-Load Purple DNA ladders 100bp (column 
#1) and 1kb (column #2) were used to compare the bp. The agarose gel electrophoresis was performed as described in 
Methodology. This was performed to determine which primers are suitable to be used. Here a primer dimer formation is 




Table 5.5 Optimal conditions to read the level of fluorescence for each primer 
Temp for signal capture oC Genes Comments 








YPEL4 Expected to be downregulated 
STEAP3  
86 EGLN3  
NOT GOOD 
CXCL10 Overlap with dimers 
CCL13 gDNA amplified 
CXCL9 Overlap with dimers 
NUPR1 Overlap with dimers, gDNA amplified 
EGR2 Partially overlap with dimers, non-specific amplification 
 
The conditions were therefore optimised, supported by evidence of PCR products on agarose gel and 
I could go ahead and confirm the findings of DGEA of RNAseq. 
 
5.4.4 Confirmation of differentially expressed genes by RT-qPCR 
Using the conditions optimised for RT-qPCR for all the primers, I performed the experiment on all the 
CLL paired samples (14 CL and 14 CN) for all the primers (8 primers). The method is described in 
Methodology with the grid outlines in the Appendix Table 7.14. 
As seen in Figure 5.16, the amplification curves were produced for all the samples (pooled) in their 
replicates for each primer.  
Individually, the cases can be analysed to compare each case (CLL alone and CLL co-cultured with NLC) 
with positive control and negative water control. As seen in Figure 5.16, the negative (water) control 
did not amplify anything suggesting no contamination. The presence of the positive control shows the 
experiment ran correctly. Observed a parallel exponential curve at threshold level, suggested the 
appropriate threshold level and quality of the experiment. The presence and distance of parallel waves 
between CL and CN shows the change in level of expression. This was performed on all primers for all 
case pairs. A representative example of #3620 is shown for each primer in Figure 5.16, where the 
negative control (water with primer), positive control (control sample) and the pair of CLL alone and 
CLL in co-culture with NLCs can all be appreciated. When one of the curves reach threshold (CT) later, 
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this means the expression of that gene is lower than a curve that reaches threshold (CT) earlier. Each 
report generated the CT at the selected fluorescence threshold. Now that all the RT-qPCR data was 







































Figure 5.16 Amplification Curves of cDNA samples (Pooled in Blue column and #3620 as representative example in Orange column) for each primer at their optimised conditions. 
A control positive (CN 3627 as grey for GAPDH, green for others) and a control negative (PCR grade water with respective primer) in beige colour. For GAPDH, #3620 pair of CLL alone as dark 
green and CLL in coculture with NLCs as pale blue. For remaining primers, #3620 pair of CLL alone as green and CLL in coculture with NLCs as pale blue. Fluorescence measured in log scale and 
threshold (red horizontal line) set at 0.4. The point in which the wave for each sample passes the red line is the CT. RT-qPCR was performed as described and the images were generated using 
Lightcycler 480 machine software. 
173 
 
5.4.4.1 Relative Gene expression changes 
Here the gene expression values were calculated by the method described (Equation 5.1). It became 
clear that with the additional evidence by the PCR products on agarose gel, the samples #3577 and 
#3637 were degraded. Additionally, EBI3 were not detected at all in any of the samples. In order to 
calculate gene expression ratio values, there was a strict requirement of GAPDH CT values to be 
present to perform the calculation. If samples from either CLL cells cultured alone or in co-culture with 
NLCs or both did not have GAPDH values, then that case cannot be used in further analysis. The next 
strict requirement is that samples from either CLL cells cultured alone or in co-culture with NLCs 
should have CT values for each primer. If both were absent then the calculation cannot be performed. 
As seen in Table 5.6, based on the values as either >1 or <1 corresponding to upregulated or 
downregulated respectively, it was colour coded for ease in visual representation. 
Table 5.6 RT-qPCR results displaying gene expression changes across all the samples for each primer. 
 
3682 3679 3684 3620 3645 3686 3605 3607 3621 3631 
MCL1 
          
CXCL12 
          
CSF1 
          
GBP1 
          
YPEL4 
          
STEAP3 
          
EGLN3 
          
           
   Increased 
         
   Decreased 
         
 
 
The samples #3577, #3599, #3627 and #3637 had to be excluded because calculation of gene 
expression ratio was not possible for the majority of the primers. #3627 was excluded entirely because 
the GAPDH of CL was very weakly expressed which would not have given a justifiable analysis of the 
primers. The empty spaces are where both the samples in the pair could not be used to calculate the 
RT-qPCR results displaying gene expression changes as green (increased) or blue (decreased) compared between CLL alone 
and CLL in co-culture with NLCs. Samples in purple font are those that were also sent for RNAseq. Gaps are indicated where 
qPCR data was not obtainable. CT values were obtained from Lightcycler 480 machine software. Gene expression ratio was 
calculated as described in Methods. Each sample was normalised to a calibration sample, and each of that was normalised 
to reference gene GAPDH. 
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relative gene expression. As seen in Table 5.6, of the 10 cases remained for 7 primers (excluding 
GAPDH) there was an increased expression of most of the genes for the majority of samples, except 
#3621 and #3631. I then proceeded to compare the expression changes of these remaining 10 cases, 
with that of the expected changes from RNAseq analysis. 
 
5.4.4.2 Compared results from RT-qPCR with RNA-seq data 
Using the gene expression changes from Table 5.6, I compared with the expected changes from 
RNAseq analysis, where if the RT-qPCR data coincided with the expected change in gene expression, 
the applied colour coding is green and similarly if they go against the expected change in gene 
expression, the applied colour coding is red (Table 5.7). 
Table 5.7 Comparison of RT-qPCR gene expression changes with that of expected changes from RNAseq analysis. 
 
3682 3679 3684 3620 3645 3686 3605 3607 3621 3631 
MCL1 
          
CXCL12 
          
CSF1 
          
GBP1 
          
YPEL4 
          
STEAP3 
          
EGLN3 
          
           
  As expected 
  Not expected 
 
 
Here it can be seen in Table 5.7, 24 gene expression change observations (red) did not agree with that 
of RNAseq analysis, but 41 did (green). It can be seen that the sample #3679 displayed all the changes 
in RT-qPCR that was expected from DGEA of RNAseq data. The next best samples were #3620 and 
#3682. A further detailed descriptive analysis seen in Table 5.8, show that among the RNAseq samples, 
3 primers were consistently differentially expressed as expected, namely MCL1, CSF1 and GBP1. 
  
Comparison of gene expression changes obtained from RT-qPCR with that from RNAseq DGEA as green (as expected with 
RNAseq results) or red (not expected with RNAseq results) compared between CLL alone (CL) and CLL in co-culture with 




Table 5.8 Descriptive analysis of RT-qPCR vs RNA seq data 
 RNAseq samples (3) Other Samples (7) All samples (10) 
MCL1 3 out of 3 100.00% 3 out of 7 42.86% 6 out of 10 60.00% 
CXCL12 2 out of 3 66.67% 4 out of 7 57.14% 6 out of 10 60.00% 
CSF1 3 out of 3 100.00% 4 out of 7 57.14% 7 out of 10 70.00% 
GBP1 3 out of 3 100.00% 4 out of 5 80.00% 7 out of 8 87.50% 
YPEL4 1 out of 3 33.33% 3 out of 7 42.86% 4 out of 10 40.00% 
STEAP3 1 out of 2 50.00% 3 out of 6 50.00% 4 out of 8 50.00% 
EGLN3 2 out of 3 66.67% 5 out of 6 83.33% 7 out of 9 77.78% 
 
 
To further understand why these specific primers (MCL1, CSF1 and GBP1) were faithful in their 
expression changes detectable by RT-qPCR and RNA-seq DGEA, I looked at the raw read counts from 
the RNA-seq data. 
 
5.4.4.3 Read counts from RNA-seq 
As shown in Table 5.9, the read counts obtained from RNA-seq in order to calculate differential gene 
expression analysis, revealed a wide range of absolute values from 0-18079. 
  
Descriptive analysis of gene expression changes of RT-qPCR compared with DGEA of RNAseq data. 7 primers were 
compared among 3 groups: RNAseq samples themselves, other samples and all samples combined. Highlighted in blue are 
the primers that were differentially expressed as expected by all the samples within their respective groups. 
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Table 5.9 Read counts of Primers investigated for each RNA sample sent for RNAseq. 
 
CL 
      
 
CL27 CL77 CL79 CL82 CL84 CL99 Average read 
YPEL4 61 32 51 53 33 90 53.33333 
CXCL12 1 0 1 1 0 0 0.5 
EGLN3 2 0 1 1 0 0 0.666667 
GBP1 34 13 12 59 26 12 26 
EBI3 2 2 0 3 3 0 1.666667 
CSF1 55 76 31 48 30 44 47.33333 
MCL1 6418 6256 4451 8709 6264 4898 6166 
STEAP3 8 189 26 18 7 14 43.66667 




      
 
CN27 CN77 CN79 CN82 CN84 CN99 Average read 
YPEL4 32 30 32 25 7 85 35.16667 
CXCL12 2 22 2 7 6 14 8.833333 
EGLN3 10 7 7 6 0 5 5.833333 
GBP1 224 59 28 1586 47 231 362.5 
EBI3 17 4 0 45 10 2 13 
CSF1 498 314 75 815 80 231 335.5 
MCL1 10638 10221 6281 18079 9243 9546 10668 
STEAP3 141 497 55 45 37 263 173 
GAPDH 3909 4220 2814 4534 3800 2312 3598.167 
 
 
Interestingly, the genes MCL1, CSF1 and GBP1 had a much higher read count (2-4 digits) than the 
remaining genes across all the samples. (1-2 digits). Those with 2 digit read counts but compared 
poorly in RT-qPCR had counts in the lower range (ie 10-50) such as YPEL4, CXCL12, EGLN3, EBI3 and 
STEAP3. The average read count for those with poor comparison with RT-qPCR were 0.5-53 (CL) and 
5.8-173 (CN).  
Raw read counts for each sample sent for RNAseq for each primer investigated. Green indicates the gene that was 
significantly differentially downregulated by DGEA. Yellow indicates genes that were significantly differentially upregulated 
by DGEA. Orange indicates the reference gene selected. Red indicates the Genes whose RT-qPCR data completely coincided 
with expected changes of RNAseq DGEA. CLL alone (CL) are those on top and CLL Co-cultured with NLCs (CN) are those 
bottom. The individual samples have numbers after their designated culture condition. Raw counts were obtained during 
DGEA by the Bioinformatics department of Computational Biology Facility. 
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Given that the majority of Primers (6/7) were validated with more than 50% of samples we can have 
good confidence on the validity of the RNAseq data by the differential gene expression analysis. 
So far, the analysis of samples for qPCR and RNAseq was more or less validated. The samples that 
were not sent for RNAseq but had qPCR performed gives a similar picture, though the findings can be 





5.4.5 Functional and Pathway analysis 
5.4.5.1 Functional annotation (DAVID) 
With the use of DAVID, as shown in Table 5.10, CLLcc vs CLL comparison showed 322 upregulated 
genes as input data, out of which 313 genes were mapped in by DAVID, resulting in 10 clusters. Out of 
these 10, 2 clusters had significant Benjamini corrected p-values. The first cluster is of inflammatory 
response (26/313 genes) and the second cluster is of platelet degranulation (10/313 genes). 
The number of differentially expressed genes in NLC was not enough to perform DAVID analysis. 






CLLcc vs CLL comparison: 322 upregulated genes were fed into DAVID and found 10 clusters, of which only 2 had significant 
Benjamini corrected p-values. 
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5.4.5.2 Gene Set Enrichment Analysis (GSEA) 
Gene sets were selected (KEGG and Gene Ontology) and were mapped onto the ranked genes. When 
comparing CLLcc with CLL, 15,796 were selected and 104 positively enriched gene sets were found to 
be significant when FWER p-value <0.05. As seen in Table 5.11, the top 10 enriched and upregulated 
gene sets included those involved in chemokine and cytokine signalling. 
Table 5.11 Gene set enrichment analysis of CLL co-cultured with NLC (CLLcc) vs CLL alone (CLL) 
 
 
Furthermore, as seen in Figure 5.17, REVIGO was used to visualize the GSEA results and showed 
involvement of ‘Regulation of response to wound’ and ‘Lymphocyte migration’.  
 
Figure 5.17 “TreeMap” view of REVIGO Gene Set Enrichment Analysis comparing CLL co-cultured with NLC vs CLL alone 
 
GS
follow link to MSigDB
1 GO_RESPONSE_TO_INTERFERON_GAMMA Details ... 115 0.7 2.6 0 0 0 2225 tags=53%, list=14%, signal=61%
2 GO_CHEMOKINE_RECEPTOR_BINDING Details ... 40 0.8 2.6 0 0 0 1936 tags=65%, list=12%, signal=74%
3 GO_CELLULAR_RESPONSE_TO_INTERFERON_GAMMA Details ... 96 0.7 2.5 0 0 0 1970 tags=49%, list=12%, signal=56%
4 GO_CHEMOKINE_ACTIVITY Details ... 32 0.8 2.5 0 0 0 1075 tags=59%, list=7%, signal=64%
5 GO_CHEMOKINE_MEDIATED_SIGNALING_PATHWAY Details ... 49 0.8 2.5 0 0 0 1936 tags=61%, list=12%, signal=70%
6 KEGG_COMPLEMENT_AND_COAGULATION_CASCADES Details ... 41 0.8 2.5 0 0 0 440 tags=44%, list=3%, signal=45%
7 GO_CYTOKINE_MEDIATED_SIGNALING_PATHWAY Details ... 350 0.6 2.4 0 0 0 2558 tags=43%, list=16%, signal=50%
8 GO_PROTEIN_ACTIVATION_CASCADE Details ... 35 0.8 2.4 0 0 0 1186 tags=51%, list=8%, signal=55%
9 GO_INNATE_IMMUNE_RESPONSE Details ... 419 0.6 2.4 0 0 0 2344 tags=39%, list=15%, signal=45%
10 GO_INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY Details ... 63 0.7 2.4 0 0 0 2130 tags=52%, list=13%, signal=60%
FWER p-val RANK AT MAX LEADING EDGEGS DETAILS SIZE ES NES NOM p-val FDR q-val
Top 10 gene sets that were enriched based on their rank on the list and with FWER p-val <0.05. Data sets are predefined 
by KEGG or GO and is ranked based on “stat” values provided by DESeq2. 
Each rectangle is a single cluster representative. The representatives are joined into ‘superclusters’ of loosely related terms, 
visualized with different colors. Size of the rectangles may be adjusted to reflect either the p-value, or the frequency of the 
GO term in the underlying GOA database. 
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A ‘‘Scatterplot & Table’’ view of REVIGO was also generated when comparing CLLcc with CLL alone, as 
seen in Figure 5.18, and showed the involvement of lymphocyte migration, extracellular matrix 
disassembly, tissue remodelling, inflammatory response, regulation of response to wounding, positive 





Figure 5.18 ‘‘Scatterplot & Table’’ view of REVIGO comparing CLL co-cultured with NLC vs CLL alone 
 
This GSEA was performed the same way again in the comparison between NLCcc and NLC using 19,595 
genes and found 18 significantly enriched gene sets with positive enrichment when p<0.0.5, which is 
displayed in Table 5.12. 
The scatterplot shows the cluster representatives (i.e. terms remaining after the redundancy reduction) in a two-
dimensional space derived by applying multidimensional scaling to a matrix of the GO terms’ semantic similarities. 
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Table 5.12 Gene set enrichment analysis of NLC co-cultured with CLL (NLCcc) vs NLC alone (NLC) 
 
GS
follow link to MSigDB
1 KEGG_RIBOSOME Details ... 85 0.6 2.4 0 0 0 4281 tags=60%, list=22%, signal=76%
2 GO_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM Details ... 102 0.6 2.4 0 0 0 4281 tags=57%, list=22%, signal=72%
3 KEGG_SPLICEOSOME Details ... 125 0.6 2.4 0 0 0 3422 tags=46%, list=17%, signal=55%
4 GO_CHEMOKINE_MEDIATED_SIGNALING_PATHWAY Details ... 59 0.6 2.4 0 0 0 4238 tags=56%, list=22%, signal=71%
5 GO_CYTOSOLIC_RIBOSOME Details ... 105 0.6 2.3 0 0 0 4281 tags=54%, list=22%, signal=69%
6 GO_RIBOSOMAL_SUBUNIT Details ... 156 0.5 2.3 0 0 0 3861 tags=48%, list=20%, signal=59%
7 GO_CYTOSOLIC_SMALL_RIBOSOMAL_SUBUNIT Details ... 42 0.7 2.3 0 0 0 3693 tags=60%, list=19%, signal=73%
8 GO_RRNA_METABOLIC_PROCESS Details ... 249 0.5 2.3 0 0 0 5074 tags=49%, list=26%, signal=66%
9 GO_CHEMOKINE_ACTIVITY Details ... 38 0.7 2.3 0 0 0 3458 tags=50%, list=18%, signal=61%
10 GO_RIBOSOME Details ... 212 0.5 2.3 0 0 0 4281 tags=45%, list=22%, signal=57%
11 GO_RIBOSOME_BIOGENESIS Details ... 298 0.5 2.3 0 0 0 5089 tags=49%, list=26%, signal=65%
12 GO_SMALL_RIBOSOMAL_SUBUNIT Details ... 66 0.6 2.3 0 0 0.001 3693 tags=53%, list=19%, signal=65%
13 GO_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM Details ... 121 0.5 2.2 0 0 0.003 4281 tags=53%, list=22%, signal=67%
14 GO_PROTEIN_TARGETING_TO_MEMBRANE Details ... 149 0.5 2.2 0 0.001 0.02 4281 tags=46%, list=22%, signal=59%
15 GO_CCR_CHEMOKINE_RECEPTOR_BINDING Details ... 26 0.7 2.1 0 0.002 0.033 4238 tags=54%, list=22%, signal=69%
16 GO_RIBONUCLEOPROTEIN_COMPLEX_BIOGENESIS Details ... 419 0.4 2.1 0 0.002 0.034 5089 tags=44%, list=26%, signal=59%
17 GO_CHEMOKINE_RECEPTOR_BINDING Details ... 47 0.6 2.1 0 0.002 0.034 3103 tags=40%, list=16%, signal=48%
18 GO_CYTOSOLIC_LARGE_RIBOSOMAL_SUBUNIT Details ... 56 0.6 2.1 0 0.002 0.039 4281 tags=55%, list=22%, signal=71%
FWER p-val RANK AT MAX LEADING EDGEGS DETAILS SIZE ES NES NOM p-val FDR q-val
All 18 gene sets that were enriched based on their rank on the list and with FWER p-val <0.05. Data sets are predefined by KEGG or GO and is ranked based on “stat” values 
provided by DESeq2. 
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5.4.5.3 Ingenuity Pathway Analysis (IPA) 
IPA was performed as described in Methods to identify any pathways that is suggested to be involved 
based on the genes that is known to promote and inhibit a function. As seen in Figure 5.19 (top), the 
TreeMap shows an involvement of several functions.  
 
5.4.5.3.1 Diseases and Functions 
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Cellular Movement migration Migration of cells 1.06E-19 Increased 4.5 A2M,ACTN1,ADGRE2,ALOX15B,APBA1,APOE,BCAR1,BHLHE41,CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD38,CD4,CDCP1,CDKN1A,CHI3L1,CLEC11A,COL6A1,CSF1,CTSB,CTSL,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,CYP2S1,EBI3,EGLN3,F3,FPR2,FSCN1,GBP1,ICAM1,IGFBP6,IL6,ITGB2,KCNMA1,LGALS3BP,LPAR1,LRP12,MMP14,MMP7,MMP9,MSR1,NCF2,NES,NFKBIA,NRP1,OLR1,PANDAR,PARP9,PKM,PLAU,PLAUR,PLXNA1,PROS1,PTAFR,PTPRF,S100A11,SDC4,SEMA3A,SERPINA1,SERPINE1,SH3PXD2B,SHC4,SIRPA,SLC7A11,SLC8A1,SOCS3,SOD2,SORT1,SPARC,SPP1,SPSB1,STAT1,TFPI,TGFA,TGM2,TIMP3,TXN,USP2,WARS87
Cellular Movement cell movement Cell movement 1.29E-18 Increased 4.809 A2M,ACTN1,ADGRE2,ALOX15B,ANOS1,APBA1,APOE,BCAR1,BHLHE41,CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD38,CD4,CDCP1,CDKN1A,CHI3L1,CLEC11A,COL6A1,CSF1,CSPG4,CTSB,CTSL,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,CYP2S1,DRAM1,DST,EBI3,EGLN3,F3,FPR2,FSCN1,GBP1,ICAM1,IGFBP6,IL6,ITGB2,KCNMA1,LGALS3BP,LPAR1,LRP12,MMP14,MMP7,MMP9,MSR1,NCF2,NES,NFKBIA,NRP1,OLR1,PANDAR,PARP9,PKM,PLAU,PLAUR,PLXNA1,PROS1,PTAFR,PTPRF,S100A11,SDC4,SEMA3A,SERPINA1,SERPINE1,SH3PXD2B,SHC4,SIRPA,SLC7A11,SLC8A1,SOCS3,SOD2,SORT1,SPARC,SPP1,SPSB1,STAT1,TFPI,TGFA,TGM2,TIMP3,TXN,USP2,WARS9
Cell-To-Cell Signaling and Interaction adhesion Adhesion of blood cells 3.23E-15 Increased 3.07 A2M,APOE,CCL22,CD4,CD59,CR1,CSF1,CXCL10,CXCL12,CXCL8,CXCL9,F3,FPR2,ICAM1,IL6,ITGB2,MARCO,MRC1,PLAU,PLAUR,SERPINA1,SERPINE1,SERPING1,SPP1,STAT1,TGM2,TXN27
Inflammatory Response inflammatory response Inflammatory response 8.25E-15 Increased 3.258 APOE,CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD4,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,FPR2,IL6,ITGB2,LGALS3BP,LYZ,MCL1,MMP9,NFKBIA,PLAU,PLAUR,PROS1,SERPINA1,SERPINE1,SERPING1,SIRPA,SOCS3,SPP1,TNFAIP6,VNN134
Cellular Movement cell movement Cell movement of myeloid cells 1.24E-14 Increased 4.372 CCL1,CCL13,CCL22,CCL24,CCL7,CCL8,CD4,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,FPR2,ICAM1,ITGB2,MMP14,MMP9,PLAU,PLAUR,SEMA3A,SERPINA1,SERPINE1,SIRPA,SPP1,TGM2,TIMP327
Cell-To-Cell Signaling and Interaction binding Binding of blood cells 2.01E-14 Increased 2.948 A2M,APOE,CCL22,CD4,CD59,CR1,CSF1,CXCL10,CXCL12,CXCL8,CXCL9,F3,FPR2,ICAM1,IL6,ITGB2,MARCO,MRC1,PLAU,PLAUR,SEMA3A,SERPINA1,SERPINE1,SERPING1,SPP1,STAT1,TGM2,TXN28
Cellular Movement,Hematological System Development and Function,Immune Cell Traffickingc ll movement Cell movement of leukocytes 3.86E-14 Increased 4.573 ADGRE2,CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD38,CD4,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,FPR2,ICAM1,IL6,ITGB2,MMP14,MMP9,PLAU,PLAUR,SEMA3A,SERPINA1,SERPINE1,SIRPA,SOCS3,SPP1,TGM2,TIMP332
Cell-To-Cell Signaling and Interaction,Hematological System Development and Function,Immune Cell Traffickingadhesion Adhesion of immune cells 5.14E-14 Increased 2.455 A2M,APOE,CCL22,CD4,CSF1,CXCL10,CXCL12,CXCL8,F3,FPR2,ICAM1,IL6,ITGB2,MARCO,MRC1,PLAU,PLAUR,SERPINA1,SERPINE1,SERPING1,SPP1,STAT1,TGM2,TXN24
Cellular Movement cell movement Cell movement of tumor cell lines 8.63E-14 Increased 4.261 A2M,ACTN1,BCAR1,BHLHE41,CCL1,CCL13,CCL18,CCL22,CCL7,CCL8,CDCP1,CDKN1A,CSF1,CTSB,CTSL,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,DRAM1,EBI3,EGLN3,F3,FPR2,FSCN1,IGFBP6,IL6,LGALS3BP,LPAR1,MMP14,MMP7,MMP9,NES,NFKBIA,NRP1,PANDAR,PKM,PLAU,PLAUR,PLXNA1,PTAFR,S100A11,SDC4,SEMA3A,SERPINA1,SERPINE1,SH3PXD2B,SHC4,SIRPA,SOCS3,SOD2,SPARC,SPP1,SPSB1,STAT1,TFPI,TGFA,TGM2,TIMP3,USP261
Cellular Movement migration Migration of tumor cell lines 1.77E-13 Increased 3.645 A2M,ACTN1,BCAR1,BHLHE41,CCL1,CCL22,CCL7,CDCP1,CDKN1A,CTSB,CTSL,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,EBI3,EGLN3,F3,FSCN1,IGFBP6,IL6,LGALS3BP,LPAR1,MMP14,MMP7,MMP9,NES,NFKBIA,NRP1,PANDAR,PKM,PLAU,PLAUR,PLXNA1,PTAFR,S100A11,SDC4,SEMA3A,SERPINA1,SERPINE1,SH3PXD2B,SHC4,SIRPA,SOCS3,SOD2,SPARC,SPP1,SPSB1,STAT1,TFPI,TGFA,TGM2,TIMP3,USP255
Cellular Movement,Hematological System Development and Function,Immune Cell Trafficking,Inflammatory Responsemigr tion Mig tion of phagocytes 2.34E-13 Increased 3.21 CCL1,CCL22,CCL7,CCL8,CD38,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,ICAM1,ITGB2,MMP14,MMP9,PLAU,SEMA3A,SERPINE1,SPP1,TIMP319
Cellular Movement,Immune Cell Trafficking migration Leukocyte migration 3.05E-13 Increased 4.702 ADGRE2,CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD38,CD4,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,FPR2,ICAM1,IL6,ITGB2,MMP14,MMP9,OLR1,PLAU,PLAUR,PROS1,SDC4,SEMA3A,SERPINA1,SERPINE1,SIRPA,SLC7A11,SOCS3,SPP1,TGM2,TIMP3,TXN37
Cellular Movement chemotaxis Chemotaxis 4.65E-13 Increased 4.501 ACTN1,ADGRE2,ANOS1,BCAR1,CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD4,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,FPR2,IL6,ITGB2,LPAR1,MMP9,NRP1,PLAU,PLAUR,SEMA3A,SERPINA1,SERPINE1,SOCS3,SPP1,TXN32
Cellular Movement,Hematological System Development and Function,Immune Cell Trafficking,Inflammatory Responsec ll movement Cell movement of phag cytes 9.12E-13 Increased 4.07 CCL1,CCL22,CCL24,CCL7,CCL8,CD38,CD4,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,FPR2,ICAM1,ITGB2,MMP14,MMP9,PLAU,PLAUR,SEMA3A,SERPINA1,SERPINE1,SPP1,TIMP325
Cellular Movement,Hematological System Development and Function,Immune Cell Trafficking,Inflammatory Responsechemotaxis Chemotaxis of leukocy es 1.3E-12 Increased 4.062 CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD4,CSF1,CXCL10,CXCL12,CXCL5,CXCL8,CXCL9,FPR2,IL6,ITGB2,MMP9,PLAU,PLAUR,SERPINA1,SERPINE1,SOCS3,SPP14
Free Radical Scavenging metabolism Metabolism of reactive oxygen species 2.3E-12 Increased 3.35 APOE,APOL6,CCL13,CDKN1A,CLEC7A,CSF1,CXCL8,FPR2,FTH1,GSN,IL4I1,IL6,ITGB2,MRC1,NCF2,NFKBIA,OLR1,PLAU,PLAUR,PRCP,SERPINA1,SH3PXD2B,SLC8A1,SMOX,SOD2,TGFA,TGM227
Cellular Movement,Hematological System Development and Function,Immune Cell Traffickingc ll movement Cell movement of mononuclear leukocytes 2.42E-12 Increased 3.783 CCL1,CCL13,CCL18,CCL22,CCL24,CCL7,CCL8,CD4,CXCL10,CXCL12,CXCL8,CXCL9,FPR2,ICAM1,ITGB2,MMP14,MMP9,PLAU,PLAUR,SEMA3A,SERPINE1,SOCS3,SPP1,TGM2,TIMP35  
Figure 5.19 “TreeMap” (hierarchical heatmap) of downstream effector analysis (DEA) comparing CLLcc with CLL alone cells 
 
 
Among the top categories are cellular movement, cell-cell signalling interaction (adhesion, binding), 
inflammatory response, free radical scavenging, cellular proliferation, shape change, cell death and 
cell viability. Details of those that are increased are shown in Figure 5.19 (bottom). 
 
  
DEA results for CLL cells in co-culture with NLCs. The visualization is a TreeMap (top) where the large boxes represents a 
category of related functions. Each smaller box are coloured at a particular biological function or disease. Orange is the 
predicted increase and blue is the predicted decrease. Darker colours indicate higher absolute Z-scores. The image has been 
cropped for better readability. The details of the functions that are top increases is listed (bottom). 
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5.4.5.3.2 Upstream Regulator analysis 
326 differentially expressed genes in CLLcc (up and downregulated) along with their logFC were 
selected and input in the IPA database. The database then analysed these genes with those of its own 
from other studies to identify the common upstream regulators for a dataset of genes. As seen in 
Table 5.13, a list of upstream regulators according to their p-value of overlap shows the involvement 
of TNF, NF-ĸB, ERK and TLR4. 
Table 5.13 Upstream Regulator analysis of the 326 differentially expressed genes in CLL co-cultured with NLCs 








Target molecules in dataset
TNF  cytokine Activated 4.249 2.42E-22 ALOX15B,APOE,CCL18,CD59,CDKN1A,CHI3L1,CLEC11A,CSF1,CXCL10,CXCL5,CXCL8,CXCL9,DCSTAMP,EBI3,F3,G0S2,GBP1,ICAM1,IFIT3,IL1RN,IL6,IRF1,MCL1,MMP9,NCF2,NFKBIA,NR1H3,PKM,PKMYT1,PLAU,PLAUR,PTGES,RRM2,SDC4,SERPINE1,SLC1A2,SLC8A1,SOD2,STAC,STAT1,TAP1,TGFA,TIMP3,TNFAIP2,USP2
IFNG  cytokine Activated 4.786 2.31E-21 ACE,APOL6,C1QA,C1QB,C1QC,CCL18,CCL22,CDKN1A,CISH,CXCL10,CXCL8,CXCL9,DAPK1,EBI3,ETV7,FPR2,GBP1,ICAM1,IFIH1,IFIT3,IL1RN,IL6,IRF1,KCNMA1,LGALS3BP,MMP9,NCF2,NFKBIA,OAS3,PTAFR,PTGES,SDC4,SOCS3,SOD2,STAT1,TAP1,TAP2,UBD
IL1B  cytokine Activated 3.921 1.23E-17 APOE,CCL13,CCL7,CHI3L1,CXCL10,CXCL5,CXCL8,CXCL9,FPR2,ICAM1,IL1RN,IL6,IRF1,MCL1,MMP7,MMP9,NFKBIA,NR1H3,NRP1,PTGDS,PTGES,SEMA3A,SERPINE1,SOCS3,SOD2,TNFAIP6,UBD
STAT1 1.982 transcription regulator Activated 3.756 6.96E-17 C1S,CDKN1A,CXCL10,CXCL9,GBP1,GBP3,GBP4,ICAM1,IFIH1,IFIT3,IRF1,MMP9,PARP9,PDCD1LG2,SAMD9L,SLAMF8,SOCS3,STAT1,TAP1,TRIM21,WARS
IL1A  cytokine Activated 3.447 3.95E-15 ALDH1A1,CCL8,CDKN1A,CSF1,CXCL10,CXCL5,CXCL8,HSD11B1,ICAM1,IL6,NFKBIA,PDCD1LG2,PLAU,PTGES,SERPINA1,SERPINE1,SOD2
NFkB (complex)  complex Activated 4.426 1.37E-14 CCL1,CCL22,CCL8,CDKN1A,CXCL10,CXCL12,CXCL8,CXCL9,F3,FTH1,G0S2,ICAM1,IL15RA,IL6,IRF1,MCL1,MMP9,NCF2,NFKBIA,PLAU,SDC4,SLC1A2,SOCS3,SOD2,TAP1,TGM2
Interferon alpha  group Activated 2.034 3.81E-14 ADAR,CCL22,CDKN1A,CXCL10,CXCL9,EPSTI1,FBXO6,GBP1,IFIH1,IFIT3,IRF1,LAP3,MCL1,NFKBIA,OAS3,PARP14,PARP9,PTGES,SAMD9L,STAT1,TAP1,TAP2,UBE2L6,WDFY1,ZBED2
RELA  transcription regulator Activated 3.488 5.23E-13 CD59,CDKN1A,CXCL10,CXCL5,CXCL8,CXCL9,FSCN1,ICAM1,IL1RN,IL6,IRF1,MMP9,NFKBIA,PKM,PLAU,SLC1A2,SOD2,TAP1,TAP2,TGM2,UBD
TREM1  transmembrane receptor Activated 2.527 3.07E-12 ARRDC4,CCL18,CCL7,CRTAM,CSF1,CXCL5,CXCL8,DCSTAMP,EBI3,EGR2,F3,IL15RA,IL6,IRF1,MT1E,NRIP3,PHLDA2,SLC1A3,SPP1,TCEAL9
IFNA2  cytokine Activated 3.113 4.43E-12 APOL6,CISH,CXCL10,GBP1,IFIH1,IFIT3,IL6,IRF1,LGALS3BP,LILRB4,MMP9,OAS3,SOCS3,STAT1,UBE2L6
RNASE2  enzyme Activated 3.113 5.49E-12 CCL1,CCL22,CCL24,CCL7,CCL8,CSF1,CXCL10,CXCL5,CXCL9,IL6
TGM2 3.191 enzyme Activated 4.518 9.66E-12 ADGRE2,CCL22,CCL24,CXCL10,CXCL8,DCSTAMP,HK3,IFIT3,MMP9,NCF2,OAS3,PARP14,PARP9,PTGES,SAMD9L,SIRPA,SPP1,STAT1,TAP1,TNFAIP2,VSIG4
IL27  cytokine Activated 3.032 1.21E-11 CCL7,CR1,CXCL10,CXCL8,CXCL9,ICAM1,IL1RN,IL6,IRF1,MRC1,SOCS3,STAT1,TAP1
JUN  transcription regulator Activated 2.47 1.21E-11 CCL8,CDKN1A,CXCL10,CXCL5,CXCL8,FTH1,ICAM1,IGFBP6,IL6,MMP7,MMP9,NCF2,NFKBIA,PLAUR,PTGES,SERPINE1,SOD2,SPP1
RNASE1  enzyme Activated 2.97 1.34E-11 CCL1,CCL22,CCL24,CCL7,CCL8,CXCL10,CXCL5,CXCL9,IL6
TLR7  transmembrane receptor Activated 3.642 6.13E-11 CD38,CXCL10,CXCL8,CXCL9,ICAM1,IFIT3,IL4I1,IL6,IRF1,KCNMA1,NFKBIA,OAS3,PLAU,STAT1
IL13  cytokine Activated 2.117 8.92E-11 ADAMDEC1,ARNTL2,CCL18,CCL22,CD1B,CD1E,CISH,CLEC4E,CXCL5,CXCL8,G0S2,GSN,HSD11B1,IL13RA1,IL1RN,MRC1,SLC8A1,SORT1,TGM2
Immunoglobulin  complex Activated 3.138 1.97E-10 CCL1,CCL7,CCL8,CISH,CXCL10,CXCL9,IL6,IRF1,NFKBIA,UBD
PRL  cytokine Activated 3.039 7.78E-10 ADAR,CDKN1A,CISH,CTSB,CXCL10,CXCL9,DTX3L,EPSTI1,IFIH1,IFIT3,OAS3,PARP14,SAMD9L
IFNL1  cytokine Activated 3.41 9.01E-10 APOL6,CXCL10,CXCL8,CXCL9,GBP1,IFIH1,IFIT3,IL6,LGALS3BP,OAS3,STAT1,UBE2L6
EGFR  kinase Activated 3.011 1.63E-09 CDCP1,CHI3L1,CXCL8,E2F2,F3,GBP1,ICAM1,NFKBIA,PKM,PLAU,PLAUR,PTGES,SLC7A11,TGM2
PRKCD  kinase Activated 2.901 1.77E-09 CD4,CDKN1A,CTSB,CXCL10,CXCL12,CXCL8,HJURP,ICAM1,IL1RN,IL6,JCAD,MMP9,NES,NFKBIA,SERPINE1
TLR9  transmembrane receptor Activated 3.229 2.61E-09 CD38,CXCL10,CXCL8,CXCL9,IFIT3,IL4I1,IL6,IRF1,MCL1,OAS3,STAT1
P38 MAPK  group Activated 3.384 2.73E-09 CCL8,CDKN1A,CXCL10,CXCL12,CXCL8,CXCL9,EGR2,GBP1,ICAM1,IL6,MMP9,RBP1,SERPINE1,STAT1,TGFA,VDR
NFKB1  transcription regulator Activated 2.744 3.64E-09 CD59,CHI3L1,CXCL10,CXCL8,CXCL9,FSCN1,IL1RN,IL6,IRF1,MMP9,NFKBIA,PLAU,SOD2
TGFB1  growth factor Activated 3.263 7.06E-09 CD59,CDKN1A,CHI3L1,COL6A3,CXCL8,FSCN1,IL6,ITGB2,MKI67,MMP9,MRC1,NFKBIA,NRP1,PLAU,PLAUR,SCD,SEMA3A,SERPINA1,SERPINE1,SPARC,TGFA,TGM2,TIMP3
ERK  group Activated 3.045 7.75E-09 CDKN1A,CXCL10,CXCL8,ICAM1,IL6,ITGB2,MCL1,MMP14,MMP9,SERPINE1,STAT1,TGFA,TGM2
JAG2  growth factor Inhibited -2.121 2.01E-08 CCL13,CCL24,CXCL5,CXCL9,IL13RA1,IL1RN,IL6,SPP1
TLR4  transmembrane receptor Activated 2.401 5.72E-08 CCL8,CD38,CXCL10,CXCL8,ICAM1,IL6,MMP9,NFKBIA,SLC7A11,SOCS3,SOD2 
 
 
Just over 100 upstream regulators produced were fed as official gene symbols into DAVID to classify 
them by function. The genes were analyzed with DAVID online tool for KEGG (Kyoto Encylopedia of 
Genes and Genomes) pathways analysis. As seen in Table 5.14, KEGG pathway were listed according 
to count, genes and FDR in order to plot out pathways connected. 
 
Segment of upstream Regulator Analysis as part of Ingenuity Pathway Analysis of 326 differentially expressed genes. The 




Table 5.14 DAVID Top 12 KEGG pathways analysis of genes directed from validated mRNA targeting 
KEGG pathway Count Genes FDR
Toll-like receptor signaling pathway 17/78 IL6, TNF, RELA, MAP2K3, NFKB1, TLR4, CD40, STAT1, TAB1, CCL5, TLR7, TLR9, IFNA2, JUN, IL1B, IRF3, SPP1 5.22E-13
Cytokine-cytokine receptor interaction 19/78 IL4, CSF2, IL6, TNF, IL18, IL13, CD40, CCL5, TGFB1, OSM, IFNA2, IFNL1, IL17A, CD40LG, IFNG, TNFRSF18, IL1B, PRL, IL1A 2.14E-09
NF-kappa B signaling pathway 12/78 TNF, PTGS2, CD40LG, RELA, IL1B, NFKB1, TLR4, UBE2I, CD40, MAP3K14, TAB1, ATM 2.47E-07
TNF signaling pathway 12/78 CSF2, IL6, TNF, PTGS2, RELA, JUN, MAP2K3, IL1B, NFKB1, CCL5, MAP3K14, TAB1 2.38E-06
HIF-1 signaling pathway 11/78 EGFR, IL6, HIF1A, RELA, ERBB2, VEGFA, IFNG, NFKB1, TLR4, EGF, GAPDH 1.22E-05
Pathways in cancer 18/78 CEBPA, EGFR, IL6, PTGS2, ERBB2, RELA, FOXO1, NFKB1, STAT1, MMP1, TGFB1, GLI1, HIF1A, JUN, VEGFA, RARB, EGF, FGF2 4.24E-05
T cell receptor signaling pathway 10/78 IL4, CSF2, TNF, CD40LG, RELA, JUN, IFNG, CTLA4, NFKB1, MAP3K14 2.56E-04
MAPK signaling pathway 14/78 EGFR, TNF, JUN, MAP2K3, RELA, IL1B, NFKB1, MAP3K14, TAB1, EGF, ECSIT, FGF2, TGFB1, IL1A 3.26E-04
Jak-STAT signaling pathway 11/78 OSM, IL4, CSF2, IFNA2, IFNL1, IL6, SOCS1, IFNG, IL13, STAT1, PRL 6.32E-04
NOD-like receptor signaling pathway 8/78 IL6, TNF, IL18, RELA, IL1B, NFKB1, CCL5, TAB1 6.63E-04
Cytosolic DNA-sensing pathway 8/78 IFNA2, IL6, IL18, RELA, IL1B, NFKB1, IRF3, CCL5 0.001678771
PI3K-Akt signaling pathway 14/78 EGFR, OSM, IL4, IFNA2, IL6, RELA, VEGFA, NFKB1, TLR4, FOXO3, EGF, FGF2, PRL, SPP1 0.010648413   
 
 
5.4.5.3.3 KEGG Pathways generated 
KEGG pathway analysis revealed pathways being the most relevant to CLL-NLC interaction and 
produced figures for Toll-like receptor (TLR) signalling (Figure 5.20) and NF-Kappa B (NF-ĸB) signalling 
(Figure 5.21) as among the top ranked pathways.  
 
Upstream regulators were fed into DAVID to classify them by function. The KEGG pathways are listed according to the 









Figure 5.21 DAVID KEGG pathway analysis; mRNA targeted genes (red star) are involved in NF-Kappa B Signalling Pathway 
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In addition to TLR and NF-ĸB signalling pathways, other pathways were also produced as being relevant 
to CLL-NLC interaction, (see Appendix 7.13) including but not limited to Tumor necrosis factor (TNF) 
signalling (Appendix Figure 7.12), Hypoxia-inducible transcription factor (HIF) signalling (Appendix Figure 
7.13), T cell receptor signalling (Appendix Figure 7.14), Mitogen-activated protein kinase (MAPK) signalling 
(Appendix Figure 7.15), Janus kinase (JAK) and signal transducer of activator of transcription (STAT) 
signalling (Appendix Figure 7.16), phosphoinositide-3-kinase (PI3K-AKT) signalling pathway (Appendix 
Figure 7.17) as well as general pathways involved in cancer (Appendix Figure 7.18). Other pathways (see 
Appendix 7.13) produced by KEGG pathway analysis include nucleotide-binding oligomerization domain 
(NOD)-like receptor signalling pathway (Appendix Figure 7.19), cytosolic DNA-sensing pathway (Appendix 
Figure 7.20) and cytokine-cytokine receptor pathway (Appendix Figure 7.21). 
On closer inspection of the pathways, it was revealed that NF-ĸB pathway seemed to be the most mutually 
connected pathway in the network of all the mentioned pathways. To decide which genes to investigate 
for further work, a number of areas of Bioinformatics results should be considered. 
The first area to investigate are the GSEA visualized by REVIGO, where Regulation of response to wounding 
was quite prominent. The next area is from IPA under diseases and functions where cellular movement 
and adhesion was among the highest rank of predicted involvement. 
Next, are the upstream regulators derived from IPA (and used for KEGG analysis) indicating which genes 
are predicted to be activated or inhibited which lead to the differentially expressed genes initially found. 
I decided to look into upstream regulators predicted as well as those differentially expressed in order to 
narrow down which genes could be investigated on next. 
Of the listed genes from the KEGG pathways, three were found to be significantly upregulated in CLL cells 
co-cultured with NLCs, namely STAT1, SPP1 and IL6. Table 5.15 summarises the genes mentioned in their 
rank, log2fold change and read count from each sample. 








Read count from CLL cells 
Range Mean among CL Mean among CN 
IL6 47 3.82 
TLR signalling 
0-15 0.33 ± 0.816 8.33 ± 5.28 
SPP1 102 2.79 15-1260 65 ± 49.52 463 ± 411.76 




Based on the information from Table 5.15, it appears that TLR signalling was the mutual pathway among 
these three genes, which is of no surprise as it was ranked as highest from Bioinformatics analysis. TLR 
itself is linked with NFĸB pathway quite closely. Based on the read count and experience during validation 
during RT-qPCR, the genes SPP1 and STAT1 would be most appropriate to investigate further in the 
practical setting. SPP1 and STAT1 are also among the highest ranked clusters in a number of functional 
annotation pathways such as inflammatory response and cell adhesion. I therefore suggest the genes 
STAT1 and SPP1 to be chosen for further work up in the setting of CLL-NLC interaction.  
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5.5 Summary of Results 
Through outsourcing the RNA sequencing, using RNA that were of good quantity and quality, >100GB of 
data was generated from the 6 cases (24 samples). With the crucial help of the Bioinformatics team of 
Computational Biology Facility, a comprehensive analysis of data was performed. Using DESeq2 package 
for R software, a list of differentially expressed genes were generated when comparing CLLcc with CLL 
alone and NLCcc with NLC alone. The overall number of genes that were upregulated were significantly 
greater when CLL cells were exposed to NLCs for 24hrs. 
Comparing with a study using ranked microarray data, generated 61 genes that were upregulated and 
coincided with my data. Using these 61 genes, I prioritized the selection process of genes to validate using 
RT-qPCR. I concluded with testing 13 designed primers for their respective genes on cDNA synthesised 
from the RNA extracted. With the aid of agarose gel electrophoresis, control samples and the reference 
gene GAPDH, I was able to optimise and run an intricate RT-qPCR on 14 case pairs with 9 primers.  
I was able to generate relative gene expression ratio values after normalising the CT with control and 
reference gene. Through exclusion of samples that were not fit to calculate relative gene expression and 
one primer that did not give confident results, I was able display an overall increase or decrease in gene 
expression. 
On comparing with the expected changes from DGEA of RNA-seq, the primers for MCL1, CSF1 and GBP1 
gave the most parallel findings with the samples sent for RNA-seq. When looking at all the samples, 41/65 
gave parallel findings with the expected changes. This gave an overall confidence of validating the data 
from DGEA. The differences can be speculated as due to heterogeneity of CLL disease. 
From the data generated from RNA-seq, it was shown by PCA that there was clear separation of all 4 
populations of cells cultured under different conditions. The most significant differences were between 
CLL cells co-cultured with NLCs and CLL cells cultured alone. A subset of 326 genes were identified that 
discriminate between both cell conditions (CLLcc vs CLL) and was able to link these genes to relevant 
biological functions and pathways. Biological functions included inflammatory response and platelet 
degranulation.  Cellular functions involved included, but not limited to, lymphocyte migration, cell death, 
cellular proliferation, tissue remodelling and regulation of response to wounding. 
My study data have shown some discrepancy of results between RNA-se and RT-qPCR.  This emphasizes 
an necessary of validating RNA-seq data, particularly those with low depth of read cover.   
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Through DAVID, KEGG analysis showed the involvement of upstream pathways including TLR signalling, 
NF-κB signalling and cytokine-cytokine receptor interactions. Pathways which are relevant to CLL-NLC 
interaction included, but not limited to, tumour necrosis factor (TNF) signalling pathway, Hypoxia-
Inducible Factor-1 (HIF-1) signalling pathway, T cell receptor signalling pathway, MAPK signalling pathway, 
JAK-STAT signalling pathway and PI3K-AKT signalling pathway. By observing the pathways, it showed that 
NF-κB was the most commonly involved pathway. Addition to that, the genes STAT1, SPP1 and IL6 were 
found to be common among the TLR pathway as well as significantly upregulated in CLL cells co-cultured 







5.6.1 Quality of RNA samples used for sequencing 
RNA samples from a total of 9 cases (4 samples each) were sent for RNA sequencing using RNA-seq 
technology by Novogene. In the end, RNA samples from 6 cases were used for RNA-seq due to the low 
quantity of RNA extracted from NLC populations in the other 3 cases. The main reason to exclude RNA 
samples with low quantity is the unreliable global profiling of miniscule RNA generated by RNA-seq 
(Ozsolak & Milos 2011). Additionally, to ensure that samples were free from contamination of non-CLL 
cells, I checked purity of CLL samples by CD5 & CD19 co-expression by flow cytometry purity testing 
(described in Methods) after observing by microscopy. The Qubit 2.0 is considered to be a more accurate 
instrument than Nanodrop in quantitating RNA, as it was found to be highly reproducible and consistent 
with qPCR measurements (Simbolo et al. 2013). It was also reported that Nanodrop was not as accurate 
in quantifying very low levels of RNA as Qubit (Nakayama et al. 2016). Therefore, I relied on Qubit for the 
measurement of RNA before sending the RNA samples to be sequenced. 
When the RNA sequencing data was produced by Novogene and released to us, it was analysed by 
Bioinformatics team of Computational Biology Facility at the University.  
 
5.6.2 Quality control of sequencing data used for subsequent analysis  
MultiQC software was initially used, as described (Ewels et al. 2016), to produce a single report visualising 
the data from all 24 samples. The sequence reads were aligned onto the reference genome 
homo_sapiens_NCBI_GRch38 (NCBI - Genome Reference Consortium Human Build 38) and subsequently 
levels of gene expression were estimated by counting the number of reads that maps to an exon (Kukurba 
& Montgomery 2015). Initially 33,121 genes were identified. However, after removing genes that had a 
sum of counts of <10 over all 6 samples within each group, 19,595 genes were taken forward for 
subsequent analysis. This included all the 24 samples i.e. 12 CLL and 12 NLC samples. Out of 19,595 genes, 
322 genes were significantly upregulated and 4 were significantly downregulated in co-cultured CLL cells 
when compared to CLL cells cultured alone. However, only 4 genes were significantly upregulated and 3 




5.6.3 Comparison of gene expression profile from my study with that from other studies 
A study performed cDNA gene expression analysis of CLL samples after 14 days of co-culture with NLCs 
(Burger et al. 2009b). The top genes induced by 14 days of NLC co-culture with at least 3-fold up-regulation 
were CC chemokine CCL4, BCMA (TNFRSF17), EGR3, CCL3, PSAT1, MYCN, EGR2, K1AA0101, KMO and 
FCRL5 (Burger et al. 2009b). Down regulated genes included HRK, RGS2, TUBB2A, KLF6, TSC22D3, 
TMEM66, CHPT1, MXI1, MAFF and RHOB (Burger et al. 2009b). They performed DNA microarray analysis 
and identified a homogenous gene expression response across 9 different CLL cells after 14 days of co-
culture with NLCs (Burger et al. 2009b). 
A study (Boissard et al. 2016b) compared NLCs from CLL patients with monocytes of healthy donors and 
found 2589 overexpressed genes, while CLL cells compared to healthy B-lymphocytes over expressed 225 
genes. After filtering out genes by applying different functional ontology criteria, the genes involved with 
NLC/CLL cell interaction included VCAM1, CD28, PECAM1 (for CD31 antigen), SELPLG (for LFA-1 antigen), 
CD2, CD86, CTLA4, SELP (for CD62 antigen) and CD58 (for LFA-3 antigen) (Boissard et al. 2016b). 
A study generated NLCs from CLL patients for 10 days and treated with lenalidomide, that were then 
harvested and microarray was performed to give whole-genome expression profiles (Fiorcari et al. 2015). 
584 genes were differentially expressed with lenalidomide treatment, of which 352 were up regulated 
and 232 were downregulated (Fiorcari et al. 2015). Categorised by Gene Ontology, the genes enriched by 
lenalidomide were those involved in immune responses, activation/proliferation of T cells, complement 
activation, antigen processing and presentation and regulation of cellular movement, cytokine and 
chemokine activity (Fiorcari et al. 2015). Specifically, CXCL11, CXCL9, CCL19, XCL1 XCL2, CCL2 and CCL12 
was apparent (Fiorcari et al. 2015). 
A study compared gene expression between NLC from purified PBMC of CLL patients with CD14 cells from 
healthy donors exposed to CLL culture (CD14CLL) and CD14 cells from healthy donors cultured on healthy 
B-lymphocytes (CD14B) (Bhattacharya et al. 2011). They found the gene expression profile (GEP) of NLCs 
to be closely similar to that of CD14CLL cells than to the GEP of CD14B cells (Bhattacharya et al. 2011). They 
also found that the antigen presenting pathway was the most significantly deregulated pathway, where 
the genes were mostly HLA class II genes and the CD74 gene. Also, the genes found dysregulated between 
NLCs and CD14CLL cells were FCGR2B, LYZ, HLA-DRA and CD74 (Bhattacharya et al. 2011). 
In a study that compared CLL monocytes with monocytes from normal controls, where the CD14+ 
monocytes were highly purified, they identified 65 significantly upregulated genes and 48 downregulated 
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genes in the CLL monocytes compared to normal controls (Maffei et al. 2013). Of the upregulated genes, 
the involved pathways include those for Wnt signalling, VEGF signalling, angiogenesis and apoptosis 
(Maffei et al. 2013). The downregulated genes were involved in inflammation signalling, cytoskeletal 
regulation and oxidative stress response (Maffei et al. 2013). Specific genes involved in the CLL CD14+ 
monocytes that were upregulated, included RAP1GAP (reported to be involved in Fcγ-receptor and 
complement-receptor phagocytosis), ARHGEF12/LARG and LPAR6/P2Y5 which are involved in cell 
migration and Raf/ERK signalling (Maffei et al. 2013). Additionally, there was upregulated genes of toll-
like receptor 4 (TLR4), Lipin-2 (LIP2), Lipin-3 (LIP3), phosphatidic acid (PA) and phosphatases (PAP). 
PLA2G4A was also upregulated (Maffei et al. 2013). Down-regulated genes in the CLL CD14+ monocytes 
were tubulins TUBB3 and TUBB2, CDC42EP3, chemokine (C-C motif) ligand 5 (CCL5) and PTGR2 (Maffei et 
al. 2013). 
A study investigated the survival of CLL cells (by trypan blue exclusion) in cultures with anti-human CD62L 
(involved in controlling the traffic of T-lymphocytes) with untreated CLL PBMCs and performed microarray 
analysis on the monocytes/macrophages after 7 days of culture and found that the NLCs did not have 
statistically significant differentially expressed transcripts between sensitive and resistant patients 
(Burgess et al. 2016). When they compared their data with that from the study by Martinez et al (Martinez 
et al. 2006), they found that day 0 monocytes were similar and the NLCs they developed displayed an M2-
like transcript profile (Burgess et al. 2016). 
A previous study investigated the changes in gene expression by microarray in CLL cells after 14 days of 
co-culture with NLCs, as compared to CLL cells without co-culture (Burger et al. 2009b).  The gene EGR2 
was found to be among the top 10 genes to be significantly upregulated in co-cultured CLL cells (in 6 out 
of 9 paired samples). The other 9 genes included CCL4, TNFRSF17, EGR3, CCL3, PSAT1, MYCN, KIAA0101, 
KMO and FCRL5. In my study EGR2 was also significantly upregulated in CLL cells following 24 h co-culture 
with NLCs. The other 9 did not match with those of my study. 
The study that compared the gene expression profiles of purified CD14 monocytes from CLL patients with 
those from normal controls, identified 65 upregulated and 48 downregulated genes (Maffei et al. 2013). 
Of the mentioned list, none had matched with my DGEA findings comparing NLC exposed and unexposed 
to CLL for 24 hours. The study did identify solute carrier family 25 (SLC25A17) to be upregulated, whereas 
my data identified solute carrier family 1 (SLC1A5) to be downregulated. The solute carrier families are a 
group of membrane transport proteins. The study used 5 sample pairs on whole human genome 
microarray, whereas I performed whole RNA sequencing using 6 sample pairs of NLC groups. It is likely 
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that the discrepancy between my study and the study mentioned is that a different method of analysis 
was used as well as a different control group was used. As mentioned earlier, the changes the study had 
identified is likely due to the heterogeneity of monocytes particularly in a heterogeneous disease of CLL 
patients. To solve this discrepancy, I would suggest performing an experiment using normal controls as 
the study used, with my two comparison groups and using whole RNA sequencing. RNA sequencing can 
detect higher percentage of differentially expressed genes than microarray. Increasing the number of 
sample pairs sent would be advantageous to provide a more accurate profile when predicting in vivo 
condition. 
Comparing to the study that identified genes differentially expressed in M1 and M2 macrophages 
(Martinez et al. 2006), I was not able to have a suitable comparison with my NLC gene sets due to the low 
number of significantly expressed genes from 6 pairs of NLC groups. An increase in N number of NLC pairs 
for RNA-seq could be used to compare with gene subsets of this study in order to explore if NLCs are 
indeed M2 type of macrophages as well as to explore if there are any changes in the phenotype in the 
absence of CLL stimuli. 
The Bioinformatics team compared the significantly upregulated genes among co-cultured CLL cells from 
my study to gene expression profile of CLL cells collected from the tissues by microarray (Herishanu et al. 
2011). In their study, when peripheral blood (PB) CLL cells were compared with lymph nodes (LN) resident 
CLL cells, 151 differentially expressed genes were detected with at least 2-fold difference (false discovery 
rate, FDR <0.2). Of these, 133 were upregulated and 18 were down regulated (Herishanu et al. 2011). 
Between bone marrow (BM) and PB CLL samples, 26 genes were differentially expressed, in which 24 were 
upregulated and 2 were downregulated (Herishanu et al. 2011). Almost all the up-regulated genes in BM-
derived CLL cells were also up-regulated in LN-derived CLL cells (Herishanu et al. 2011).  
In comparison, the bioinformatics team found that 61 differentially expressed genes in co-cultured CLL 
cells from my study coincided with ranks of expression (See Gene Set Enrichment Analysis) based on “stat” 
values from DESeq2. These 61 genes were also found to be upregulated in LN CLL cells, but not PB CLL or 
BM CLL cells.  This showed that the gene expression profile of CLL cells co-cultured with NLCs resemble 
that of LN CLL cells. Based on this observation, I selected 13 genes from a list of 63 genes for validation by 
RT-qPCR. 
Validation of differentially expressed genes by RT-qPCR conformed changes detected by RNA-seq, in 
particular Myeloid Cell Leukaemia sequence 1 (MCL1, an apoptosis regulator which is a member of the 
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Bcl-2 family) (Pepper et al. 2008), Colony Stimulating Factor 1 (CSF1, produces cytokine that plays a role 
in survival, proliferation and differentiation of macrophages and monocytes) (Janowska-Wieczorek et al. 
1991; Polk et al. 2016) and Guanylate Binding Protein 1 (GBP1, induced by interferon, the proteins are 
able to specifically bind to guanine nucleotides such as GMP, GDP and GTP) (Honkala, Tailor & Malhotra 
2020).  
Similarly, a study that showed that lenalidomide treated CLL patients identified 79 responded genes, of 
which 67 were upregulated included GBP1 (Aue et al. 2018). This study investigated the response of 
tumour microenvironment to lenalidomide through lymph node biopsy samples and microarray analysis. 
They found that IFN-y signalling pathway was of the most significantly overrepresented pathway. In my 
study, using RNA-seq data from CLL PBMC samples, GBP1 was among those significantly upregulated and 
IFN-y signalling pathway was among the highest predicted pathway involved. 
 
5.6.4 A possible explanation to the findings from validating RNAseq DESeq2 list using RT-qPCR 
results: 
Although both my study and the study by Burger et al (Burger et al. 2009b) found EGR2 to be upregulated 
in CLL cells after co-culture with NLCs, I was not able to validate by RT-qPCR because the primers available 
overlapped with the reading temperatures of primer dimers as well as produced a non-specific PCR 
product detected by agarose gel electrophoresis. Perhaps a better designed set of primers for EGR2 may 
be used to further validate the RNA-seq data. 
In addition, both my study and the study by Boissard et al. (2016c) found CD28 to be upregulated in NLCs 
co-cultured with CLL cells, I was not able to validate this result as there were not enough cDNA samples 
to perform thorough optimisation and validation experiments. More NLCs collection is needed to confirm 
the findings in future. 
Nonetheless, given that the majority of validated genes (6/7) were confirmed by RT-qPCR in more than 





5.6.5 Significantly Enriched Functional Pathways 
Functional pathway analysis based on the differentially expressed genes was then performed, which 
revealed enriched set of genes involved in chemokine and cytokine signalling. REVIGO, a web server that 
summarizes and visualizes list of Gene ontology terms (Supek et al. 2011), identified that regulation of 
response to wounding and lymphocyte migration were the largest categories. This is not surprising as it is 
well known that CLL lymphocytes migrate into lymph nodes giving rise to the clinical feature of 
lymphadenopathy among CLL patients. It is also known that the tumour microenvironment exhibits 
features of chronic inflammation or response to wound healing, such as the differentiation of 
macrophages to M2 class, the production of CCL3 and CCL4, the release of IL-10, IL-6, the decreased pH, 
increased vasculature and remodelling to incorporate the involvement of various cell types (Krzyszczyk et 
al. 2018). 
When comparing NLCcc with NLC using the same method described above, 18 enriched gene sets were 
identified including those for chemokine activity. This is also not surprising as one of the functions of 
macrophages are to move to the site of inflammation as a result of secreted chemokines and chemo 
attractants (Martinez et al. 2006). Given that only, 7 differentially expressed genes were detected, the 
predicted gene sets should be scrutinized. Perhaps a larger sample number of NLC would provide more 
detected differentially expressed genes and thus more accurate gene sets after GSEA. 
A study investigating NLC from CLL patients with CD14 monocytes with CLL cells found 149 differentially 
expressed genes and 5 involved pathways (IPA) and 4 annotations (DAVID) (Bhattacharya et al. 2011). Due 
to the lower number of differentially expressed genes (n=7), the Bioinformatics team was not able to 
perform IPA and DAVID analysis. 
 
5.6.6 Upstream Regulators and Pathways Involved 
When feeding the 326 differentially expressed genes in co-cultured CLL cells (both up and downregulated) 
along with their fold-changes in log conversion (logFC) into IPA database of diseases and biological 
functions, it was found that the top categories of functions were of Cellular movement, Cell-cell signalling 
interaction (adhesion, binding), Inflammatory response, Free Radical Scavenging, Cellular Proliferation, 
shape change and cell death and viability. This is in agreement to what has been reported through 
numerous studies on CLL microenvironment (Kipps et al. 2017; Ten Hacken & Burger 2016). 
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Finally, Upstream Regulator analysis of the 326 differentially expressed genes in co-cultured CLL cells 
showed the top most enriched regulators included tumour necrosis factor (TNF) and interferon gamma 
(IFNγ). This was further evidenced by functional annotation using DAVID where major pathways involved 
were Toll-like receptor (TLR) signalling pathway, cytokine-cytokine receptor interactions and nuclear 
factor kappa B (NF-ĸB) signalling pathway. This is in agreement with numerous studies in literature 
investigating pathways involved in CLL (Arvaniti et al. 2011; Aue et al. 2018; Herishanu et al. 2011; Kipps 
et al. 2017; Muzio, Fonte & Caligaris-Cappio 2012). Through further DAVID KEGG pathway analysis, the 
pathways found to be relevant to CLL-NLC interaction included but not limited to, tumour necrosis factor 
(TNF) signalling pathway, Hypoxia-Inducible Factor-1 (HIF-1) signalling pathway, T cell receptor signalling 
pathway, MAPK signalling pathway, JAK-STAT signalling pathway and PI3K-AKT signalling pathway. In 
literature these pathways are also found to be involved (Ten Hacken & Burger 2016) as well as the basis 
of developing targeted drug therapy (e.g. PI3K inhibitor Idelalisib). 
Activation of toll-like receptor (TLR) signalling pathway has been identified in CLL cells from the lymph 
node, which is consistent with the notion that CLL cells in the microenvironment behave differently from 
that in circulation (Dadashian et al. 2019). TLR pathway is involved in mediating immune surveillance and 
is known to promote pro-tumorigenic pathways (Ridnour et al. 2013). Depending on the type of TLR ligand 
binding, it produces pro-inflammatory cytokines (Spaner & Masellis 2007) that influence the immune 
response with T cell-mediated responses (via CD40), angiogenesis as well as initiate downstream response 
via NF-ĸB pathway (Spaner & Masellis 2007).  The resulting effects include CLL proliferation, increased 
expression of adhesion molecules and CD40 (Spaner & Masellis 2007). This leads to pro-survival, 
proliferation and tissue homing of CLL cells. 
JAK-STAT3 pathway consisting of Janus kinase (JAK) family of non-receptor kinase and signal transducer 
of activator of transcription (STAT) family of transcription factors are normally short and strictly regulated 
(Severin et al. 2019). In CLL there is aberrant activation which support survival, proliferation and 
metabolism of neoplastic cells (Severin et al. 2019). This pathway has also been implicated in CLL cells, its 
activation resulting in increased transcription of pro-survival and anti-apoptotic genes such as MCL-1 and 
BCL-2 (Severin et al. 2019). It has also been shown that the targeting of this pathway with inhibitors 
resulted in CLL-cell apoptosis (Severin et al. 2019). 
Mitogen-activated protein kinase (MAPK) signalling pathway is a common event in pathogenesis of CLL 
(Shukla, Shukla & Joshi 2018). This pathway plays a fundamental role in the maintenance of basic cellular 
processes such as proliferation, differentiation, migration and inflammation (Shukla, Shukla & Joshi 2018). 
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In CLL, the level of MAPK activation is considered to link to the level of BCR signalling (Shukla, Shukla & 
Joshi 2018). In the microenvironment, molecules such as CD38, BCR and CXCR4 may modulate MAPK of 
proliferation centres (Shukla, Shukla & Joshi 2018). It was reported that an increased MAPK activation was 
seen in patients who displayed prognostic markers associated with poor disease outcomes (Shukla, Shukla 
& Joshi 2018). Novel molecularly targeted drugs such as ibrutinib, Idelalisib and fostamatinib show a 
suppressive effect on this pathway in CLL cells (Shukla, Shukla & Joshi 2018). 
Activation of tumour necrosis factor (TNF) signalling pathway, particularly involving TNF receptor 1 
(TNFR1), has been shown to activate NF-κB which promotes cell proliferation and survival of CLL cells (Dürr 
et al. 2018). It has also been shown that TNFR1 was highly expressed in CLL cells and its high expression 
in CLL patients has been associated with disease poor outcome (Dürr et al. 2018). High level expression of 
TNFR1 was also detected in proliferation centres of lymph nodes in patients with CLL (Dürr et al. 2018).  
Hypoxia-inducible transcription factor (HIF) signalling, particularly with HIF protein 1α (HIF-1α), regulates 
the interaction between CLL cells and the microenvironment and is involved in a positive feedback loop 
that promotes cell survival and adaptation to hypoxic environment (Valsecchi et al. 2016). HIF-1α is found 
to be increased in CLL cells compared to non-malignant B and T cells in hypoxic conditions (Yosifov et al. 
2020). It was shown that inhibiting this pathway impaired the interaction between CLL cells and its 
microenvironment (Valsecchi et al. 2016). HIF-signalling has also been implicated in vascular endothelial 
growth factor (VEGF) signalling that promotes angiogenesis (Shachar et al. 2012). Targeting this pathway 
could aid in preventing CLL cells from adapting and retuning the microenvironment. 
In my study, it was observed that the most significant pathway enriched by the 326 differentially 
expressed genes of co-cultured CLL cells included NF-ĸB pathway. This is not unexpected, as NF-ĸB has 
been shown to be constitutively activated in CLL cells (Mansouri et al. 2016). NF-κB pathway has also been 
implicated as playing a central role in the pathology of CLL (Mansouri et al. 2016). Therefore, the result 
from my study provides further evidence that this gene expression data as measured by RNA-seq was 
consistent with what was published in the literature.  
Furthermore, the genes that were found to be significantly upregulated in co-cultured CLL cells and in the 
top ranked pathways predicted by KEGG pathway analysis include Signal Transducer and Activator of 




The role of STAT1 has been well documented in CLL disease where it plays a role in the differentiation of 
CLL cells (Battle & Frank 2003). It has been shown that lenalidomide acts on STAT1 phosphorylation via 
interleukin 10 (IL-10) secretion, which leads to disruption of CLL-NLC interaction (Schulz et al. 2013).  
IL6, a mediator of normal B cell differentiation and proliferation (Zhu et al. 2018), has also been 
documented in relation to CLL where it was shown to be secreted at high levels in bloodstream of CLL 
patients as well as correlated with poor prognosis (Zhu et al. 2018).  
In contrast, the role of SPP1 (also known as osteopontin) in CLL is not well known. Only a handful studies 
have been performed and reported its overexpression in CLL cells in comparison to normal B cells 
(Dielschneider et al. 2016; Shukla 2013). One study showed that pharmacologically targeting lysosomes 
in CLL cells can be effective to lysosomal disruption leading to CLL cell apoptosis (Dielschneider et al. 







Collectively, the results from this chapter suggests that, there are numerous pathways involved in CLL-
NLC interaction, that are supported by published studies in the literature. RNA sequencing is a valuable 
tool to identify such pathways, however, care must be taken when deriving conclusions from the data. In 
the cases of small changes, perhaps a sensitive (although more expensive) approach should be used to 
validate the changes biologically i.e. digital droplet PCR. In other cases, I have shown RT-qPCR is a useful 
efficient method to validate the changes detected by differential gene expression analysis (DGEA). 
Therefore, the pathways highlighted by the bioinformatics analysis from the RNA-seq data merit further 
investigations.  
Numerous pathways have been identified that are well known in the research community of CLL such as 
NF-ĸB, PI3K, JAK-STAT3 and T-cell receptor signalling particularly on CD40L. The effect of NLCs on the gene 
expression of CLL cells shown from my study confirms that these pathways are indeed involved and may 
represent the mode of action of NLCs in CLL microenvironment in vivo. Pathways involving angiogenesis 
such as HIF-signalling pathway, however, have not been as intensively investigated as other pathways in 
CLL, and merits further study. The most significantly enriched pathway is the NF-B Pathway as it is an 
integral player in the network of involved pathways. Additionally, identifying the genes STAT1, SPP1 and 








6 General Discussion 
 
In CLL microenvironment, one of the main components are the NLCs which provide pro-survival signals to 
the CLL cells (Burger et al. 2000). The NLCs appear to be a large oval adherent macrophages (Burger et al. 
2000). NLCs which express CD163, was found in lymph node and spleen sections of CLL patients (Blonska, 
Agarwal & Vega 2015; Burger 2011a; Hanna et al. 2015; Ysebaert et al. 2010). The presence of NLCs may 
represent an unfavourable prognostic marker in patients with CLL, where the number of NLCs were 
positively correlated with beta 2 microglobulin (B2M) serum levels and SURVIVIN gene expression in CLL 
cells ex vivo (Filip et al., 2009 and 2013). It was also shown that a high density of CD68+ CD163+ NLCs at 
diagnosis was significantly correlated with unfavourable prognostic markers and to poor clinical outcomes 
in patients with DLBCL (Marchesi et al. 2015). A study investigating hepatocellular carcinoma showed a 
possible association between overexpression of CD163+ NLCs and worse patient outcome (Minami et al. 
2018). 
Although studies in this area of tumour microenvironment has been ongoing for the last two decades, 
exactly how NLCs protect CLL cells is still unclear. CLL remains an incurable disease and it is known that 
the microenvironment plays an important part in disease progression and the development of drug 
resistance. It becomes clear to me that more studies are required to comprehensively characterise the 
NLC development, in particular understanding the molecular mechanisms mediating the interaction 
between CLL cells and NLCs.  
In my PhD study, I hypothesised that interactions between NLCs and CLL cells activate certain genes and 
pathways which are responsible for survival and drug resistance of CLL cells. To address this hypothesis, I 
attempted to first independently characterise NLCs developed in vitro. I then set up co-culture 
experiments and extracted RNA from the cultured CLL cells and NLCs using their respective counterparts 
cultured alone as controls, and identify the differentially expressed genes using NGS sequencing 
technology. Through the bioinformatics analysis, I identified a few molecules and pathways that are likely 





6.1 Independent confirmation of development of NLCs from primary CLL PBMC cells 
In the first part of my PhD study, I sought to optimise the culture conditions for developing NLCs in vitro 
by modifying the established cell culture techniques published in literature. 
Previous studies have reported that various densities of CLL PBMCs were used for developing NLCs (Burger 
et al. 2000; Filip et al. 2009; Jia et al. 2014; Nishio et al. 2005; Polk et al. 2016). In my study, the use of a 
high cell density is found to be more favourable for NLC development and a cell density of 10 x 106/ml 
was an optimal concentration of CLL PBMC cells used to develop NLCs under the culture conditions used. 
Although, to truly assess the in vivo microenvironmental influences, bone marrow and lymph node 
samples would be ideal, I was only able to experiment on the available fresh PBMC. I next tried to 
independently confirm the morphology and immunophenotype of NLCs. 
 
6.1.1 Morphology 
The morphology of NLCs was first described as ‘large oval adherent shape’ by Burger et al. (2000). I 
investigated the morphological features of NLCs developed using a density of 10 x 106/ml CLL PBMC 
cultures throughout my study for consistency.  
The morphology of NLCs was found to be more complex than that described in literature, particularly the 
cell shape and size were more dynamic than just becoming large oval adherent.  
In addition, in order to distinguish the cellular components of the NLCs in development, I used MGG 
staining as detailed in results Chapter 1. Careful observations of morphology revealed that the NLCs 
appear not only as ‘large oval adherent cells’, but also display pleomorphism in appearance such as looking 
‘elongated’, ‘spindle-shaped’ and ‘clustered’. This detailed assessment of morphology of NLCs showed 




To further confirm the immunophenotype of the NLCs, I performed immunofluorescent staining of the 
NLCs following morphologic identification. I investigated the several surface markers that were reported 
to be expressed by NLCs. In addition, the cellular localisation of these proteins has also been examined. 
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I confirmed that NLCs express CD68, CD163 and CD14, but not CD19 the CLL specific marker. CD163 
expression was cytoplasmic and seen in all NLCs from all the CLL samples, whereas expression of CD68 
and CD14 was variable and not as strong as CD163 although they were both detected. This suggests that 
CD163 is a better marker to identify NLCs in a research setting. My observation on the localisation and 
expression of the above markers for NLCs is largely in agreement with findings from others reported in 
the literature (Boissard et al. 2015a; Fiorcari et al. 2015; Marchesi et al. 2015). One study also showed 
that CD163 was a reliable marker for NLCs and has been used to investigate the link of NLCs with disease 
progression of CLL (Boissard et al. 2016a). 
 
6.1.3 Biological function 
It was known that NLCs provide pro-survival signals to CLL cells which protect the leukemic cells against 
spontaneous apoptosis, which I also confirmed in the co-culture experiments of my study. 
I demonstrated that there was significant protection of CLL cells from spontaneous apoptosis following 
the first 24 h of co-culture when compared to CLL cells cultured alone. This was confirmed by apoptosis 
assays using flow cytometry with the reagents Annexin V and Propidium Iodide. It was also noted that NLC 
cultures which contained higher number of NLCs (observed by microscope) gave a greater protection to 
CLL cells. This was similarly shown in a study that found a positive correlation between number of NLCs 
counted and the viability of CLL cells (Boissard et al. 2016a).  
I also investigated the levels of the T cell chemokines CCL3 and CCL4 in the supernatant of fresh CLL PBMC 
cultures in a time-course experiment and found that levels of CCL3 and CCL4 were increased over time, 
which was consistent with the findings of a previous study (Burger et al, 2009). In that study, authors also 
detected the increased levels of CCL3 and CCL4 in blood plasma from CLL patients who had adverse 
prognostic features (Burger et al, 2009), suggesting that by secreting these chemokines to attract T cells 
to the lymph node microenvironment CLL cells actively contribute to the development of CLL 
microenvironment. Due to time constraints, I did not perform correlation study of plasma levels of CCL3 
and CCL4 from CLL patients with their clinical characteristics. 
It is worth noting that I also observed interesting, previously unreported effects of the CLL cells on NLCs 
when in co-culture. I found that NLCs also displayed a healthy-looking appearance in co-culture with CLL 
cells when compared to their counterparts cultured alone. Although this was not thoroughly studied, the 
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presence of CLL cells appeared to be conducive to NLCs, implying that there is a two-way, mutual influence 
taking place between CLL cells and NLCs. 
 
6.2 Wide variation in the NLC development between CLL samples 
6.2.1 Variation in the magnitude of NLCs development 
During the time period of developing the NLCs, I observed that not all the CLL samples had developed the 
similar number of NLCs, in fact some sample did not develop any NLCs. Some samples had less than 10 
NLCs per field when viewed under light microscope (at 10 x magnification), whereas others had between 
10-30 and in some cases more than 30. This finding was also reported by others (Filip et al. 2013a; Jia et 
al. 2014). Therefore, I confirmed that number of NLCs observed is variable from sample to sample, which 
makes it a challenge to reproduce the similar results using individual CLL samples. 
 
6.2.2 Variation in the dynamic of NLC development 
Most strikingly, I observed that the speed of NLC development were also variable from sample to sample. 
Whilst the changes in the shape and size were observed over the course of NLC development in the 
majority of NLC samples, these changes were not happening at the same rate. I observed changes in shape 
and size during NLC development under phase contrast microscope and confirmed these changes by MGG 
staining. Most other studies have reported that NLCs were developed following 14 days in culture, 
displaying a flattened adherent appearance (Burger et al. 2000; Gautam et al. 2016; Jia et al. 2014). My 
work largely confirmed this finding in many CLL samples I studied. However, I also noticed that there are 
many cases where mature, fully developed NLCs were seen as early as 8 days after culturing. 
The observation of wide variation in development of NLCs between CLL samples led to the development 
of a unique NLC scoring system which assigns a number (from 0 to 3) to individual samples based on how 
well the CLL PBMC cells develop NLCs. This was done in order to determine whether the variation in 
developing NLCs may be correlated to the clinical features of the CLL samples used in the study.   
 
6.2.3 Lack of correlation between NLC development and clinical features of CLL samples 
To address the above question, I collected available clinical information of all the CLL samples used. 
However, I did not detect any statistically significant correlation of NLC development with gender, IGHV 
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mutational status, clinical staging, chromosomal abnormalities or treatment history. Therefore, exactly 
why there is such wide variation in generation of NLCs between CLL samples from individual patients 
remains unclear. Interestingly, one study reported that, in a 6-year follow-up, a longer survival rate in CLL 
patients who had a lower NLC count was observed, although this finding was not statistically significant 
(Filip et al, 2013). Therefore, whether the NLC number developed in vitro can be used to predict the clinical 
outcome of patients with CLL still remains to be seen.  
 
6.3 Need for a cell line model of NLCs 
Over the course of my PhD study, I encountered many technical difficulties in establishing optimal 
conditions to produce consistent results of developing NLCs using primary CLL PBMC samples. In 
particular, a continuous supply of fresh CLL PBMC samples poses a logistical challenge to me. Together 
with the variation in generating NLCs, it becomes clear to me that an alternative system to carry out NLC 
experiments needed to be explored. 
 
6.3.1 Justification for selection of THP-1 cell line 
In the next part of my PhD study, I attempted to determine if THP-1 cells can be developed as an in-vitro 
cell line model of NLCs. THP-1 cells derived from human monocytic leukemic cells and can be 
differentiated into macrophages and further polarised to M1 and M2 macrophages. This cell line has been 
commonly used for studies into behaviour of monocytes and macrophages (Tedesco et al. 2018). There 
are other cell lines which were also considered, such as U937, ML-2, HL-60 and Mono Mac 6 (Chanput, 
Peters & Wichers 2015).  However, large number of studies have used THP-1 cells in preference to other 
cell lines (Aldo et al. 2013; Daigneault et al. 2010; Forrester et al. 2018; Park et al. 2007; Tedesco et al. 
2018). It was soon evident that THP-1 cells were far more befitting to my requirements. First, comparing 
to the tissue resident monocyte-derived U937 cell line, THP-1 cells originated from blood monocytes and 
are more closely resembling to blood monocyte-derived NLCs (Chanput, Peters & Wichers 2015). Second, 
THP-1 cells is known to produce a phenotype of macrophage only with no expression of dendritic cell 
markers (Riddy et al. 2018). Finally, U937 cells do not display chemoattractant behaviour when using 
trans-well migration assay, whereas THP-1 cells (Riddy et al. 2018) and NLCs (Boissard et al. 2016b) share 
the similar chemoattractant property. Based on the above considerations, I chose THP-1 cells for my study.  
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An optimised density of 0.5 x 106/ml of THP-1 cells was used following a modified protocol to produce 
adherent macrophages (M0), which were further polarised to become M1 and M2 populations of 
macrophages using established protocol. M1 and M2 macrophages were confirmed by 
immunofluorescent microscopy using CD markers EGR2 and CD38, respectively. 
6.3.2 Similarities of cell line model to primary NLCs 
I then proceeded to compare the similarities and differences of this cell line model to primary NLCs in 
aspects of morphology, phenotype and biological functions. 
The morphology of differentiated THP-1 cells largely matched those of NLCs. They exhibited the adherent 
macrophage property, as reported previously in other studies (Chimal-Ramirez et al. 2016; Genin et al. 
2015). The phenotype of NLCs being of M2 subtype macrophages was replicated in differentiated THP-1 
cells in which the expression of CD14 and CD163 as well as the elongated morphology were observed 
following polarisation to M2 subtype. 
The NLCs were described as having predominantly M2 macrophage phenotype (Hanna et al, 2015; 
Marchesi et al, 2015, Ysebaert and Fournie, 2011; Ysebaert et al, 2010). I therefore induced the THP-1 
cell-derived M0 macrophages to differentiate into M1 and M2 subtypes of macrophages and compared 
their relative contribution to the pro-survival effect towards CLL cells. My results showed that M2 
macrophages conferred greater protection than M1 macrophages against spontaneous and fludarabine-
induced cell death of CLL cells. Therefore, the cell line model using differentiated THP-1 cells can 
recapitulate the cytoprotective effect of NLCs on CLL cells.  
 
6.3.3 Limitations of the cell line model  
As with any model, there are limitations with the THP-1 cell line model which precludes it to completely 
replace primary NLCs. First, there were difficulties of using this model to verify the increased levels of 
CCL3 and CCL4 secreted by CLL cells when in co-culture with NLCs, as reported (Burger et al, 2009). This is 
due to the observations that the differentiated THP-1 cells alone spontaneously produce a high level of 
CCL3 and CCL4 as reported here in my study (Figure 4.10 in Section 4.4.4.3) and by others (Harrison et al. 
2005; Mantovani et al. 2002). This makes it very difficult to measure the difference in the levels of the 
chemokines in the cultures of THP-1 cells with or without CLL cells. 
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Another limitation to this model was its inability to mimic the effect of NLCs on the levels of surface 
expression of IgM and IgD on CLL cells. It was reported that the expression levels of sIgM and sIgD of CLL 
cells were reduced when co-cultured with NLCs (Ten Hacken et al. 2016). However, the THP-1 cell-derived, 
polarised macrophages were not able to replicate this effect. This could be caused by addition of cytokine 
such as IL-4 that was used to induce polarisation of THP-1 cells to M2 macrophages. IL-4 has been shown 
to enhance the expression of sIgM in CLL cells (Aguilar-Hernandez et al. 2016). It has also been shown that 
small amounts of IL-4 are secreted by macrophages (La Flamme et al. 2012). Therefore, presence of 
exogenous IL-4 may have prevented the reduction in expression of sIgM and sIgD in CLL cells by the THP-
1 cell-derived macrophages.   
Therefore, it became clear that there are limitations to the use of cell line model as to how much it is truly 
representative of NLCs. Caution is thus required when interpreting the results generated from the use of 
cell line model and further extrapolating such interpretation to explain in-vivo events. 
 
6.4 Comparison of global gene expression in CLL cells cultured with or without NLCs  
Due to the limitations of the cell line model outlined above, in the final part of my PhD study I chose to 
use fresh CLL PBMCs samples to develop NLCs and apply cryopreserved autologous CLL cells for co-culture 
experiments and investigated at the level of gene expression the molecules and pathways involved in 
survival and resistance of CLL cells to therapy as a result of interaction between NLCs and CLL cells. Thus, 
my intention was to identify differentially expressed genes that could be targeted by future therapy to 
overcome resistance. 
 
6.4.1 Identification of differentially expressed genes 
I first sought to establish a comprehensive list of differentially expressed genes in primary CLL samples 
that were cultured with or without NLCs through RNA sequencing analysis. RNA samples were thus 
extracted from CLL cells cultured with NLCs for 24 h as well as cultured alone for the same time period 
and RNA sequencing was performed by a commercial biotechnology firm Novogene using RNA-seq 
technology. Bioinformatics analysis of the sequencing data was performed by Computational Biology 
Facility (CBF) of University of Liverpool. In total, 6 CLL samples were used to generate the RNA samples 
for sequencing. Out of 19,595 genes analysed, 326 genes were significantly differentially expressed among 
CLL cells in co-culture with NLCs in comparison with CLL cells cultured alone. Among the 326 differentially 
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expressed genes, 322 gene were upregulated in CLL cells co-cultured with NLCs. When compared to 
published comparative gene expression data from CLL cells isolated from lymph nodes versus peripheral 
blood (Herishanu et al. 2011), 61 out of 322 upregulated genes in our study were found in the list of the 
overly expressed genes (133 in total) in CLL cells from lymph nodes. Gene set enrichment analysis also 
produced a statistically significant positive enrichment of the two data sets, indicating that gene 
expression profile of CLL cells co-cultured with NLCs shared a high degree of similarity to that of CLL cells 
from the lymph nodes. Encouraged by the above results, I selected some of the 61 differentially expressed 
genes identified by RNA-seq for validation using RT-qPCR.  
In the end, I managed to validate 9 genes for which RT-qPCR were optimised and performed on 14 CLL 
samples (with or without co-culture). Results from RT-qPCR largely confirmed the findings from RNA-seq 
analysis. 
 
6.4.2 Molecules and pathways critically involved in the survival and resistance of CLL cells to 
therapy in vivo 
Using the list of differentially expressed genes described above, I attempted to identify molecules and 
pathways critically involved in the survival and resistance of CLL cells to therapy in vivo through 
bioinformatics analysis. With the support from the CBF team of University of Liverpool, using the Ingenuity 
Pathway Analysis I was able to identify several significantly enriched upstream regulators, with the top 
most significantly enriched regulators including tumour necrosis factor (TNF) and interferon gamma 
(IFNγ). Using the identified upstream regulators, KEGG pathway analysis revealed several highly enriched 
signalling pathways involved in mediating the CLL-NLC interaction. The highest ranked pathway included 
the toll-like receptor (TLR), TNF, hypoxia-inducible factor (HIF) and NF-ĸB signalling pathways. NF-ĸB 
signalling pathway is known to be activated in the CLL cells that are localised within the lymph node 
microenvironment (Mansouri et al. 2016). The activation of NF-ĸB pathway leads to sustaining CLL 
proliferation and survival in vivo. My study therefore confirms the findings of NF-ĸB pathway involvement 
in survival signalling of CLL cells.   
TLR signalling pathway is also known to be activated in CLL cells (Arvaniti et al. 2011; Dadashian et al. 
2019; Muzio, Fonte & Caligaris-Cappio 2012), where it cooperates with BCR signalling to activate NF-ĸB 
pathway (Dadashian et al. 2019). My study is thus in agreement with this finding by implicating that TLR 
signalling pathway is strongly activated following NLC-CLL interaction. 
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Activation of TNF signalling pathway is known to play a role in CLL pathology (Dürr et al. 2018). Thus, it 
has been shown that the level of TNF receptor is increased in CLL cells (Dürr et al. 2018). Also, level of 
TNF-α is increased in CLL cells and high levels of TNF- are indicative of aggressive disease states (Dürr et 
al. 2018). Activation of TNF signalling pathway can also activate NF-ĸB signalling pathway, contributing to 
the survival of CLL cells and their resistance to apoptosis (Dürr et al. 2018). 
HIF signalling pathway has been reported to be activated in CLL cells residing in hypoxic tumour 
microenvironment where the upregulated HIF-1α regulates the interactions between CLL cells and the 
microenvironment, promoting cell survival and adapting to hypoxic environments (Valsecchi et al. 2016). 
However, in my knowledge there are not many studies reporting findings from experiments that were 
performed under hypoxic conditions in CLL, further investigation is warranted to investigate NLC-CLL 
interaction in a hypoxic culturing condition. 
Further analysis also revealed some significantly enriched genes critically involved in these signalling 
pathways. They include STAT1, SPP1 and IL6.  
It has been shown that STAT1 plays a role in the differentiation of CLL cells mediated by Byrostatin 1 
(Battle & Frank 2003). Tyrosine phosphorylation of STAT1 promotes further maturation of CLL B cells 
leading to up-regulation of CD22 expression and IgM production (Battle & Frank 2003). It was also shown 
that lenalidomide treatment resulted in an increased level of the immunosuppressive cytokine IL-10 which 
was shown to induce apoptosis in CLL cells via STAT1 activation (Schulz et al. 2013). The activated STAT1 
was shown to inhibit matrix metallopeptidase 9 (MMP9) expression in CLL cells, which is normally 
upregulated and important in cell migration and promote survival of CLL cells (Schulz et al. 2013). 
IL6 is also a known mediator of B cell differentiation and proliferation (Zhu et al. 2018).  High levels of IL-
6 in CLL patients have been reported to be correlated with poor prognosis (Zhu et al. 2018).  
The exact role of SPP1 (osteopontin) is not well known in the context of CLL. The role of osteopontin has 
been documented in a number of other cancers such as breast cancer, colorectal cancer and lung cancer 
(Shevde & Samant 2014) and disruption of the lysosomes has been shown to induce cell death in the 
cancer cells (Dielschneider et al. 2016). It was shown that SPP1 was overexpressed in CLL cells at the mRNA 
level as well as at protein level compared to normal B cells, but no difference between CLL patients with 
mutated IGHV and unmutated IGHV (Dielschneider et al. 2016). However, the clinical significance of this 
finding is not clear. It was suggested that in the sphingolipid pathway, the dephosphorylation of S1P by 
SPP1 (to produce sphingosine) makes CLL cells more sensitive to lysosome permeability (Dielschneider et 
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al. 2016). However, the exact mechanism of lysosome permeabilization leading to loss of mitochondrial 
potential in CLL cells is unknown (Dielschneider et al. 2016). It was speculated that the lysosome 
membrane oxidation can open the pore of the mitochondria which leads to cell death cascade 
(Dielschneider et al. 2016).  
The role of SPP1 in survival of CLL cells following interaction with NLCs is still unclear, which requires 
further investigation.  
 
6.5 Suggestions for future experiments 
It is my view that the study of NLCs is still in its infancy, despite being researched for almost two decades. 
NLCs remain a key component of the CLL microenvironment. The interaction between NLCs and CLL cells 
in the microenvironment, to a large degree, resembles reciprocal interaction of cancer cells with the 
tumour microenvironments in general. It is still not yet known the exact mechanisms of how CLL cells are 
supported by NLCs. Further studies are required to not only understand better the underlying pathways 
that sustain a tumour microenvironment, but also help identify molecular targets for therapeutic 
intervention.  
A pathway that was significantly activated following KEGG pathway analysis of the gene expression data 
from co-cultured CLL cells is the HIF signalling pathway. There are not many studies specifically looking at 
role of this pathway in mediating NLC-CLL interactions (Koczula et al. 2016; Yosifov et al. 2020). 
Considering that tumour microenvironment produces a hypoxic condition in vivo (Kim et al. 2009; Lyssiotis 
& Kimmelman 2017), it would be worth investigating of involvement of the HIF pathway in CLL-NLC 
interaction, ideally in a hypoxic condition. The protocols of creating hypoxic conditions using cobalt 
chloride (CoCl2) solution or in Modular Incubator Chamber may be adapted when performing such 
experiments (Wu & Yotnda 2011). The pursuit of NLC study using CLL cells in a hypoxic environment would 
create a closer replica of environmental conditions in vivo. I hypothesize that in a hypoxic condition, there 
will be an enhanced development of NLCs as well as the greater protective effects on CLL cells. Since it 
has been shown that M2 macrophages are present more in hypoxic conditions (Bingle, Brown & Lewis 
2002b; Petrova et al. 2018), more NLCs may develop in most CLL samples and protect the CLL from 
spontaneous apoptosis for a longer duration. A hypoxic condition experiment may uncover a trait of NLC 
interaction with CLL that would not have been so obvious in a standard non-hypoxic culture condition. 
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One of the upstream regulators that was also among the top “significantly enriched pathways” was SPP1 
(osteopontin). Currently there are only two studies that investigated SPP1 in the CLL setting (Dielschneider 
et al. 2016; Shukla 2013). Since the understanding of the biological function of this gene in CLL is in its 
infancy, independent studies are required to first ascertain if findings from the two studies (Dielschneider 
et al. 2016; Shukla 2013) could be reproduced in CLL cells cultured with or without NLCs. If the pro-survival 
effect of SPP1 is confirmed, further experiments will be needed to provide definitive evidence of its 
function by manipulating gene expression (up or down regulation) and clear explanation on the 
mechanism of how SPP1 mediates its function. Finally, therapeutic potential of targeting SPP1 should be 
explored using pharmacological inhibitors.  
Finally, a model system encompassing multiple components and stimuli relevant to an in vivo 
microenvironment has yet to be produced in a laboratory setting. The pursuit of such a model system can 
allow researchers to use such platform to perform cell death assay with drugs that target various 
components of the microenvironment, including CLL cells, NLCs, cancer associated stromal cells, in a 
hypoxic, vasculature environment. Current advances in this direction include development of cancer-on-
a-chip models where microfluidic chips contain chambers for cell culture, which control fluid flow, oxygen 
diffusion, tissue mechanics and composition of cellular components (Asghar et al. 2015; Sleeboom et al. 
2018; Wu & Swartz 2014). Although the in vitro models will not fully reproduce the microenvironment  
conditions in vivo and produce a truly representation of the responses from primary cells (Goodspeed et 
al. 2016), development of the in vitro system to mimic the in vivo conditions would enable researchers to 
gain an better understanding of an underlying pathology of a disease. This in turn will facilitate testing of 
the new drugs that target the molecules/pathways associated with survival and resistance to therapy. It 
is obvious that achieving such objectives will require the teamwork of bioengineering, cell culture 
specialists, computational biologists and histopathologists. 
 
6.6 Conclusions 
I independently confirmed many features of NLCs developed in vitro using primary CLL samples, but also 
produced an NLC scoring system based on the number and morphology of NLCs developed to reflect the 
wide variation in the development of NLCs between individual CLL samples. The NLCs indeed prolonged 
the survival of CLL cells as well as contributed to the increasedserum levels of CCL3 and CCL4. To 
determine if these effects can be reproduced using a cell line model, I showed that THP-1 cells can be 
used as a cell line model to mimic the pro-survival effect of NLCs and evaluated advantage and 
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disadvantage of the use of cell line model. Finally, I identified a list of differentially expressed genes 
involved in mediating the pro-survival effect of NLCs on CLL cells, some of which was validated using RT-
qPCR techniques. Using contemporary bioinformatics tool, I analysed in depth the role of several 
molecules and pathways that are likely critically involved in the survival and resistance of CLL cells to 
therapy in vivo, and highlighted some molecules/pathways that could be therapeutically targeted to 
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7.1 Clinical Data 
Appendix Table 7.1 Clinical data on CLL Samples used in my study. 
IGHV status refers to somatic mutations in IGHV gene of CLL cells compared to gene sequence of the nearest germ line. IGHV mutation rates of ≥2% difference from germline are 
considered mutated, while un-mutated disease has a <2% mutation rate (Crombie & Davids 2017). WBC, White Blood Cell (109/l); Absolute Lymphocyte Count (109/l); Absolute 



















3259 209 123.1 1.4 other NA NA NA 70 Male NA 
3314 359.8 351.2 NA NA NA 17p- 13q- NA 51 Male C 
3369 163.5 157 2.2 untreated NA 13q- 37 39 Male NA 
3379 228.5 NA NA NA NA NA 69 70 Male NA 
3381 157.4 149.7 3.1 ritux, bendamustine NA normal 67 74 Female NA 
3385 56.5 53.1 0.6 ritux, bendamustine unmutated normal 70 76.9 Male C 
3436 144.3 137 2.2 untreated NA 13q- NA 72 Male B 
3460 80.5 73.7 2 ibrutinib NA 17p-13q- NA 51 Male NA 
3461 22.6 15.3 1.1 untreated NA NA 73 74 Male A 
3463 52.7 46.7 1.1 DIB4 NA normal 67 76 Female A 
3464 224.9 220.8 2 CLL210 induction NA 17p- 13q- NA 68 Male B 
235 
 
3465 32.1 29.7 0.3 ibrutinib NA 17p- NA 55 Male C 
3469 65.4 63.3 0.5 FCR NA normal 55 63 Male C 
3470 159.6 149.9 2.7 untreated NA 13q- 77 97 Female A 
3471 23.6 21.7 0.5 ibrutinib NA 17p- NA 55 Male C 
3472 149.9 144.8 0.7 untreated NA 13q- 75 77 Female B 
3481 21.3 16.5 0.6 ritux, bendamustine unmutated normal 70 78 Male C 
3482 61.8 56.5 0.6 untreated NA 11q- 13q- 70 71 Male B 
3483 3.7 1.3 0.3 ibrutinib NA 17p- NA 56 Male C 
3484 212.2 208.2 2.2 untreated unmutated 13q- 58 65 Male B 
3485 100.8 89.6 3.2 untreated NA NA 74 79 Female A 
3490 196.3 190.8 NA untreated NA 13q- 82 82 Male C 
3491 66.4 62.7 1.1 ritux, idelalisib NA 11q- 13q- NA 66 Male C 
3492 67.6 63.8 0.8 FCR NA 11q- NA 77 Male A 
3493 72.8 67.6 1.3 untreated NA 13q- 62 68 Female A 
3494 111.1 108.6 1.2 ritux, idelalisib unmutated 17p-, trisomy 12 NA 74 Male C 
3500 226.7 224.5 NA venetoclax NA trisomy 12 67 76 Male C 
3502 196.3 194.3 NA venetoclax NA trisomy 12 67 76 Male C 
3504 129.5 126.7 1.6 venetoclax NA trisomy 12 67 76 Male C 
3505 38.1 36.9 0.8 venetoclax NA trisomy 12 67 76 Male C 
3506 5.7 0.6 0.1 venetoclax NA trisomy 12 67 76 Male C 
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3507 33 30.7 0.3 untreated NA NA 63 65 Female A 
3510 275.6 268.8 2.7 untreated NA 13q-, trisomy 12 73 80 Male C 
3511 226 221.9 1 untreated NA 13q-, trisomy 12 73 80 Male C 
3512 138.3 130.3 2.3 FCR, Ibrutinib NA 13q- NA 67 Male C 
3513 112.8 109.8 0.8 fcr NA 11q- NA 67 Male C 
3516 55.9 53.4 1.5 ibr NA 11q-, 13q- NA 66 Male C 
3519 39.3 30.1 1 ibr NA 17p-, 13q- NA 52 Male NA 
3520 51.2 44.2 1.1 untreated mutated 17p- 13q- 75 77 Female A 
3522 79.7 76.7 0.6 ibr NA 11q-, 13q- NA 71 Male C 
3523 15.7 14.8 0.1 FCR NA 13q- NA 68 Male C 
3526 244 224.7 NA NA NA trisomy 12 NA 74 Male C 
3527 98 95 1.1 untreated mutated normal 69 75 Female C 
3528 23.3 17.5 1.4 FCRM NA 11q- 55 68 Male A 
3529 42.1 36.2 1 ibrutinib NA 11q- 13q- NA 59 Male C 
3530 243.2 234 1.4 untreated unmutated normal 56 56 Male C 
3536 7 3 0.7 dex, ofatumumab, lenalid NA 17p- 76 80 Male A 
3537 9.7 1.8 1.2 venetoclax NA 17p- NA 52 Male A 
3538 20.8 16.1 0.8 untreated NA 11q- NA 66 male C 
3539 56.6 50.7 1 untreated NA 13q- 93 94 Male B 
3542 45.8 40.6 0.9 FCRM NA 11q- 55 68 Male A 
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3544 13.5 0.4 2.3 venetoclax NA 17p-  57 Male A 
3561 85.8 76.8 1.7 untreated unmutated 11q- 30 38 Male B 
3564 63 58.7 0.8 ofatumumab, chloramb NA 11q- 13q- 52 84 Male C 
3566 70.3 63 1.6 untreated mutated 13q- 59 66 Male C 
3568 155.8 148.9 1.4 
ofatumumab, chloramb, 
idelalisib 
unmutated normal 72 76 Male C 
3574 71 65  ritux and idelalisib normal trisomy 12 NA 86 Male B 
3576 47.5 43.9 0.5 fludarabine mutated NA 57 82 Female C 
3577 85.7 75.8 1.4 ibrutinib NA 17p- NA 55 Male A 
3579 162.8 159.4 2 bendamustine, ritux NA 11q-, 13q- NA 58 Male C 
3582 147.8 143.9 1.2 untreated 
no clonal rearranged 
IGHV detected 
normal 62 66 Male A 
3585 109.9 101.4 1.5 untreated unmutated 11q-, 13q- 66 68 Male A 
3587 257.2 >200 5.3 untreated mutated 13q- 54 55 Male  
3589 170.6 104.9 1 untreated mutated normal 69 76 Female C 
3599 63.9 59.2 0.9 untreated NA 13q- 62 70 Female A 
3602 50.8 49.9 0.6 untreated unmutated 11q- NA 61 Male C 
3603 106.2 101.7 2.5 
ofatumumab, chloramb, 
idelalisib 
unmutated normal 72 77 Male B 
3605 252.8 244 1.6 untreated mutated 13q- 60 63 Male B 
3606 109.2 103.6 1.8 ofatumumab, chlor, idel unmutated 13q- 58 67 Male B 
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3607 254.2 247.7 2.2 untreated mutated normal 66 69 Male B 
3609 120.8 109 3.7 untreated NA normal 46 62 Male B 
3610 240.9 237.9 1 ibr, ritux NA normal 62 66 Male A 
3611 74.3 65.5 1.5 untreated NA 11q- 13q- 88 89 Female A 
3612 59 54.3 1.7 untreated mutated 13q- 79 81 Female B 
3613 147.8 145.5 1.2 untreated mutated normal 56 67 Female A 
3620 145.9 142.6 1.2 untreated mutated normal 69 76 Female C 
3621 70.2 60.6 2 ibrutinib mutated 13q- 58 59 Female B 
3627 136.7 129.4 2 ibrutinib unmutated 13q del 58 68 Male C 
3631 256.1 >200 4.7 ibrutinib mutated 13q- 60 64 Male B 
3637 144.6 134.9 2.2 untreated unmutated 11q-, 13q- 66 69 Male A 
3639 277.2 266.1 2.4 ofatumumab, chloramb unmutated normal 72 77 Male C 
3640 177.5 163.4 2.3 untreated unmutated 13q- equivocal 78 82.9 Male A 
3642 129.4 122.8 1.3 ibrutinib unmutated normal 67 73 Male C 
3644 187.6 174.1 5.1 ibrutinib unmutated normal 72 77 Male C 
3645 264.1 258.8 1.5 untreated unmutated normal 68 72 male C 
3647 145.9 138.2 2.8 untreated mutated IGHV2-21 normal 66 67 Female A 
3650 119.6 110 1.9 untreated mutated normal 63 70 Female B 
3674 116.1 108.7 1.5 untreated mutated normal 63 70 Female B 
3679 171.4 164.7 1.6 untreated NA 13q- 53 54 male C 
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3682 33.2 25.8 0.5 untreated NA  71 74 female A 
3684 230.1 220.8 NA untreated mutated 13q- 75 84 male A 
3686 38.5 31.3 1 untreated mutated trisomy 12 70 71 female A 
3691 226.5 216.1 2.9 ibrutinib, ritux unmutated 13q-, trisomy 12 65 69 female NA 
3694 119.8 99.3 NA ibrutinib NA normal 55 66 Male C 
3696 125.4 116.8 1.7 untreated NA 13q- 61 71 Female NA 
3697 113.7 96.2 2.3 ibrutinib, ritux unmutated 13q-, trisomy 12 65 69 female NA 





Appendix Table 7.2 Summary of Clinical features with context of treatment 
 
Untreated Treated 
Frequency Percentage Frequency Percentage 
Staging 
A 17 42.5 8 19.5 
B 12 30.0 6 14.6 
C 11 27.5 27 65.9 
NLC Score 
0 2 4.8 1 2.2 
1 16 38.1 26 57.8 
2 11 26.2 7 15.6 




Appendix Figure 7.1 NLC score changes with time among patients with multiple re-bleeds.  





7.2 Phenotyping NLCs using Flow Cytometry 
Similar to analysis of cell purity, when the cells of interest are harvested, spun and washed with PBS 
at 300G at 4oC, Fixation/Permeabilisation is done to allow antibodies to cross and bind to selected 
intracellular CD Markers. The cells are washed to remove excess debris with fixation/permeabilisation 
solution. After this, the cells are dehydrated so the size of the cells and overall pellet size is smaller. 
Fluorochrome-conjugated antibodies are added at appropriate volume and incubated for at least 1 
hour. The cells are washed thoroughly to remove the excess unbound antibodies. The remaining 
complexes are then sent for FACS analysis. Compensation using beads are used to allow well spread 
out peaks of each fluorochromes and an isotype control and test is done on each sample harvested. 
Data Collection is performed using Attune software and Analysis is done by both Attune software and 
Flowing Software. 
When analyzing, appropriate gating strategies are made to ensure that CLL cells (the majority) are 
identified and not selected seen in Appendix Figure 7.2. It is known that macrophages are bigger and 
more complex (higher granularity and vacuoles) so it is expected to see that their population would 
have a higher Forward Scatter. This was also observed in early literature pertaining to NLCs (Burger et 
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Sample 3492 and 3511, when harvesting NLCs using a plate scraper (left), the gated region of NLCs is selected as R1 and the level 
of antibody is detected with the histograms comparing the test with isotype control. Image taken from Attune Flow Cytometry 
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7.3 RNA Sequencing 
7.3.1 Library Preparation 
RNA samples are sent in ice cold temperature following extraction from harvested cells and checked 
for eligible purity and quantity as per requirements of the outsourced sequencing company 
(Novogene). 
The mRNA is enriched and fragmented, followed by reverse transcription to produce cDNA fragments 
from the mRNA template (Appendix Figure 7.3). Adapters are added to the ends to make it easier to 
perform cluster generation. This is known as Next Generation Sequencing (NGS) Library preparation.  
 
Appendix Figure 7.3 Diagram of New England Biolabs (NEB) library preparation of mRNA for RNAseq. Image adapted from 




7.3.2 Cluster generation 
This is where the fragments with adapters are added onto a glass slide with lanes (Appendix Figure 
7.4). The lanes are coated with a lawn. Here, the lawn is composed of two types of oligos that are 
complimentary to one of the two ends of the DNA fragments. Polymerase action occurs to amplify the 
strands into millions. 
 
 




Sequencing starts with the reading of the primer (Appendix Figure 7.4). Fluorescently tagged 
nucleotides then come and bind complement to the strand. On binding, the fluorescence is excited 
and detected by the machine. Forward and reverse reads occur to avoid ambiguous alignments. 
The machine converts the signals detected into digital representations of the sequence and produces 





7.4 Phases/ progression of Monocyte/macrophage differentiation observed 
These observations are made on following cultures from the start of plating the PBMC from CLL 
patients. 
1. Well defined monocyte seen with spherical/oval shape that is slightly larger than 
lymphocytes. Nucleus show chromatin pattern and cytoplasm appear grey. Granules appear 
as very fine specs in cytoplasm. Slight gap may be seen between monocyte and lymphocytes 
giving a sort of halo like appearance around the monocyte. Almost no pleomorphism 
2. Monocytes appear larger now with more granules giving a darker denser appearance than 
other monocytes. Shape is still spherical/ oval. Some may show some fine fibrous extensions 
from well-defined cell membrane. Slight pleomorphism. 
3. Shape of monocyte is altered giving an elongated look, where nucleus and cytoplasm is harder 
to distinguish under PC. Obvious pleomorphism is observed. 
4. Tail-like projections are observed extending from the cytoplasm as if leaving a trail. This is 
seen on one pole of the cell giving a distinct head and tail appearance, suggestive of active 
motion of the cell. Cell membrane at tip of tail is not well defined. 
5. Tail-like projections increase in number to give a spindle shaped appearance, where the 
nucleus appears to be in the middle and the tails are at separate ends extending or projecting 
outwards, giving a strong adherent appearance. Usually in close proximity with lymphocytes 
or other earlier monocytes. (monocytes in general appear very pleomorphic) 
6. Monocytes may form clusters near less healthy (dead or dying lymphocytes), others may join. 
Mix of spherical/oval and elongated, tailed monocytes. 
7. Cluster may grow consisting of more pleomorphic monocytes and lymphocytes. 
8. Period of plateau where this not much difference in size, shape, density appearance of 
monocytes, clusters. 
9. Clusters reduce in number, with darker looking cells yet not as granulated. Pleomorphism may 
be less. Most monocytes may appear smaller with occasional giant-sized monocytes 
10. More dead/dying cells are observed where lymphocytes appear dark and shrunken if adhered 
and floating aggregate bodies. Number of both lymphocytes and monocytes seem reduced, 
predominantly the lymphocytes. Mild apoptotic background is observed where small particle 
bodies are seen, giving a darker background. Areas of dead cells appear as black opaque 
aggregates. 
11. Tail like projectioned monocytes and occasional giant-sized monocytes remain unaltered in 
number, however, other forms appear reduced or nil. Background appears more apoptotic. 
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12. Under the dark opaque dead aggregates if washed, may show some early Phased monocytes. 
Overall number of monocytes is reduced. 
13. Number of live cells in general is severely reduced leaving behind a darkly apoptotic 







7.5 Integrity of RNA 
The integrity of RNA was analysed using Agilent Bioanalyzer by Novogene. Samples that achieve RIN 
≥7.0 are acceptable and used for sequencing. Samples which do not meet the required RIN can 
undergo an additional step of purification by Novogene to raise the RIN to acceptable level. 
The Agilent Bioanalyzer is based on microfluidics technology and is also capable of performing 
electrophoretic separations using capillary electrophoresis. The Bioanalyzer uses Lab-on-a-chip 
technology which have tiny channels analogous to capillary tubing, where the proteins or other 
analytes are subjected to an electric field, migrate along a separation channel and are picked up by 
the detector.  These LabChip Kits are now a standard in RNA quality assessment and quantitation. 
Using electrophoresis-based techniques on micro-fabricated chips, RNA samples are separated and 
subsequently detected via laser induced fluorescence detection. 
The machine can run small sample volumes, requiring short analysis time and is generally automated 
which improves accuracy, precision and productivity.  
The software generates an electropherogram and gel-like image and displays results such as sample 
concentration and the ribosomal ratio. The electropherogram provides a detailed visual assessment 
of the quality of the RNA sample.  
RNA degradation is a gradual process where there is a decrease in the 18S to 28S ribosomal band ratio 
and increase in the baseline signal between the two ribosomal peaks and the lower marker. The 
software automatically generates the ratio of the 18S to 28S ribosomal subunits. However, a further 
analysis using RNA Integrity Number (RIN) can adequately describe the sample integrity. The RIN 
considers the entire electrophoretic trace. The software algorithm for RIN allows for the classification 
of total RNA based on a numbering system from 1 to 10, with 1 being the most degraded profile and 
10 being the most intact. RIN is generated based on a number of features such as: Peak 
height/position, Areas/Area ratio, Signal/Noise ratio, Max Min values, waviness of the curve etc 
(Schroeder et al. 2006). The total RNA ratio measures the fraction of the area covered by 18S and 28S 
compared to the total area under the curve (Schroeder et al. 2006). The height of 28S peak gives 
additional information on the state of degradation process where the 28S band vanishes faster than 
18S during degradation (Schroeder et al. 2006). Accurate RIN values can be obtained when 
concentration values are above 50ng/ul. The RIN, however, cannot predict the usefulness of gene 
expression data without prior validation work (Schroeder et al. 2006). As seen in Appendix Figure 7.5, 
the sample has a distinct high 28S and 18S peak that contributes to most of the total area, giving a 








Bioanalyzer report of a sample sent for RNAseq. 18S (pink) seen as the middle peak and 28S (green) seen as the peak on the 
right. The sample was harvested and RNA was extracted as described in Methods. Bioanalyzer report was generated using 
outsourced Agilent machine by Novogene 
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7.6 Purification of sample 
Some of the RNA extracted unfortunately do not meet the RIN requirements to perform the RNAseq 
and so an option of purification of RNA is offered. This technology combines the selective binding 
properties of a silica-based membrane with speed of microspin technology. First lyzed and 
homogenized in presence of denaturing guanidine-thiocyanate-containing buffer, which inactivates 
the RNases to ensure purification of intact RNA. Ethanol is used to provide appropriate binding 
conditions. The sample is applied into RNeasy Mini spin column, where the total RNA binds to the 
membrane and the contaminants are efficiently washed away. This procedure provides enrichment of 
mRNA since most RNAs <200 nucleotides (such as ribosomal RNA and translational RNA, which 
together comprises of 15-20% of total RNA) are selectively excluded. This was done solely by the 
outsourced agent Novogene. As seen in Appendix Figure 7.6, the sample 3679 CL had an initially low 
RIN value and undergone purification and as seen in Appendix Figure 7.7 the same sample then had 
an improved RIN value, acceptable for RNAseq experiment. 
 
 
Appendix Figure 7.6 Bioanlayzer report and Agarose gel electrophoresis of RNA sample with low RIN value. 
 
Bioanalyzer data (left) of Sample 3679 CL with low RIN number (5.1), Agarose gel electrophoresis (right) where the sample 
is in well #1 with the conditions of Gel Conc.: 1%,  Voltage: 180v and Run Time of 16min. The sample was harvested and 







Appendix Figure 7.7 Bioanalyzer report and Agarose gel electrophoresis of an RNA sample following purification with a good 




Following purification of Sample 3679 CL, Bioanalyzer data (left) with encouraging RIN number (8.8), Agarose gel 
electrophoresis (right) where the sample is in well #1 with the conditions of Gel Conc.: 1%,  Voltage: 180v and Run Time of 
16min. The sample was harvested and RNA was extracted as described in Methods. Bioanalyzer report was generated using 
outsourced Agilent machine by Novogene. 
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7.7 Preliminary steps to confirm quality of cDNA and PCR primers 
To confirm the quality of the cDNA, cDNA from CLL samples was first used to measure the expression 
of GAPDH using PCR primers by agarose gel electrophoresis. As shown in Appendix Figure 7.8, it 
showed that the old stock of GAPDH primer was not suitable as all the samples did not properly 
express GAPDH, but rather showed expression below the expected length. This suggested that new 
stock of GAPDH was imperative for subsequent experiments. 
 
Appendix Figure 7.8 PCR gel run on four samples with an old stock of GAPDH 
 
 
After ordering new GAPDH primers and preparing them (as described in Methodology 2.1.8.3), I 
repeated agarose gel electrophoresis and as seen in Appendix Figure 7.9, GAPDH was detected at the 
expected location at around 400bp. This suggested that this stock of GAPDH was suitable. 
An old stock of GAPDH primers was used on 4 RNA samples (Wells #3-6). The Quick-Load Purple DNA ladders 100bp (Well #1) 








A new stock of GAPDH primers was used on 2 RNA samples (Wells #3-4). The Quick-Load Purple DNA ladders 100bp (Well 




7.8 Quality Control 
Briefly, as mentioned in Methods, the MultiQC report was generated from the FastQ files. As seen in 
Appendix Figure 7.10, the number of unique reads were more than duplicate reads as well as being 
quite high. This was indicative of good quality of the reads. Mean quality scores were produced based 
on Phred Score. It was found that the scores were all above 30 in the ‘green zone’ which was indicative 
of a pass. The average %GC content of reads was calculated, all the samples were around 51-54% 
which was considered a pass. Sequence duplication levels was represented and showed that the levels 
were all low thereby considered to be a pass. The percentage reads of T, C, A and G nucleotides were 
measured according to position (bp) and except for the first 10bp or so, the levels were all 
approximately 25%. As with every template the beginning would have oligo reads and so the initial 
part is expected to have a jagged graph. The remaining portion of the positions in the graph was flat 
line and excluding the first 10bp it was considered a pass. Two measurements that usually results in 
failure because they are very sensitive. Per-base sequence content and Per-sequence GC content. Per-
base sequence content is common to show variation in the first 10 base pairs which was seen in our 




A     B     C     D 
     
E     F      G 
 
Appendix Figure 7.10 RNAseq MultiQC Report generated from FastQ files 
MultiQC Report generated from FastQ files from RNAseq raw data. The report consists of Sequence Counts (A), Mean Quality Scores (B), Average %GC content (C), Per Base N Content (D), 
Sequence Duplication Levels (E), Adapter Content (F) and %Reads of T, C, A and G nucleotides measured according to position (G). 
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7.9 Differential Gene Expression List 
Appendix Table 7.3 Differential Gene Expression Analysis of significantly upregulated genes in CLL samples 
 
Gene log2FoldChange lfcSE stat pvalue padj ExpressionLevelCLL ExpressionLevelCLLcc 
CHI3L1 6.626538 0.547598 12.10109 1.04E-33 8.23E-30 7.018133985 8.97364278 
CCL13 6.623863635 0.762716 8.684575 3.80E-18 8.58E-15 3.741797174 6.108092264 
CXCL9 6.472251527 1.002515 6.456016 1.07E-10 7.38E-08 4.007903563 5.975133685 
SPARC 6.28328509 0.501492 12.52918 5.17E-36 8.17E-32 6.088225541 8.319318944 
C1QA 5.605885135 0.542476 10.33389 4.95E-25 1.96E-21 7.053632523 9.382525933 
ANKRD22 5.543077736 0.973897 5.691645 1.26E-08 4.42E-06 1.33334491 2.919537681 
SLC1A2 5.463363463 0.875512 6.240193 4.37E-10 2.56E-07 2.432986191 3.930114202 
C1QB 5.319892541 0.6103 8.716848 2.86E-18 7.53E-15 6.075224015 8.329537997 
GPC4 5.251611677 0.75173 6.986033 2.83E-12 2.79E-09 5.128599786 6.593348076 
APOE 5.111120844 0.480545 10.6361 2.02E-26 1.07E-22 9.055853644 11.18368727 
KREMEN1 5.08319543 0.891993 5.698697 1.21E-08 4.33E-06 2.347373709 3.822795255 
KAL1 5.036022762 0.946592 5.320162 1.04E-07 2.78E-05 1.989989525 3.16329548 
CCL18 5.008110973 0.658317 7.607441 2.80E-14 4.91E-11 3.680027204 5.52084199 
NUPR1 4.998388338 0.81886 6.104085 1.03E-09 5.83E-07 3.334462361 4.982100132 
STAC 4.954662635 0.725022 6.833806 8.27E-12 7.26E-09 3.175955907 5.303174349 
Differential Gene Expression of significantly upregulated genes in the comparison between CLL alone (CLL) with CLL cultured with NLC (CLLcc). The genes are listed according to their 
log2fold change among CLLcc where CLL alone is the control. All the genes are statistically significant with their pvalue and padj values mentioned. Highlighted are those that were also 
upregulated in the literature study mentioned (Herishanu et al. 2011). 
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DCSTAMP 4.846985448 0.659995 7.343971 2.07E-13 2.52E-10 4.600787681 6.028399576 
IGFBP6 4.735214774 1.063908 4.450775 8.56E-06 0.001165 2.604781652 3.848555095 
AK4 4.729690626 0.837811 5.645296 1.65E-08 5.66E-06 2.255642297 3.640282549 
SLITRK4 4.661927929 0.955611 4.878478 1.07E-06 0.000201 1.690721383 2.74645581 
TSKU 4.610341963 0.643165 7.168209 7.60E-13 8.57E-10 3.836114315 5.436698925 
ZBED2 4.609355576 0.79343 5.809403 6.27E-09 2.54E-06 1.959037927 3.701267881 
UBD 4.594555212 0.798702 5.752525 8.79E-09 3.39E-06 2.500421617 4.336665778 
PRRG1 4.535987405 0.93604 4.845931 1.26E-06 0.000226 2.020187683 3.057216291 
ZBTB7C 4.53E+00 0.953224 4.756361 1.97E-06 0.000328 1.940282272 2.848593146 
P2RY13 4.438806046 0.850559 5.218695 1.80E-07 4.31E-05 1.966519088 3.478319838 
TRPV4 4.431821585 0.748424 5.921535 3.19E-09 1.57E-06 2.840077584 4.374728274 
TNFAIP6 4.378211526 0.868035 5.04382 4.56E-07 9.48E-05 2.084370432 3.444422059 
HJURP 4.353566596 0.820154 5.308228 1.11E-07 2.91E-05 1.163358911 2.400684275 
HSD11B1 4.263068739 0.953851 4.469325 7.85E-06 0.001084 1.732209015 2.605374498 
CD1B 4.261200749 0.90875 4.68908 2.74E-06 0.000442 1.482004733 2.613510067 
GNG4 4.228534081 0.806909 5.240407 1.60E-07 3.89E-05 0.963593869 2.182950795 
SUCNR1 4.183642328 0.792086 5.2818 1.28E-07 3.31E-05 2.906331676 4.158310801 
LCNL1 4.156275291 0.959284 4.332684 1.47E-05 0.001711 2.182145481 3.201184587 
GJB2 4.142628894 0.839569 4.934234 8.05E-07 0.000159 2.858312722 4.257472156 
ALOX15B 4.090781412 0.938938 4.356818 1.32E-05 0.001604 2.30671985 3.621888841 
CXCL10 4.089416869 1.013389 4.035385 5.45E-05 0.005156 2.638053066 4.17251983 
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CXCL12 4.079820404 1.021651 3.993359 6.51E-05 0.00588 1.55402758 2.826468618 
SH3PXD2B 4.03504769 0.41138 9.808568 1.03E-22 3.27E-19 5.477802162 7.344849929 
NPR1 4.030785297 1.061584 3.796952 0.000146 0.011287 2.332771802 3.387439989 
CCL1 4.021500827 0.936356 4.294844 1.75E-05 0.001972 1.838320702 2.806584649 
SERPING1 3.981529848 0.745435 5.341218 9.23E-08 2.60E-05 3.624071175 5.438191304 
F3 3.939404622 0.840849 4.685033 2.80E-06 0.000447 3.15458496 4.125749821 
KCNF1 3.914441753 0.899025 4.354097 1.34E-05 0.001611 2.051602963 2.984318707 
TMTC1 3.894855418 0.882287 4.414498 1.01E-05 0.0013 1.868938318 3.043258983 
BCAR1 3.823695239 0.7295 5.241528 1.59E-07 3.89E-05 3.17706564 4.363881608 
IL6 3.820445498 0.923348 4.137599 3.51E-05 0.003465 1.607223176 2.916593341 
LINC01010 3.802950694 0.846245 4.493912 6.99E-06 0.001004 2.920231489 3.797758229 
SSPN 3.78830165 0.73605 5.146802 2.65E-07 5.98E-05 2.070894758 3.310948344 
SEZ6L2 3.7552522 0.788793 4.76076 1.93E-06 0.000328 1.803568957 2.871153306 
PTGES 3.72938821 0.824049 4.525689 6.02E-06 0.000872 1.72875144 2.847733269 
SLC30A3 3.719924818 0.918314 4.050818 5.10E-05 0.004857 1.900486089 2.562603033 
CCL8 3.717788937 0.695538 5.3452 9.03E-08 2.59E-05 3.134032515 4.630204181 
C1QC 3.699102233 0.558358 6.624961 3.47E-11 2.74E-08 7.962435867 9.920848403 
SULT1C2 3.694020337 0.891696 4.14269 3.43E-05 0.00341 1.844328993 2.599796633 
RRM2 3.684022831 0.755041 4.879236 1.06E-06 0.000201 2.077368816 3.453782845 
SHC4 3.680497755 0.977372 3.765707 0.000166 0.012259 1.487501245 2.390795804 
NES 3.664349132 0.77722 4.714689 2.42E-06 0.000394 3.537111122 4.647522845 
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UNQ6494 3.652027398 1.075025 3.397156 0.000681 0.036708 1.008573869 1.941173679 
SLC6A12 3.627039533 0.777236 4.666588 3.06E-06 0.000479 2.556788927 3.528327743 
GPR85 3.601887213 1.049371 3.432424 0.000598 0.033628 0.814492825 1.526694072 
KIAA1462 3.49309833 1.036551 3.369924 0.000752 0.039589 0.906553991 1.749111651 
PROS1 3.470245452 0.88182 3.935321 8.31E-05 0.007172 1.767187088 2.841225116 
MMP7 3.456616895 0.681633 5.071086 3.96E-07 8.44E-05 3.474453786 4.514641131 
TMEM130 3.451263435 1.00128 3.446851 0.000567 0.032379 0.651995921 1.512203112 
VNN1 3.431769903 0.53583 6.404581 1.51E-10 9.53E-08 3.723711811 5.049868843 
COL6A3 3.407492601 0.714617 4.768277 1.86E-06 0.000323 2.129063163 3.409556138 
KCNMA1 3.391712798 0.794424 4.269397 1.96E-05 0.002112 4.206601342 5.746010893 
TFCP2L1 3.382286955 0.711103 4.756397 1.97E-06 0.000328 2.363376541 3.364466008 
CLEC6A 3.354986484 0.940165 3.568508 0.000359 0.022684 1.396445349 2.126641153 
ETV7 3.354168829 0.832662 4.028247 5.62E-05 0.005284 0.947260402 1.905024354 
RP11-1008C21.1 3.353940458 0.811997 4.130486 3.62E-05 0.00353 1.404456006 2.387237331 
RBP1 3.350847524 0.686901 4.878211 1.07E-06 0.000201 2.383067794 3.61545953 
CLEC1A 3.303857379 0.977185 3.380993 0.000722 0.038413 1.340837097 2.047449498 
UNC13A 3.303187894 0.942694 3.503986 0.000458 0.027321 1.915654819 2.976503112 
DIRAS2 3.268983297 0.936438 3.490869 0.000481 0.028453 1.515874934 2.213049072 
ACOX2 3.265349343 0.984634 3.316307 0.000912 0.045887 0.799834348 1.5833897 
SLC28A3 3.239167139 0.647832 5.000009 5.73E-07 0.000118 3.219850144 4.259834449 
STOX2 3.232196196 0.782185 4.132264 3.59E-05 0.003524 2.041684395 2.940638303 
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ALDH1A1 3.224246257 0.553085 5.829567 5.56E-09 2.31E-06 3.525088345 4.932737576 
LILRB5 3.209866305 0.737627 4.351614 1.35E-05 0.001617 5.280097282 7.099933041 
LOC101928716 3.206469862 0.767099 4.179997 2.92E-05 0.002952 2.237089859 3.007439665 
TGM2 3.19071212 0.458486 6.959236 3.42E-12 3.18E-09 6.628500378 8.031114549 
PIR 3.177872627 0.926577 3.429689 0.000604 0.033728 1.445906959 2.274696327 
EGLN3 3.177700594 0.848007 3.747257 0.000179 0.012895 1.597394375 2.577946667 
MKI67 3.165215913 0.574545 5.509086 3.61E-08 1.14E-05 3.909497173 5.826288065 
RAI14 3.095768613 0.794785 3.895101 9.82E-05 0.008076 2.32760727 3.299609543 
PGM5 3.075041485 0.847871 3.626779 0.000287 0.019108 1.438239416 2.384984401 
C3 3.036073249 0.779399 3.895402 9.80E-05 0.008076 2.5428523 3.690269073 
CD1E 2.965642577 0.839192 3.533927 0.000409 0.025165 1.201941975 2.08749124 
ACE 2.959932995 0.50061 5.912648 3.37E-09 1.61E-06 5.285715512 6.765415501 
STAC2 2.928547428 0.823014 3.558319 0.000373 0.023211 2.707554667 3.358691357 
GPRC5B 2.926645251 0.849394 3.44557 0.00057 0.032379 1.25605411 1.932332848 
TCN2 2.917771807 0.639284 4.564123 5.02E-06 0.00074 3.687374274 5.039426127 
CCL24 2.882530445 0.762078 3.782462 0.000155 0.01185 4.754146721 6.486863487 
C5orf20 2.877608007 0.67666 4.252667 2.11E-05 0.002224 3.380267591 4.727984181 
FGD5 2.875595942 0.769633 3.736323 0.000187 0.013347 2.054799134 2.832587351 
SLAMF8 2.868013916 0.378328 7.580769 3.44E-14 5.43E-11 6.616365029 8.102927884 
LYZ 2.810718653 0.424889 6.615179 3.71E-11 2.79E-08 11.01941977 12.50647395 
CCL7 2.805728662 0.625242 4.487429 7.21E-06 0.001017 3.154842062 4.496967665 
261 
 
GBP1 2.79436008 0.543899 5.137647 2.78E-07 6.15E-05 5.470164254 7.090013599 
SPP1 2.788645231 0.344373 8.097737 5.60E-16 1.11E-12 8.054320427 9.224239119 
USP2 2.779727582 0.796448 3.490158 0.000483 0.028453 2.808053936 3.526143712 
MMP9 2.770866693 0.370179 7.485208 7.14E-14 9.40E-11 10.59207459 12.14787944 
CLEC4E 2.767874458 0.508155 5.44691 5.13E-08 1.59E-05 3.53636976 4.776920727 
SHOX2 2.766616748 0.828377 3.339803 0.000838 0.042858 1.844631378 2.604162233 
TICRR 2.761454998 0.738661 3.738462 0.000185 0.013294 1.315315689 2.417409092 
CSPG4 2.760948304 0.662223 4.169215 3.06E-05 0.003075 3.21514844 4.163186054 
PKMYT1 2.759253811 0.76035 3.628928 0.000285 0.019049 1.704284485 2.746633491 
BHLHE41 2.757111192 0.435531 6.330454 2.44E-10 1.49E-07 5.946217502 7.316384931 
FAM213A 2.737070334 0.555965 4.923101 8.52E-07 0.000166 3.830178907 5.066674648 
LOC101927029 2.726699572 0.784229 3.476919 0.000507 0.029564 1.592828889 2.449367305 
TMEM119 2.726549108 0.815821 3.342092 0.000831 0.042644 4.044543288 5.39719044 
PTPRF 2.724727353 0.744212 3.661223 0.000251 0.017165 2.530394599 3.753364658 
MYOF 2.722972101 0.501278 5.432061 5.57E-08 1.68E-05 3.801199821 4.967605769 
MT1G 2.720817084 0.649719 4.187682 2.82E-05 0.002872 2.30734131 3.139373622 
PADI2 2.720103321 0.755537 3.600223 0.000318 0.020668 3.189776968 4.26230293 
ACOT11 2.69E+00 0.811978 3.307069 0.000943 0.047127 1.803145581 2.675574747 
MARCO 2.67898073 0.815608 3.284644 0.001021 0.049629 1.235895595 2.054373152 
EBI3 2.659217679 0.632781 4.202429 2.64E-05 0.002726 2.061149028 3.0127506 
SLCO5A1 2.653973418 0.77056 3.444212 0.000573 0.032426 1.357637485 2.548511567 
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CCL22 2.653022873 0.767905 3.454885 0.000551 0.031854 7.122369841 8.392779356 
COL6A1 2.645220064 0.480097 5.509761 3.59E-08 1.14E-05 5.407021025 6.665951187 
FBP1 2.642875468 0.396407 6.667074 2.61E-11 2.17E-08 6.207922368 7.547922296 
ARNTL2 2.638560879 0.451181 5.848123 4.97E-09 2.12E-06 4.185195333 5.510800143 
GPR84 2.615458358 0.498819 5.243296 1.58E-07 3.89E-05 4.562793111 5.923592934 
CDC42EP1 2.584476285 0.503192 5.136161 2.80E-07 6.15E-05 3.850052746 5.047192383 
CDA 2.511516789 0.494641 5.077451 3.83E-07 8.28E-05 3.795760363 4.905958734 
LPAR1 2.489597482 0.430616 5.781482 7.40E-09 2.92E-06 4.309036284 5.61479244 
FAM127C 2.484470805 0.649126 3.827411 0.000129 0.010279 2.703005591 3.527991494 
CXCL5 2.471649939 0.509193 4.854052 1.21E-06 0.000221 7.815298248 9.353058605 
TIFAB 2.470237877 0.738775 3.343694 0.000827 0.042537 2.946708582 3.905951445 
MSR1 2.464043688 0.506729 4.862644 1.16E-06 0.000215 5.730586603 7.057665376 
RTN1 2.459389725 0.452945 5.42977 5.64E-08 1.68E-05 4.814632831 6.13663653 
FPR2 2.447902115 0.458717 5.336407 9.48E-08 2.63E-05 3.217218036 4.441548028 
C2 2.429211788 0.376893 6.445369 1.15E-10 7.59E-08 5.077187028 6.383838821 
MT1E 2.425969555 0.718355 3.377116 0.000733 0.038827 1.8587446 2.659906651 
PTGDS 2.418592411 0.600898 4.024964 5.70E-05 0.005295 4.35620859 5.613856277 
TIMP3 2.41150927 0.661106 3.647687 0.000265 0.017862 4.939966201 5.940408997 
DSC2 2.400472724 0.501573 4.785886 1.70E-06 0.0003 3.794322575 5.037415027 
TNFRSF9 2.398691656 0.50504 4.749513 2.04E-06 0.000336 5.043936003 6.340854187 
TFPI 2.389388921 0.624174 3.828081 0.000129 0.010279 2.812443585 3.705247277 
263 
 
SAMD4A 2.385365493 0.557682 4.27729 1.89E-05 0.002061 4.374930783 5.57454348 
TIE1 2.38341902 0.63878 3.731207 0.000191 0.013559 4.012050775 4.885536361 
CSF1 2.37726335 0.415585 5.720284 1.06E-08 4.00E-06 7.404226384 8.565177123 
ADAMDEC1 2.362678981 0.393012 6.011722 1.84E-09 1.00E-06 6.462885682 7.747883958 
RTN4RL2 2.328651608 0.643397 3.619305 0.000295 0.019442 3.980305975 4.934984123 
IL1RN 2.30478328 0.532014 4.332188 1.48E-05 0.001711 6.084326651 6.963612062 
TGFA 2.294242964 0.415541 5.521096 3.37E-08 1.11E-05 3.52472785 4.693753884 
LDHD 2.27964988 0.653997 3.485718 0.000491 0.028715 2.209035353 2.855411095 
TSPAN15 2.264951581 0.397169 5.702733 1.18E-08 4.33E-06 4.1508152 5.208028694 
A2M 2.262830322 0.528847 4.2788 1.88E-05 0.002061 4.8079415 5.815978803 
CBX2 2.246039797 0.648436 3.46378 0.000533 0.030932 1.535814257 2.418783091 
PHLDA3 2.216261722 0.493825 4.487948 7.19E-06 0.001017 5.681075852 6.862112308 
MREG 2.202493167 0.413215 5.330141 9.81E-08 2.67E-05 5.513168253 6.584007332 
GPR150 2.189617865 0.660511 3.315037 0.000916 0.045949 2.498785733 3.395116423 
PPM1H 2.158482329 0.599986 3.597554 0.000321 0.020772 3.361673765 4.370781455 
ZNF366 2.145760737 0.601813 3.565496 0.000363 0.022855 3.255714277 4.107759816 
C17orf96 2.144970685 0.489167 4.384942 1.16E-05 0.001454 6.132419143 7.307959685 
PLAU 2.144497271 0.501344 4.277493 1.89E-05 0.002061 5.4716579 6.75269536 
ZNF618 2.137287136 0.566022 3.775982 0.000159 0.012104 3.10857692 4.086807059 
TMEM176B 2.132997105 0.512796 4.159547 3.19E-05 0.003188 6.849769687 8.019348051 
PLAUR 2.111031835 0.280184 7.53444 4.90E-14 7.04E-11 5.727854979 6.816071225 
264 
 
PDCD1LG2 2.098348 0.452356 4.638705 3.51E-06 0.000538 3.8515348 4.995069464 
PRKCDBP 2.097546699 0.472707 4.437304 9.11E-06 0.001209 3.774291278 4.704240818 
DST 2.096791802 0.404277 5.186523 2.14E-07 5.05E-05 3.403828787 4.445323266 
LILRB4 2.090648151 0.317599 6.582658 4.62E-11 3.32E-08 7.023214378 8.143477734 
SIGLEC15 2.079723103 0.596395 3.487154 0.000488 0.028667 3.34345732 4.138771974 
STEAP3 2.077690072 0.538506 3.858248 0.000114 0.009204 5.676499042 6.949527809 
C1S 2.073592619 0.418188 4.958522 7.10E-07 0.000142 5.032248321 6.16824813 
IL4I1 2.0720521 0.627954 3.299687 0.000968 0.048231 6.753139574 8.018442978 
CRTAM 2.058016668 0.397966 5.171334 2.32E-07 5.32E-05 3.421394275 4.447714953 
E2F2 2.048348164 0.539164 3.799121 0.000145 0.011244 2.753861549 3.89767876 
SERPINA1 2.03150396 0.378247 5.37084 7.84E-08 2.29E-05 5.710689004 6.969767601 
GADD45G 2.031244364 0.518212 3.919716 8.87E-05 0.007489 3.401437528 4.369301519 
SLC1A3 1.99517996 0.584703 3.412295 0.000644 0.035332 5.477782165 6.47126489 
QPCT 1.991083695 0.410293 4.852838 1.22E-06 0.000221 3.666247963 4.746379519 
APBA1 1.983135603 0.504194 3.933275 8.38E-05 0.007194 3.739169082 4.709318248 
STAT1 1.981890105 0.356148 5.564791 2.62E-08 8.82E-06 9.495398091 10.74298069 
SEMA3A 1.962978794 0.542346 3.619419 0.000295 0.019442 3.482740835 4.345685706 
ADAMTS14 1.945162117 0.569193 3.417405 0.000632 0.034917 3.18210349 4.288981994 
CECR6 1.931012046 0.432183 4.468046 7.89E-06 0.001084 3.721786856 4.637300096 
LGALS3BP 1.925234014 0.441184 4.363785 1.28E-05 0.001565 6.019772323 7.189864882 
OLR1 1.91422206 0.444873 4.30285 1.69E-05 0.001918 4.567127206 5.666832353 
265 
 
MSC 1.904327179 0.400119 4.759404 1.94E-06 0.000328 6.007669842 7.0151259 
NHS 1.891086119 0.555742 3.402812 0.000667 0.03608 2.500424126 3.358133897 
SDC4 1.886936549 0.322086 5.858485 4.67E-09 2.05E-06 5.598424331 6.622193422 
FSCN1 1.884562399 0.410634 4.589399 4.45E-06 0.000675 6.268463806 7.283809482 
SERPINE1 1.868627725 0.528946 3.532738 0.000411 0.02518 5.039959913 6.113502445 
ICAM1 1.865175567 0.454343 4.105213 4.04E-05 0.003915 8.159556908 9.272797397 
CRIM1 1.8595304 0.473016 3.931222 8.45E-05 0.007216 6.251741337 7.249421139 
TTC7B 1.855936865 0.431351 4.302614 1.69E-05 0.001918 4.139051105 5.045587965 
MMP14 1.85207004 0.426737 4.340078 1.42E-05 0.001679 9.851417816 10.85562218 
QPRT 1.827217727 0.538365 3.394014 0.000689 0.037006 3.983546535 4.847414531 
CLEC7A 1.8259118 0.26056 7.007655 2.42E-12 2.55E-09 6.787067164 7.813706321 
PVRL2 1.816874544 0.308624 5.887023 3.93E-09 1.77E-06 6.284927503 7.29920649 
SCN1B 1.804112598 0.503165 3.585529 0.000336 0.021426 3.546342209 4.373289918 
GPR141 1.799936523 0.538271 3.343923 0.000826 0.042537 4.129112945 5.148662041 
NRP1 1.770450064 0.350115 5.056769 4.26E-07 8.98E-05 7.602675168 8.637881655 
LINC01094 1.769017525 0.50248 3.520573 0.000431 0.026061 3.700976562 4.633324057 
CTSB 1.759837871 0.378671 4.647407 3.36E-06 0.000521 12.71276193 13.72257275 
MAP1A 1.740909391 0.455333 3.82338 0.000132 0.010397 3.983916724 4.79438377 
TMEM176A 1.737015584 0.517542 3.356283 0.00079 0.040913 5.345163698 6.30735233 
G0S2 1.727882546 0.501464 3.445678 0.00057 0.032379 3.936498337 4.792955296 
GBP4 1.721031323 0.473705 3.63313 0.00028 0.018821 8.127818706 9.398371407 
266 
 
IFIT3 1.717430495 0.386377 4.444957 8.79E-06 0.001177 5.78840605 6.885662806 
EMILIN1 1.71319934 0.383255 4.470127 7.82E-06 0.001084 6.688811307 7.625877516 
CR1 1.703994902 0.40333 4.22482 2.39E-05 0.002485 4.315474518 5.234952521 
LRP3 1.697773835 0.445617 3.809943 0.000139 0.010869 4.533592527 5.353975101 
RNF207 1.687143094 0.461491 3.655852 0.000256 0.017452 2.811595968 3.643489424 
FXYD6 1.687080663 0.480339 3.512272 0.000444 0.026719 3.363256865 4.320780463 
CISH 1.678065571 0.37905 4.427031 9.55E-06 0.001247 5.400595563 6.361826753 
KIAA1522 1.671504444 0.416317 4.014978 5.95E-05 0.005463 4.73952298 5.587551326 
PXDC1 1.666247472 0.374798 4.445724 8.76E-06 0.001177 5.087743736 6.00327779 
CACNA1A 1.664383947 0.446551 3.727196 0.000194 0.013593 6.167550872 7.345509983 
CYP2S1 1.663761947 0.426342 3.90241 9.52E-05 0.00796 4.48900512 5.367128626 
MGST1 1.649673448 0.417058 3.955504 7.64E-05 0.006665 4.902050939 5.711915634 
CLEC11A 1.648301024 0.4372 3.770128 0.000163 0.012244 4.168739036 5.028223137 
SPSB1 1.646824213 0.441712 3.728277 0.000193 0.013593 4.647949985 5.438176002 
PRR11 1.638520221 0.273176 5.998042 2.00E-09 1.05E-06 4.598553953 5.548284217 
CD38 1.628108205 0.483855 3.364869 0.000766 0.040177 3.184110173 4.052285894 
HK3 1.627280516 0.44568 3.65123 0.000261 0.017693 6.328672451 7.156113749 
TUSC1 1.62E+00 4.76E-01 3.414283 0.00064 0.035197 3.688615425 4.503893379 
LOC100132891 1.621025043 0.438862 3.6937 0.000221 0.015245 3.539717581 4.324697037 
CDCP1 1.613470182 0.42803 3.769524 0.000164 0.012244 3.576578679 4.377385621 
SOCS3 1.606208769 0.402692 3.988675 6.64E-05 0.005963 6.850228029 7.822685109 
267 
 
CD300LF 1.586723111 0.349081 4.545433 5.48E-06 0.000802 4.398984912 5.193485115 
ME1 1.575592507 0.299892 5.253859 1.49E-07 3.79E-05 4.430867963 5.207767067 
NCS1 1.567630826 0.356399 4.398523 1.09E-05 0.001377 5.083364237 5.887082715 
VSIG4 1.552228188 0.455146 3.410397 0.000649 0.035374 5.800552769 6.689975459 
LAMB2 1.541601983 0.467975 3.294198 0.000987 0.048875 4.010206668 4.715167414 
DAPK1 1.529660386 0.407361 3.755047 0.000173 0.012674 7.410945644 8.287764988 
DRAM1 1.523557209 0.305749 4.983037 6.26E-07 0.000127 7.843388471 8.737692116 
IGSF6 1.494036504 0.401289 3.723095 0.000197 0.013755 6.017348311 6.85664924 
ZNF697 1.481319249 0.286314 5.173766 2.29E-07 5.32E-05 4.701802982 5.494242723 
SLC7A11 1.455268134 0.304145 4.784789 1.71E-06 0.0003 8.404588054 9.28026671 
GAS2L1 1.454118799 0.402813 3.609913 0.000306 0.019993 5.761362354 6.511316796 
TBC1D16 1.426997086 0.408325 3.494754 0.000474 0.028177 5.387439627 6.142566086 
EGR2 1.421167023 0.358133 3.968266 7.24E-05 0.006353 7.715223942 8.502206279 
RCN1 1.415075253 0.39148 3.614685 0.000301 0.01971 4.84984228 5.773138518 
IL13RA1 1.413919314 0.302262 4.677791 2.90E-06 0.000458 7.214300426 8.044699452 
IL8 1.412098876 0.354772 3.980305 6.88E-05 0.006074 8.800519427 9.688728538 
GSN 1.379571635 0.323789 4.260711 2.04E-05 0.002175 6.667014682 7.413904327 
CYP1B1 1.379508647 0.314961 4.37994 1.19E-05 0.001477 11.12625466 11.91698286 
PSTPIP2 1.3751902 0.418523 3.285814 0.001017 0.049616 6.826314333 7.612555235 
COL8A2 1.374888112 0.361421 3.804113 0.000142 0.011074 6.048610369 6.860703528 
IRF1 1.372668205 0.324528 4.229737 2.34E-05 0.002447 9.271304747 10.31693483 
268 
 
NR1H3 1.360850229 0.335129 4.060675 4.89E-05 0.004684 6.782265023 7.545468109 
TNFAIP2 1.341269991 0.40851 3.283324 0.001026 0.049709 8.418716987 9.143392848 
SMOX 1.338071113 0.354951 3.769739 0.000163 0.012244 4.650555634 5.394482567 
SOD2 1.337102015 0.338985 3.944433 8.00E-05 0.006942 9.622857587 10.41539699 
NRIP3 1.327510857 0.389328 3.409747 0.00065 0.035374 4.412116485 5.048162113 
SLC8A1 1.319245512 0.288364 4.574932 4.76E-06 0.00071 6.186571119 6.94467915 
EMR2 1.318678174 0.223206 5.907896 3.47E-09 1.61E-06 5.492923793 6.22111072 
PHLDA2 1.316825898 0.345439 3.812037 0.000138 0.010831 3.518929106 4.160671923 
FTH1 1.314352465 0.296534 4.432386 9.32E-06 0.001227 12.42247851 13.17506191 
WBP5 1.310263131 0.326826 4.009052 6.10E-05 0.005534 4.480915332 5.185931098 
LRP12 1.308681837 0.296702 4.41076 1.03E-05 0.001312 5.237593393 5.956953544 
CTSL 1.307064611 0.36769 3.554803 0.000378 0.023432 8.165076798 9.003925476 
NFAM1 1.293022788 0.375897 3.43983 0.000582 0.032838 7.893941397 8.661703406 
MRC1 1.286677548 0.320591 4.013461 5.98E-05 0.005463 7.63812517 8.41236587 
PTAFR 1.282629734 0.299627 4.280756 1.86E-05 0.002061 8.696884507 9.473556166 
SCD 1.279602037 0.371262 3.446625 0.000568 0.032379 8.094244092 8.904858601 
FBXO6 1.252642656 0.336008 3.728019 0.000193 0.013593 6.222487869 6.975905348 
VDR 1.252341943 0.351775 3.560063 0.000371 0.023149 6.334891336 7.077692429 
PRRG4 1.250462185 0.336774 3.713055 0.000205 0.014249 4.283328343 5.05196881 
GLRX 1.224291998 0.322556 3.795596 0.000147 0.011294 6.066187111 6.784797888 
SORT1 1.192866223 0.274473 4.346026 1.39E-05 0.001646 5.61722794 6.273527354 
269 
 
WARS 1.174485949 0.349514 3.360341 0.000778 0.040583 9.895620744 10.7103906 
CD4 1.142979836 0.317778 3.596783 0.000322 0.020772 8.357101769 9.016755566 
GALNT6 1.141681455 0.267452 4.268736 1.97E-05 0.002112 5.760946748 6.463982597 
VANGL1 1.141398977 0.311227 3.667411 0.000245 0.016827 3.758494531 4.394404335 
APOL6 1.137911252 0.260124 4.374499 1.22E-05 0.001502 9.482012437 10.33195001 
PARP9 1.134157438 0.264915 4.281219 1.86E-05 0.002061 8.64216067 9.439790228 
ITGB2 1.101961942 0.273781 4.024974 5.70E-05 0.005295 9.787509346 10.45695783 
FNDC3B 1.097825905 0.291397 3.767461 0.000165 0.012259 6.630309259 7.293599959 
ARHGAP31 1.096869722 0.184199 5.954805 2.60E-09 1.33E-06 8.102767813 8.787197005 
ACTN1 1.032773883 0.313724 3.291982 0.000995 0.048955 6.270576905 6.867922322 
ARRDC4 1.028201506 0.256184 4.013524 5.98E-05 0.005463 6.034255799 6.623128108 
PLD3 1.012249133 0.247666 4.087159 4.37E-05 0.004206 10.59298382 11.18672339 
SGMS2 1.005630188 0.286347 3.511929 0.000445 0.026719 4.497613558 5.116981833 
UBE2L6 1.00070244 0.259785 3.85204 0.000117 0.009392 8.597448871 9.330144786 
TXN 0.97339544 0.289844 3.358343 0.000784 0.040743 4.616988131 5.156539 
NFKBIA 0.971499409 0.274468 3.539571 0.000401 0.024729 9.086207819 9.775131437 
IL15RA 0.951760798 0.28226 3.371926 0.000746 0.039434 5.951039122 6.637743017 
EPSTI1 0.920621967 0.276221 3.332912 0.000859 0.043651 7.305540578 7.990038534 
CDKN1A 0.917031452 0.207578 4.417774 9.97E-06 0.001291 9.086247563 9.674095561 
OAS3 0.911452261 0.258666 3.523663 0.000426 0.025858 8.089851891 8.767542925 
PLEK 0.909576196 0.241499 3.766371 0.000166 0.012259 9.049542707 9.60947955 
270 
 
SIRPA 0.896194474 0.264959 3.382387 0.000719 0.038347 9.224259594 9.762751504 
DTX3L 0.89335188 0.209908 4.255916 2.08E-05 0.002207 10.03192658 10.65075862 
MOB3B 0.889248009 0.260161 3.418065 0.000631 0.034917 5.103679081 5.653567799 
CREG1 0.884129157 0.265135 3.334634 0.000854 0.043521 9.77881841 10.30289055 
TRIM21 0.871340446 0.221963 3.92561 8.65E-05 0.007347 7.67616144 8.274978937 
LAP3 0.869162439 0.235269 3.694342 0.00022 0.015245 6.640079525 7.221350461 
SAMD9L 0.858141057 0.257549 3.331958 0.000862 0.04366 9.450360184 10.10564841 
PANDAR 0.844434633 0.215836 3.912388 9.14E-05 0.007679 8.1406666 8.707774192 
SQRDL 0.809132638 0.208456 3.881554 0.000104 0.008495 6.795210478 7.306393762 
STX11 0.805145162 0.206669 3.895819 9.79E-05 0.008076 8.227171916 8.770137681 
IFIH1 0.79526682 0.212194 3.747825 0.000178 0.012895 7.769123303 8.315472393 
TAP1 0.793857952 0.22478 3.531713 0.000413 0.025181 10.10645246 10.72183956 
NCF2 0.782352206 0.234875 3.330928 0.000866 0.043682 8.159922926 8.63589692 
GBP3 0.766277835 0.232721 3.292689 0.000992 0.048955 6.569272518 7.105437543 
PARP14 0.759049027 0.196615 3.860587 0.000113 0.009163 10.40799141 10.94856917 
PLXNA1 0.743149699 0.197736 3.75829 0.000171 0.012569 8.397245163 8.882458581 
S100A11 0.71940713 0.166106 4.331 1.48E-05 0.001711 7.331013641 7.766355143 
MCL1 0.678802868 0.161914 4.192367 2.76E-05 0.002832 12.42520851 12.90463029 
BPGM 0.675198951 0.169395 3.985942 6.72E-05 0.005969 6.869370351 7.341985072 
PLOD1 0.66587457 0.185647 3.586782 0.000335 0.02141 6.352201592 6.776201013 
GNS 0.651923791 0.142149 4.586207 4.51E-06 0.000679 10.20985295 10.61944687 
271 
 
CD59 0.63123875 0.1628 3.87738 0.000106 0.008597 9.246134461 9.663956475 
PGD 6.23E-01 1.72E-01 3.625947 0.000288 0.019108 8.270082583 8.658090527 
ACO1 0.579587026 0.176171 3.28992 0.001002 0.049162 6.461648692 6.820603187 
PRCP 0.563449449 0.167492 3.36403 0.000768 0.040177 8.259459453 8.637617111 
WDFY1 0.562897437 0.149968 3.753442 0.000174 0.012697 10.0799269 10.47454181 
PKM 0.554604485 0.163931 3.383159 0.000717 0.038347 11.09969364 11.46298606 
ATP6V1A 0.519134428 0.150471 3.450053 0.00056 0.032311 8.859468141 9.196640715 
TAP2 0.50549182 0.144042 3.509336 0.000449 0.026879 10.31773321 10.68956285 
PLIN3 0.497820508 0.138705 3.589047 0.000332 0.021311 8.473635063 8.805794073 
ARHGAP17 0.458817886 0.128772 3.56302 0.000367 0.02298 8.866751019 9.193224248 
NECAP2 0.407313225 0.118964 3.423827 0.000617 0.034343 9.135100424 9.413017019 
ADAR 0.314667647 0.087922 3.578937 0.000345 0.021886 11.99512068 12.22772073 





Appendix Table 7.4 Differential Gene Expression Analysis of significantly downregulated genes in CLL samples. 
 
Gene log2FoldChange lfcSE stat pvalue padj ExpressionLevelCLL ExpressionLevelCLLcc 
SLC12A9 -0.277864424 0.069714 -3.98576 6.73E-05 0.005969 9.832294893 9.62873565 
ABHD16A -0.400266298 0.121825 -3.29E+00 0.001018 0.049616 7.635560807 7.348312123 
YPEL4 -0.859812745 0.250681 -3.4299 0.000604 0.033728 5.777184655 5.233534269 
RN7SK -1.211002739 0.355222 -3.41E+00 6.52E-04 0.035374 6.430653545 5.559862195 
 
Appendix Table 7.5 Differential Gene Expression Analysis of significantly upregulated genes in NLC samples. 
 
Gene log2FoldChange lfcSE stat pvalue padj ExpressionLevelNLC ExpressionLevelNLCcc 
GLRA3 3.918075639 0.901167 4.35E+00 1.38E-05 0.044912 1.387227048 2.730208571 
PPBP 3.175807416 0.636214 4.991726 5.98E-07 0.005863 4.312860313 6.851488588 
CD28 2.619639645 5.21E-01 5.028325 4.95E-07 0.005863 7.156489894 8.83889896 
CXCL1 2.062421425 4.79E-01 4.31E+00 1.63E-05 0.045677 7.216240319 8.879749244 
 
  
Differential Gene Expression of significantly downregulated genes in the comparison between CLL alone (CLL) with CLL cultured with NLC (CLLcc). The genes are listed according to their 
log2fold change among CLLcc where CLL alone is the control. All the genes are statistically significant with their pvalue and padj values mentioned. 
Differential Gene Expression of significantly upregulated genes in the comparison between NLC alone (NLC) with NLC cultured with CLL (NLCcc). The genes are listed according to their 
log2fold change among NLCcc where NLC alone is the control. All the genes are statistically significant with their pvalue and padj values mentioned. 
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Appendix Table 7.6 Differential Gene Expression Analysis of significantly downregulated genes in NLC samples. 
 
Gene log2FoldChange lfcSE stat pvalue padj ExpressionLevelNLC ExpressionLevelNLCcc 
SLC1A5 -0.775945044 1.77E-01 -4.38E+00 1.18E-05 0.044912 11.29980371 10.71055042 
GATA4 -1.79E+01 3.744001 -4.77E+00 1.83E-06 0.011974 -1.249859707 -1.474156508 
RP11-40F8.2 -1.91E+01 4.23E+00 -4.52E+00 6.32E-06 0.030963 -1.294469758 -1.415283878 
Differential Gene Expression of significantly downregulated genes in the comparison between NLC alone (NLC) with NLC cultured with CLL (NLCcc). The genes are listed according to their 
log2fold change among NLCcc where NLC alone is the control. All the genes are statistically significant with their pvalue and padj values mentioned. 
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7.10 Primer Designing 
Appendix Table 7.7 Sequence of the primers used to validate DGEA of RNAseq data. 
 











































































R TCCCTTCCTTGTACTTCTGGC 52.38 61.2 
GAPDH 
F TCACCATCTTCCAGGAGCGA 401 905 55 60.5 
R GATGATGTTCTGGAGAGCCC   55 60.5 
 
Genes of interest and their primer sequences, product lengths, genotype length, GC content and expected Tm. Genes are 
selected as described from DGEA. 
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7.11 Reference Gene comparisons 
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Correlation between the reference genes GAPDH (G), RL27 (R) and Beta Actin (A) of samples from CLL cultured alone (CL) and CLL cultured with NLCs (CN). 
276 
 
7.12 Clinical Data analysis of the combined data 
I attempted to analyse the samples based on their clinical data (See Appendix Table 7.1) to explain the 
findings and found that the majority of the samples were untreated (except for 2) and originating from 
different patients (except two). As seen in Appendix Table 7.8, a comparison between samples treated 
(with ibrutinib) and untreated of the same patient, shows an almost complete reversal in gene 
expression changes of each gene of interest.  





 3605 3631 
MCL1   
CXCL12   
CSF1   
GBP1   
YPEL4   
STEAP3   
EGLN3   
 
 Expected 
 Not Expected 
 
 
It is possible to consider that based on this finding, that the treatment with ibrutinib in this patient 
may have caused a change in the direction of gene expression of these selected genes. However, 
further investigations are required. 
Given that the reliability of the RNA-seq results were confirmed, I then proceeded with pathway 
analysis by the Bioinformatics team. 
Comparison of gene expression changes from samples #3605 and #3631 which were derived from the same patient. 
Sample #3631 was collected after the patient was treated with ibrutinib for approximately one month. Changes that are 
in agreement by both RT-qPCR and DGEA of RNA-seq are in green and those that are not in agreement are in red. The gene 
expression changes are those from samples that are CLL alone and CLL in co-culture with NLCs. Gaps are indicated where 
qPCR data was not obtainable. These samples were not sent for RNA-seq. 
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7.13 Other Pathways generated from DAVID KEGG analysis 
 












































7.14.1 PBMC and Plasma Separation 
Into 50ml falcon tubes, pour Lymphoprep solution in a ratio of 2:1 ratio of blood to Lymphoprep. Blood 
sample is slowly poured on top of the lymphoprep making sure that blood doesn’t disturb the layers. 
Centrifuge at 800RCF for 30 minutes where the brake setting is off. 
Following centrifuge, carefully remove some of the plasma layer starting from the top most part using 
sterile Pasteur pipette. 
Using a sterile Pasteur pipette, collect the dense cloud of mononuclear cells, careful not to disturb nor 
collect any of the other layers. Collect into a labelled falcon tube. Wash the collected later by filling 
the tube with RPMI up to 50ml. Centrifuge at 550RCF for 10 minutes with standard brake settings. 
Following centrifugation, remove the supernatant and resuspend the pellet with a known volume of 
100% Fetal calf serum (FCS) media. Take a small diluted volume for cell counting. 
Based on cell counting, take a known volume of fresh PBMC for primary cell culture experiments, the 
remainder is for storage in freezing conditions. 
After cell counting, while in 4oC ice cold temperature, add media containing DMSO in a drop wise 
fashion slowly, to ensure the final media contains 10% DMSO. Aliquot the sample in pre-labelled 
cryovials at 1ml each and immediately transfer to freezing storage (-80oC and then -150oC). The 






7.14.2 Cell Counting 
7.14.2.1 Automated 
CLL cells and cell lines were counted for experimental purposes using an automated cell counter 
(Nexcelom USA CellometerTM Auto T4 cell counter), using disposable cell counting slide (Nexcelom 
Cat# CHT4/PD100/002), after mixing the cells 1:10 with a 0.1% Trypan blue dye solution in PBS. Errors 
in this method of counting are usually from introducing too high a concentration of cells into the 
machine. 
Appendix Equation 7.1 was used to calculate the volume of cell suspension required to obtain desired 
cell density for each experiment as indicated. 
Appendix Equation 7.1 Calculating concentration of desired suspension from current suspension 
V1C1=V2C2 
Where V1= volume of current suspension, C1= concentration of current suspension, V2= volume of desired suspension and 
C2= concentration of desired suspension. 
Eg. If the Volume of the current suspension is 3ml with a concentration of 15x106/ml, the desired 




7.14.2.2 Neubauer Chamber 
The Neubauer chamber, a hemocytometer, is a counting-chamber device that was designed to count 
blood cells. It consists of a thick glass microscope slide with indentations that make up a chamber. 
Within the chamber are perpendicular lines (Appendix Figure 7.22) that are of known distance and 
depth. Cells are counted within the gridlines and subsequently the number of cells can be counted 
within a specific volume, thereby calculating the concentration in the original solution overall. 
The chamber and cover slip are first cleaned with 70% ethanol, the cover slip is placed on the counting 
area and pressed down until rainbow spectrum waves are seen. A diluted known volume of cells (up 
to 20ul) stained with trypan blue is added into the chamber under the cover slip. The chamber is then 
placed under the microscope and focused to the desired counting region. CLL cells are counted within 




Errors are common in this method due to pipetting errors, statistical errors, chamber volume errors, 
and errors from volume of sample introduced into the chamber. Regardless, the Neubauer chamber 
remains the most widely used cell counting method in the world. 
 
 




To calculate the number of viable cells/mL: 
Take the average cell count from each of the sets of 16 corner squares. 
Multiply by 10,000 (104). 
Multiply by dilution factor. 
The final value is the number of viable cells/mL in the original cell suspension. 
 
Appendix Equation 7.2 Concentration of cells in original mixture 
Cells in suspensionx104/mL= Number of cells counted  x  Dilution Factor 
Number of large squares counted 
 
Example:  
If the cell counts for each of the 16 squares were 50, 40, 45, 52 and dilution factor of 5 the average 
cell count would be: 
(50 + 40 + 45 +52) ÷ 4 = 46.75 
46.75 x 104 
46.75 x 5 = 233.75x104 live cells/mL in original cell suspension 
 
7.14.3 Calibrating and adding a scale bar using ImageJ software 
The pictures were captured using phase contrast microscope at 20x objective lens, Light microscope 
with 40x objective lens or Light microscope 100x objective lens. In order to provide a scale, an image 
of a section of a Neubauer Chamber grid is also captured at the same magnification of objective lens 
using the same microscope. Using the ImageJ software, the known distance on the grid is calibrated 
to the number of pixels in the image. Once this is set, the other images can therefore have the same 
scale (ie. Number of pixels equate to a known distance). The scale is then added using tools of ImageJ 




7.14.4 Viability assay using FACS Attune 
FITC Annexin V, Propidium Iodide, (BD Pharmingen 556420), (BD Pharmingen 556463) 
Annexin Binding Buffer preparation: 
(From Data Sheet) 10x Binding Buffer: 0.1M Hepes (pH7.4), 1.4M NaCl, 25mM CaCl2 
1x Binding buffer is therefore: 10mM Hepes (pH7.4), 140mM NaCl, 2.5mM CaCl2 
 
For 500ml stock: 
5ml of 1M Hepes Stock 
14ml of 5M NaCl stock 
1.25ml of 1M CaCl2 stock 
Then add 479.75ml of distilled H20, mix well, then filter with 0.45um through syringe. 
 
1. Wash with cold PBS and re-suspend cells in 1x Binding buffer at concentration of 1x10^6/ml 
volume of 100ul. 
2. Add 2.5µl of FITC Annexin V, incubate for 8 minutes at RT 
3. Add 5µl of PI (concentration of 50µg/ml), incubate for further 2 minutes. 





7.14.5 Immunofluorescence Microscopy 
7.14.5.1 Coverslip Preparation 
Sterilize by cleaning with absolute ethanol, dry in hood for 10-30mins (May use UV light for 10mins). 
 
7.14.5.2 Grow the cells 
Place the coverslips in culture plate for adding cells in medium. Gently press on coverslips with pipette 
tip to remove air bubbles to avoid cells from growing under the coverslip. 
Once ready, drain the medium, gently wash with PBS, drain the PBS (leave some behind). Transfer the 




Fixation using 4% Paraformaldehyde for 10mins, then Permeabilisation with 0.5%Triton X (in PBS) for 
10mins in room temperature. 
 
7.14.5.4 Removing Autofluorescence 
Prepare 0.1% sodium borohydride (NaBH4) (in PBS). CAUTION: Hydrogen gas is produced, FLAMMABLE 
Prepare 0.2g powder NaBH4 and dissolve in 20ml of PBS to make 0.1% in Fume cupboard. 
Place plate on ice and add the NaBH4 approx. 250-400ml in each well. There will be bubble formations, 
so this needs to be replaced after 5mins. Do twice. (5mins, replace, 5mins) 
When completed, wash properly 3x with PBS. 
 
7.14.5.5 Blocking 
Leaving behind some PBS from last wash, lift the coverslips, drain from the side on tissue. If possible, 
wipe the surface of the coverslip NOT with cells. 
Drop approx. 100ul of blocking solution (1%BSA in PBS) on parafilm. Place coverslip face down on the 
drop. Leave for 30mins room temperature. This step can be prolonged. Additional step of using 
TruStain Fc blocker can be used in the same manner. 
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7.14.5.6 Incubate with Antibody 
Remove blocking buffer by holding at angle over fibre-free paper or tissue. No need to wash with PBS. 
Dilute antibody to 1.0-10ug/ml in blocking buffer, Add 100ul onto parafilm and place coverslip face 
down on it. Incubate at room temperature for 30mins in humidified chamber. Remove antibody by 
lifting coverslip off it, wash with PBS 3x 5mins each wash. 
If more than one antibody, (secondary antibody) then block with Serum of that species (eg. Donkey 
Serum) as before, then repeat procedure using secondary antibody (prepare dilution in Donkey 
serum). Incubate for 30mins at room temperature in humidified chamber. Remove antibody by lifting 
coverslip off it, wash with PBS 3x 5mins each wash. 
 
7.14.5.7 Incubate with DAPI/Hoechst stain 
Prepare DAPI/Hoechst stain (with staining buffer) in covered Eppendorf tube (100ul per coverslip). 
Place a drop on parafilm. Transfer coverslip face down on the drop. Incubate for 5mins at room 
temperature in humidified chamber. Remove excess stain by lifting coverslip off it, wash with staining 
buffer 3x 5mins each wash. 
Make sure to let the coverslip dry as much as possible before mounting. 
 
7.14.5.8 Preparation for Microscopy 
Take a clean slide. Add 10ul of mounting medium. Invert coverslip and apply onto that. 
Remove excess mounting media with fiber-free paper. Allow to solidify for a few hours (overnight is 
best). Avoid touching the coverslip as this would alter the volume of medium underneath and 
introduce air bubbles. 
Seal the edges of coverslip with nail polish. Allow to dry for 3mins. Keep slides in dark (cover with 
aluminium foil) and in 4oC till microscopy. 
At the time of microscopy, observe in dark room. Using Q-tip, dip in distilled water and gently wipe 





Prepare machine: switch on camera, laser, microscope and computer. Open ImageJ Microscopy 
Software. Adjust magnification at 40x. Locate, focus and identify cells using DAPI at LOW exposure. 




7.14.6 Optimizing IF protocol 
As shown in Appendix Figure 7.23 using PMA differentiated THP1 cell line, it seemed there was clear 
spill-over of Hoechst 33342 (blue) over to green, with co-expression of both antibodies in same 
location giving an orange colour. In addition to that, there wasn’t any difference in intensity of either 
colours with their respective isotype controls. Even their unstained counterpart showed expression in 
both the antibody colours. The level of expressions of the antibodies were quite weak despite using 
low dilution.  
The use of secondary antibodies was advised and the experiment was repeated. The results (Appendix 
Figure 7.24) showed that there was a greater intensity seen at greater dilutions, however the problem 
of auto fluorescence, spill over and nonspecific binding persisted. 
The use of Fc-receptor blocker reagent was suggested to reduce non-specific binding, the reason was 
that the monocyte-lineage cells are essentially immune cells that express Fc-receptors for antigen 
binding (Andersen et al. 2016; Forrester et al. 2018). By blocking these Fc sites, this reduces or 
eliminates the chances of false positive detection. As seen in Appendix Figure 7.25, despite using the 
Fc-receptor blocker, there was still non-specific binding as well as auto-fluorescence. 
To tackle the auto-fluorescence, 0.1% Sodium Borohydride was used based on literature 
recommendations (Clancy & Cauller 1998; Davis et al. 2014). The results (Appendix Figure 7.26) 
showed a decrease in auto fluorescence however there was still nonspecific binding. 
The presence of non-specific binding was resolved using an additional blocking step using donkey 
serum (of same species as secondary antibody) and as seen in Appendix Figure 7.27, it showed further 
reduction in nonspecific binding. 
Despite optimising secondary antibody and performing stains on primary cells, there was still too 
much spill-over of blue (Hoechst 33342) onto green, despite using greater dilution of Hoechst 33342 
of 1:20,000 Appendix Figure 7.28) 
It was then suggested to use DAPI as alternative to Hoechst 33341 as a nuclear stain. Using different 
concentrations, (Appendix Figure 7.29), it was found that DAPI was indeed stained much better and 
clear staining of nucleus was achieved even at a dilution of 1:10,000. In addition, the duration of 
exposure to DAPI was compared at 2 minutes versus 20 minutes and it was found that there was less 
spill-over at short exposure time.  
Using the previous adjustments, the final protocol was used and there was minimal spill-over from 
blue to green. 
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Using the optimised conditions to remove auto-fluorescence, non-specific binding (by using 0.1% 
NaBH4 and Fc-receptor blocker and DAPI respectively) and DAPI for nuclear staining, I then proceeded 
to perform IF on primary cells. 
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THP1 PMA Hoechst 33342 FITC-CD14 PE-CD68 Merged 
Unstained 
    
Isotype 
Control 
    
Test 
    
Appendix Figure 7.23 Initial IF staining showed auto-fluorescence, non-specific fluorescence and spill-overs of nuclear stain. 
 
  
Immunofluorescence staining of PMA differentiated THP1 cell line to test out fluorescent conjugated anti CD14 (green), anti CD68 (red) and counterstained with Hoechst 33342 (blue)nuclear 
staining. THP-1 cells were PMA differentiated for 24-48 hr as described, fixed, stained with fluorochrome-conjugated antibodies as described, counterstained with nuclear stain as described and 
viewed under fluorescence microscope in the dark. Corresponding Isotype controls were used for each antibody. Images were prepared using ImageJ software. 
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Appendix Figure 7.24 Use of secondary antibodies improved the IF staining. 
 
  
Immunofluorescence staining using chemically differentiated THP1 cell line with anti-CD14 and secondary antibody (green), counterstained with Hoechst 33342 nuclear stain (blue). THP-1 
cells were PMA differentiated for 24-48 hr as described, fixed, stained with primary and secondary antibodies as described, counterstained with nuclear stain as described and viewed under 
fluorescence microscope in the dark. Corresponding Isotype controls were used for each primary antibody. Images were prepared using ImageJ software. 
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Appendix Figure 7.25 Use of Fc-receptor blocker reduced non-significant fluorescence. 
 
 
Immunofluorescence staining using chemically differentiated THP1 cell line with anti-CD163 and secondary antibody (red), counterstained with Hoechst 33342 nuclear stain (blue). Fc-receptor 
blocker was used. THP-1 cells were PMA differentiated for 24-48 hr as described, fixed, stained with primary and secondary antibodies as described, counterstained with nuclear stain as 









   
Appendix Figure 7.26 Auto-fluorescence was removed using 0.1% sodium borohydride. 
 
  
Immunofluorescence staining using chemically differentiated THP1 cell line under green light merged with blue, without any primary antibody but with secondary antibody (green), 
counterstained with Hoechst 33342 nuclear stain (blue). Here Fc-receptor Blocker was used. 0.1% Sodium Borohydride incubation was introduced and compared with those not incubated. 
Secondary antibody was either absent or present as indicated. THP-1 cells were PMA differentiated for 24-48 hr as described, fixed, stained with secondary antibodies as described, 




Hoechst 33342 CD14 Merged 
   
 
   
Appendix Figure 7.27 The combined used of Fc-receptor blocker and Donkey serum reduced non-specific fluorescence. 
 
  
Immunofluorescence staining using chemically differentiated THP1 cell line with anti-CD14 and secondary antibody (green), counterstained with Hoechst 33342 nuclear stain (blue). Here 
0.1% sodium borohydride, Fc-receptor Blocker and donkey serum blocking step was used. THP-1 cells were PMA differentiated for 24-48 hr as described, fixed, stained with primary and 
secondary antibodies as described, counterstained with nuclear stain as described and viewed under fluorescence microscope in the dark. Images were prepared using ImageJ software. 
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3528 D8 Hoechst 33342 CD14 CD163 Merged 
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Appendix Figure 7.28 Spill-over was still seen using Hoechst 33342 nuclear stain. 
 
  
Immunofluorescence staining using sample 3528 at day 8, with anti-CD14 (green), anti-CD163 (red) and counterstained with Hoechst 33342 nuclear stain (blue). Here 0.1% sodium 
borohydride, Fc-receptor Blocker and donkey serum blocking step was used. Fresh PBMC were cultured as described till Day 8, fixed, stained with primary and secondary antibodies as 
described, counterstained with nuclear stain as described and viewed under fluorescence microscope in the dark. Corresponding Isotype controls were used for each primary antibody. 
Images were prepared using ImageJ software. 
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Appendix Figure 7.29 Use of DAPI nuclear staining significantly reduced the spill-over and still efficiently fluoresced at diluted concentrations. 
Immunofluorescence staining using chemically differentiated THP1 cell line with anti-CD14 and secondary antibody (green), counterstained with either Hoechst 33342 or DAPI nuclear stain 
(blue). Here 0.1% sodium borohydride, Fc-receptor Blocker and donkey serum blocking step was used. THP-1 cells were PMA differentiated for 24-48 hr as described, fixed, stained with primary 




7.14.7 Reagent preparation for THP-1 cell line experiments 
IL-4 stock of 10ng/ul. In order to achieve 20-30 ng/ml, take 1 vial and add either 2ul of stock (20ng/ml) or 
3ul of stock (30ng/ml). 
IFNγ stock of 1000ng/ul (100ul). Aliquoted into 5ul of 20ng/ul). In order to achieve 20ng/ml, take 1ul and 
add into 1ml of cells. 
LPS stock of 500ng/ml (500pg/ul) where each vial has 1ul. To achieve 10pg/ml, on the day of experiment, 










o Wash buffer: 1x PBS, 0.05% Tween-20 (or Thermo Fisher ELISA Wash Buffer Powder, Cat 
No. 00-0400) 
o Stop Solution: 1M H3PO4 (recommended or 2N H2SO4 
• Pipettes 
• Refrigerator & frost-free -20oC freezer 
• 96-well plate (Corning Costar 9018 or NUNC MaxicorpTM)  
• 96-well ELISA plate reader (microplate spectrophotometer 
• ELISA plate washer (highly recommended) 
 
Time Requirements 
• 1 overnight incubation 
• 4.5 hour incubations 
• 1 hour washing and analysing samples 
 
Experimental Procedure 
1. Coat ELISA plate with 100 μL/well of capture antibody in 1X Coating Buffer. Seal the plate and 
incubate overnight at 4°C.  
2. Aspirate wells and wash 3 times with >250 μL/well Wash Buffer. Allowing time for soaking (~ 1 
minute) during each wash step increases the effectiveness of the washes. Blot plate on absorbent 
paper to remove any residual buffer.  
3. Dilute 1 part 5X ELISA/ELISPOT Diluent with 4 parts DI water. Block wells with 200 μL/well of 1X 
ELISA/ELISPOT Diluent. Incubate at room temperature for 1 hour.  
4. Optional: Aspirate and wash at least once with Wash Buffer.  
5. Using 1X ELISA/ELISPOT Diluent, dilute standards to prepare the top concentration of the 
standard. Add 100 μL/well of top standard concentration to the appropriate wells. Perform 2-fold 
serial dilutions of the top standards to make the standard curve for a total of 8 points. Add 100 
μL/well of your samples to the appropriate wells. Seal the plate and incubate at room 
temperature for 2 hours (or overnight at 4°C for maximal sensitivity).  
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6. Aspirate/wash as in step 2. Repeat for a total of 3-5 washes.  
7. Add 100 μL/well of detection antibody diluted in 1X ELISA/ELISPOT Diluent. Seal the plate and 
incubate at room temperature for 1 hour.  
8. Aspirate/wash as in step 2. Repeat for a total of 3-5 washes.  
9. Add 100 μL/well of Avidin-HRP diluted in 1X ELISA/ELISPOT Diluent. Seal the plate and incubate at 
room temperature for 30 minutes.  
10. Aspirate and wash as in step 2. In this wash step, soak wells in Wash Buffer for 1 to 2 minutes 
prior to aspiration. Repeat for a total of 5-7 washes.  
11. Add 100 μL/well of 1X TMB Solution to each well. Incubate plate at room temperature for 15 
minutes.  
12. Add 50 μL of Stop Solution to each well.  
13. Read plate at 450 nm. If wavelength subtraction is available, subtract the values of 570 nm from 




7.14.8.1 Grid Outline for CCL3 CCL4 for 3605, 3606 and 3607 with cell line or with primary cocultures and alone 
Appendix Table 7.9 An example of Grid Outline for measuring CCL3 and CCL4 using ELISA 
Duplicates are prepared for each. Standards are prepared as instructed (Std); Supernatant from freshly prepared THP-1, M0, M1 and M2 cell line cultures; Supernatant from Samples (3605, 
3607, 3606, 3605 and 3607) were used as either cultured alone, with M0, with M1, with M2; Supernatant of primary samples from fresh PBMC of Days 4, 5, 6, 7 and 8; Supernatant from co-
culture experiments of 3607 and 3605 from the 3 conditions; Supernatant from co-cultures after CLL samples were removed; Control wells containing only RPMI and diluent used for the 
samples. 
Std1 Std1 3605 3605 3605 M0 3605 M0 3607 3607 3607 M0 3607 M0 3607 D6 3607 D6 
Std2 Std2 3605 M1 3605 M1 3605 M2 3605 M2 3607 M1 3607 M1 3607 M2 3607 M2 3607 D8 3607 D8 



























7.14.8.2 Grid Outline of Primary Cells time course experiment 
Appendix Table 7.10 An example of Grid outline of measuring CCL3 and CCL4 on Primary Cells in time course 
Duplicates are prepared for each. Standards are prepared as instructed (Std); Supernatant from Samples (3561, 3577, 3621, 3627, 3609, 3585, 3510, 3589, 3492, 3564, 3493, 3523, 3507, 3612, 
3530, 3483, 3512, 3484, 3491 and 3599) from fresh PBMC of Days 4-14; Control wells containing only RPMI and diluent used for the samples. 
STD1 STD1 3561 D4 3561 D4 3577 D4 3577 D4 3621 D4 3621 D4 3627 D4 3627 D4 3609 D4 3609 D4 
STD2 STD2 3561 D10 3561 D10 3577 D10 3577 D10 3621 D8 3621 D8 3627 D8 3627 D8 3585 D5 3585 D5 
STD3 STD3 3510 D5 3510 D5 3492 D6 3492 D6 3564 D6 3564 D6 3523 D6 3523 D6 3507 D6 3507 D6 
STD4 STD4 3589 D5 3589 D5 3492 D10 3492 D10 3564 D9 3564 D9 3523 D9 3523 D9 3507 D10 3507 D10 
STD5 STD5 3529 D5 3529 D5 3492 D13 3492 D13 3493 D7 3493 D7 3612 D8 3612 D8 3507 D13 3507 D13 
STD6 STD6 3530 D6 3530 D6 3483 D7 3483 D7 3512 D8 3512 D8 3484 D9 3484 D9 3491 D7 3491 D7 
STD7 STD7 3530 D8 3530 D8 3483 D11 3483 D11 3512 D14 3512 D14 3484 D12 3484 D12 3491 D9 3491 D9 




7.14.8.3 Grid outline of Cell line coculture time course 
Appendix Table 7.11 An example of Grid outline to measure CCL3 and CCL4 using Cell lines with Sandwich ELISA method 
Duplicates are prepared for each. Standards are prepared as instructed (Std); Supernatant from Samples (3587, 3379 and 2916) were used as either cultured alone, with M0, with M1, with M2; 
Each culture mixture is taken on Days 1, 2 and 3; Supernatant from M0, M1 and M2 cultured alone at day 1, 2 and 3; Control wells containing only RPMI and diluent used for the samples. 


































































































































































































7.14.9 Homogenising samples using QiaShredder – purple columns 
1. Thaw samples if frozen 
2. Spin to get all of the sample down to the bottom 
3. Label columns – number them and keep a list of what the numbers correspond to! 
4. Add a maximum of 700uL to each column  
5. This can be done in the UV hood, or at the bench but if at the bench be careful not to 
contaminate – the RNA is very delicate and easily contaminated! So: obtain sample from tube 
using filter tip – open lid, take up sample and then close. Open cap from column add sample 
and close quickly – try not to pick up the columns as its quicker to do it from the stand 
6. Spin the samples for 2 mins at maximum speed 
7. The flow through is then used for the RNeasy protocol 
 
7.14.10 RNeasy Protocol 
1. Label RNeasy spin columns with the corresponding numbers you used for the QiaShredder 
2. Add the same volume of 70% ethanol as you did of RLT buffer (ie 350uL or 600uL) 
3. Mix well by pipetting 
4. Following RNeasy steps 
5. Use nanodrop to quantify RNA 
6. You need 1ug of RNA for to convert to cDNA 




7.14.11 RNA extraction using RNeasy mini kit (Qiagen) 
1. Clean the hood with 10%bleach and 70% ethanol and turn on UV light for at least 30min to 
get read off RNAs. 
2. Prepare RLT buffer under the hood according the final volume you want (for each 1ml RLT + 
10πl β-mercaptoethanol) 
3. Add 700 µl of RLT buffer to lysis cells, mix by pipetting than transfer into labelled Q1Ashredder 
column for homogenizing, Spin for 2min at 14000g. 
4. Add 700 µl of 70% ethanol to the sample, mix and transfer 700 µl of the mix to a new labelled 
RNeasy spin column, centrifuge for 30sec at ≥8000 x g, discard the flow-through, add the 
remaining lysis cells from the main sample to the same RNeasy column and repeat the spin, 
discard to maximize the RNA yield. 
5. Add 350 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and centrifuge for 
30sec at ≥8000 x g. Discard the flow-through. 
6. (on-column DNase digestion) calculate the mount needed of DNase I stock, each sample 
column will take 10 μl DNase I stock to 70 μl buffer RDD. So, for 2 samples>> 22 μl DNase+154 
buffer RDD>> give 176μl from which we add 80μl to each sample 
7. Add DNase I incubation mix (80 μl) directly to RNeasy column membrane, and place on 
benchtop for 15 min. 
8. Add 350 μl Buffer RW1 to the RNeasy spin column. Centrifuge for 30sec at ≥8000 x g. Discard 
the flow-through. 
9. Add 500 μl Buffer RPE to the RNeasy spin column. Centrifuge for 30sec at ≥8000 x g. Discard 
the flow-through. 
10. Add 500 μl Buffer RPE to the RNeasy spin column, centrifuge for 2min at ≥8000 x g to wash 
the spin column membrane. 
11. Place the RNeasy spin column in a new 2 ml collection tube (supplied), and discard the old 
collection tube with the flow-through. Centrifuge at full speed for 1 min to dry the membrane. 
12. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 50 μl RNase-free 
water directly to the spin column membrane, incubate for 5min and centrifuge for 1 min at 
≥8000 x g to elute the RNA. Put the samples on ice. 




7.14.12 Nanodrop measurement 
Blank with 1μl RNase-free water and measure RNA by adding 1μl of the sample into the reader. 
(260/280) represent RNA & DNA purity. 
(260/230) represent DNA purity. 
Both should be between (1.8 - 2.1) 
RNA calculation: Concentration X dilution factor X 40 (Constant) = ? ng/µl 
                                                                                                           ?/1000 = ? µg/µl in total 
if the expected RNA yield is >30 μg, repeat last step using another 30–50 μl RNase free water, or using 
the eluate (if high RNA concentration is required). Reuse the collection tube from last step. 






7.14.13 Reverse transcription protocol (RT) 
Reagents: 
dNTP 10mM 
Oligo (dT) 15 primers (Promega UK, C1101) 
RNase inhibitor (Promega UK, N2511) 
Superscript III (Invitrogen UK, 18080-044) 
 
Procedure: 
- To a labelled RNase-free tube, add: 
Oligo (dT) 15 primers (0.5μg/μl)       1.0 μl 
dNTPs (10 mM)                                    1.0 μl  
Total mRNA                                           1μg (up to 9.5 μl) 
RNase free H2O                                    variable (final volume 20 μl) 
Heat at 70°C for 5 mins, then cool on ice for 5 mins. 
5x Reaction buffer                                 4.0 μl 
DTT (0.1M)                                             1.0 μl 
Superscript III                                         1.0 μl 
RNase inhibitor (40u/μl)                       1.0 μl 
____________________________________ 
Total                                                          20 μl 
 
- Heat tubes on heating block for 50°C for 60 min and then 95°C for 5 min. Store cDNA samples 




7.14.14 Polymerase Chain Reaction (PCR) 
Reaction mix (20µl) 
One-Taq 2Xmm (#M0486S)       10 µl 
20 µM Forward primer              (1 µl of 100 µM primer + 4 µl free RNA water, mix and then take 1 µl) 
20 µM Reverse primer               (1 µl of 100 µM primer + 4 µl free RNA water, mix and then take 1 µl) 
cDNA                                             1.0 µl 
Free RNA water                           7 µl 
 
PCR programme (GAPDH)                                                          
Stage 1       95°c for 2 min 
Stage 2       95°c for 30 sec 
                    56°c for 30 sec (annealing) 
                    72°c for 1 min 
                    (Repeated for 35 cycles) 
Stage 3       72°c for 5 min 





7.14.15 Agarose gel electrophoresis 
Materials 
Agarose (ULTRAPURE) 
1X TBE (Tris-Borate electrophoresis buffer) (1L= 20ml 50XTBE + 980ml dH2O) 
Midori Green Advance DNA Stain 
Procedure 
1. For a 1 % gel, add 0.5 g agarose to 50 ml 1x TBE. (for 1.5% gel, add 0.75g to 50ml) 
2. Heat the solution in the microwave to dissolve the agarose. Let it cool down (~5min) and 5 μl 
of Midori Green Advance DNA Stain to the dissolved agarose and mix. 
3. Prepare the gel assembling box, pour the melted agarose and place the comb on the top. 
4. Allow the gel to solidify (about 20 minutes); then carefully remove the comb and tape, transfer 
the gel to the electrophoresis box. Make sure that the comb is nearest to the black electrode 
(cathode), as the DNA migrates towards the red electrode (anode).  
5. Top up the box 1X TAE buffer, make sure it covers the gel. 
6. Load the gel with 8μl of Ladder and 20μl samples. 
7. Electrophorese at 110 V for 25 minutes. 
8. View the gel against a white light box or bright surface. 
Quick-Load Purple 100bp DNA Ladder 
Size range: 100 bp to 1,517 bp 
 
 
Quick-Load Purple 1kb DNA Ladder 











7.14.16 Protocol for Resuspending PCR Primers 
7.14.16.1 Materials 
• Molecular Grade H2O 
• Primers (dry) 
• Sterile Microcentrifuge Tubes 
 
7.14.16.2 Method 
Primers are often shipped and received in a lyophilized state. First create a master 100× stock (for 
each primer and then dilute it to a 10× working stock. 
This reduces the number of freeze/thaw cycles that the master primer stock goes through and reduces 
the chances of contaminating the primary source for the primer.  
 
Spin Down Tubes 
Primers should always be spun down before opening the tube for the first time.  The pellet can often 
come dislodged during shipping and may be in the cap! 
 
Master stock, 100 µM  
100 µM = X moles lyophilized primer + (X × 10 µl molecular grade H2O)  
To determine the amount of H2O to add to the lyophilized primer simply multiply the number of nmol 
of primer in the tube by 10 and that will be the amount of H2O to add to make a 100 µM primer stock.  
For example, if there are 38.2 nmol of primer then by adding 382 µl of H2O, a 100 µM primer stock is 
created. 
The original primer tubes are often used for this 100 µM stock. 
Master stock primers newly suspended in H2O should be allowed to sit at room temperature for 10 
minutes before they are used for working stock dilutions.  Mix well before making working stock 
dilutions. 
Mix the solution by vortexing to reconstitute the primers. Store primer stocks at -20oC. 
 
Working stock, 10 µM 
Dilute the primer master stock in a sterile microcentrifuge tube 1:10 with molecular grade H2O.  
You should never use the stock primers directly into a PCR because they are so concentrated. Working 
from one tube is also a bad idea. It only takes a bit of contamination to creep in to the tube and you 
will have to re-order the primers again. 
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Therefore, it is best practise to create working solutions that are of lower concentrations. The 
concentration of choice for the working primer solution is totally user-determined. The most common 
concentration for a working primer solution is 10 μM. 
To make a 10 μM working primer solution, follow these steps: (1 in 10 dilution) 
1 Add 10 μL of primer stock solution to an RNase- and DNAse-free tube. 
2 Add 90 μL of PCR-grade water. 
3 Mix by vortexing. 
Aliquot and store working primer solutions at -20oC. Avoid excessive freeze-thawing of working 
primers. 
 
Thaw SYBR Green Mix and Water PCR grade. 
While thawing: 
1. Dilute cDNA (1+4) in H2O 
2. Work out total volume of diluted cDNA needed. 
Total reactions = 8(primers) x2(duplicates)= 16 reactions 
In each reaction you need 2 ul of diluted cDNA. 
So… total vol of diluted working stock of cDNA is 16x2=32ul 
7ul of Master stock of cDNA + 28ul of H2O= 35ul of working stock cDNA 
3. Dilute stock of primers from Master stock of 100mM to 10mM in H2O (1ul Primer + 9ul H2O)= 
10ul working stock of primer. 
Then add 0.8-1ul of diluted primers to each tube 
Seal and spin in centrifuge. 






7.14.17 Protocol for RT-qPCR 
7.14.17.1 Preparation of Primers 
1. Dilute cDNA 
1+4 (H2O) 
2. Work out total volume of diluted cDNA needed 
Total reactions = 8 x 2 = 16 
In each reaction 2ul of diluted cDNA needed 
Therefore, Total volume of diluted cDNA = 16 x 2 = 32 ul 
7ul original cDNA + 28ul of H2O = 35ul (enough for 32ul of reactions) 
3. Dilute Stock Primers (100pmol) to 10 pmol in H2O 
1ul of primer + 9ul of H2O 
Then add 0.8-1ul of diluted primer in each tube 
 
7.14.17.2 qPCR Programming for Light Cycler 480 
Name   Cycles   Analysis Model 
Preincubation  1   None 
Amplification  45   Quantification 
Melting   1   Melting Curve 
Cooling   1   None 
 
Preincubation 
None  95oC  x10min  RamptT. 4.4C/s 
 
Amplification 
None  95oC  x15s  RamptT. 4.4C/s 
None  58oC  x20s  RamptT. 2.2C/s 
None  72oC  x20s  RamptT. 4.4C/s 
Single  81oC  x10s  RamptT. 4.4C/s 
 
Melting 
None  95oC  x1s  RamptT. 4.4C/s 
None  65oC  x10s  RamptT. 2.2C/s 
Continuous 97oC  acquisition 4-5/per oC  0.14C/s 
 
Cooling 





7.14.17.3 Grid Outline for qPCR for Primer Optimizing 
Appendix Table 7.12 An example of Grid outline of optimising qPCR for selected primers 
Duplicates were done for each sample; cDNA from a control sample was used for all coloured wells; Primers (CXCL12, EGLN3, GBP1, EBI3, MCL1, CXCL10, YPEL4 and GAPDH) were 
used in combination with the control sample or alone in PCR water (+ Water); Control of only water was used to detect contamination. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A CXCL12 CXCL12  EGLN3 EGLN3  GBP1 GBP1  EBI3 EBI3  
B + WATER + WATER  + WATER + WATER  + WATER + WATER  + WATER + WATER  
C             
D MCL1 MCL1  CXCL10 CXCL10  YPEL4 YPEL4     
E + WATER + WATER  + WATER + WATER  + WATER + WATER     
F             
G GAPDH GAPDH           





Appendix Table 7.13 An example of Grid outline to optimize the qPCR reading temperature for selected Primers 
Duplicates were done for each sample; cDNA from a control sample was used for all coloured wells; Primers (CCL13, CXCL9, NUPR1, CSF1, STEAP3, EGR2 and GAPDH) were used 
in combination with the control sample or alone in PCR water (+ Water); Control of only water was used to detect contamination. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A CCL13 CCL13  CXCL9 CXCL9  NUPR1 NUPR1  CSF1 CSF1  
B + WATER + WATER  + WATER + WATER  + WATER + WATER  + WATER + WATER  
C             
D STEAP3 STEAP3  EGR2 EGR2        
E + WATER + WATER  + WATER + WATER        
F             
G GAPDH GAPDH           






7.14.17.4 Grid Outline for qPCR after optimizing 
Appendix Table 7.14 An example of Grid outline to perform optimized qPCR on cDNA samples for each Primers of Interest 
Triplicate wells were done for each sample; cDNA from a sample (3599, 3627, 3682, 3577, 3679, 3684, 3620, 3637, 3645, 3686, 3605, 3607, 3621 and 3631) was used for all 
coloured wells as CLL cultured alone (CL) or CLL cultured with NLCs (CN); A selected control sample was used; Single primer and GAPDH were used in combination with the samples; 
Control of primer with water was used. 
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